


**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 11
November 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content.....	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	ix
1.5 Availability of the Edition.....	xi
1.6 Report of Counts for the Prescription Drug Product List.....	xi
1.7 Cumulative Supplement Legend	xiii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 11
NOVEMBER 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been

discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AMNEAL PHARMACEUTICALS CO GMBH
(AMNEAL PHARMS CO)

G AND W LABORATORIES INC
(G AND W LABS)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AMNEAL EU LTD
(AMNEAL EU)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

G AND W LABORATORIES INC (G AND W LABS INC)	ACP NIMBLE BUYER INC (ACP NIMBLE)
INVATECH PHARMA SOLUTION INC (INVATECH)	ATHEM HOLDINGS LLC (ATHEM)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
MIKART LLC (MIKART)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
PD PARTNERS IV LLC (PD PARTNERS)	PHARMACEUTICAL ASSOCIATES INC (PHARM ASSOC)
PFIZER CONSUMER HEALTHCARE (PFIZER CONS HLTHCARE)	GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC (GLAXOSMITHKLINE)
PFIZER INC (PFIZER)	GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC (GLAXOSMITHKLINE)
RISING HOLDINGS INC (RISING)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
RISING PHARMACEUTICALS INC (RISING PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICIAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	SUN PHARMACEUTICIAL INDUSTRIES LTD (SUN PHARM)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)

WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC (WATSON LABS)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	DR REDDYS LABORATORIES INC (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS INC)	HERITAGE PHARMA LABS INC (WATSON LABS INC)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), Levo-T (Cediprot Inc NDA 021342), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Stevens J NDA 021210) tablets.

Levo-T (Cediprog Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), Unithroid (Stevens J NDA 021210), Thyro-tabs (Alvogen NDA 021116), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprog Inc NDA 021342), Unithroid (Stevens J NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-tabs (Alvogen NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB1	209713	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
THYRO-TABS	ALVOGEN	0.025MG	AB2	021116	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB3	209713	001
THYRO-TABS	ALVOGEN	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section

505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580	20693	20688	
LISTED SINGLE	2724	2713	2729	2713	
SOURCE	(13.4%)	(13.2%)	(13.2%)	(13.1%)	
MULTISOURCE	17571	17867	17964	17975	
	(86.6%)	(86.8%)	(86.8%)	(86.9%)	
THERAPEUTICALLY	17483	17777	17964	17892	
EQUIVALENT	(86.1%)	(86.4%)	(86.8%)	(86.5%)	
NOT THERAPEUTICALLY	88	90	85	83	
EQUIVALENT	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
EXCEPTIONS ¹	58	58	58	54	
	(0.3%)	(0.3%)	(0.3%)	(0.3%)	
NEW MOLECULAR	25	3	16	21	
ENTITIES APPROVED					
NUMBER OF	1133	1129	1132	1140	
APPLICANTS					

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB	GLENMARK PHARMS	250MG	A209227	001	Oct 16, 2019	Sep NEWA
AB	MSN LABS PVT LTD	250MG	A210686	001	Jul 10, 2019	Jun NEWA
AB	QILU	250MG	A212462	001	Sep 27, 2019	Sep NEWA
AB	WOCKHARDT BIO AG	250MG	A208380	001	Feb 27, 2019	Feb NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

>D>	AB	BARR LABS DIV TEVA	333MG	A200143	001	Nov 18, 2013	Nov DISC
>A>		@	333MG	A200143	001	Nov 18, 2013	Nov DISC

ACARBOSE

TABLET;ORAL

ACARBOSE

	@ MYLAN	25MG	A091053	001	Jan 06, 2011	Jun DISC
	@	50MG	A091053	002	Jan 06, 2011	Jun DISC
	@	100MG	A091053	003	Jan 06, 2011	Jun DISC
AB	! STRIDES PHARMA	25MG	A090912	001	Jul 27, 2011	Oct CHRS
	PRECOSE					
	+ @ BAYER HLTHCARE	25MG	N020482	004	May 29, 1997	Oct DISC
	+ @	50MG	N020482	001	Sep 06, 1995	Oct DISC
	+ @	100MG	N020482	002	Sep 06, 1995	Oct DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

	@ ANI PHARMS INC	EQ 200MG BASE	A074007	001	Oct 18, 1995	Jul CAHN
	@	EQ 400MG BASE	A074007	002	Oct 18, 1995	Jul CAHN

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+	KEMPHARM	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Jan NEWA
+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Jan NEWA
+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019	Feb CAHN
+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018	Feb CAHN
+	!	325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Aug CHRS
+		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019	Feb CAHN

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

>A>	AA	GRANULES PHARMS	300MG;50MG	A213115	001	Nov 22, 2019	Nov NFTG
>D>	!	MAYNE PHARMA INC	300MG;50MG	A207313	001	Dec 27, 2017	Nov CFTG
>A>	AA	!	300MG;50MG	A207313	001	Dec 27, 2017	Nov CFTG

TABLET;ORAL

ALLZITAL

!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015	Sep CHRS
---	-----------------	------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC	120MG/5ML;12MG/5ML	A091238	001	Nov 10, 2011	Jan DISC
------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	ELITE LABS INC	300MG;15MG	A212418	001	Sep 10, 2019	Aug NEWA
AA		300MG;30MG	A212418	002	Sep 10, 2019	Aug NEWA
AA		300MG;60MG	A212418	003	Sep 10, 2019	Aug NEWA
AA	EYWA	300MG;15MG	A211610	001	Jun 27, 2019	Sep CAHN
AA		300MG;30MG	A211610	002	Jun 27, 2019	Sep CAHN
AA		300MG;60MG	A211610	003	Jun 27, 2019	Sep CAHN
AA	WES PHARMA INC	300MG;15MG	A211610	001	Jun 27, 2019	Jun NEWA

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE					
AA	300MG;30MG	A211610	002	Jun 27, 2019	Jun NEWA
AA	300MG;60MG	A211610	003	Jun 27, 2019	Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
AA	WES PHARMA INC 325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN					
	@ ALVOGEN PINE BROOK 300MG;5MG	A208540	001	Nov 08, 2018	Apr DISC
	@ 300MG;7.5MG	A208540	002	Nov 08, 2018	Apr DISC
	@ 300MG;10MG	A208540	003	Nov 08, 2018	Apr DISC
	@ 325MG;2.5MG	A209958	001	Oct 24, 2018	Apr DISC
	@ 325MG;5MG	A209958	002	Oct 24, 2018	Apr DISC
	@ 325MG;7.5MG	A209958	003	Oct 24, 2018	Apr DISC
	@ 325MG;10MG	A209958	004	Oct 24, 2018	Apr DISC
	@ LANNETT CO INC 300MG;5MG	A207171	001	Jun 20, 2017	Sep DISC
	@ 300MG;7.5MG	A207171	002	Jun 20, 2017	Sep DISC
	@ 300MG;10MG	A207171	003	Jun 20, 2017	Sep DISC
	@ 325MG;5MG	A207172	001	Jun 22, 2017	Sep DISC
	@ 325MG;7.5MG	A207172	002	Jun 22, 2017	Sep DISC
	@ 325MG;10MG	A207172	003	Jun 22, 2017	Sep DISC
	@ UPSHER SMITH LABS 325MG;5MG	A206484	001	Mar 24, 2017	Jan DISC
	@ 325MG;7.5MG	A206484	002	Mar 24, 2017	Jan DISC
	@ 325MG;10MG	A206484	003	Mar 24, 2017	Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN					
	@ MIKART INC 300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018	May DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN					
AA	ANDA REPOSITORY 325MG;5MG	A207834	001	Aug 15, 2019	Sep CAHN
AA	325MG;7.5MG	A207834	002	Aug 15, 2019	Sep CAHN
AA	325MG;10MG	A207834	003	Aug 15, 2019	Sep CAHN
AA	GRANULES PHARMS 325MG;2.5MG	A211708	001	Oct 31, 2019	Oct NEWA
AA	325MG;5MG	A211708	002	Oct 31, 2019	Oct NEWA
AA	325MG;7.5MG	A211708	003	Oct 31, 2019	Oct NEWA
AA	325MG;10MG	A211708	004	Oct 31, 2019	Oct NEWA
AA	HALO PHARM CANADA 325MG;5MG	A207834	001	Aug 15, 2019	Aug NEWA
AA	325MG;7.5MG	A207834	002	Aug 15, 2019	Aug NEWA
AA	325MG;10MG	A207834	003	Aug 15, 2019	Aug NEWA
AA	XIROMED 325MG;5MG	A207574	001	Dec 13, 2016	Aug CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
>D> AB	PAR PHARM 325MG;37.5MG	A076475	001	Apr 21, 2005	Nov DISC
>A>	@ 325MG;37.5MG	A076475	001	Apr 21, 2005	Nov DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE					
	@ ACCORD HLTHCARE 500MG	A207659	001	Oct 18, 2018	Apr DISC
AB	ALEMBIC PHARMS LTD 500MG	A210423	001	Feb 19, 2019	Feb NEWA
AB	CADILA 500MG	A205301	001	Jan 16, 2019	Mar CAHN
AB	HERITAGE PHARMA 500MG	A040904	001	Dec 10, 2008	Jul CAHN
AB	! HERITAGE PHARMS INC 500MG	A090779	001	Jul 14, 2011	Jul CHRS
	@ MYLAN 500MG	A203917	001	Jun 18, 2019	Jul DISC
AB	500MG	A203917	001	Jun 18, 2019	Jun NEWA
DIAMOX					
	+ @ TEVA BRANDED PHARM 500MG	N012945	001		Jul DISC

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM					
AP	ZYDUS PHARMS EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Apr NEWA

TABLET;ORAL

ACETAZOLAMIDE					
AB	EYWA PHARMA 125MG	A211556	001	Oct 18, 2019	Oct NEWA
AB	250MG	A211556	002	Oct 18, 2019	Oct NEWA
AB	NOVITIUM PHARMA 125MG	A210588	001	Oct 17, 2019	Oct NEWA

TABLET;ORAL									
ACETAZOLAMIDE									
AB		250MG		A210588	002	Oct 17, 2019	Oct	NEWA	
	@ SUN PHARM INDUSTRIES	125MG		A089753	002	Jun 22, 1988	Oct	DISC	
<u>ACETAZOLAMIDE SODIUM</u>									
INJECTABLE;INJECTION									
ACETAZOLAMIDE SODIUM									
>D>	AP	EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014	Nov	DISC	
>A>		@	EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014	Nov	DISC	
		@ PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Apr	DISC	
	AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Jun	CAIN	
<u>ACETIC ACID, GLACIAL</u>									
SOLUTION/DROPS;OTIC									
ACETIC ACID									
AT		MLV	2%	A040607	001	Feb 24, 2005	Sep	CAHN	
AT		SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	May	CAHN	
<u>ACETIC ACID, GLACIAL; HYDROCORTISONE</u>									
SOLUTION/DROPS;OTIC									
ACETASOL HC									
	@ ACTAVIS MID ATLANTIC	2%;1%		A087143	001	Jan 13, 1982	Jun	DISC	
<u>ACETYLCYSTEINE</u>									
INJECTABLE;INTRAVENOUS									
ACETYLCYSTEINE									
	@ MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)		A203624	001	Jun 19, 2015	Mar	DISC	
TABLET, EFFERVESCENT;ORAL									
CETYLEV									
+	@ ARBOR PHARMS LLC	500MG		N207916	001	Jan 29, 2016	Mar	DISC	
+	@	2.5GM		N207916	002	Jan 29, 2016	Mar	DISC	
<u>ACITRETIN</u>									
CAPSULE;ORAL									
SORIATANE									
+	@ STIEFEL LABS INC	17.5MG		N019821	003	Aug 06, 2009	Jan	DISC	
+	@	22.5MG		N019821	004	Aug 06, 2009	Jan	DISC	
<u>ACLIDINIUM BROMIDE</u>									
POWDER, METERED;INHALATION									
TUDORZA PRESSAIR									
+	! CIRCASSIA	0.4MG/INH		N202450	001	Jul 23, 2012	Jun	CAHN	
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE</u>									
POWDER, METERED;INHALATION									
DUAKLIR PRESSAIR									
	ASTRAZENECA PHARMS	0.4MG/INH;0.012MG/INH		N210595	001	Mar 29, 2019	Mar	NEWA	
	CIRCASSIA	0.4MG/INH;0.012MG/INH		N210595	001	Mar 29, 2019	Apr	CAHN	
<u>ACYCLOVIR</u>									
CAPSULE;ORAL									
ACYCLOVIR									
AB		CADILA	200MG	A204313	001	Mar 25, 2016	Aug	CAHN	
AB		KENTON	200MG	A075090	001	Jan 26, 1999	Mar	CAHN	
>D>		ZOVIRAX							
>D>	AB	+ MYLAN	200MG	N018828	001	Jan 25, 1985	Nov	DISC	
>A>		+ @	200MG	N018828	001	Jan 25, 1985	Nov	DISC	
CREAM;TOPICAL									
ACYCLOVIR									
AB		PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan	NFTG	
		ZOVIRAX							
AB	+	! BAUSCH	5%	N021478	001	Dec 30, 2002	Feb	CAHN	
AB	+	! VIB	5%	N021478	001	Dec 30, 2002	Jan	CFTG	
OINTMENT;OPHTHALMIC									
AVACLYR									
+	@ FERA PHARMS LLC	3%		N202408	001	Mar 29, 2019	Aug	DISC	
+	!	3%		N202408	001	Mar 29, 2019	Mar	NEWA	
OINTMENT;TOPICAL									
ACYCLOVIR									
AB		APOTEX	5%	A210774	001	Sep 06, 2019	Aug	NEWA	

OINTMENT; TOPICAL

ACYCLOVIR

AB	CADILA	5%	A205974	001	Mar 15, 2019	Oct CAHN
AB	CIPLA	5%	A211794	001	Jan 18, 2019	Jan NEWA
AB	GLENMARK PHARMS SA	5%	A205510	001	Jul 31, 2017	Jun CAHN
	@ PERRIGO UK FINCO	5%	A205659	001	Feb 20, 2019	Aug DISC
AB		5%	A205659	001	Feb 20, 2019	Feb NEWA
AB	ZYDUS PHARMS	5%	A205974	001	Mar 15, 2019	Mar NEWA

ZOVIRAX

AB	+! BAUSCH	5%	N018604	001	Mar 29, 1982	Feb CAHN
----	-----------	----	---------	-----	--------------	----------

TABLET; ORAL

ACYCLOVIR

AB	SQUARE PHARMS LTD	400MG	A209366	001	Oct 07, 2019	Sep NEWA
AB		800MG	A209366	002	Oct 07, 2019	Sep NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

!	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Jan CHRS
!		EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Jan CHRS

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009	Feb CAHN
----	--------	-------	---------	-----	--------------	----------

ADAPALENE

GEL; TOPICAL

ADAPALENE

AB	P AND L	0.1%	A090962	001	Jun 02, 2010	Jul CAHN
----	---------	------	---------	-----	--------------	----------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB	GLENMARK PHARMS LTD	0.1%;2.5%	A208108	001	Nov 08, 2019	Oct NEWA
AB	PERRIGO UK FINCO	0.1%;2.5%	A205033	001	Jan 23, 2018	May CAHN
	@ TARO	0.3%;2.5%	A209148	001	Oct 17, 2018	May DISC

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@	LUITPOLD	3MG/ML	A090010	001	Apr 28, 2009	Mar DISC
---	----------	--------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS

ADENOSINE

>D>	AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Nov DISC
>D>		@	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Nov DISC
>D>	AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Nov DISC
>A>		@	90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Nov DISC

AFAMELANOTIDE

IMPLANT; SUBCUTANEOUS

SCENESSE

+!	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019	Oct NEWA
----	--------------	------	---------	-----	--------------	----------

>A> AIR POLYMER-TYPE A

>A> FOAM; INTRAUTERINE

>A> EXEM FOAM KIT

>A>	+!	GISKIT	10ML	N212279	001	Nov 07, 2019	Nov NEWA
-----	----	--------	------	---------	-----	--------------	----------

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB	ACTAVIS ELIZABETH	200MG	A208094	001	May 20, 2019	May NEWA
AB	EDENBRIDGE PHARMS	200MG	A211117	001	May 14, 2019	Apr NEWA
AB	STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018	Aug CAHN

ALBUTEROL SULFATEPOWDER, METERED; INHALATION
PROAIR DIGIHALER

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jan NEWA
---	--------------------	--------------------	---------	-----	--------------	----------

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Jan CPOT
---	--------------------	--------------------	---------	-----	--------------	----------

SYRUP; ORAL

ALBUTEROL SULFATE

>A>	AA	COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Nov CAHN
-----	----	---------	-----------------	---------	-----	--------------	----------

>D>	AA	G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Nov CAHN
-----	----	------------------	-----------------	---------	-----	--------------	----------

AA	QUAGEN	EQ 2MG BASE/5ML	A212197	001	Sep 06, 2019	Aug NEWA
----	--------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Mar NEWA
----	--------	-------------	---------	-----	--------------	----------

AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Mar NEWA
----	--	-------------	---------	-----	--------------	----------

AB	APPCO	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb CAHN
----	-------	-------------	---------	-----	--------------	----------

AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb CAHN
----	--	-------------	---------	-----	--------------	----------

AB	ARISE	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep CAHN
----	-------	-------------	---------	-----	--------------	----------

AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep CAHN
----	--	-------------	---------	-----	--------------	----------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

@	MYLAN	EQ 5MG BASE	A076584	001	Aug 04, 2008	Jul DISC
---	-------	-------------	---------	-----	--------------	----------

@		EQ 10MG BASE	A076584	002	Aug 04, 2008	Jul DISC
---	--	--------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT; ORAL
BINOSTO

+	ASCEND THERAPS US	EQ 70MG BASE	N202344	001	Mar 12, 2012	Sep CAHN
---	-------------------	--------------	---------	-----	--------------	----------

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB	@ HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011	Sep DISC
----	-------------------	------	---------	-----	--------------	----------

		10MG	A079056	001	Jul 18, 2011	May CAHN
--	--	------	---------	-----	--------------	----------

	@ MYLAN	10MG	A079014	001	Jul 18, 2011	Oct DISC
--	---------	------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

AB	ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar NFTG
----	---------------	---------------	---------	-----	--------------	----------

AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar NFTG
----	--	---------------	---------	-----	--------------	----------

TEKTURNIA

AB	+	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar CFTG
----	---	--------------	---------------	---------	-----	--------------	----------

AB	+		EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar CFTG
----	---	--	---------------	---------	-----	--------------	----------

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Jul CAHN
---	-----------	--------------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

@	SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007	Oct DISC
---	--------------------	-------	---------	-----	--------------	----------

@		300MG	A078390	002	Aug 30, 2007	Oct DISC
---	--	-------	---------	-----	--------------	----------

AB	UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb NEWA
----	------------------	-------	---------	-----	--------------	----------

AB		300MG	A211820	002	Mar 12, 2019	Feb NEWA
----	--	-------	---------	-----	--------------	----------

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+	@ IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Apr DISC
---	-----------------------	--------------	---------	-----	--------------	----------

+	@	300MG; 200MG	N209203	002	Aug 18, 2017	Apr DISC
---	---	--------------	---------	-----	--------------	----------

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	!	AJANTA PHARMA LTD	EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Sep CHRS
----	---	-------------------	----------------	---------	-----	--------------	----------

AXERT

+	@	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Sep DISC
---	---	----------------	----------------	---------	-----	--------------	----------

+	@		EQ 12.5MG BASE	N021001	002	May 07, 2001	Sep DISC
---	---	--	----------------	---------	-----	--------------	----------

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep NEWA
AB		EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep NEWA

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019	May NEWA
+		150MG	N212526	002	May 24, 2019	May NEWA
+	!	200MG	N212526	003	May 24, 2019	May NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jul CAHN
+	!	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163	002	Jun 16, 2003	Sep CMS1

ALTRETAMINE

CAPSULE; ORAL

HEXALEN

+	@ EISAI INC	50MG	N019926	001	Dec 26, 1990	Feb DISC
---	-------------	------	---------	-----	--------------	----------

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	INVAGEN PHARMS	100MG	A207570	001	Sep 30, 2016	Sep CAHN
AB	UPSHER SMITH LABS	100MG	A070589	001	Aug 05, 1986	Jul CAHN

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

AB	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Sep CAHN
AB	! UPSHER SMITH LABS	100MG	A076186	001	Dec 16, 2002	Jul CAHN

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

AB	CIPLA	5MG	A210715	001	Apr 26, 2019	Apr NEWA
AB		10MG	A210715	002	Apr 26, 2019	Apr NEWA
AB	MYLAN	5MG	A208441	001	Mar 28, 2019	Mar NFTG
AB		10MG	A208441	002	Mar 28, 2019	Mar NFTG
AB	PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Mar NEWA
AB		10MG	A209509	002	Apr 10, 2019	Mar NEWA
AB	SIGMAPHARM LABS LLC	5MG	A208354	001	Apr 10, 2019	Mar NEWA
AB		10MG	A208354	002	Apr 10, 2019	Mar NEWA
AB	SUN PHARM	5MG	A210784	001	Mar 28, 2019	Mar NFTG
AB		10MG	A210784	002	Mar 28, 2019	Mar NFTG
AB	WATSON LABS INC	5MG	A208252	001	Mar 28, 2019	Mar NFTG
AB		10MG	A208252	002	Mar 28, 2019	Mar NFTG
AB	ZYDUS PHARMS	5MG	A210058	001	Mar 28, 2019	Mar NFTG
AB		10MG	A210058	002	Mar 28, 2019	Mar NFTG
	LETAIRIS					
AB	+ GILEAD	5MG	N022081	001	Jun 15, 2007	Mar CFTG
AB	+	10MG	N022081	002	Jun 15, 2007	Mar CFTG

AMIFAMPRIDINE

TABLET; ORAL

RUZURGI

+	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019	May NEWA
---	----------------------	------	---------	-----	--------------	----------

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

@ TEVA PHARMS USA

EQ 250MG BASE/ML

A064045 002 Sep 28, 1993 Sep DISC

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB WINDLAS HLTHCARE

5MG

A204180 001 Aug 07, 2015 Feb CAHN

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 10%

@ ICU MEDICAL INC

10% (10GM/100ML)

N017673 003

Jul DISC

AMINOSYN 8.5%

@ ICU MEDICAL INC

8.5% (8.5GM/100ML)

N017673 004

Jul DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

@ ICU MEDICAL INC

3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML

N017789 003

Jul DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

@ ICU MEDICAL INC

8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML

N017673 009 Oct 25, 2002

Jul DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMICAR

AA +! CLOVER PHARMS

1.25GM/5ML

N015230 002

Aug CTEC

AMINOCAPROIC ACID

AA AMNEAL PHARMS LLC

1.25GM/5ML

A212780 001 Aug 23, 2019

Aug NEWA

TABLET;ORAL

AMICAR

AB + CLOVER PHARMS

1GM

N015197 002 Jun 24, 2004

Feb CHRS

AMINOCAPROIC ACID

>A> AB AMNEAL PHARMS CO

500MG

A212492 001 Nov 26, 2019

Nov NEWA

AB ! SUNNY PHARMTECH INC

1GM

A209060 002 Nov 27, 2018

Feb CHRS

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

! HOSPIRA

25MG/ML

A087242 001 Oct 26, 1983

Feb CTEC

@ LUITPOLD

25MG/ML

A087600 001

Feb DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

@ DR REDDYS

50MG/ML

A076163 001 Sep 05, 2003 May CAHN

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB RUBICON

200MG

A078578 001 Nov 06, 2008 Jul CAHN

AMLODIPINE BENZOATE

>D> SOLUTION;ORAL

>D> KATERZIA

>D> +! SILVERGATE PHARMS

EQ 1MG BASE/ML

N211340 001 Jul 08, 2019

Nov CDFFR

+! EQ 1MG BASE/ML

N211340 001 Jul 08, 2019

Jul NEWA

>A> SUSPENSION;ORAL

>A> KATERZIA

>A> +! SILVERGATE PHARMS

EQ 1MG BASE/ML

N211340 001 Jul 08, 2019

Nov CDFFR

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr CAHN
	@ SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Oct DISC
	@	EQ 5MG BASE	A078231	002	Nov 30, 2007	Oct DISC
	@	EQ 10MG BASE	A078231	003	Nov 30, 2007	Oct DISC
	@ TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Oct DISC
	@	EQ 5MG BASE	A076846	002	Jun 28, 2007	Oct DISC
	@	EQ 10MG BASE	A076846	003	Jun 28, 2007	Oct DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

>A> AB	APOTEX	EQ 5MG BASE;EQ 10MG BASE	A205199	001	Nov 18, 2019	Nov NEWA
>A> AB		EQ 5MG BASE;EQ 20MG BASE	A205199	002	Nov 18, 2019	Nov NEWA
>A> AB		EQ 5MG BASE;EQ 40MG BASE	A205199	003	Nov 18, 2019	Nov NEWA
>A> AB		EQ 5MG BASE;EQ 80MG BASE	A205199	004	Nov 18, 2019	Nov NEWA
>A> AB		EQ 10MG BASE;EQ 10MG BASE	A205199	005	Nov 18, 2019	Nov NEWA
>A> AB		EQ 10MG BASE;EQ 20MG BASE	A205199	006	Nov 18, 2019	Nov NEWA
>A> AB		EQ 10MG BASE;EQ 40MG BASE	A205199	007	Nov 18, 2019	Nov NEWA
>A> AB		EQ 10MG BASE;EQ 80MG BASE	A205199	008	Nov 18, 2019	Nov NEWA
	@ ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun DISC
	@	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun DISC
	@	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun DISC
	@	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun DISC
	@	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun DISC
	@	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun DISC
	@	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun DISC
	@	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun DISC
	@	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun DISC
	@	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun DISC
	@	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@ CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	May DISC
@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	May DISC
@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	May DISC
@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	May DISC
@ MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Feb DISC
@	EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Feb DISC
@	EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Feb DISC
@	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Feb DISC
@	EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb DISC
@	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb DISC
@ TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007	Jun DISC
@	EQ 5MG BASE;10MG	A077179	002	May 18, 2007	Jun DISC
@	EQ 5MG BASE;20MG	A077179	003	May 18, 2007	Jun DISC
@	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun DISC
@	EQ 10MG BASE;20MG	A077179	004	May 18, 2007	Jun DISC
@	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun DISC

AMLODIPINE BESYLATE; CELECOXIB

TABLET; ORAL

CONSENSI

+ COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Mar CAHN
+	EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Mar CAHN
+	EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Mar CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

@ TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul DISC
@	EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul DISC
@	EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul DISC
@	EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul DISC
@	EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

	@	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul	DISC
	@		5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul	DISC
	@		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul	DISC
	@		10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul	DISC
	@		10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul	DISC
>D> AB		TORRENT	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Nov	DISC
>A>	@		5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Nov	DISC
>D> AB			5MG;25MG;160MG	A201593	002	Jun 03, 2015	Nov	DISC
>A>	@		5MG;25MG;160MG	A201593	002	Jun 03, 2015	Nov	DISC
>D> AB			10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Nov	DISC
>A>	@		10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Nov	DISC
>D> AB			10MG;25MG;160MG	A201593	004	Jun 03, 2015	Nov	DISC
>A>	@		10MG;25MG;160MG	A201593	004	Jun 03, 2015	Nov	DISC
>D> AB			10MG;25MG;320MG	A201593	005	Jun 03, 2015	Nov	DISC
>A>	@		10MG;25MG;320MG	A201593	005	Jun 03, 2015	Nov	DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar	DISC
@		EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar	DISC
@		EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar	DISC
@		EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar	DISC
@	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun	DISC
@		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun	DISC
@		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun	DISC
@		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr	CAHN
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr	CAHN
+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr	CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

	@	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul	DISC
	@		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul	DISC
	@		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul	DISC
	@		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul	DISC
>D> AB		TORRENT	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Nov	DISC
>A>	@		EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Nov	DISC
>D> AB			EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Nov	DISC
>A>	@		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Nov	DISC
>D> AB			EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Nov	DISC
>A>	@		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Nov	DISC
>D> AB			EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Nov	DISC
>A>	@		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Nov	DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr	CAHN
AP	UNIV TX SW MEDCTR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A209507	001	Nov 01, 2019	Oct	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	May	CAHN
----	---	----------------	-------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075570	001	Jun 23, 2004	May	CAHN
----	---	----------------	-------------	---------	-----	--------------	-----	------

AMOXICILLINFOR SUSPENSION; ORAL
AMOXICILLIN

@ TEVA 125MG/5ML A061931 001 Jun DISC

AMOXICILLIN; CLAVULANATE POTASSIUMFOR SUSPENSION; ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUMAB AUROBINDO PHARMA LTD 125MG/5ML; EQ 31.25MG BASE/5ML A209371 001 Apr 19, 2019 Apr NFTG
AB 250MG/5ML; EQ 62.5MG BASE/5ML A209371 002 Apr 19, 2019 Apr NEWA

AUGMENTIN '125'

AB + NEOPHARMA 125MG/5ML; EQ 31.25MG BASE/5ML N050575 001 Aug 06, 1984 Apr CFTG
TABLET; ORAL

AUGMENTIN '875'

AB + NEOPHARMA 875MG; EQ 125MG BASE N050720 001 Feb 13, 1996 Feb CAHN

>A> AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

>A> CAPSULE, DELAYED RELEASE; ORAL

>A> TALICIA

>A> +! REDHILL 250MG; EQ 10MG BASE; 12.5MG N213004 001 Nov 01, 2019 Nov NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

>D> DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE

>D> AB	PAR PHARM INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	Nov CTNA
AB		1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	May NEWA
>D> AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	Nov CTNA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	May NEWA
>D> AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	Nov CTNA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	May NEWA
>D> AB		5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	Nov CTNA
AB		5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	May NEWA
>D> AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	Nov CTNA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	May NEWA
>D> AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	Nov CTNA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	May NEWA

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	AMERIGEN PHARMS LTD	1.25MG; 1.25MG; 1.25MG; 1.25MG	A205401	001	Jan 22, 2019	Jan NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Jan NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019	Jan NEWA
AB		5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019	Jan NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019	Jan NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019	Jan NEWA
AB	NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210080	001	Jul 17, 2019	Jul NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210080	002	Jul 17, 2019	Jul NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210080	003	Jul 17, 2019	Jul NEWA
AB		5MG; 5MG; 5MG; 5MG	A210080	004	Jul 17, 2019	Jul NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210080	005	Jul 17, 2019	Jul NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210080	006	Jul 17, 2019	Jul NEWA
>A> AB	PAR PHARM INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	Nov CTNA
>A> AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	Nov CTNA
>A> AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	Nov CTNA
>A> AB		5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	Nov CTNA
>A> AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	Nov CTNA
>A> AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	Nov CTNA
AB	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	May NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	May NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	May NEWA
AB		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	May NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	May NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	May NEWA
AB	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Apr NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Apr NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Apr NEWA
AB		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Apr NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Apr NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Apr NEWA
>D> AB	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Nov DISC
>A> @		1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Nov DISC
AB		1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	May NEWA
>D> AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Nov DISC
>A> @		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Nov DISC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	May NEWA
>D>	AB	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Nov DISC
>A>	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Nov DISC
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	May NEWA
>D>	AB	5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Nov DISC
>A>	@	5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Nov DISC
AB		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	May NEWA
>D>	AB	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Nov DISC
>A>	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Nov DISC
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	May NEWA
>D>	AB	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Nov DISC
>A>	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Nov DISC
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	May NEWA
>A>	AB	SUNGEN PHARMA 1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	Nov NEWA
>A>	AB	2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	Nov NEWA
>A>	AB	3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	Nov NEWA
>A>	AB	5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	Nov NEWA
>A>	AB	6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	Nov NEWA
>A>	AB	7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	Nov NEWA

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr NEWA
AA		10MG	A211639	002	Apr 17, 2019	Apr NEWA
>A>	AA	BIONPHARMA INC 5MG	A212919	001	Nov 22, 2019	Nov NEWA
>A>	AA	10MG	A212919	002	Nov 22, 2019	Nov NEWA
AA	GRANULES PHARMS	5MG	A212619	001	Aug 05, 2019	Jul NEWA
AA		10MG	A212619	002	Aug 05, 2019	Jul NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan NEWA
+		10MG	N209905	002	Jan 30, 2019	Jan NEWA
+		15MG	N209905	003	Jan 30, 2019	Jan NEWA
+		20MG	N209905	004	Jan 30, 2019	Jan NEWA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

@	HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Oct DISC
@		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Oct DISC
@		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Oct DISC
@		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Oct DISC
@		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Sep DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

@	HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011	Sep DISC
@		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011	Sep DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011	Sep DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011	Sep DISC
@		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011	Sep DISC
@	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

@	HERITAGE PHARMA	EQ 250MG BASE	A061502	001		May CAHN
@		EQ 500MG BASE	A061502	002		May CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB	FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb CAHN
AB	KENTON	1MG	A078944	001	Jun 28, 2010	Mar CAHN

APREPITANTCAPSULE; ORAL
EMEND

+ @ MERCK 40MG N021549 003 Jun 30, 2006 Oct DISC

ARIPIPIRAZOLESOLUTION; ORAL
ARIPIPIRAZOLE

AA AUROBINDO PHARMA LTD 1MG/ML A210479 001 Jan 29, 2019 Jan NEWA

TABLET; ORAL

ARIPIPIRAZOLE

AB ALKEM LABS LTD 2MG A207105 001 Feb 21, 2019 Feb NEWA

AB 5MG A207105 002 Feb 21, 2019 Feb NEWA

AB 10MG A207105 003 Feb 21, 2019 Feb NEWA

AB 15MG A207105 004 Feb 21, 2019 Feb NEWA

AB 20MG A207105 005 Feb 21, 2019 Feb NEWA

AB 30MG A207105 006 Feb 21, 2019 Feb NEWA

@ TEVA PHARMS USA 2MG A078607 001 Apr 28, 2015 Jun DISC

@ 5MG A078607 002 Apr 28, 2015 Jun DISC

@ 10MG A078608 001 Apr 28, 2015 May DISC

@ 15MG A078708 001 Apr 28, 2015 May DISC

@ 20MG A078708 002 Apr 28, 2015 May DISC

@ 30MG A078708 003 Apr 28, 2015 May DISC

@ ZYDUS PHARMS 2MG A090472 001 Jan 07, 2019 Jun DISC

@ 5MG A090472 002 Jan 07, 2019 Jun DISC

@ 10MG A090472 003 Jan 07, 2019 Jun DISC

@ 15MG A090472 004 Jan 07, 2019 Jun DISC

@ 20MG A090472 005 Jan 07, 2019 Jun DISC

@ 30MG A090472 006 Jan 07, 2019 Jun DISC

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB @ APOTEX INC 50MG A201514 001 Mar 25, 2019 Sep DISC

AB 50MG A201514 001 Mar 25, 2019 Mar NEWA

AB @ 150MG A201514 002 Mar 25, 2019 Sep DISC

AB 150MG A201514 002 Mar 25, 2019 Mar NEWA

AB @ 250MG A201514 003 Mar 25, 2019 Sep DISC

AB 250MG A201514 003 Mar 25, 2019 Mar NEWA

AB AUROBINDO PHARMA LTD 200MG A206069 004 Dec 07, 2018 Mar NEWA

AB MYLAN PHARMS INC 100MG A200043 004 May 09, 2019 Apr NEWA

AB 200MG A200043 005 May 09, 2019 Apr NEWA

AB NATCO PHARMA LTD 100MG A202768 004 Sep 28, 2017 Apr CTEC

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

AP STI PHARMA LLC 1MG/ML A209873 001 May 06, 2019 Apr NEWA

AP ZYDUS PHARMS 2MG/ML A206228 002 Aug 30, 2019 Aug NFTG

TRISENOX

AP +! CEPHALON 2MG/ML N021248 002 Oct 13, 2017 Aug CFTG

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC

+! SANDOZ CANADA INC 80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL N021265 001 Feb 21, 2001 Jul CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+! SANDOZ CANADA INC 80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL N021265 002 Jan 29, 2004 Sep CMS1

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATEFOR SOLUTION;ORAL
MOVIPREP

>D>	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	N021881	001	Aug 02, 2006	Nov CTEC
>A>	AA	+	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	N021881	001	Aug 02, 2006	Nov CTEC
>D>		PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID @ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A090145	001	Jan 25, 2012	Nov CMFD
>A>	AA		4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A090145	001	Jan 25, 2012	Nov CMFD

ASENAPINESYSTEM;TRANSDERMAL
SECUADO

+	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Oct NEWA
+		5.7MG/24HR	N212268	002	Oct 11, 2019	Oct NEWA
+	!	7.6MG/24HR	N212268	003	Oct 11, 2019	Oct NEWA

ASENAPINE MALEATETABLET;SUBLINGUAL
SAPHRIS

+	ALLERGAN	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Oct CAHN
+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Oct CAHN
+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Oct CAHN
+	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb CTEC
+	!	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		BRECKENRIDGE	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Aug CAHN
----	--	--------------	-----------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	!	SANDOZ	770MG;60MG;50MG	A074654	002	Dec 31, 1996	May CTEC
AB		ORPHENGESIC FORTE					
AB		GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	May CMFD

ASPIRIN; DIPYRIDAMOLECAPSULE, EXTENDED RELEASE;ORAL
ASPIRIN AND DIPYRIDAMOLE

AB		GLENMARK PHARMS LTD	25MG;200MG	A210318	001	May 24, 2019	May NEWA
AB		GLENMARK PHARMS SA	25MG;200MG	A210318	001	May 24, 2019	Jun CAHN
AB		LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Mar NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		HLTHCARE	25MG	A074052	001	May 01, 1992	Sep CAHN
AB			50MG	A073025	001	Sep 17, 1991	Sep CAHN
AB			100MG	A073026	001	Sep 17, 1991	Sep CAHN
		@ SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007	Oct DISC
		@	50MG	A078210	002	Jul 10, 2007	Oct DISC
		@	100MG	A078210	003	Jul 10, 2007	Oct DISC
		@ SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997	Oct DISC
		@	50MG	A073475	001	Mar 30, 1993	Oct DISC
		@	100MG	A073476	001	Mar 30, 1993	Oct DISC
>A>	AB	UNICHEM LABS LTD	25MG	A213136	001	Nov 21, 2019	Nov NEWA
>A>	AB		50MG	A213136	002	Nov 21, 2019	Nov NEWA
>A>	AB		100MG	A213136	003	Nov 21, 2019	Nov NEWA

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

		@ SUN PHARM INDUSTRIES	50MG;25MG	A073582	002	Apr 29, 1993	Oct DISC
		@	100MG;25MG	A073582	001	Apr 29, 1993	Oct DISC
AB		ZYDUS PHARMS	50MG;25MG	A210028	001	Mar 08, 2019	Feb NEWA
AB			100MG;25MG	A210028	002	Mar 08, 2019	Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar	CMFD
AB		25MG	A079017	002	Sep 17, 2010	Mar	CMFD
AB		40MG	A079017	003	Sep 17, 2010	Mar	CMFD
AB		60MG	A079017	004	Sep 17, 2010	Mar	CMFD
AB		80MG	A079017	005	Sep 17, 2010	Mar	CMFD
AB		100MG	A079017	006	Sep 17, 2010	Mar	CMFD

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

	@ LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Oct	DISC
AB		EQ 10MG BASE	A204991	001	Mar 06, 2019	Feb	NEWA
	@	EQ 20MG BASE	A204991	002	Mar 06, 2019	Oct	DISC
AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Feb	NEWA
	@	EQ 40MG BASE	A204991	003	Mar 06, 2019	Oct	DISC
AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Feb	NEWA
	@	EQ 80MG BASE	A204991	004	Mar 06, 2019	Oct	DISC
AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Feb	NEWA
AB	MICRO LABS LTD INDIA	EQ 10MG BASE	A205945	001	Nov 07, 2019	Oct	NEWA
AB		EQ 20MG BASE	A205945	002	Nov 07, 2019	Oct	NEWA
AB		EQ 40MG BASE	A205945	003	Nov 07, 2019	Oct	NEWA
AB		EQ 80MG BASE	A205945	004	Nov 07, 2019	Oct	NEWA
AB	MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb	NEWA
AB		EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb	NEWA
AB		EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb	NEWA
AB		EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb	NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	ABHAI LLC	750MG/5ML	A210510	001	May 31, 2019	May	NEWA
----	-----------	-----------	---------	-----	--------------	-----	------

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

>D>	AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Nov	CAHN
	AP		10MG/ML	A091489	001	Feb 17, 2012	Feb	CAHN
>A>	AP	MEITHEAL	10MG/ML	A091489	001	Feb 17, 2012	Nov	CAHN
		@ MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Sep	DISC
		ATRACURIUM BESYLATE PRESERVATIVE FREE						
>D>	AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Nov	CAHN
	AP		10MG/ML	A091488	001	Feb 17, 2012	Feb	CAHN
>A>	AP	MEITHEAL	10MG/ML	A091488	001	Feb 17, 2012	Nov	CAHN
		@ MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Sep	DISC

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar	CPOT
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar	CPOT
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar	CPOT
+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar	CPOT
		ATROPINE						
		@ ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar	CDFR

ATROPINE SULFATE

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May	CDFR
---	---	--------------------	---------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

	@ LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Sep	DISC
AP		100MG/VIAL	A210748	001	Feb 27, 2019	Feb	NEWA

AZELAIC ACID

	CREAM; TOPICAL						
	AZELEX						
	+! ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr	CAHN
	GEL; TOPICAL						
	AZELAIC ACID						
AB	TARO	15%	A210549	001	Aug 23, 2019	Aug	NEWA

AZELASTINE HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC						
	AZELASTINE HYDROCHLORIDE						
AT	ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar	NEWA
AT	SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar	NEWA
	SPRAY, METERED; NASAL						
	AZELASTINE HYDROCHLORIDE						
AB	HI TECH	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	May	NEWA
AB		EQ 0.1876MG BASE/SPRAY	A210032	001	Aug 23, 2019	Aug	NEWA

AZITHROMYCIN

	FOR SUSPENSION; ORAL						
	AZITHROMYCIN						
>A> AB	TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Nov	NEWA
	TABLET; ORAL						
	AZITHROMYCIN						
AB	BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb	NEWA
AB		EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb	NEWA
AB	CSPC OUYI	EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr	NEWA
AB	! PLIVA	EQ 600MG BASE	A065218	001	Nov 14, 2005	Jul	CHRS
	@ TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005	Jul	DISC
	@	EQ 600MG BASE	A065150	001	Nov 14, 2005	Jul	DISC

AZTREONAM

	INJECTABLE; INJECTION						
	AZACTAM IN PLASTIC CONTAINER						
	+ @ BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989	Jul	DISC
	+ @	40MG/ML	N050632	001	May 24, 1989	Jul	DISC

BACLOFEN

	INJECTABLE; INTRATHECAL						
	BACLOFEN						
AP	MAIA PHARMS INC	0.5MG/ML	A210048	001	Sep 11, 2019	Aug	NEWA
AP		1MG/ML	A210315	001	Jul 30, 2019	Jul	NEWA
AP		2MG/ML	A210048	002	Sep 11, 2019	Aug	NEWA
	GABLOFEN						
AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Aug	CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	Aug	CAHN
AP	+!	1MG/ML	N022462	004	Jun 22, 2012	Aug	CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	Aug	CAHN
	SOLUTION; ORAL						
	OZOBAX						
	+! METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019	Sep	NEWA
	TABLET; ORAL						
	BACLOFEN						
AB	EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan	NEWA
AB		20MG	A211555	002	Feb 01, 2019	Jan	NEWA
	@ SUN PHARM INDS INC	10MG	A077862	001	Aug 14, 2006	Oct	DISC
	@	20MG	A077862	002	Aug 14, 2006	Oct	DISC
AB	UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996	Jul	CAHN
AB		20MG	A074584	002	Aug 19, 1996	Jul	CAHN

BALSALAZIDE DISODIUM

	CAPSULE; ORAL						
	BALSALAZIDE DISODIUM						
	@ MYLAN	750MG	A077807	001	Dec 28, 2007	Feb	DISC
	TABLET; ORAL						
	BALSALAZIDE DISODIUM						
	@ PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Apr	DISC
	GIAZO						
	+ @ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Apr	DISC

BARICITINIBTABLET; ORAL
OLUMIANT

+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Oct	NEWA
---	------------------	-----	---------	-----	--------------	-----	------

BARIUM SULFATEFOR SUSPENSION; ORAL
VARIBAR THIN LIQUID

+	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019	May	NEWA
---	--------	-----------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL
READI-CAT 2 SMOOTHIE

+	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Sep	CMS1
---	--------	--------------	---------	-----	--------------	-----	------

BELINOSTATPOWDER; INTRAVENOUS
BELEODAQ

+	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014	Mar	CAHN
---	----------	------------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ HERITAGE PHARMA

5MG

A076267	001	Feb 11, 2004	Feb	CAHN
---------	-----	--------------	-----	------

@

10MG

A076267	002	Feb 11, 2004	Feb	CAHN
---------	-----	--------------	-----	------

@

20MG

A076267	003	Feb 11, 2004	Feb	CAHN
---------	-----	--------------	-----	------

@

40MG

A076267	004	Feb 11, 2004	Feb	CAHN
---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC

5MG; 6.25MG

A076342	001	Feb 11, 2004	May	CAHN
---------	-----	--------------	-----	------

@

10MG; 12.5MG

A076342	002	Feb 11, 2004	May	CAHN
---------	-----	--------------	-----	------

@

20MG; 12.5MG

A076342	003	Feb 11, 2004	May	CAHN
---------	-----	--------------	-----	------

@

20MG; 25MG

A076342	004	Feb 11, 2004	May	CAHN
---------	-----	--------------	-----	------

BENDAMUSTINE HYDROCHLORIDEPOWDER; IV (INFUSION)
TREANDA

+	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb	CTEC
---	----------	-----------	---------	-----	--------------	-----	------

+		100MG/VIAL	N022249	001	Mar 20, 2008	Feb	CTEC
---	--	------------	---------	-----	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA ASCENT PHARMS INC

100MG

A211518	001	Feb 22, 2019	Feb	NEWA
---------	-----	--------------	-----	------

AA

150MG

A211518	002	Feb 22, 2019	Feb	NEWA
---------	-----	--------------	-----	------

AA

200MG

A211518	003	Feb 22, 2019	Feb	NEWA
---------	-----	--------------	-----	------

AA CSPC OUYI

100MG

A202765	002	Aug 25, 2017	Feb	CAHN
---------	-----	--------------	-----	------

AA

200MG

A202765	001	Jul 31, 2015	Feb	CAHN
---------	-----	--------------	-----	------

AA QINGDAO BAHEAL PHARM

100MG

A210562	001	Nov 09, 2018	May	CAHN
---------	-----	--------------	-----	------

AA

150MG

A210562	002	Nov 09, 2018	May	CAHN
---------	-----	--------------	-----	------

AA

200MG

A210562	003	Nov 09, 2018	May	CAHN
---------	-----	--------------	-----	------

@ SUN PHARM INDS INC

100MG

A040587	001	Mar 19, 2008	Oct	DISC
---------	-----	--------------	-----	------

@

200MG

A040587	002	Mar 19, 2008	Oct	DISC
---------	-----	--------------	-----	------

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

AB +! BAUSCH

2.5%; EQ 1.2% BASE

N050819	001	Oct 23, 2008	Aug	CAHN
---------	-----	--------------	-----	------

BENZACLIN

AB +! BAUSCH

5%; EQ 1% BASE

N050756	001	Dec 21, 2000	Aug	CAHN
---------	-----	--------------	-----	------

@

5%; EQ 1% BASE

N050756	002	Apr 20, 2007	Aug	CAHN
---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

@ ANDA REPOSITORY

2.5%; EQ 1.2% BASE

A207194	001	Aug 19, 2019	Oct	DISC
---------	-----	--------------	-----	------

AB

2.5%; EQ 1.2% BASE

A207194	001	Aug 19, 2019	Aug	NEWA
---------	-----	--------------	-----	------

AB

GLENMARK PHARMS

5%; EQ 1% BASE

A209252	001	Mar 14, 2019	Jun	CMS1
---------	-----	--------------	-----	------

AB

5%; 1% BASE

A209252	001	Mar 14, 2019	Mar	NEWA
---------	-----	--------------	-----	------

AB

PERRIGO ISRAEL

2.5%; EQ 1.2% BASE

A205397	001	Sep 09, 2019	Aug	NEWA
---------	-----	--------------	-----	------

AB

PERRIGO UK FINCO

5%; EQ 1% BASE

A202440	001	Sep 21, 2015	May	CAHN
---------	-----	--------------	-----	------

AB

TARO

2.5%; EQ 1.2% BASE

A206575	001	Aug 19, 2019	Aug	NEWA
---------	-----	--------------	-----	------

@

3.75%; EQ 1.2% BASE

A208683	001	Jun 05, 2018	May	DISC
---------	-----	--------------	-----	------

GEL;TOPICAL								
ONEXTON								
+	BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug	CAHN	
+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May	CTEC	
<u>BENZOYL PEROXIDE; ERYTHROMYCIN</u>								
GEL;TOPICAL								
AKTIPAK								
+	@ BIOFRONTERA	5%;3%	N050769	001	Nov 27, 2000	Aug	DISC	
+	!	5%;3%	N050769	001	Nov 27, 2000	May	CAHN	
<u>BENZTROPINE MESYLATE</u>								
INJECTABLE;INJECTION								
BENZTROPINE MESYLATE								
	@ LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	DISC	
TABLET;ORAL								
BENZTROPINE MESYLATE								
AA	!	ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Apr	CHRS
AA	!		1MG	A204713	002	Apr 14, 2015	Apr	CHRS
AA	!		2MG	A204713	003	Apr 14, 2015	Apr	CHRS
	@	OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	Mar	DISC
	@		1MG	A040706	003	Feb 14, 2008	Mar	DISC
	@	UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Jul	CAHN
	@		1MG	A040103	002	Dec 12, 1996	Jul	CAHN
	@		2MG	A040103	003	Dec 12, 1996	Jul	CAHN
	@	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Apr	DISC
	@		1MG	A040103	002	Dec 12, 1996	Apr	DISC
	@		2MG	A040103	003	Dec 12, 1996	Apr	DISC
<u>BENZYL ALCOHOL</u>								
LOTION;TOPICAL								
ULESFIA								
+	@ SHIONOGI INC	5%	N022129	001	Apr 09, 2009	Sep	DISC	
<u>BEPOTASTINE BESILATE</u>								
SOLUTION/DROPS;OPHTHALMIC								
BEPOTASTINE BESILATE								
	@ APOTEX	1.5%	A206066	001	Mar 05, 2019	Sep	DISC	
AT		APOTEX INC	1.5%	A206066	001	Mar 05, 2019	Feb	NFTG
AT		MICRO LABS	1.5%	A206220	001	Mar 18, 2019	Mar	NEWA
AT		MYLAN	1.5%	A206220	001	Mar 18, 2019	Apr	CAHN
BEPREVE								
AT	+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb	CFTG
<u>BETAMETHASONE DIPROPIONATE</u>								
CREAM, AUGMENTED;TOPICAL								
BETAMETHASONE DIPROPIONATE								
AB		PERRIGO ISRAEL	EQ 0.05% BASE	A076592	001	Dec 09, 2003	May	CAHN
LOTION, AUGMENTED;TOPICAL								
BETAMETHASONE DIPROPIONATE								
AB		HI TECH	EQ 0.05% BASE	A208849	001	Oct 11, 2019	Sep	NEWA
SPRAY;TOPICAL								
SERNIVO								
+	!	ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar	CAHN
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE</u>								
OINTMENT;TOPICAL								
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE								
AB		PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014	Mar	CAIN
AB		PERRIGO UK FINCO	0.064%;0.005%	A200174	001	Dec 12, 2014	May	CAHN
AB		TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Mar	CAIN
TACLONEX								
AB	+	LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Mar	CAIN
SUSPENSION;TOPICAL								
TACLONEX								
+	!	LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Mar	CAIN

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	ANIMA	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Sep CAHN
----	-------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

DUVOID

AA	CHARTWELL RX	10MG	A086262	001		Mar CAHN
AA		25MG	A086263	001		Mar CAHN
AA		50MG	A085882	003		Mar CAHN

BEXAROTENE

GEL; TOPICAL

TARGRETIN

+	BAUSCH	1%	N021056	001	Jun 28, 2000	Jun CAHN
---	--------	----	---------	-----	--------------	----------

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

	@ FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010	Oct DISC
AB		50MG	A079045	001	May 13, 2010	Feb CAHN
AB	KENTON	50MG	A091011	001	Jun 10, 2015	Jun CAHN
	@ TEVA	50MG	A076932	001	Jul 06, 2009	Sep DISC

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Apr NEWA
AT	GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019	Mar NEWA
	@ HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018	Jul DISC
AT	SOMERSET THERAPS LLC	0.03%	A207601	001	Jun 19, 2019	Jun NEWA

>D> BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

>D> CAPSULE; ORAL

>D> PYLERA

>D>	+	ALLERGAN	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Nov CAIN
-----	---	----------	---------------------	---------	-----	--------------	----------

>A> BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

>A> CAPSULE; ORAL

>A> PYLERA

>A>	+	ALLERGAN	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Nov CAIN
-----	---	----------	---------------------	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul CMFD
	@	5MG	A075474	001	Oct 25, 2002	Jan CAHN
AB		10MG	A075474	002	Oct 25, 2002	Jul CMFD
	@	10MG	A075474	002	Oct 25, 2002	Jan CAHN
>D> AB	MYLAN	5MG	A075831	001	Dec 14, 2005	Nov DISC
>A>	@	5MG	A075831	001	Dec 14, 2005	Nov DISC
>D> AB		10MG	A075831	002	Dec 14, 2005	Nov DISC
>A>	@	10MG	A075831	002	Dec 14, 2005	Nov DISC
AB		10MG	A075831	002	Dec 14, 2005	Jul CHRS
AB	! UNICHEM PHARMS (USA)	10MG	A078635	002	Aug 18, 2009	Jul CHRS

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@ MYLAN

2.5MG; 6.25MG

A075768	001	Sep 25, 2000	Jul DISC
---------	-----	--------------	----------

@

5MG; 6.25MG

A075768	002	Sep 25, 2000	Jul DISC
---------	-----	--------------	----------

@

10MG; 6.25MG

A075768	003	Sep 25, 2000	Jul DISC
---------	-----	--------------	----------

BIVALIRUDIN

SOLUTION; INTRAVENOUS

ANGIOMAX RTU

+	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019	Jul NEWA
---	-----------------	---------------------	---------	-----	--------------	----------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Feb	NEWA
>D>	AP	HONG KONG	EQ 15 UNITS BASE/VIAL	A205030	001	Apr 20, 2018	Nov CAHN
>D>	AP		EQ 30 UNITS BASE/VIAL	A205030	002	Apr 20, 2018	Nov CAHN
>A>	AP	MEITHEAL	EQ 15 UNITS BASE/VIAL	A205030	001	Apr 20, 2018	Nov CAHN
>A>	AP		EQ 30 UNITS BASE/VIAL	A205030	002	Apr 20, 2018	Nov CAHN

BORTEZOMIB

POWDER; INTRAVENOUS
BORTEZOMIB

	DR REDDYS LABS LTD	3.5MG/VIAL	N206927	001	Oct 04, 2019	Oct	NEWA
	POWDER; INTRAVENOUS, SUBCUTANEOUS						
	BORTEZOMIB						
	+ @ HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018	Mar	DISC

BOSENTAN

TABLET; ORAL
BOSENTAN

	@ ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019	Oct	DISC
AB		62.5MG	A206002	001	Apr 26, 2019	Apr	NFTG
	@	125MG	A206002	002	Apr 26, 2019	Oct	DISC
AB		125MG	A206002	002	Apr 26, 2019	Apr	NFTG
AB	AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209742	002	Apr 26, 2019	Apr	NFTG
AB	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A206987	002	Apr 26, 2019	Apr	NFTG
AB	PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A205699	002	Apr 26, 2019	Apr	NFTG
AB	SUN PHARM	62.5MG	A209324	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A209324	002	Apr 26, 2019	Apr	NFTG
AB	WATSON LABS INC	62.5MG	A207110	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207110	002	Apr 26, 2019	Apr	NFTG
AB	ZYDUS PHARMS	62.5MG	A207760	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A207760	002	Apr 26, 2019	Apr	NFTG
	TRACLEER						
AB	+ ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Apr	CFTG
AB	+!	125MG	N021290	002	Nov 20, 2001	Apr	CFTG

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS
VYLEESI (AUTOINJECTOR)

	+! AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jun	NEWA
--	--------------------	--	---------	-----	--------------	-----	------

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

!	BAS ANDA	50MG/ML	A204386	001	Dec 21, 2018	Jun	CAHN
!	BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Aug	CAHN

BREXANOLONE

SOLUTION; INTRAVENOUS
ZULRESSO

	+! SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun	NEWA
--	----------------	---------------------	---------	-----	--------------	-----	------

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT	SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb	NEWA
----	----------------------	------	---------	-----	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMFENAC SODIUM

AT2	ALEMBIC PHARMS LTD	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun	NEWA
AT2	! HI TECH	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
>D>	AT2	INNOPHARMA LICENSING	EQ 0.09% ACID	A203368	001	Jun 03, 2019	Nov CAHN
	AT2		EQ 0.09% ACID	A203368	001	Jun 03, 2019	May NEWA
>A>	AT2	MYLAN	EQ 0.09% ACID	A203368	001	Jun 03, 2019	Nov CAHN
>D>	@ PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Nov	CAHN

SOLUTION/DROPS;OPHTHALMIC									
BROMFENAC SODIUM									
>A>	@ VISTAPHARM	EQ 0.09% ACID		A201941	001	Feb 10, 2015	Nov	CAHN	
<u>BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE									
>D> AA	VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML		A202940	001	Jul 21, 2014	Nov	DISC	
>A>	@	2MG/5ML;10MG/5ML;30MG/5ML		A202940	001	Jul 21, 2014	Nov	DISC	
<u>BUDESONIDE</u>									
CAPSULE;ORAL									
BUDESONIDE									
AB	APPCO	3MG		A207367	001	Apr 07, 2017	Feb	CAHN	
CAPSULE, EXTENDED RELEASE;ORAL									
ORTIKOS									
+	SUN PHARMA GLOBAL	6MG		N211929	001	Jun 13, 2019	Jun	NEWA	
+	!	9MG		N211929	002	Jun 13, 2019	Jun	NEWA	
SUSPENSION;INHALATION									
BUDESONIDE									
AN	NEPHRON	0.25MG/2ML		A078202	001	Mar 30, 2009	Sep	CAHN	
AN		0.5MG/2ML		A078202	002	Mar 30, 2009	Sep	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
UCERIS									
AB	+! SALIX	9MG		N203634	001	Jan 14, 2013	Mar	CAHN	
<u>BUMETANIDE</u>									
TABLET;ORAL									
BUMETANIDE									
AB	HERITAGE PHARMA	0.5MG		A074225	001	Apr 24, 1995	Feb	CAHN	
AB		1MG		A074225	002	Apr 24, 1995	Feb	CAHN	
AB		2MG		A074225	003	Apr 24, 1995	Feb	CAHN	
<u>BUPIVACAINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
BUPIVACAINE HYDROCHLORIDE									
	@ MYLAN ASI	0.25%		A091503	001	Oct 18, 2011	Sep	DISC	
	@	0.5%		A091503	002	Oct 18, 2011	Sep	DISC	
	@ NOVOCOL HEALTHCARE	0.5%		A211096	001	Feb 19, 2019	Jun	DISC	
AP		0.5%		A211096	001	Feb 19, 2019	Feb	NEWA	
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE									
	@ MYLAN ASI	0.25%		A091487	002	Oct 18, 2011	Sep	DISC	
	@	0.5%		A091487	001	Oct 18, 2011	Sep	DISC	
	@	0.75%		A091487	003	Oct 18, 2011	Sep	DISC	
INJECTABLE;SPINAL									
BUPIVACAINE HYDROCHLORIDE									
AP	B BRAUN MEDICAL INC	0.75%		A209087	001	Apr 02, 2019	Mar	NEWA	
<u>BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE</u>									
INJECTABLE;INJECTION									
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE									
+	@ HOSPIRA	0.5%;0.0091MG/ML		N022046	001	Jul 13, 1983	Sep	CMS1	
!	SEPTODONT	0.5%;0.0091MG/ML		A077250	001	Sep 27, 2006	Sep	CHRS	
		0.5%;0.0091MG/ML		A077250	001	Sep 27, 2006	Sep	CTEC	
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE									
+	@ HOSPIRA	0.5%;0.0091MG/ML		N022046	001	Jul 13, 1983	Sep	DISC	
<u>BUPRENORPHINE HYDROCHLORIDE</u>									
TABLET;SUBLINGUAL									
BUPRENORPHINE HYDROCHLORIDE									
	@ BARR	EQ 2MG BASE		A090360	001	May 07, 2010	Jul	DISC	
	@	EQ 8MG BASE		A090360	002	May 07, 2010	Jul	DISC	
	@ MYLAN	EQ 2MG BASE		A201066	001	Mar 06, 2015	Sep	DISC	
	@	EQ 8MG BASE		A201066	002	Mar 06, 2015	Sep	DISC	
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE</u>									
FILM;BUCCAL, SUBLINGUAL									
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE									
AB	ALVOGEN PINE BROOK	EQ 2MG BASE;EQ 0.5MG BASE		A205954	001	Jan 24, 2019	Jan	NEWA	
AB		EQ 4MG BASE;EQ 1MG BASE		A205954	002	Jan 24, 2019	Jan	NEWA	
AB		EQ 8MG BASE;EQ 2MG BASE		A205954	003	Jan 24, 2019	Jan	NEWA	

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
AB	EQ 12MG BASE;EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan NEWA
FILM;SUBLINGUAL					
CASSIPA					
+ @ TEVA PHARMS USA					
	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar DISC
TABLET;SUBLINGUAL					
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
@ TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Jan DISC
@	EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Jan DISC

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE						
AB	APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Jun CAHN
AB		100MG	A075584	002	Feb 07, 2000	Jun CAHN
	@ HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999	May CAHN
	@	100MG	A075310	002	Nov 29, 1999	May CAHN
TABLET, EXTENDED RELEASE;ORAL						
BUPROPION HYDROCHLORIDE						
AB2	! ACTAVIS LABS FL INC	150MG	A079094	001	Mar 24, 2009	Jul CHRS
AB3	GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan NEWA
AB3		300MG	A211020	002	Jan 28, 2019	Jan NEWA
AB1	MYLAN	100MG	A090325	001	Apr 08, 2010	Nov DISC
	@	100MG	A090325	001	Apr 08, 2010	Nov DISC
AB1		150MG	A090325	002	Apr 08, 2010	Nov DISC
	@	150MG	A090325	002	Apr 08, 2010	Nov DISC
AB2		150MG	A090941	001	May 03, 2010	Nov DISC
	@	150MG	A090941	001	May 03, 2010	Nov DISC
	@	150MG	A090942	001	Jul 14, 2010	Jul DISC
AB1		200MG	A090325	003	Apr 08, 2010	Nov DISC
	@	200MG	A090325	003	Apr 08, 2010	Nov DISC
	@	300MG	A090942	002	Jul 14, 2010	Oct DISC
	@ SUN PHARM	150MG	A200695	001	Dec 18, 2014	Sep DISC
	@ YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr DISC
	@	150MG	A211347	002	Oct 16, 2018	Apr DISC
	@	200MG	A211347	003	Oct 16, 2018	Apr DISC
AB3	ZHEJIANG JUTAI PHARM	300MG	A211200	001	Sep 05, 2019	Aug NEWA
ZYBAN						
	+ @ GLAXOSMITHKLINE	150MG	N020711	003	May 14, 1997	Jul DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE						
AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr NEWA
AB		7.5MG	A208972	002	Apr 16, 2019	Apr NEWA
AB		10MG	A208972	003	Apr 16, 2019	Apr NEWA
AB		15MG	A208972	004	Apr 16, 2019	Apr NEWA
AB		30MG	A208972	005	Apr 16, 2019	Apr NEWA
	@ RUBICON	5MG	A075521	001	Apr 05, 2002	Aug CAHN
	@	10MG	A075521	002	Apr 05, 2002	Aug CAHN
	@	15MG	A075521	003	Apr 05, 2002	Aug CAHN
AB	UNICHEM LABS LTD	5MG	A210907	001	Nov 14, 2019	Oct NEWA
AB		10MG	A210907	002	Nov 14, 2019	Oct NEWA
AB		15MG	A210907	003	Nov 14, 2019	Oct NEWA
AB		30MG	A210907	004	Nov 14, 2019	Oct NEWA

BUSULFAN

INJECTABLE;INJECTION

	BUSULFAN						
AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA
AP	APOTEX	6MG/ML	A210448	001	May 07, 2019	Apr	NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN
AP	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Sep	CMFD
	@	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr	NEWA
	MYLERAN						
AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jul	CAHN

CABERGOLINETABLET; ORAL
CABERGOLINE

@ ACTAVIS LABS FL INC 0.5MG

A078035 001 Apr 21, 2008 Aug DISC

CAFFEINE CITRATESOLUTION; INTRAVENOUS
CAFCIT

AP +! HIKMA EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 001 Sep 21, 1999 Aug CAHN

SOLUTION; ORAL
CAFCIT

AA +! HIKMA EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 002 Apr 12, 2000 Aug CAHN

CAFFEINE CITRATE

@ LUITPOLD

EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A090064 001 Nov 20, 2009 Mar DISC

CAFFEINE; ERGOTAMINE TARTRATESUPPOSITORY; RECTAL
MIGERGOT

! COSETTE 100MG; 2MG

A086557 001 Oct 04, 1983 Jul CAHN

CALCITONIN SALMONINJECTABLE; INJECTION
MIACALCIN

+ @ MYLAN IRELAND LTD 100 IU/ML

N017808 001 Jul 03, 1986 Aug CRLD

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

@ SUN PHARM

0.25MCG

A204556 001 Feb 21, 2019 Jul DISC

AB 0.25MCG

A204556 001 Feb 21, 2019 Feb NEWA

@

0.5MCG

A204556 002 Feb 21, 2019 Jul DISC

AB 0.5MCG

A204556 002 Feb 21, 2019 Feb NEWA

SOLUTION; ORAL
CALCITRIOL

ELYSIUM

1MCG/ML

A209798 001 Nov 21, 2018 Sep CAHN

CALCIUM ACETATETABLET; ORAL
CALCIUM ACETATE

AB CHARTWELL MOLECULAR 667MG

A202420 001 Feb 05, 2013 Jan CAHN

CALCIUM CHLORIDEINJECTABLE; INJECTION
CALCIUM CHLORIDE 10%

AP MEDEFIL INC 100MG/ML

A211553 001 May 01, 2019 Apr NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT + BAXTER HLTHCARE 18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 001 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT + BAXTER HLTHCARE 18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 002 Dec 04, 1992 Aug CTEC

+ 18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 002 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE 18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 003 Dec 04, 1992 Sep DISC

+ 18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 003 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT + BAXTER HLTHCARE 18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 004 Dec 04, 1992 Aug CTEC

+ 18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N020183 004 Dec 04, 1992 Jun CRLD

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT + BAXTER HLTHCARE 18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 012 Jan 10, 1989 Aug NEWA

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT + BAXTER HLTHCARE 18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML N017512 013 Jul 11, 1990 Aug NEWA

SOLUTION;INTRAPERITONEAL									
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER									
AT	+	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990	Aug	NEWA	
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	015	Jul 11, 1990	Aug	NEWA	
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	BAXTER HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Jun	CRLD	
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Aug	CPOT	
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	001	Dec 04, 1992	Jun	CRLD	
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	005		Jun	CRLD	
AT	+		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	002	Dec 04, 1992	Jun	CRLD	
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	@ BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Jun	CRLD	
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	006		Jun	CRLD	
AT	+		25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	003	Dec 04, 1992	Jun	CRLD	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION									
LACTATED RINGER'S IN PLASTIC CONTAINER									
AP		FRESENIUS KABI USA	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A209338	001	Jan 28, 2019	Jan	NEWA	

CAPECITABINE

TABLET;ORAL									
CAPECITABINE									
AB		SUN PHARM	150MG	A204668	001	Jun 21, 2019	Jun	NEWA	
AB			500MG	A204668	002	Jun 21, 2019	Jun	NEWA	

CAPTOPRIL

TABLET;ORAL									
CAPTOPRIL									
AB		BOSCOGEN	12.5MG	A074677	004	May 30, 1997	Jun	CMFD	
AB			25MG	A074677	002	May 30, 1997	Jun	CMFD	
AB			50MG	A074677	001	May 30, 1997	Jun	CMFD	
AB			100MG	A074677	003	May 30, 1997	Jun	CMFD	
AB		SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	Oct	NEWA	
AB			25MG	A212223	002	Oct 30, 2019	Oct	NEWA	
AB			50MG	A212223	003	Oct 30, 2019	Oct	NEWA	
AB			100MG	A212223	004	Oct 30, 2019	Oct	NEWA	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL									
CARBAMAZEPINE									
		@ MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jul	DISC	
		@	200MG	A076697	002	May 20, 2011	Jul	DISC	
		@	300MG	A076697	003	May 20, 2011	Jul	DISC	
CARBATROL									
AB	+	SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan	CAHN	
AB	+		200MG	N020712	001	Sep 30, 1997	Jan	CAHN	
AB	+	!	300MG	N020712	002	Sep 30, 1997	Jan	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
CARBAMAZEPINE									
AB		ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan	NEWA	
AB			200MG	A205571	002	Feb 07, 2019	Jan	NEWA	
AB			400MG	A205571	003	Feb 07, 2019	Jan	NEWA	

CARBIDOPA

TABLET;ORAL									
CARBIDOPA									
AB		AUROBINDO PHARMA LTD	25MG	A211055	001	Oct 21, 2019	Oct	NEWA	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

@	WOCKHARDT LTD	18.75MG;200MG;75MG	A 090833	001	Nov 20, 2012	Aug DISC
@		25MG;200MG;100MG	A 090833	002	Nov 20, 2012	Aug DISC
@		31.25MG;200MG;125MG	A 090833	003	Nov 20, 2012	Aug DISC
@		37.5MG;200MG;150MG	A 090833	004	Nov 20, 2012	Aug DISC
@		50MG;200MG;200MG	A 090833	005	Nov 20, 2012	Aug DISC
	STALEVO 125					
+	ORION PHARMA	31.25MG;200MG;125MG	N 021485	006	Aug 29, 2008	Aug CTEC
	STALEVO 200					
+	ORION PHARMA	50MG;200MG;200MG	N 021485	004	Aug 02, 2007	Aug CTEC
	STALEVO 50					
+	ORION PHARMA	12.5MG;200MG;50MG	N 021485	001	Jun 11, 2003	Aug CTEC
	STALEVO 75					
+	ORION PHARMA	18.75MG;200MG;75MG	N 021485	005	Aug 29, 2008	Aug CTEC

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ALEMBIC PHARMS LTD	25MG;100MG	A 210341	001	Jun 05, 2019	May NEWA
AB		50MG;200MG	A 210341	002	Jun 05, 2019	May NEWA
AB	! SUN PHARM INDS	50MG;200MG	A 077828	002	Aug 23, 2007	Oct CHRS
	SINEMET CR					
+	@ MERCK SHARP DOHME	50MG;200MG	N 019856	001	May 30, 1991	Oct DISC

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

!	MIKART	4MG/5ML	A 040458	001	Apr 25, 2003	Jun CTEC
@	VINTAGE PHARMS	4MG/5ML	A 040814	001	Feb 26, 2008	Jun DISC

TABLET; ORAL

CARBINOXAMINE MALEATE

!	MIKART	6MG	A 207484	001	May 31, 2016	Mar CHRS
>D> AA	VINTAGE PHARMS	4MG	A 040639	002	May 30, 2008	Nov DISC
>A>	@	4MG	A 040639	002	May 30, 2008	Nov DISC

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A 206775	001	Feb 09, 2017	May CDFR
AP		150MG/15ML (10MG/ML)	A 206775	002	Feb 09, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A 206775	003	Feb 09, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A 206775	004	Feb 09, 2017	May CDFR
	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A 078732	001	Feb 06, 2012	Mar CDFR
	@	150MG/15ML (10MG/ML)	A 078732	002	Feb 06, 2012	Mar CDFR
	@	450MG/45ML (10MG/ML)	A 078732	003	Feb 06, 2012	Mar CDFR
	@	600MG/60ML (10MG/ML)	A 078732	004	Feb 06, 2012	Mar CDFR
AP	AKORN	50MG/5ML (10MG/ML)	A 090475	001	Jul 29, 2009	May CDFR
AP		150MG/15ML (10MG/ML)	A 090475	002	Jul 29, 2009	May CDFR
AP		450MG/45ML (10MG/ML)	A 090475	003	Jul 29, 2009	May CDFR
AP		600MG/60ML (10MG/ML)	A 091268	002	Jul 28, 2010	May CDFR
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A 077861	001	Jan 18, 2007	May CDFR
AP		150MG/15ML (10MG/ML)	A 077861	002	Jan 18, 2007	May CDFR
AP		450MG/45ML (10MG/ML)	A 077861	003	Jan 18, 2007	May CDFR
AP		600MG/60ML (10MG/ML)	A 077861	004	Jan 18, 2007	May CDFR
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A 205487	001	Mar 28, 2016	May CDFR
AP		150MG/15ML (10MG/ML)	A 205487	002	Mar 28, 2016	May CDFR
AP		450MG/45ML (10MG/ML)	A 205487	003	Mar 28, 2016	May CDFR
	@ FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A 077432	001	Sep 29, 2006	Oct DISC
AP		50MG/5ML (10MG/ML)	A 077432	001	Sep 29, 2006	May CDFR
	@	150MG/15ML (10MG/ML)	A 077432	002	Sep 29, 2006	Oct DISC
AP		150MG/15ML (10MG/ML)	A 077432	002	Sep 29, 2006	May CDFR
	@	450MG/45ML (10MG/ML)	A 077432	003	Sep 29, 2006	Oct DISC
AP		450MG/45ML (10MG/ML)	A 077432	003	Sep 29, 2006	May CDFR
	@	50MG/5ML (10MG/ML)	A 077247	001	Oct 21, 2004	Mar CDFR
	@	50MG/5ML (10MG/ML)	A 077266	001	Feb 15, 2006	Mar CDFR
	@	150MG/15ML (10MG/ML)	A 077247	002	Oct 21, 2004	Mar CDFR
	@	150MG/15ML (10MG/ML)	A 077266	002	Feb 15, 2006	Mar CDFR
AP		450MG/45ML (10MG/ML)	A 077247	003	Oct 21, 2004	Mar CDFR
AP		450MG/45ML (10MG/ML)	A 077266	003	Feb 15, 2006	May CDFR
AP		600MG/60ML (10MG/ML)	A 077266	004	Feb 15, 2006	May CDFR

INJECTABLE; INTRAVENOUS
CARBOPLATIN

AP	GLAND PHARMA LTD	150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	May CDFR	
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	May CDFR	
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	May CDFR	
>D>	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Nov CAHN	
AP		50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	May CDFR	
>D>	AP	150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Nov CAHN	
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	May CDFR	
>D>	AP	450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Nov CAHN	
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	May CDFR	
>D>	AP	600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Nov CAHN	
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	May CDFR	
AP	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	May CDFR	
AP		150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	May CDFR	
AP		450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	May CDFR	
AP		600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	May CDFR	
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May CDFR	
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May CDFR	
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CDFR	
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CDFR	
>A>	AP	MEITHEAL	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Nov CAHN
>A>	AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Nov CAHN
>A>	AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Nov CAHN
>A>	AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Nov CAHN
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr CDFR	
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr CDFR	
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr CDFR	
	@ MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	Oct DISC	
AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CDFR	
	@	150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	Oct DISC	
AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CDFR	
	@	450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	Oct DISC	
AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CDFR	
	@	600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	Oct DISC	
AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CDFR	
	@	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar CDFR	
AP	! PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	May CDFR	
	@	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar CDFR	
AP	!	150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	May CDFR	
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar CDFR	
AP	!	450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	May CDFR	
	@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar CDFR	
AP	!	600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	May CDFR	
AP	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	May CDFR	
AP		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	May CDFR	
AP		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	May CDFR	
AP		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	May CDFR	
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	May CDFR	
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	May CDFR	
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	May CDFR	
AP	SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008	May CDFR	
AP		150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008	May CDFR	
AP		450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008	May CDFR	
	@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar CDFR	
	@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar CDFR	
	@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar CDFR	
AP	! TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May CDFR	
AP	!	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May CDFR	
AP	!	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May CDFR	
AP	!	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May CDFR	
AP	WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	May CDFR	
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	May CDFR	
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	May CDFR	
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	May CDFR	
PARAPLATIN							
+	@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar CDFR	
+	@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar CDFR	
+	@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar CDFR	
+	@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar CDFR	
INJECTABLE; IV (INFUSION)							
CARBOPLATIN							
AP	GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	May CDFR	
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb CAHN	

INJECTABLE;IV (INFUSION)
CARBOPLATIN

AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb CAHN
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb CAHN
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb CAHN
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar DISC
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar DISC
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar DISC

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION
CARBOPROST TROMETHAMINE

AP	DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941	001	Jul 02, 2019	Jun NFTG
	HEMABATE					
AP	+! PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001		Jun CFTG

CARFILZOMIB

POWDER;INTRAVENOUS
CARFILZOMIB

AP	DR REDDYS	60MG/VIAL	A209422	001	Sep 09, 2019	Aug NFTG
	KYPROLIS					
AP	+! ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Aug CFTG

CARGLUMIC ACID

TABLET;ORAL
CARBAGLU

	+! RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	May CAHN
--	-------------------	-------	---------	-----	--------------	----------

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AA	ALLIED	350MG	A040245	001	Sep 08, 1997	Aug CMFD
	@	350MG	A040245	001	Sep 08, 1997	Jun CAHN
	@ SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991	Oct DISC
	@ VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997	Feb DISC

CARMUSTINE

INJECTABLE;INJECTION
CARMUSTINE

AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar NEWA
----	----------------	------------	---------	-----	--------------	----------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CARTEOLOL HYDROCHLORIDE

	@ BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000	May DISC
	! SANDOZ INC	1%	A075476	001	Jan 03, 2000	May CTEC

CARVEDILOL

TABLET;ORAL
CARVEDILOL

AB	RUBICON	3.125MG	A078165	001	Sep 05, 2007	Aug CAHN
AB		6.25MG	A078165	002	Sep 05, 2007	Aug CAHN
AB		12.5MG	A078165	003	Sep 05, 2007	Aug CAHN
AB		25MG	A078165	004	Sep 05, 2007	Aug CAHN
	@ SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Oct DISC
	@	6.25MG	A077346	001	Sep 05, 2007	Oct DISC
	@	12.5MG	A077346	002	Sep 05, 2007	Oct DISC
	@	25MG	A077346	003	Sep 05, 2007	Oct DISC

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS
CASPOFUNGIN ACETATE

	@ CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018	Jan DISC
	@	70MG/VIAL	A209489	002	Jul 12, 2018	Jan DISC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

	+ @ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983	Aug CRLD
	+ @	EQ 20MG BASE/ML	N050566	004	Jun 08, 1983	Aug CRLD

INJECTABLE;INJECTION

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983	Aug CRLD
+ @	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983	Aug CRLD

CEFAZOLIN SODIUM

>D> AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A065047	001	Sep 18, 2001	Nov CHRS
>A> AP	!	EQ 500MG BASE/VIAL	A065047	001	Sep 18, 2001	Nov CHRS
>D> AP		EQ 1GM BASE/VIAL	A065047	002	Sep 18, 2001	Nov CHRS
>A> AP	!	EQ 1GM BASE/VIAL	A065047	002	Sep 18, 2001	Nov CHRS
>D> AP	! HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Nov DISC
>A>	@	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Nov DISC
>D> AP	!	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Nov DISC
>A>	@	EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Nov DISC
	@	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Oct DISC
	@	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Oct DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

@ HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Sep DISC
@	EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Sep DISC
@	EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012	Sep DISC
@	EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Sep DISC
@	EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012	Sep DISC

>A> CEFIDEROCOL SULFATE TOSYLATE

>A> POWDER;INTRAVENOUS

>A> FETROJA

>A>	+! SHIONOGI INC	EQ 1GM BASE/VIAL	N209445	001	Nov 14, 2019	Nov NEWA
-----	-----------------	------------------	---------	-----	--------------	----------

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017	Feb DISC
@	200MG/5ML	A206144	002	Nov 17, 2017	Feb DISC

SUPRAX

AB	! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr CHRS
----	----------------	-----------	---------	-----	--------------	----------

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

CEFOTAXIME

>D> AP	!	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Nov CTEC
>A>	!		EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002	Nov CTEC
>D> AP	!		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Nov CTEC
>A>	!		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002	Nov CTEC
>D> AP	!		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Nov CTEC
>A>	!		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002	Nov CTEC
>D> AP	!		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Nov CTEC
>A>	!		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Nov CTEC
>D> AP		WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006	Nov DISC
>A>	@		EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006	Nov DISC

CEFOTAXIME SODIUM

@ HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Sep DISC		
@	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Sep DISC		
@	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Sep DISC		
@	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Sep DISC		
@	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Sep DISC		
@	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Sep DISC		
@	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Sep DISC		
>D> AP		EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Nov DISC	
>A>	@	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Nov DISC	
>D> AP		WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008	Nov DISC
>A>	@	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008	Nov DISC	
>D> AP		EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008	Nov DISC	
>A>	@	EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008	Nov DISC	

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTETAN

>D> AP	!	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007	Nov DISC
>A>	@		EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007	Nov DISC
>D> AP		WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011	Nov DISC
>A>	@		EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011	Nov DISC

CEFOXITIN SODIUMINJECTABLE; INJECTION
CEFOXITIN

@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Sep DISC
@	EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Sep DISC

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CEFUROXIME SODIUMINJECTABLE; INJECTION
CEFUROXIME SODIUM

@ HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Sep DISC
@	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Sep DISC
@	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Sep DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM

@ HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Sep DISC
---------------	--------------------	---------	-----	--------------	----------

CELECOXIBCAPSULE; ORAL
CELECOXIB

>A> AB	CADILA PHARMS LTD	50MG	A208701	001	Nov 14, 2019	Nov NEWA
>A> AB		100MG	A208701	002	Nov 14, 2019	Nov NEWA
>A> AB		200MG	A208701	003	Nov 14, 2019	Nov NEWA
>A> AB		400MG	A208701	004	Nov 14, 2019	Nov NEWA
AB	QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Jul NEWA
AB		100MG	A208856	002	Aug 07, 2019	Jul NEWA
AB		200MG	A208856	003	Aug 07, 2019	Jul NEWA
AB		400MG	A208856	004	Aug 07, 2019	Jul NEWA

TABLET; ORAL
CELECOXIB

>A> AB	UMEDICA LABS PVT LTD	50MG	A210628	001	Nov 27, 2019	Nov NEWA
>A> AB		100MG	A210628	002	Nov 27, 2019	Nov NEWA
>A> AB		200MG	A210628	003	Nov 27, 2019	Nov NEWA
>A> AB		400MG	A210628	004	Nov 27, 2019	Nov NEWA

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN

@ SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987	Oct DISC
@	EQ 500MG BASE	A062791	002	Jun 11, 1987	Oct DISC

FOR SUSPENSION; ORAL
CEPHALEXIN

AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar NEWA
AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar NEWA

CERITINIBCAPSULE; ORAL
ZYKADIA

+ @ NOVARTIS	150MG	N205755	001	Apr 29, 2014	Jun DISC
--------------	-------	---------	-----	--------------	----------

TABLET; ORAL
ZYKADIA

+! NOVARTIS	150MG	N211225	001	Mar 18, 2019	Mar NEWA
-------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDESOLUTION; INTRAVENOUS
QUZYTTIR

+! JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Oct NEWA
--------	-------------------	---------	-----	--------------	----------

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	May DISC
AA MLV	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
AA ! PERRIGO PHARMS CO	5MG/5ML	A078398	001	Jun 17, 2008	May CAHN

SYRUP; ORAL									
CETIRIZINE HYDROCHLORIDE									
>D>	AA	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Nov	DISC	
>A>		@	5MG/5ML	A078870	001	Apr 27, 2009	Nov	DISC	
	AA		5MG/5ML	A078870	001	Apr 27, 2009	Jan	CAHN	
<u>CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN</u>									
OINTMENT; TOPICAL									
ELASE-CHLOROMYCETIN									
		+ @ PARKE DAVIS	10MG/GM; 666 UNITS/GM; 1 UNITS/GM	N050294	001		Aug	CRLD	
<u>CHLORDIAZEPOXIDE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
LIBRIUM									
		@ BAUSCH	100MG/AMP	N012301	001		Mar	CAHN	
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE</u>									
SOLUTION; ORAL									
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE									
		@ ACELLA	4MG/5ML; 5MG/5ML	A206891	001	Jun 09, 2017	Aug	DISC	
		VITUZ							
		+ @ PERSION	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Aug	DISC	
AA		+!	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Apr	CAHN	
<u>CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>									
SOLUTION; ORAL									
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE									
AA	!	PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Jun	CHRS	
		@ TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan	CAHN	
		ZUTRIPRO							
		+ @ PERSION	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Jul	DISC	
AA		+!	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr	CAHN	
<u>CHLORPROMAZINE HYDROCHLORIDE</u>									
CONCENTRATE; ORAL									
CHLORPROMAZINE HYDROCHLORIDE INTENSOL									
		@ HIKMA	30MG/ML	A088157	001	Apr 27, 1983	Sep	CAHN	
		@	100MG/ML	A088158	001	Apr 27, 1983	Sep	CAHN	
TABLET; ORAL									
CHLORPROMAZINE HYDROCHLORIDE									
AB		UPSHER SMITH LABS	10MG	A083386	001		Jul	CAHN	
AB	!		25MG	A084112	001		Jul	CAHN	
AB			50MG	A084113	001		Jul	CAHN	
AB	!		100MG	A084114	001		Jul	CAHN	
AB			200MG	A084115	001		Jul	CAHN	
<u>CHLORPROPAMIDE</u>									
TABLET; ORAL									
CHLORPROPAMIDE									
		@ MYLAN	100MG	A088549	002	Jun 01, 1984	May	DISC	
		@	250MG	A088549	001	Jun 01, 1984	May	DISC	
<u>CHLORTHALIDONE</u>									
TABLET; ORAL									
CHLORTHALIDONE									
AB		AMNEAL PHARMS CO	25MG	A207204	001	Jul 01, 2019	Jun	NEWA	
AB			50MG	A207204	002	Jul 01, 2019	Jun	NEWA	
AB		ARISE	25MG	A210742	001	Oct 12, 2018	Sep	CAHN	
AB			50MG	A210742	002	Oct 12, 2018	Sep	CAHN	
AB		UNICHEM LABS LTD	25MG	A211627	001	Aug 06, 2019	Jul	NEWA	
AB			50MG	A211627	002	Aug 06, 2019	Jul	NEWA	
AB		ZYDUS PHARMS	25MG	A207813	001	May 10, 2019	Apr	NEWA	
AB			50MG	A207813	002	May 10, 2019	Apr	NEWA	
<u>CHLORZOXAZONE</u>									
TABLET; ORAL									
CHLORZOXAZONE									
>D>		MIKART	375MG	A040861	001	Jun 01, 2010	Nov	CTEC	
>A>	AB	!	375MG	A040861	001	Jun 01, 2010	Nov	CTEC	
>D>		!	750MG	A040861	002	Jun 01, 2010	Nov	CTEC	
>A>	AB	!	750MG	A040861	002	Jun 01, 2010	Nov	CTEC	
>A>	AB		375MG	A212253	001	Nov 27, 2019	Nov	NEWA	

TABLET;ORAL							
CHLORZOXAZONE							
AA		500MG	A212254	001	Sep 12, 2019	Sep	NEWA
>A> AB		750MG	A212253	002	Nov 27, 2019	Nov	NEWA
AA	! WATSON LABS	500MG	A089859	001	May 04, 1988	Sep	CTEC
<u>CHOLINE C-11</u>							
INJECTABLE;INTRAVENOUS							
CHOLINE C-11							
AP	DECATUR	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr	CAHN
<u>CHOLINE FENOFIBRATE</u>							
CAPSULE, DELAYED RELEASE;ORAL							
FENOFIBRIC ACID							
AB	AUROBINDO PHARMA LTD	EQ 45MG FENOFIBRIC ACID	A212598	001	Jul 25, 2019	Jul	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Jul	NEWA
AB	GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Jul	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Jul	NEWA
	@ MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	May	DISC
	@	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	May	DISC
<u>CHROMIC PHOSPHATE P-32</u>							
INJECTABLE;INJECTION							
PHOSPHOCOL P32							
	@ CURIUM	5mCi/ML	N017084	001		Jan	CAHN
<u>CICLESONIDE</u>							
AEROSOL, METERED;INHALATION							
ALVESCO							
+	COVIS PHARMA BV	0.08MG/INH	N021658	002	Jan 10, 2008	Mar	CAHN
+		0.16MG/INH	N021658	003	Jan 10, 2008	Mar	CAHN
AEROSOL, METERED;NASAL							
ZETONNA							
+	COVIS PHARMA BV	0.037MG/INH	N202129	001	Jan 20, 2012	Mar	CAHN
SPRAY, METERED;NASAL							
OMNARIS							
+	COVIS PHARMA BV	0.05MG/INH	N022004	001	Oct 20, 2006	Mar	CAHN
<u>CICLOPIROX</u>							
CREAM;TOPICAL							
CICLOPIROX							
AB	PERRIGO ISRAEL	0.77%	A077364	001	Mar 03, 2006	May	CAHN
SHAMPOO;TOPICAL							
LOPROX							
AT	+! BAUSCH	1%	N021159	001	Feb 28, 2003	Apr	CAHN
SOLUTION;TOPICAL							
CICLOPIROX							
AT	ACELLA	8%	A078172	001	Sep 18, 2007	May	CAHN
AT	ANDA REPOSITORY	8%	A077687	001	Sep 18, 2007	Aug	CAHN
AT	NOVAST LABS	8%	A078124	001	Sep 18, 2007	Sep	CAHN
<u>CILASTATIN SODIUM; IMIPENEM</u>							
POWDER;INTRAVENOUS							
IMIPENEM AND CILASTATIN							
	@ HOSPIRA INC	EQ 500MG BASE/VIAL;500MG/VIAL	A090825	002	Nov 16, 2011	Sep	DISC
	@	EQ 500MG BASE/VIAL;500MG/VIAL	A091007	001	Nov 16, 2011	Sep	DISC
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM</u>							
POWDER;INTRAVENOUS							
RECARBRIO							
+	MSD MERCK CO	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	N212819	001	Jul 16, 2019	Jul	NEWA
<u>CILOSTAZOL</u>							
TABLET;ORAL							
CILOSTAZOL							
AB	SLATE	50MG	A077208	002	Mar 29, 2006	Aug	CAHN
AB		100MG	A077208	001	Mar 29, 2006	Aug	CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 30MG BASE	A210570	001	May 17, 2019	May NEWA
AB		EQ 60MG BASE	A210570	002	May 17, 2019	May NEWA
AB		EQ 90MG BASE	A210570	003	May 17, 2019	May NEWA
AB	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jun NEWA
AB		EQ 60MG BASE	A210548	002	Jun 28, 2019	Jun NEWA
AB		EQ 90MG BASE	A210548	003	Jun 28, 2019	Jun NEWA

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	DR REDDYS	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	May CAHN
@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	May CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@	RUBICON	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Jul CAHN
---	---------	--------------	---------	-----	--------------	----------

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	CHARTWELL	EQ 250MG BASE	A076896	001	Nov 04, 2004	Sep CAHN
AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Sep CAHN
AB		EQ 750MG BASE	A076896	003	Nov 04, 2004	Sep CAHN
AB	CHARTWELL MOLECULES	EQ 250MG BASE	A076896	001	Nov 04, 2004	Jul CAHN
AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Jul CAHN
AB		EQ 750MG BASE	A076896	003	Nov 04, 2004	Jul CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CTEC
AB	!	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CHRS
AB	!	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May CHRS
@	ANI PHARMS INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	May CAHN
@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	May CAHN
@	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May DISC
@		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May DISC

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

	@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb DISC
	AP	ANDA REPOSITORY	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Sep CAHN
>D>	@	HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Nov CMFD
>A>	AP		EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Nov CMFD
>D>	@		EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Nov CMFD
>A>	AP		EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Nov CMFD
>A>	AP	MEITHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Nov CAHN
>A>	AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Nov CAHN
>A>	AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Nov CAHN
>D>	AP	NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Nov CAHN
	AP		EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr NEWA
>D>	AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Nov CAHN
	AP		EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr NEWA
>D>	AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Nov CAHN
	AP		EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr NEWA
	AP	SOMERSET	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Oct CAHN
	AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr NEWA
	AP	ZYDUS PHARMS	EQ 2MG BASE/ML	A212171	001	Nov 04, 2019	Oct NEWA
	AP		EQ 10MG BASE/ML	A212171	002	Nov 04, 2019	Oct NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE					
	@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb DISC
	@		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb DISC
	AP	SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb NEWA
	AP		EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb NEWA
		NIMBEX PRESERVATIVE FREE					
AP	+	ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb CTEC

CISPLATININJECTABLE; INJECTION
CISPLATIN

@ MYLAN LABS LTD	1MG/ML	A091062	001	Apr 18, 2012	Oct DISC
------------------	--------	---------	-----	--------------	----------

CITALOPRAM HYDROBROMIDETABLET; ORAL
CITALOPRAM HYDROBROMIDE

	@ HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004	May CAHN
	@	EQ 10MG BASE	A077213	001	Mar 31, 2006	May CAHN
AB		EQ 10MG BASE	A077232	001	Oct 31, 2005	May CAHN
	@	EQ 20MG BASE	A077033	002	Oct 28, 2004	May CAHN
	@	EQ 20MG BASE	A077213	002	Mar 31, 2006	May CAHN
AB		EQ 20MG BASE	A077232	002	Oct 31, 2005	May CAHN
	@	EQ 40MG BASE	A077033	003	Oct 28, 2004	May CAHN
	@	EQ 40MG BASE	A077213	003	Mar 31, 2006	May CAHN
AB		EQ 40MG BASE	A077232	003	Oct 31, 2005	May CAHN
	@ SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004	Oct DISC
	@	EQ 20MG BASE	A077032	002	Nov 12, 2004	Oct DISC
	@	EQ 40MG BASE	A077032	003	Nov 12, 2004	Oct DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATEFOR SOLUTION; ORAL
PREPOPIK

+ @ FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK	N202535	001	Jul 16, 2012	Sep DISC
	ET				
+!	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK	N202535	001	Jul 16, 2012	Jun CMFD
	ET				
+ @	12GM/PACKET; 3.5GM/PACKET; 10MG/PACK	N202535	001	Jul 16, 2012	Apr DISC
	ET				

CLADRIBINEINJECTABLE; INJECTION
CLADRIBINE

>A> AP	HISUN PHARM HANGZHOU	1MG/ML	A210856	001	Nov 25, 2019	Nov NEWA
	TABLET; ORAL					
	MAVENCLAD					
	+! EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Mar NEWA

CLARITHROMYCINTABLET; ORAL
CLARITHROMYCIN

	@ AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Sep DISC
AB		250MG	A206714	001	Apr 25, 2019	Apr NEWA
	@	500MG	A206714	002	Apr 25, 2019	Sep DISC
AB		500MG	A206714	002	Apr 25, 2019	Apr NEWA
AB	CHARTWELL	250MG	A065384	001	Aug 20, 2007	Aug CAHN
AB		500MG	A065384	002	Aug 20, 2007	Aug CAHN
AB	STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb CAHN
AB		500MG	A202710	002	Jun 10, 2013	Feb CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	CLARITHROMYCIN					
AB	NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	Jul CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

@ MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar DISC
---------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATEGEL; TOPICAL
CLINDAGEL

BT	+! BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	May CAHN
	SOLUTION; TOPICAL					
	CLINDAMYCIN PHOSPHATE					
AT	CADILA	EQ 1% BASE	A208767	001	Jul 16, 2018	Oct CAHN
AT	ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan NEWA

CLINDAMYCIN PHOSPHATE; TRETINOINGEL; TOPICAL
VELTIN

BX	+!	ALMIRALL	1.2%; 0.025%	N050803	001	Jul 16, 2010	Feb CAHN
----	----	----------	--------------	---------	-----	--------------	----------

CLOBAZAMSUSPENSION; ORAL
CLOBAZAM

	@	TARO	2.5MG/ML	A210978	001	Apr 15, 2019	Sep DISC
AB			2.5MG/ML	A210978	001	Apr 15, 2019	Apr NEWA
AB		VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019	Jun NEWA

TABLET; ORAL
CLOBAZAM

AB		ALKEM LABS LTD	10MG	A212714	001	Sep 06, 2019	Aug NEWA
AB			20MG	A212714	002	Sep 06, 2019	Aug NEWA
AB		LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Oct NEWA
AB			20MG	A212092	002	Oct 30, 2019	Oct NEWA
AB		MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan NEWA
AB			20MG	A211711	002	Jan 30, 2019	Jan NEWA
	@	TARO	10MG	A209440	001	Oct 22, 2018	Jul DISC
	@		20MG	A209440	002	Oct 22, 2018	Jul DISC

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL
CLOBETASOL PROPIONATE

AB1		GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb NEWA
AB2			0.05%	A211450	001	Sep 09, 2019	Aug NEWA
AB2		PERRIGO UK FINCO	0.05%	A201402	001	Aug 14, 2012	May CAHN

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1		RISING	0.05%	A211401	001	Jan 11, 2019	Sep CAHN
AB1		XIROMED	0.05%	A210034	001	Jun 15, 2018	Aug CAHN

LOTION; TOPICAL
CLOBETASOL PROPIONATE

	@	HI TECH	0.05%	A211348	001	Oct 26, 2018	Jul DISC
AB		ZYDUS PHARMS	0.05%	A205249	001	Sep 24, 2019	Sep NEWA

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

AB		ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb NEWA
	@	AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb DISC
>A> AB		ENCUBE	0.05%	A211295	001	Nov 15, 2019	Nov NEWA
AB		TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan NEWA
AB		TORRENT	0.05%	A212926	001	Oct 25, 2019	Oct NEWA
AB		XIROMED	0.05%	A209701	001	Apr 17, 2018	Aug CAHN

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT		ALEOR DERMACEUTICALS	0.05%	A212881	001	Oct 21, 2019	Oct NEWA
AT		SAPTALIS PHARMS	0.05%	A211494	001	Oct 02, 2019	Sep NEWA

SPRAY; TOPICAL
CLOBETASOL PROPIONATE

AT		ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Sep NEWA
AT		GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Aug CAHN

CLOFARABINESOLUTION; INTRAVENOUS
CLOFARABINE

AP		ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb NEWA
	@	HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb DISC

CLOMIPRAMINE HYDROCHLORIDECAPSULE; ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB		JUBILANT CADISTA	25MG	A212218	001	Oct 21, 2019	Oct NEWA
AB			50MG	A212218	002	Oct 21, 2019	Oct NEWA
AB			75MG	A212218	003	Oct 21, 2019	Oct NEWA
	@	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Oct DISC
AB			25MG	A211767	001	Apr 08, 2019	Mar NEWA
	@		50MG	A211767	002	Apr 08, 2019	Oct DISC
AB			50MG	A211767	002	Apr 08, 2019	Mar NEWA
	@		75MG	A211767	003	Apr 08, 2019	Oct DISC
AB			75MG	A211767	003	Apr 08, 2019	Mar NEWA

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

@ RUBICON	0.5MG	A075468	001	Oct 06, 2000	Aug CAHN
@	1MG	A075468	002	Oct 06, 2000	Aug CAHN
@	2MG	A075468	003	Oct 06, 2000	Aug CAHN
@ SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Oct DISC
@	1MG	A075423	002	Apr 27, 2001	Oct DISC
@	2MG	A075423	003	Apr 27, 2001	Oct DISC

TABLET, ORALLY DISINTEGRATING; ORAL
CLONAZEPAM

AB	ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
AB		0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
AB		0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
AB		1MG	A211033	004	Jun 28, 2019	Jun NEWA
AB		2MG	A211033	005	Jun 28, 2019	Jun NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

@ LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
@	5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB	FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CMS1
@ SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Oct DISC	
@	0.2MG	A090329	002	Jul 03, 2014	Oct DISC	
@	0.3MG	A090329	003	Jul 03, 2014	Oct DISC	

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB1	NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
@ UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	May DISC	

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ANI PHARMS INC	EQ 300MG BASE	A091216	001	May 17, 2012	May CAHN
@ CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC	
AB		EQ 75MG BASE	A201686	001	Oct 10, 2012	Apr CAHN
AB	CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Aug CAHN
AB		EQ 300MG BASE	A202266	002	Nov 20, 2012	Aug CAHN
@ MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Sep DISC	
@	EQ 300MG BASE	A077665	002	May 17, 2012	Feb DISC	
@ SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133	001	Jun 10, 2013	Oct DISC	

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990	Jan CMS1
@	7.5MG	A072514	003	May 11, 1990	Jan CMS1

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT	NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019	Feb NEWA
AT	TASMAN PHARMA	1%	A212281	001	Jul 25, 2019	Jul NEWA

CLOZAPINE

TABLET; ORAL

CLOZARIL

AB	+ HERITAGE LIFE	50MG	N019758	003	May 20, 2019	May NEWA
AB	+	200MG	N019758	004	May 20, 2019	May NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
CLOZAPINE

>D>	AB	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Nov CTEC
>A>			12.5MG	A090308	003	Apr 09, 2018	Nov CTEC
>D>	AB		100MG	A090308	002	Nov 25, 2015	Nov CHRS
>A>	AB	!	100MG	A090308	002	Nov 25, 2015	Nov CHRS
>D>	AB	TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015	Nov CTEC
>A>			150MG	A203039	001	Nov 25, 2015	Nov CTEC

TABLET, ORALLY DISINTEGRATING;ORAL
CLOZAPINE

>D>	AB	200MG	A203039	002	Nov 25, 2015	Nov CTEC
>A>		200MG	A203039	002	Nov 25, 2015	Nov CTEC
>D>	FAZACLO ODT					
>D>	AB	+ JAZZ 12.5MG	N021590	004	May 30, 2007	Nov DISC
>A>		+ @ 12.5MG	N021590	004	May 30, 2007	Nov DISC
	AB	+ 12.5MG	N021590	004	May 30, 2007	Jun CAHN
>D>	AB	+ 25MG	N021590	001	Feb 10, 2004	Nov DISC
>A>		+ @ 25MG	N021590	001	Feb 10, 2004	Nov DISC
	AB	+ 25MG	N021590	001	Feb 10, 2004	Jun CAHN
		@ 50MG	N021590	003	Jun 03, 2005	Jun CAHN
>D>	AB	+! 100MG	N021590	002	Feb 10, 2004	Nov DISC
>A>		+ @ 100MG	N021590	002	Feb 10, 2004	Nov DISC
	AB	+! 100MG	N021590	002	Feb 10, 2004	Jun CAHN
>D>	AB	+ 150MG	N021590	005	Jul 09, 2010	Nov DISC
>A>		+ @ 150MG	N021590	005	Jul 09, 2010	Nov DISC
	AB	+ 150MG	N021590	005	Jul 09, 2010	Jun CAHN
>D>	AB	+ 200MG	N021590	006	Jul 09, 2010	Nov DISC
>A>		+ @ 200MG	N021590	006	Jul 09, 2010	Nov DISC
	AB	+ 200MG	N021590	006	Jul 09, 2010	Jun CAHN

COBICISTAT; DARUNAVIR

TABLET;ORAL
PREZCOBIX

+!	JANSEN PRODS	150MG;800MG	N205395	001	Jan 29, 2015	Sep CAIN
----	--------------	-------------	---------	-----	--------------	----------

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
SYM TUZA

+!	JANSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct CAIN
+!		150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct CAIN

COLCHICINE

CAPSULE;ORAL
COLCHICINE

@	PAR PHARM INC	0.6MG	A208678	001	Nov 29, 2018	May DISC
MITIGARE						
+!	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	May CTEC

SOLUTION;ORAL
GLOPERBA

+!	AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jul CAHN
+!	ROMEG THERAPS LLC	0.6MG/5ML	N210942	001	Jan 30, 2019	Jan NEWA

TABLET;ORAL
COLCHICINE

AB	ALKEM LABS LTD	0.6MG	A211250	001	Feb 08, 2019	Feb NEWA
	@ AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Oct DISC
AB		0.6MG	A204711	001	Sep 28, 2016	Jan NEWA
AB	DR REDDYS	0.6MG	A209876	001	Sep 06, 2019	Aug NEWA
AB	MYLAN	0.6MG	A209470	001	Sep 16, 2019	Sep NEWA
AB	WATSON LABS INC	0.6MG	A204461	001	Jul 31, 2019	Jul NEWA
	@ ZYDUS PHARMS	0.6MG	A211519	001	Feb 19, 2019	Jul DISC
AB		0.6MG	A211519	001	Feb 19, 2019	Feb NEWA
COLCRYST						
AB	+! TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Jan CTEC

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL
WELCHOL

+!	DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Apr NEWA
----	--------------------	--------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB	ALKEM LABS LTD	3.75GM/PACKET	A210316	001	May 06, 2019	Apr NEWA
	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Mar CTEC
WELCHOL						
	+ @ DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Mar DISC

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB	BIONPHARMA INC	625MG	A208670	001	Sep 13, 2019	Sep NEWA
AB	ZYDUS PHARMS	625MG	A207765	001	Oct 07, 2019	Sep NEWA

CROMOLYN SODIUMSOLUTION; INHALATION
CROMOLYN SODIUM

@ MYLAN SPECIALITY LP 10MG/ML

A074209 001 Apr 26, 1994 Mar DISC

CROTAMITONCREAM; TOPICAL
EURAX

+ @ SUN PHARM INDS INC 10%

N006927 001 Aug DISC

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
AMRIX

AB + TEVA PHARMS INTL 15MG
+ 15MG
AB +! 30MG
+! 30MG

N021777 001 Feb 01, 2007 Mar CTEC
N021777 001 Feb 01, 2007 Jan CTEC
N021777 002 Feb 01, 2007 Mar CTEC
N021777 002 Feb 01, 2007 Jan CTEC

CYCLOBENZAPRINE HYDROCHLORIDE

AB APOTEX 15MG
AB 30MG
@ APOTEX INC 15MG
@ 30MG
AB TWI PHARMS INC 15MG
AB 30MG

A206703 001 Jul 24, 2018 Feb CMFD
A206703 002 Jul 24, 2018 Feb CMFD
A206703 001 Jul 24, 2018 Jan DISC
A206703 002 Jul 24, 2018 Jan DISC
A091281 001 Jan 31, 2013 Mar CMFD
A091281 002 Jan 31, 2013 Mar CMFD

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB ANDA REPOSITORY 5MG
AB 10MG

A073541 002 Apr 06, 2006 Aug CAHN
A073541 001 May 23, 1995 Aug CAHN

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB CIPLA 25MG
AB 50MG
AB + HIKMA 25MG
AB +! 50MG

A211608 001 Jan 18, 2019 Jan NEWA
A211608 002 Jan 18, 2019 Jan NEWA
N203856 001 Sep 16, 2013 Oct CAHN
N203856 002 Sep 16, 2013 Oct CAHN

CYCLOSERINECAPSULE; ORAL
SEROMYCIN

! PURDUE 250MG

A060593 001 Aug CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1 APOTEX 25MG
AB1 50MG
AB1 100MG
AB1 IVAX SUB TEVA PHARMS 50MG

A210721 001 Jul 10, 2019 Jun NEWA
A210721 002 Jul 10, 2019 Jun NEWA
A210721 003 Jul 10, 2019 Jun NEWA
A065110 001 Mar 29, 2005 Jun CTEC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA ANDA REPOSITORY 2MG/5ML
AA ELYSIUM 2MG/5ML
AA PATRIN PHARMA INC 2MG/5ML
AA QUAGEN 2MG/5ML
AA TORRENT 2MG/5ML

A204823 001 Dec 27, 2016 Sep CAHN
A209108 001 Oct 16, 2018 Sep CAHN
A204823 001 Dec 27, 2016 Jul CAHN
A212423 001 May 22, 2019 May NEWA
A204823 001 Dec 27, 2016 Jan CAHN

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA BEXIMCO PHARMS USA 4MG
AA ELYSIUM 4MG
AA ! HERITAGE PHARMA 4MG

A206676 001 Apr 12, 2019 Apr NEWA
A207555 001 Jan 31, 2017 Sep CAHN
A087056 001 Feb CAHN

CYSTEINE HYDROCHLORIDESOLUTION; INTRAVENOUS
ELCYS

+! EXELA PHARMA SCS LLC 500MG/10ML (50MG/ML)

N210660 001 Apr 16, 2019 Apr NEWA

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

>D>	AP	HONG KONG	20MG/ML	A206190	001	Nov 09, 2017	Nov CAHN
>D>	AP		100MG/ML	A205696	001	Jul 17, 2018	Nov CAHN
>A>	AP	MEITHEAL	20MG/ML	A206190	001	Nov 09, 2017	Nov CAHN
>A>	AP		100MG/ML	A205696	001	Jul 17, 2018	Nov CAHN
		@ MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Sep DISC

DACLATASVIR DIHYDROCHLORIDETABLET; ORAL
DAKLINZA

+	@	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jun DISC
+	@		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun DISC
+	@		EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb DISC

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

AP		HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232	001	Jul 16, 2019	Jul NEWA
AP		X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May NEWA

DALFAMPRIDINETABLET, EXTENDED RELEASE; ORAL
DALFAMPRIDINE

AB		MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb NEWA
AB		SUN PHARM	10MG	A208292	001	May 21, 2019	May NEWA

DANTROLENE SODIUMINJECTABLE; INJECTION
DANTROLENE SODIUM

	@	MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar DISC
--	---	---------------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
QTERNMET XR

+		ASTRAZENECA AB	2.5MG; 1GM; EQ 2.5MG BASE	N210874	001	May 02, 2019	May NEWA
+			5MG; 1GM; EQ 2.5MG BASE	N210874	002	May 02, 2019	May NEWA
+			5MG; 1GM; EQ 5MG BASE	N210874	003	May 02, 2019	May NEWA
+	!		10MG; 1GM; EQ 5MG BASE	N210874	004	May 02, 2019	May NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
QTERN

+		ASTRAZENECA AB	5MG; EQ 5MG BASE	N209091	002	May 02, 2019	May NEWA
---	--	----------------	------------------	---------	-----	--------------	----------

DAPIPRAZOLE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

	@	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Oct DISC
			0.5%	A204902	001	May 30, 2019	May NEWA

DAPSONEGEL; TOPICAL
ACZONE

>D>	AB	+	!	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Nov CTEC
>A>		+	!		7.5%	N207154	001	Feb 24, 2016	Nov CTEC
	AB	+	!		7.5%	N207154	001	Feb 24, 2016	Jun CFTG
		+	!		7.5%	N207154	001	Feb 24, 2016	Feb CAHN

DAPSONE

>D>	AB			TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Nov DISC
>A>		@			7.5%	A210191	001	Jun 26, 2019	Nov DISC
	AB				7.5%	A210191	001	Jun 26, 2019	Jun NFTG

TABLET; ORAL
DAPSONE

AB		SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr NEWA
	@	TARO	25MG	A209430	001	Mar 01, 2019	May DISC
	@		100MG	A209430	002	Mar 01, 2019	May DISC
AB		TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb NEWA
AB			100MG	A209430	002	Mar 01, 2019	Feb NEWA

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN@ CUBIST PHARMS LLC 250MG/VIAL
DAPTOMYCIN

N021572 001 Sep 12, 2003 Oct CDFR

AP ACCORD HLTHCARE 500MG/VIAL A211961 001 Jun 24, 2019 Jun NEWA

AP BE PHARMS 500MG/VIAL A212513 001 Jun 26, 2019 Jun NEWA

AP DR REDDYS 500MG/VIAL A208375 001 May 01, 2019 Apr NEWA

AP JIANGSU HENGRUI MED 500MG/VIAL A212022 001 Aug 22, 2019 Aug NEWA

>A> AP SAGENT PHARMS INC 500MG/VIAL A207104 001 Nov 15, 2019 Nov NEWA

AP XELLIA PHARMS APS 500MG/VIAL A206005 001 Jun 15, 2016 Mar CAHN

POWDER; IV (INFUSION)
DAPTOMYCIN

AP ACCORD HLTHCARE 350MG/VIAL A212667 001 Jul 12, 2019 Jul NFTG

AP +! SAGENT PHARMS INC 350MG/VIAL N208385 001 Sep 12, 2017 Jul CTEC

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

AB ALAN LABS INC EQ 7.5MG BASE A209571 002 Oct 22, 2019 Oct NEWA

AB EQ 15MG BASE A209571 001 Oct 22, 2019 Oct NEWA

DAROLUTAMIDETABLET; ORAL
NUBEQA

+! BAYER HEALTHCARE 300MG

N212099 001 Jul 30, 2019 Jul NEWA

DARUNAVIRSUSPENSION; ORAL
PREZISTA

+! JANSSEN PRODS 100MG/ML

N202895 001 Dec 16, 2011 Sep CAIN

TABLET; ORAL
DARUNAVIR

AB TEVA PHARMS USA 600MG A202118 001 Nov 21, 2017 Oct CTNA

AB 600MG A202118 001 Nov 21, 2017 Sep CAIN

PREZISTA

+ JANSSEN PRODS 75MG N021976 004 Dec 18, 2008 Sep CAIN

+ 150MG N021976 005 Dec 18, 2008 Sep CAIN

+ @ 300MG N021976 001 Jun 23, 2006 Sep CAIN

+ @ 400MG N021976 003 Oct 21, 2008 Sep CAIN

AB + 600MG N021976 002 Feb 25, 2008 Sep CAIN

+! 800MG N021976 006 Nov 09, 2012 Sep CAIN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+ @ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG

N208624 001 Jul 22, 2016 Apr DISC

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DAUNORUBICIN HYDROCHLORIDE

AP HISUN PHARM HANGZHOU EQ 5MG BASE/ML A208759 001 Apr 12, 2019 Apr NEWA

@ EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Oct DISC

AP EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Apr NEWA

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP INGENUS PHARMS LLC 50MG/VIAL A210984 001 Sep 16, 2019 Sep NEWA

AP MSN LABS PVT LTD 50MG/VIAL A212265 001 Aug 28, 2019 Aug NEWA

AP WOCKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019 Mar NEWA

DEFERASIROX

TABLET; ORAL

DEFERASIROX

>A> AB ALEMBIC PHARMS LTD 90MG A211824 001 Nov 20, 2019 Nov NFTG

>A> AB 360MG A211824 002 Nov 20, 2019 Nov NFTG

>A> AB MSN LABS PVT LTD 90MG A210945 001 Nov 20, 2019 Nov NFTG

>A> AB 360MG A210945 002 Nov 20, 2019 Nov NFTG

>A> AB TEVA PHARMS USA 90MG A209223 001 Nov 25, 2019 Nov NEWA

>A> AB 360MG A209223 002 Nov 25, 2019 Nov NEWA

TABLET;ORAL							
>A>	DEFERASIROX						
>A> AB	ZYDUS PHARMS	90MG	A211383	001	Nov 20, 2019	Nov	NFTG
>A> AB		360MG	A211383	002	Nov 20, 2019	Nov	NFTG
JADENU							
>D>	+ NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Nov	CFTG
>A> AB	+	90MG	N206910	001	Mar 30, 2015	Nov	CFTG
>D>	+!	360MG	N206910	003	Mar 30, 2015	Nov	CFTG
>A> AB	+!	360MG	N206910	003	Mar 30, 2015	Nov	CFTG
TABLET, FOR SUSPENSION;ORAL							
DEFERASIROX							
>A> AB	ALEMBIC PHARMS LTD	125MG	A210060	001	Nov 20, 2019	Nov	NEWA
>A> AB		250MG	A210060	002	Nov 20, 2019	Nov	NEWA
>A> AB		500MG	A210060	003	Nov 20, 2019	Nov	NEWA
>A> AB	ALKEM LABS LTD	125MG	A210519	001	Nov 20, 2019	Nov	NEWA
>A> AB		250MG	A210519	002	Nov 20, 2019	Nov	NEWA
>A> AB		500MG	A210519	003	Nov 20, 2019	Nov	NEWA
>A> AB	BIONPHARMA INC	125MG	A210920	001	Nov 20, 2019	Nov	NEWA
>A> AB		250MG	A210920	002	Nov 20, 2019	Nov	NEWA
>A> AB		500MG	A210920	003	Nov 20, 2019	Nov	NEWA
>A> AB	MSN LABS PVT LTD	125MG	A209878	001	Nov 20, 2019	Nov	NEWA
>A> AB		250MG	A209878	002	Nov 20, 2019	Nov	NEWA
>A> AB		500MG	A209878	003	Nov 20, 2019	Nov	NEWA
>A> AB	SUN PHARM	125MG	A209782	001	Nov 20, 2019	Nov	NEWA
>A> AB		250MG	A209782	002	Nov 20, 2019	Nov	NEWA
>A> AB		500MG	A209782	003	Nov 20, 2019	Nov	NEWA
<u>DEFERIPRONE</u>							
TABLET;ORAL							
DEFERIPRONE							
	@ TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	May	DISC
AB		500MG	A208800	001	Feb 08, 2019	Feb	NFTG
FERRIPROX							
	+! APOPHARMA INC	500MG	N021825	001	Oct 14, 2011	May	CTEC
AB	+!	500MG	N021825	001	Oct 14, 2011	Feb	CFTG
	+	1GM	N021825	002	Jul 25, 2019	Jul	NEWA
<u>DELAVIDINE MESYLATE</u>							
TABLET;ORAL							
RESCRIPTOR							
	+ @ VIIV HLHCARE	100MG	N020705	001	Apr 04, 1997	Jun	DISC
<u>DESIPRAMINE HYDROCHLORIDE</u>							
TABLET;ORAL							
DESIPRAMINE HYDROCHLORIDE							
AB	NOVAST LABS	10MG	A204963	001	Dec 26, 2017	Sep	CAHN
AB		25MG	A204963	002	Dec 26, 2017	Sep	CAHN
AB		50MG	A204963	003	Dec 26, 2017	Sep	CAHN
AB		75MG	A204963	004	Dec 26, 2017	Sep	CAHN
AB		100MG	A204963	005	Dec 26, 2017	Sep	CAHN
AB		150MG	A204963	006	Dec 26, 2017	Sep	CAHN
<u>DESLORATADINE</u>							
TABLET;ORAL							
DESLORATADINE							
	@ MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	May	DISC
AB	PERRIGO	5MG	A078361	001	Dec 22, 2011	Apr	CAHN
<u>DESMOPRESSIN ACETATE</u>							
INJECTABLE;INJECTION							
DESMOPRESSIN ACETATE							
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD
SOLUTION;NASAL							
DDAVP							
	+! FERRING PHARMS INC	0.01%	N017922	001		Jul	CTEC
DESMOPRESSIN ACETATE							
	@ SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Jul	DISC
SPRAY, METERED;NASAL							
NOCTIVA							
	+ @ ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Jun	DISC
	+	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Jun	DISC

SOLUTION/DROPS;OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CTEC
@	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

	@ CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jul DISC
AP		EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA
>A> AP	SLAYBACK PHARMA LLC	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A212791	001	Dec 04, 2019	Nov NEWA
>A> AP		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A212791	002	Dec 04, 2019	Nov NEWA

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

+	HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	ALKEM LABS LTD	2.5MG	A212631	001	Jul 19, 2019	Jul NEWA
AB		5MG	A212631	002	Jul 19, 2019	Jul NEWA
AB		10MG	A212631	003	Jul 19, 2019	Jul NEWA
	@ TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007	May DISC
	@	5MG	A077107	001	Jan 29, 2007	May DISC
	@	10MG	A077107	002	Jan 29, 2007	May DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB	ANDA REPOSITORY	5MG	A205077	001	Jun 21, 2019	Aug CAHN
AB		10MG	A205077	002	Jun 21, 2019	Aug CAHN
AB		15MG	A205077	003	Jun 21, 2019	Aug CAHN
	@ MYLAN	5MG	A206735	001	Jan 27, 2016	Aug DISC
	@	10MG	A206735	002	Jan 27, 2016	Aug DISC
	@	15MG	A206735	003	Jan 27, 2016	Aug DISC
AB	PII	5MG	A205077	001	Jun 21, 2019	Jun NEWA
AB		10MG	A205077	002	Jun 21, 2019	Jun NEWA
AB		15MG	A205077	003	Jun 21, 2019	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

@	VINTAGE	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	May DISC
---	---------	---------------------	---------	-----	--------------	----------

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 70% IN PLASTIC CONTAINER

+	@ BAXTER HLTHCARE	70GM/100ML	N017521	006	Mar 26, 1982	Sep DISC
---	-------------------	------------	---------	-----	--------------	----------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@	ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003		Jul DISC
---	-----------------	-----------------------	---------	-----	--	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@	ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002		Jul DISC
---	-----------------	-----------------------	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+	@ ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	002	Jul 05, 1983	Jul DISC
---	-------------------	------------------------------------	---------	-----	--------------	----------

+	@	5GM/100ML;149MG/100ML;225MG/100ML	N018365	006	Mar 28, 1988	Jul DISC
---	---	-----------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	001	Jan 17, 1986	Jul DISC
---	-----------------	------------------------------------	---------	-----	--------------	----------

@		5GM/100ML;149MG/100ML;300MG/100ML	N018876	006	Mar 28, 1988	Jul DISC
---	--	-----------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	008	Mar 28, 1988	Jul DISC
---	-----------------	-----------------------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	007	Mar 28, 1988	Jul DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
+	@ ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365	009	Mar 28, 1988	Jul DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	008	Mar 28, 1988	Jul DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML	N018876	002	Jan 17, 1986	Jul DISC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML	N018365	003	Jul 05, 1983	Jul DISC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML	N018876	003	Jan 17, 1986	Jul DISC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML	N018365	004	Jul 05, 1983	Jul DISC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML	N018876	004	Mar 28, 1988	Jul DISC
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML	N018365	005	Mar 28, 1988	Jul DISC
@		5GM/100ML;149MG/100ML;225MG/100ML	N018365	007	Mar 28, 1988	Jul DISC
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER						
@	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876	005	Mar 28, 1988	Jul DISC
@		5GM/100ML;149MG/100ML;300MG/100ML	N018876	009	Mar 28, 1988	Jul DISC

DIAZEPAM

GEL;RECTAL

DIASTAT

+	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb CAHN
+	@	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb CAHN
+	@	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb CAHN
+	@	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb CAHN
+	@	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb CAHN

DIASTAT ACUDIAL

+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb CAHN
+	!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb CAHN

INJECTABLE;INJECTION

DIAZEPAM

AP	BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar NEWA
AP	!	HOSPIRA	A072079	001	Dec 20, 1988	Mar CTEC

DICLOFENAC

CAPSULE;ORAL

ZORVOLEX

+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Feb CAHN
+	ZYLA	18MG	N204592	001	Oct 18, 2013	Jul CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Jul CAHN

DICLOFENAC EPOLAMINE

SYSTEM;TOPICAL

LICART

+	@	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC
---	---	---------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

>A>	AB	STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Nov NEWA
-----	----	----------------	------	---------	-----	--------------	----------

TABLET;ORAL

DICLOFENAC POTASSIUM

AB		AMICI	50MG	A076561	001	Mar 18, 2004	May CAHN
----	--	-------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AB		MYLAN	1%	A204306	001	May 06, 2019	Apr NEWA
AB		PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May NEWA

SOLUTION;INTRAVENOUS

DICLOFENAC SODIUM

@	MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
		37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun NEWA

SOLUTION; TOPICAL

DICLOFENAC SODIUM

@ RICONPHARMA LLC 1.5%

A206715 001 Aug 07, 2017 Oct DISC

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>D> AB ! CASI PHARMS INC 25MG

A074376 001 Sep 28, 1995 Nov DISC

>A> @ 25MG

A074376 001 Sep 28, 1995 Nov DISC

>D> AB ! 50MG

A074376 002 Sep 28, 1995 Nov DISC

>A> @ 50MG

A074376 002 Sep 28, 1995 Nov DISC

>D> AB ! 75MG

A074394 001 Nov 30, 1995 Nov DISC

>A> @ 75MG

A074394 001 Nov 30, 1995 Nov DISC

>D> AB UNIQUE PHARM LABS 25MG

A090066 001 Dec 01, 2010 Nov CHRS

>A> AB ! 25MG

A090066 001 Dec 01, 2010 Nov CHRS

>D> AB 50MG

A090066 002 Dec 01, 2010 Nov CHRS

>A> AB ! 50MG

A090066 002 Dec 01, 2010 Nov CHRS

>D> AB 75MG

A077863 003 Jun 08, 2007 Nov CHRS

>A> AB ! 75MG

A077863 003 Jun 08, 2007 Nov CHRS

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

@ MYLAN 100MG

A076152 001 Dec 13, 2001 Jun DISC

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

@ EXELA HOLDINGS 50MG; 0.2MG

A200540 001 Mar 14, 2014 Sep DISC

@ 75MG; 0.2MG

A200540 002 Mar 14, 2014 Sep DISC

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

AP @ APC PHARMS LLC 10MG/ML

A210979 001 Jul 02, 2018 Feb DISC

CUSTOPHARM INC 10MG/ML

A210788 001 Feb 11, 2019 Jan NEWA

@ FOSUN PHARMA 10MG/ML

A210979 001 Jul 02, 2018 Sep CAHN

AP FRESENIUS KABI USA 10MG/ML

A210257 001 Jan 25, 2019 Jan NEWA

AP NEXUS PHARMS 10MG/ML

A206468 001 Feb 01, 2019 Jan NEWA

AP SLATE 10MG/ML

A207076 001 Nov 02, 2018 Feb CAHN

AP SUNGEN PHARMA 10MG/ML

A212058 001 Apr 26, 2019 Apr NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

AA ! LANNETT CO INC 25MG

A200177 001 Jul 18, 2011 Jul CHRS

TENUATE

+ @ TEVA BRANDED PHARM 25MG

N011722 002 Jul DISC

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE

AB ! LANNETT CO INC 75MG

A091680 001 Oct 24, 2011 Jul CHRS

TENUATE DOSPAN

+ @ TEVA BRANDED PHARM 75MG

N012546 001 Jul DISC

DIGOXIN

ELIXIR; ORAL

DIGOXIN

>D> AA NOVITIUM PHARMA 0.05MG/ML

A213000 001 Oct 04, 2019 Nov CAHN

AA 0.05MG/ML

A213000 001 Oct 04, 2019 Sep NFTG

>A> AA VISTAPHARM 0.05MG/ML

A213000 001 Oct 04, 2019 Nov CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

AP +! BAUSCH 1MG/ML

N005929 001 Apr CAHN

SPRAY, METERED; NASAL

MIGRANAL

+! BAUSCH 0.5MG/SPRAY

N020148 001 Dec 08, 1997 Apr CAHN

+! VALEANT 0.5MG/SPRAY

N020148 001 Dec 08, 1997 Jan CPOT

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
CARDIZEM CD

AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb CAHN
AB3	+		360MG	N020062	005	Aug 24, 1999	Feb CAHN

DILTIAZEM HYDROCHLORIDE

		APOTEX	120MG	A074943	003	Dec 19, 2000	Aug CTEC
AB2	!		240MG	A074943	001	Aug 06, 1998	May CHRS
	@	MYLAN	120MG	A075124	002	Mar 18, 1998	Aug DISC
	@		180MG	A075124	003	Mar 18, 1998	Oct DISC
	@		240MG	A075124	001	Mar 18, 1998	Oct DISC
AB2			240MG	A075124	001	Mar 18, 1998	May CHRS
AB3		NOVAST LABS	120MG	A208783	001	Jun 14, 2019	Jun NEWA
AB3			180MG	A208783	002	Jun 14, 2019	Jun NEWA
AB3			240MG	A208783	003	Jun 14, 2019	Jun NEWA
AB3			300MG	A208783	004	Jun 14, 2019	Jun NEWA
AB3			360MG	A208783	005	Jun 14, 2019	Jun NEWA
	@	PAR PHARM	360MG	A209766	001	May 30, 2018	Mar DISC

TIAZAC

AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

@ DR REDDYS 5MG/ML

A074894 001 Aug 26, 1997 May CAHN

TABLET;ORAL

CARDIZEM

AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar CAHN
AB	+		60MG	N018602	002	Nov 05, 1982	Mar CAHN
AB	+		90MG	N018602	003	Dec 08, 1986	Mar CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Mar CAHN

DILTIAZEM HYDROCHLORIDE

>A>	AB	EDENBRIDGE PHARMS	30MG	A211596	001	Nov 18, 2019	Nov NEWA
>A>	AB		60MG	A211596	002	Nov 18, 2019	Nov NEWA
>A>	AB		90MG	A211596	003	Nov 18, 2019	Nov NEWA
>A>	AB		120MG	A211596	004	Nov 18, 2019	Nov NEWA

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar CAHN
AB	+		180MG	N021392	002	Feb 06, 2003	Mar CAHN
AB	+		240MG	N021392	003	Feb 06, 2003	Mar CAHN
AB	+		300MG	N021392	004	Feb 06, 2003	Mar CAHN
AB	+		360MG	N021392	005	Feb 06, 2003	Mar CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Mar CAHN

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

DIMETHYL SULFOXIDE

@ MYLAN INSTITUTIONAL 50%

A076185 001 Nov 29, 2002 Mar DISC

RIMSO-50

+! MYLAN INSTITUTIONAL 50% N017788 001 Mar CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@ HERITAGE PHARMA 50MG

A080738 001 Oct DISC

! 50MG A080738 001 May CAHN

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ DR REDDYS 10MG/ML

A080873 001 May CAHN

@ 50MG/ML A080873 002 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ DR REDDYS 50MG/ML

A080873 003 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ DR REDDYS

5MG/ML

A074952 001 Nov 26, 1997 May CAHN

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

VUMERITY

+! BIOGEN

231MG

N211855 001 Oct 29, 2019 Oct NEWA

DISULFIRAM

TABLET; ORAL

DISULFIRAM

@ MYLAN

250MG

A203916 001 Mar 04, 2015 Oct DISC

@

500MG

A203916 002 Mar 04, 2015 Oct DISC

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB CELLTRION

EQ 125MG VALPROIC ACID

A077296 001 Jul 31, 2008 Aug CAHN

AB EQ 250MG VALPROIC ACID

A077296 002 Jul 31, 2008 Aug CAHN

AB EQ 500MG VALPROIC ACID

A077296 003 Jul 31, 2008 Aug CAHN

@ TEVA

EQ 125MG VALPROIC ACID

A076941 001 Jul 29, 2008 Sep DISC

@

EQ 250MG VALPROIC ACID

A076941 002 Jul 29, 2008 Sep DISC

@

EQ 500MG VALPROIC ACID

A076941 003 Jul 29, 2008 Sep DISC

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

@ ANCHEN PHARMS

EQ 250MG VALPROIC ACID

A078445 001 Feb 26, 2009 Sep DISC

@

EQ 500MG VALPROIC ACID

A078445 002 Aug 04, 2009 Sep DISC

AB LUPIN LTD

EQ 250MG VALPROIC ACID

A209286 001 Oct 18, 2019 Oct NEWA

AB EQ 500MG VALPROIC ACID

A209286 002 Oct 18, 2019 Oct NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP ACTAVIS LLC

160MG/8ML (20MG/ML)

N203551 004 Sep 21, 2015 Jun NEWA

@ CIPLA

20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018 Mar DISC

@

80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018 Mar DISC

@

160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018 Mar DISC

AP MYLAN LABS LTD

160MG/8ML (20MG/ML)

A208137 001 Apr 01, 2019 Mar NEWA

@ SHILPA MEDICARE LTD

20MG/ML (20MG/ML)

A210327 001 May 16, 2019 Oct DISC

AP 20MG/ML (20MG/ML)

A210327 001 May 16, 2019 May NEWA

@

80MG/4ML (20MG/ML)

A210327 002 May 16, 2019 Oct DISC

AP 80MG/4ML (20MG/ML)

A210327 002 May 16, 2019 May NEWA

@

160MG/8ML (20MG/ML)

A210327 003 May 16, 2019 Oct DISC

AP 160MG/8ML (20MG/ML)

A210327 003 May 16, 2019 May NEWA

AP TEIKOKU PHARMA

20MG/ML (20MG/ML)

N205934 001 Dec 22, 2015 Mar CAHN

AP 80MG/4ML (20MG/ML)

N205934 002 Dec 22, 2015 Mar CAHN

AP 160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015 Mar CAHN

>D> AP TEVA PHARMS USA

20MG/ML (20MG/ML)

A203877 001 Sep 16, 2015 Nov DISC

>A> @ 20MG/ML (20MG/ML)

A203877 001 Sep 16, 2015 Nov DISC

>D> AP 80MG/4ML (20MG/ML)

A203877 002 Sep 16, 2015 Nov DISC

>A> @ 80MG/4ML (20MG/ML)

A203877 002 Sep 16, 2015 Nov DISC

SOLUTION; INTRAVENOUS

DOCETAXEL

AP SUN PHARMA GLOBAL

20MG/ML (20MG/ML)

N022534 003 Jan 08, 2019 Jan NEWA

AP 80MG/4ML (20MG/ML)

N022534 004 Jan 08, 2019 Jan NEWA

AP 160MG/8ML (20MG/ML)

N022534 005 Jan 08, 2019 Jan NEWA

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB AUROBINDO PHARMA LTD

0.125MG

A210740 001 Jan 22, 2019 Jan NEWA

AB 0.25MG

A210740 002 Jan 22, 2019 Jan NEWA

AB 0.5MG

A210740 003 Jan 22, 2019 Jan NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

DOVATO

+!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019	Apr	NEWA
----	---------------	--------------------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	CADILA	5MG	A090100	001	Oct 24, 2012	Mar	CAHN
AB		10MG	A090100	002	Oct 24, 2012	Mar	CAHN
AB	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May	CAHN
AB		10MG	A077344	002	May 31, 2011	May	CAHN
	@ OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar	DISC
>D> AB	PAR PHARM	23MG	A202542	001	Jul 24, 2013	Nov	DISC
>A>	@	23MG	A202542	001	Jul 24, 2013	Nov	DISC
AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr	CAHN
AB		10MG	A090551	002	May 31, 2011	Apr	CAHN
	@ SUN PHARM	23MG	A204293	001	Jun 05, 2015	Jul	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

@	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May	CAHN
@		10MG	A078388	001	Nov 26, 2010	May	CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE	A212639	001	Aug 09, 2019	Jul	NEWA
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan	NEWA
	@ LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar	DISC
AT	MICRO LABS	EQ 2% BASE	A204778	001	Nov 08, 2019	Oct	NEWA
	@ RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	ANDA REPOSITORY	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Sep	CAHN
	@ RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul	CAHN
AT	SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Oct	CAHN
AT	SOMERSET THERAPS LLC	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Jun	NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+! HIKMA	20MG/ML	N014879	001		Mar	CAHN
----	----------	---------	---------	-----	--	-----	------

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212624	001	Sep 13, 2019	Sep	NEWA
AB		EQ 25MG BASE	A212624	002	Sep 13, 2019	Sep	NEWA
AB		EQ 50MG BASE	A212624	003	Sep 13, 2019	Sep	NEWA
AB		EQ 75MG BASE	A212624	004	Sep 13, 2019	Sep	NEWA
AB		EQ 100MG BASE	A212624	005	Sep 13, 2019	Sep	NEWA
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar	NEWA
AB		EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar	NEWA
AB		EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar	NEWA
AB		EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar	NEWA
AB		EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar	NEWA
AB	PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Aug	CMS1
AB		EQ 25MG BASE	A071422	003	Nov 09, 1987	Aug	CMS1
AB		EQ 50MG BASE	A071422	004	Nov 09, 1987	Aug	CMS1
AB		EQ 75MG BASE	A071422	005	Nov 09, 1987	Aug	CMS1
>D> AB		EQ 150MG BASE	A071422	006	Nov 09, 1987	Nov	CHRS
>A>	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Nov	CHRS
AB		EQ 150MG BASE	A071422	006	Nov 09, 1987	Aug	CMS1

TABLET;ORAL

SILENOR

+	CURRAX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN
+	PERNIX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Feb	CAHN
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Feb	CAHN

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP	GLAND PHARMA LTD	4MCG/2ML (2MCG/ML)	A210452	001	Sep 26, 2019	Sep NEWA
	+ @ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun DISC
>A> AP	SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Nov NEWA
>A> AP		4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Nov NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP	@ HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019	Oct DISC
		20MG/VIAL	A206062	001	May 13, 2019	Apr NEWA
	@ HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012	Sep CAHN
	@ MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012	Sep DISC
	INJECTABLE, LIPOSOMAL; INJECTION					
	DOXIL (LIPOSOMAL)					
AB	+ BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Aug CAHN
AB	+	50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Aug CAHN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB	! SUN PHARM INDS LTD	EQ 100MG BASE	A065053	002	Nov 22, 2000	Oct CHRS
	MONODOX					
	+ @ ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Oct DISC
AB	+	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb CAHN
	+ @	EQ 75MG BASE	N050641	003	Oct 18, 2006	Oct DISC
AB	+	EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb CAHN
	+ @	EQ 100MG BASE	N050641	001	Dec 29, 1989	Oct DISC
AB	+!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb CAHN
	TABLET; ORAL					
	DOXYCYCLINE					
	@ MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006	Apr DISC
	@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Apr DISC
	@	EQ 100MG BASE	A065377	003	Nov 07, 2006	May DISC
	@	EQ 150MG BASE	A065427	001	Jun 07, 2007	May DISC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
ACTICLATE CAP

	+ @ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb CAHN
	DOXYCYCLINE HYCLATE					
	@ AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar DISC
	@	EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar DISC
AB	CHANGZHOU PHARM	EQ 100MG BASE	A209402	001	Oct 07, 2019	Sep NEWA
	@ MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Apr DISC
	@	EQ 100MG BASE	A062337	002	Mar 29, 1982	Apr DISC
	TABLET; ORAL					
	ACTICLATE					
AB	+ ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb CAHN
AB	+!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb CAHN
	DOXYCYCLINE HYCLATE					
AB	APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr NEWA
AB		EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr NEWA
AB	CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb CAHN
AB	CHANGZHOU PHARM	EQ 100MG BASE	A211343	001	Oct 09, 2019	Sep NEWA
AB	EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	Aug CMFD
AB	HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	May CAHN
	TABLET, DELAYED RELEASE; ORAL					
	DOXYCYCLINE HYCLATE					
	@ MYLAN	EQ 75MG BASE	A090431	001	Dec 28, 2010	Jul DISC
	@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
	@	EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
	@ MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Sep DISC
	@ ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May DISC
	@	EQ 100MG BASE	A206772	002	Dec 21, 2018	May DISC
	@	EQ 150MG BASE	A206772	003	Dec 21, 2018	May DISC

DROSPIRENONETABLET;ORAL
SLYND

+! EXELTIS USA INC 4MG N211367 001 May 23, 2019 May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB ANDA REPOSITORY 3MG;0.02MG A203291 001 Jul 18, 2017 Aug CAHN

AB HETERO LABS LTD 3MG;0.02MG A211944 001 Mar 22, 2019 Mar NEWA

KYRA

AB SUN PHARM 3MG;0.02MG A202318 001 Jul 23, 2019 Jul NEWA

LORYNA

AB XIROMED 3MG;0.02MG A079221 001 Mar 28, 2011 Aug CAHN

TABLET;ORAL-28

KEMEYA

AB SUN PHARM 3MG;0.03MG A202138 001 Mar 13, 2019 Feb NEWA

SYEDA

AB XIROMED 3MG;0.03MG A090114 001 Mar 28, 2011 Aug CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB AJANTA PHARMA LTD EQ 40MG BASE A208706 004 Mar 11, 2019 Feb NEWA

AB INVENTIA EQ 20MG BASE A202336 001 Oct 28, 2015 Aug CAHN

AB EQ 30MG BASE A202336 002 Oct 28, 2015 Aug CAHN

AB EQ 60MG BASE A202336 003 Oct 28, 2015 Aug CAHN

AB QINGDAO BAHEAL PHARM EQ 20MG BASE A210599 001 Apr 17, 2019 Apr NEWA

AB EQ 30MG BASE A210599 002 Apr 17, 2019 Apr NEWA

AB EQ 60MG BASE A210599 003 Apr 17, 2019 Apr NEWA

@ TEVA PHARMS USA EQ 20MG BASE A090783 001 Dec 11, 2013 Aug DISC

@ EQ 30MG BASE A090783 002 Dec 11, 2013 Aug DISC

@ EQ 60MG BASE A090783 003 Dec 11, 2013 Aug DISC

AB YAOPHARMA CO LTD EQ 20MG BASE A207219 001 Aug 16, 2019 Aug NEWA

AB EQ 30MG BASE A207219 002 Aug 16, 2019 Aug NEWA

AB EQ 60MG BASE A207219 003 Aug 16, 2019 Aug NEWA

CAPSULE, DELAYED RELEASE;ORAL

DRIZALMA SPRINKLE

+ SUN PHARMA GLOBAL EQ 20MG BASE N212516 001 Jul 19, 2019 Jul NEWA

+ EQ 30MG BASE N212516 002 Jul 19, 2019 Jul NEWA

+ EQ 40MG BASE N212516 003 Jul 19, 2019 Jul NEWA

+! EQ 60MG BASE N212516 004 Jul 19, 2019 Jul NEWA

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

@ BRECKENRIDGE 0.5MG A204705 001 Nov 20, 2015 Jun DISC

@ 0.5MG A208227 001 Jun 22, 2018 Jun DISC

AB CADILA 0.5MG A204373 001 Oct 04, 2017 Feb CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

@ CASI PHARMS INC 1% A076075 001 Nov 26, 2002 Jun DISC

AB ! PERRIGO ISRAEL 1% A076479 001 Jun 23, 2004 May CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

@ AUROBINDO PHARMA LTD 600MG A077673 001 Sep 21, 2018 Feb DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB CIPLA 600MG;200MG;300MG A206894 001 Jun 03, 2019 May NEWA

@ TEVA PHARMS USA 600MG;200MG;300MG A091215 001 Nov 09, 2018 May DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

@ MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019	Jun DISC
	400MG;300MG;300MG	N210649	001	Mar 15, 2019	Mar NEWA

EFINACONAZOLE

SOLUTION;TOPICAL

JUBLIA

+! BAUSCH	10%	N203567	001	Jun 06, 2014	Feb CAHN
-----------	-----	---------	-----	--------------	----------

ELEXACAFITOR, IVACAFITOR, TEZACAFITOR; IVACAFITOR

TABLET, TABLET;ORAL

TRIKAFTA (COPACKAGED)

+! VERTEX PHARMS INC	100MG,75MG,50MG;N/A,150MG,N/A	N212273	001	Oct 21, 2019	Oct NEWA
----------------------	-------------------------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

+ @ NOVARTIS	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb DISC
--------------	---------------	---------	-----	--------------	----------

EMEDASTINE DIFUMARATE

SOLUTION/DROPS;OPHTHALMIC

EMADINE

+ @ NOVARTIS	0.05%	N020706	001	Dec 29, 1997	Jul DISC
--------------	-------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ AMNEAL PHARMS CO	100MG;150MG	A209721	001	Aug 22, 2018	Feb DISC
@	133MG;200MG	A209721	002	Aug 22, 2018	Feb DISC
@	167MG;250MG	A209721	003	Aug 22, 2018	Feb DISC
@	200MG;300MG	A209721	004	Aug 22, 2018	Feb DISC
@ LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Aug DISC
AB	200MG;300MG	A212114	001	Jul 26, 2019	Jul NEWA
TRUVADA					
+ GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Feb CTEC
+	133MG;200MG	N021752	003	Mar 10, 2016	Feb CTEC
+	167MG;250MG	N021752	004	Mar 10, 2016	Feb CTEC

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+ @ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar DISC
-----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ENALAPRIL MALEATE

@ BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000	Feb CAHN
@	5MG	A075621	002	Aug 22, 2000	Feb CAHN
@	10MG	A075621	003	Aug 22, 2000	Feb CAHN
@	20MG	A075621	004	Aug 22, 2000	Feb CAHN
AB HERITAGE PHARMA	2.5MG	A075479	001	Aug 22, 2000	Feb CAHN
AB	5MG	A075479	002	Aug 22, 2000	Feb CAHN
AB	10MG	A075479	003	Aug 22, 2000	Feb CAHN
AB	20MG	A075479	004	Aug 22, 2000	Feb CAHN
@ MYLAN	5MG	A075480	002	Aug 22, 2000	Jun DISC
@	10MG	A075480	003	Aug 22, 2000	Feb DISC
AB NOSTRUM LABS INC	2.5MG	A075178	002	Mar 23, 2001	Oct CAHN
AB	5MG	A075178	001	Mar 23, 2001	Oct CAHN
AB	10MG	A075178	003	Mar 23, 2001	Oct CAHN
AB	20MG	A075178	004	Mar 23, 2001	Oct CAHN
VASOTEC					
AB + BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar CAHN
AB +	5MG	N018998	001	Dec 24, 1985	Mar CAHN
AB +	10MG	N018998	002	Dec 24, 1985	Mar CAHN
AB +!	20MG	N018998	003	Dec 24, 1985	Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	NOSTRUM LABS INC	5MG;12.5MG	A076486	001	Oct 27, 2004	Oct CAHN
AB		10MG;25MG	A076486	002	Oct 27, 2004	Oct CAHN
	VASERETIC					
AB	+ BAUSCH	5MG;12.5MG	N019221	003	Jul 12, 1995	Mar CAHN
AB	+!	10MG;25MG	N019221	001	Oct 31, 1986	Mar CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
----	-----------	-----------	---------	-----	--------------	----------

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

	+ @ ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jul DISC
--	-------------------------	------	---------	-----	--------------	----------

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB	AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar NEWA
----	----------------------	----------------------	---------	-----	--------------	----------

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

>A>	AP	NANJING KING-FRIEND	30MG/0.3ML (100MG/ML)	A206834	001	Nov 29, 2019	Nov NEWA
>A>	AP		40MG/0.4ML (100MG/ML)	A206834	002	Nov 29, 2019	Nov NEWA
>A>	AP		60MG/0.6ML (100MG/ML)	A206834	003	Nov 29, 2019	Nov NEWA
>A>	AP		80MG/0.8ML (100MG/ML)	A206834	004	Nov 29, 2019	Nov NEWA
>A>	AP		100MG/ML (100MG/ML)	A206834	005	Nov 29, 2019	Nov NEWA
>A>	AP		120MG/0.8ML (150MG/ML)	A206834	006	Nov 29, 2019	Nov NEWA
>A>	AP		150MG/ML (150MG/ML)	A206834	007	Nov 29, 2019	Nov NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

	AB	BRIGHTGENE	0.5MG	A212126	001	Sep 25, 2019	Sep NEWA
	AB		1MG	A212126	002	Sep 25, 2019	Sep NEWA
	AB	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar NEWA
	AB		1MG	A206226	002	Mar 26, 2019	Mar NEWA
>D>	AB	PAR PHARM INC	0.5MG	A206294	001	Nov 23, 2016	Nov DISC
>A>	@		0.5MG	A206294	001	Nov 23, 2016	Nov DISC
>D>	AB		1MG	A206294	002	Nov 23, 2016	Nov DISC
>A>	@		1MG	A206294	002	Nov 23, 2016	Nov DISC
	AB	YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Oct NEWA
	AB		1MG	A212201	002	Nov 04, 2019	Oct NEWA

ENTRECTINIB

CAPSULE; ORAL

ROZLYTREK

	+ GENENTECH INC	100MG	N212725	001	Aug 15, 2019	Aug NEWA
	+!	200MG	N212725	002	Aug 15, 2019	Aug NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

>A>	AP	+	AVADEL LEGACY	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Nov CAHN
>D>	AP	+	FLAMEL IRELAND LTD	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016	Nov CAHN
			EPHEDRINE SULFATE					
>A>	AP		AMNEAL	50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019	Nov CAHN
>D>	AP		AMNEAL PHARMS CO	50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019	Nov CAHN
	AP			50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019	Oct NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

	@ CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Jun DISC
	@ SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011	Jul DISC

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE (AUTOINJECTOR)

AB	TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul CMFD
	@	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar DISC
	EPIPEN JR.					
AB	+! MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CTEC
	+!	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar CTEC
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
	ADRENALIN					
	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CTEC
AP	+!	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan CDFR
	+!	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan CDFR
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
	EPINEPHRINE					
	@ AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Aug DISC
	SOLUTION;INTRAVENOUS					
>A>	EPINEPHRINE (COPACKAGED)					
>A>	+! HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019	Nov NEWA
	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
	EPINEPHRINE					
	+! BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	May CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

	@ ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Sep DISC
	FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007	Sep CTEC
		150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar CTEC
	@	200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007	Oct DISC
	@	50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007	Oct DISC
	@ MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Sep DISC
	@	200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Sep DISC
	@ ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep CAHN
	@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep CAHN

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan CAHN
AP		75MG/100ML	A208554	002	Nov 23, 2018	Jan CAHN
AP	HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan NEWA
AP		75MG/100ML	A209864	002	Jan 25, 2019	Jan NEWA
	@ USV	2MG/ML	A204361	001	Mar 14, 2019	Oct DISC
AP		2MG/ML	A204361	001	Mar 14, 2019	Mar NEWA
	@	2MG/ML	A204362	001	Mar 11, 2019	Oct DISC
AP		2MG/ML	A204362	001	Mar 11, 2019	Feb NEWA
	@	75MG/100ML	A204361	002	Mar 14, 2019	Oct DISC
AP		75MG/100ML	A204361	002	Mar 14, 2019	Mar NEWA

ERDAFITINIB

TABLET;ORAL
BALVERSA

+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr NEWA
+		4MG	N212018	002	Apr 12, 2019	Apr NEWA
+!		5MG	N212018	003	Apr 12, 2019	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

AB	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Oct NEWA
AB		EQ 100MG BASE	A208396	002	Nov 05, 2019	Oct NEWA
AB		EQ 150MG BASE	A208396	003	Nov 05, 2019	Oct NEWA
AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD
AB	NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Oct NEWA
AB		EQ 100MG BASE	A208488	002	Nov 05, 2019	Oct NEWA
AB		EQ 150MG BASE	A208488	003	Nov 05, 2019	Oct NEWA
AB	SHILPA MEDICARE LTD	EQ 25MG BASE	A211960	001	Nov 05, 2019	Oct NEWA
AB		EQ 100MG BASE	A211960	002	Nov 05, 2019	Oct NEWA

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB		EQ 150MG BASE	A211960	003	Nov 05, 2019	Oct NEWA
AB	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Oct NEWA
AB		EQ 100MG BASE	A210300	002	Nov 05, 2019	Oct NEWA
AB		EQ 150MG BASE	A210300	003	Nov 05, 2019	Oct NEWA
AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar CMFD
AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar CMFD
TARCEVA						
AB	+ OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar CAHN
AB	+	EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb CTEC
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar CAHN
AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar CAHN
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP	SAVIOR LIFETEC CORP	EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar NEWA
----	---------------------	------------------	---------	-----	--------------	----------

ERYTHROMYCIN

OINTMENT;TOPICAL

AKNE-MYCIN

+	@ BAUSCH	2%	N050584	001	Jan 10, 1985	Apr CAHN
---	----------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

ERYTHRA-DERM

@ MLV 2%

A062687 001 Feb 05, 1988 Aug CAHN

@ SAPTALIS PHARMS 2%

A062687 001 Feb 05, 1988 Feb CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB	ARBOR PHARMS LLC	250MG	A062298	001		Jun CTEC
AB		333MG	A062298	003	Mar 29, 1982	Jun CTEC
AB	!	500MG	A062298	002		Jun CTEC

ERYTHROMYCIN

AB	AMNEAL PHARMS CO	250MG	A210954	001	Jul 02, 2019	Jun NEWA
AB		333MG	A210954	002	Jul 02, 2019	Jun NEWA
AB		500MG	A210954	003	Jul 02, 2019	Jun NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	+ ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001		Sep CTEC
----	--------------------	-------------------	---------	-----	--	----------

ERYPED

AB	+ ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep CTEC
----	--------------------	-------------------	---------	-----	--------------	----------

ERYTHROMYCIN ETHYLSUCCINATE

AB	AMNEAL PHARMS	EQ 200MG BASE/5ML	A211204	001	Nov 01, 2019	Oct NEWA
AB		EQ 400MG BASE/5ML	A211204	002	Nov 01, 2019	Oct NEWA
AB	ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Sep CTEC
AB		EQ 200MG BASE/5ML	A062055	003	Nov 02, 2018	Sep CTEC
AB	PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	Oct NEWA
AB		EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	Oct NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	ALLIED	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Sep CAHN
----	--------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

ESCITALOPRAM OXALATE

>D>	AB	APOTEX INC	EQ 5MG BASE	A078777	001	Sep 11, 2012	Nov CAHN
>D>	AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Nov CAHN
>D>	AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Nov CAHN
	AB	CADILA	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr CAHN
	AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr CAHN
	AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr CAHN
>A>	AB	GRAVITI PHARMS	EQ 5MG BASE	A078777	001	Sep 11, 2012	Nov CAHN
>A>	AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Nov CAHN
>A>	AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Nov CAHN

ESKETAMINE HYDROCHLORIDE

SPRAY;NASAL
SPRAVATO

+! JANSSEN PHARMS EQ 28MG BASE N211243 001 Mar 05, 2019 Mar NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION
ESMOLOL HYDROCHLORIDE

AP GLAND PHARMA LTD 10MG/ML A208538 001 Aug 14, 2019 Jul NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

	@ AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun DISC
AB		EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar NEWA
	@	EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar NEWA
AB	GLENMARK PHARMS	EQ 20MG BASE	A209495	001	May 10, 2019	Apr NEWA
AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr NEWA
	@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar DISC
	@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar DISC
AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun CTEC
AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun CTEC
AB	ZYDUS PHARMS	EQ 20MG BASE	A206296	001	May 22, 2019	May NEWA
AB		EQ 40MG BASE	A206296	002	May 22, 2019	May NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

+ @ R2 PHARMA LLC 49.3MG N202342 002 Aug 06, 2013 Aug DISC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
ESTRADIOL

AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan NEWA
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan NEWA
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan NEWA
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan NEWA
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan NEWA

GEL;TRANSDERMAL
DIVIGEL

+! VERTICAL PHARMS LLC 0.1% N022038 001 Jun 04, 2007 Jan CHRS

ESTRADIOL VALERATE

INJECTABLE;INJECTION
ESTRADIOL VALERATE

@ DR REDDYS 40MG/ML A083714 001 May CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
ESTRADIOL AND NORETHINDRONE ACETATE

	@ ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Mar DISC
AB	NOVAST LABS	0.5MG;0.1MG	A210612	001	Apr 03, 2019	Mar NEWA
AB		1MG;0.5MG	A210612	002	Apr 03, 2019	Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL
CENESTIN

+ @ ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
+ @	0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
+ @	0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
+ @	0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
+ @	1.25MG	N020992	004	Mar 13, 2000	Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL
ENJUVIA

@ ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
@	0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
@	0.625MG	N021443	003	May 10, 2004	Feb CAHN
@	0.9MG	N021443	005	Apr 27, 2007	Feb CAHN

TABLET;ORAL

ENJUVA

@

1.25MG

N021443 004 May 10, 2004 Feb CAHN

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

@ BRECKENRIDGE

1MG

A203087 001 May 08, 2019 May DISC

@

2MG

A203087 002 May 08, 2019 May DISC

@

3MG

A203087 003 May 08, 2019 May DISC

AB BRECKENRIDGE PHARM

1MG

A203087 001 May 08, 2019 Apr NEWA

AB

2MG

A203087 002 May 08, 2019 Apr NEWA

AB

3MG

A203087 003 May 08, 2019 Apr NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECIN

AP +! BAUSCH

EQ 50MG BASE/VIAL

N016093 001

Mar CAHN

AP +! VALEANT PHARMS INTL

EQ 50MG BASE/VIAL

N016093 001

Jan CAHN

ETHACRYNIC ACID

TABLET;ORAL

EDECIN

AB +! BAUSCH

25MG

N016092 001

Mar CAHN

@

50MG

N016092 002

Mar CAHN

AB +! VALEANT PHARMS INTL

25MG

N016092 001

Jan CAHN

@

50MG

N016092 002

Jan CAHN

ETHACRYNIC ACID

AB AGNITIO

25MG

A211809 001 Jul 12, 2019

Jul NEWA

AB LUPIN LTD

25MG

A211719 001 Sep 06, 2019

Aug NEWA

AB SCIEGEN PHARMS INC

25MG

A211232 001 Aug 27, 2019

Aug NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

LO-MALMOREDE

AB NOVAST LABS

0.035MG;1MG

A209548 001 Feb 11, 2019 Jan NEWA

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ELURYNG

>A>

>A> AB AMNEAL PHARMS LLC

0.015MG/24HR;0.12MG/24HR

A210830 001 Dec 11, 2019 Nov NFTG

NUVARING

>D> +! ORGANON SUB MERCK

0.015MG/24HR;0.12MG/24HR

N021187 001 Oct 03, 2001 Nov CFTG

>A> AB +!

0.015MG/24HR;0.12MG/24HR

N021187 001 Oct 03, 2001 Nov CFTG

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

INTROVALE

AB XIROMED

0.03MG;0.15MG

A079064 001 Sep 27, 2010 Aug CAHN

JAIMIESS

AB XIROMED

0.03MG,0.01MG;0.15MG,N/A

A203770 001 Dec 27, 2017 Aug CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB XIROMED

0.02MG,0.1MG;0.01MG,N/A

A205131 001 Dec 14, 2017 Aug CAHN

SYLEVIA

AB SUN PHARM

0.03MG;0.15MG

A202988 001 Feb 06, 2019 Jan NEWA

TABLET;ORAL-28

ALTAVERA

AB XIROMED

0.03MG;0.15MG

A079102 001 Aug 03, 2010 Aug CAHN

ELIFEMME

AB XIROMED

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A202507 001 Dec 04, 2015 Aug CAHN

LEVONORGESTREL AND ETHINYL ESTRADIOL

@ MYLAN LABS LTD

0.02MG;0.1MG

A202247 001 Dec 08, 2014 Jun DISC

VIENVA

AB1 XIROMED

0.02MG;0.1MG

A201088 001 May 21, 2015 Aug CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28					
NORETHINDRONE AND ETHINYL ESTRADIOL					
	@ MYLAN LABS LTD	0.05MG; 1MG	A203006	001	Aug 05, 2013 Sep DISC
NORTREL 1/35-28					
AB	! BARR	0.035MG; 1MG	A072696	001	Feb 28, 1992 Mar CHRS
ORTHO-NOVUM 1/35-28					
	+ @ JANSSEN PHARMS	0.035MG; 1MG	N017919	002	Mar DISC
TABLET, CHEWABLE; ORAL					
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	! MYLAN LABS LTD	0.035MG; 0.4MG	A202086	001	Apr 01, 2015 Mar CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21					
HAILEY 1.5/30					
AB	GLENMARK PHARMS	0.03MG; 1.5MG	A209297	001	Jun 05, 2018 Jan CDFR
LOESTRIN 21 1.5/30					
AB	+ APIL	0.03MG; 1.5MG	N017875	001	Jan CRLD
LOESTRIN 21 1/20					
AB	+ APIL	0.02MG; 1MG	N017876	001	Jan CRLD
TABLET, CHEWABLE; ORAL					
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	@ MYLAN LABS LTD	0.02MG; 1MG	A206120	001	Sep 12, 2017 Oct DISC
AB	XIROMED	0.02MG; 1MG	A209609	001	Jul 16, 2018 Aug CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28					
ESTARYLLA					
AB	XIROMED	0.035MG; 0.25MG	A090794	001	Jan 30, 2013 Aug CAHN
NORGESTIMATE AND ETHINYL ESTRADIOL					
	@ MYLAN LABS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A202132	001	Sep 09, 2015 Jan DISC
15MG, 0.25MG					
AB	NAARI PTE LTD	0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.2	A200383	001	Apr 07, 2015 Sep CAHN
15MG; 0.25MG					
AB		0.035MG; 0.25MG	A200384	001	Apr 07, 2015 Sep CAHN
ORTHO CYCLEN-28					
	+ @ JANSSEN PHARMS	0.035MG; 0.25MG	N019653	002	Dec 29, 1989 Apr DISC
SPRINTEC					
AB	! BARR	0.035MG; 0.25MG	A075804	001	Sep 25, 2002 Apr CHRS
TRI-ESTARYLLA					
AB	XIROMED	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.2	A090793	001	Jan 30, 2013 Aug CAHN
15MG, 0.25MG					
TRI-LO-ESTARYLLA					
AB	XIROMED	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.2	A091232	001	Jun 29, 2015 Aug CAHN
15MG, 0.25MG					

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL					
ANNOVERA					
	+! THERAPEUTICSMD INC	0.013MG/24HR; 0.15MG/24HR	N209627	001	Aug 10, 2018 May CMFD
	+ @	0.013MG/24HR; 0.15MG/24HR	N209627	001	Aug 10, 2018 Feb DISC

ETHOSUXIMIDE

CAPSULE; ORAL					
ETHOSUXIMIDE					
AB	STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019 Feb NEWA
SYRUP; ORAL					
ETHOSUXIMIDE					
	@ TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993 May DISC

ETIDRONATE DISODIUM

TABLET; ORAL					
ETIDRONATE DISODIUM					
>D>	MYLAN	200MG	A075800	001	Jan 24, 2003 Nov DISC
>A>	@	200MG	A075800	001	Jan 24, 2003 Nov DISC
>D>	!	400MG	A075800	002	Jan 24, 2003 Nov DISC
>A>	@	400MG	A075800	002	Jan 24, 2003 Nov DISC

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

@ LUITPOLD 2MG/ML

A078867 001 Dec 22, 2009 Feb DISC

@ PAR STERILE PRODUCTS 2MG/ML

A091297 001 Jun 20, 2012 Apr DISC

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+! CHEPLAPHARM EQ 100MG BASE/VIAL

N020457 001 May 17, 1996 May CAHN

EVEROLIMUS

TABLET; ORAL

AFINITOR

>D> + NOVARTIS 2.5MG

N022334 003 Jul 09, 2010 Nov CFTG

>A> AB + 2.5MG

N022334 003 Jul 09, 2010 Nov CFTG

>D> +! 5MG

N022334 001 Mar 30, 2009 Nov CFTG

>A> AB +! 5MG

N022334 001 Mar 30, 2009 Nov CFTG

+! 5MG

N022334 001 Mar 30, 2009 Apr CHRS

>D> + 7.5MG

N022334 004 Mar 30, 2012 Nov CFTG

>A> AB + 7.5MG

N022334 004 Mar 30, 2012 Nov CFTG

>D> + 10MG

N022334 002 Mar 30, 2009 Nov CFTG

>A> AB + 10MG

N022334 002 Mar 30, 2009 Nov CFTG

+ 10MG

N022334 002 Mar 30, 2009 Apr CHRS

EVEROLIMUS

>A> AB PAR PHARM 2.5MG

A207934 001 Dec 09, 2019 Nov NFTG

>A> AB 5MG

A207934 002 Dec 09, 2019 Nov NFTG

>A> AB 7.5MG

A207934 003 Dec 09, 2019 Nov NFTG

>A> AB TEVA PHARMS USA 2.5MG

A210050 001 Dec 09, 2019 Nov NFTG

>A> AB 5MG

A210050 002 Dec 09, 2019 Nov NFTG

>A> AB 7.5MG

A210050 003 Dec 09, 2019 Nov NFTG

>A> AB 10MG

A210050 004 Dec 09, 2019 Nov NFTG

ZORTRESS

+ NOVARTIS 1MG

N021560 004 Aug 10, 2018 Mar NEWA

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

+ NOVARTIS PHARM 2MG

N203985 001 Aug 29, 2012 Apr CTEC

AB + 2MG

N203985 001 Aug 29, 2012 Apr CFTG

+ 3MG

N203985 002 Aug 29, 2012 Apr CTEC

AB + 3MG

N203985 002 Aug 29, 2012 Apr CFTG

+! 5MG

N203985 003 Aug 29, 2012 Apr CTEC

AB +! 5MG

N203985 003 Aug 29, 2012 Apr CFTG

EVEROLIMUS

@ MYLAN 2MG

A210130 001 Apr 19, 2019 Apr NFTG

@ 3MG

A210130 002 Apr 19, 2019 Apr NFTG

@ 5MG

A210130 003 Apr 19, 2019 Apr NFTG

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ AMNEAL PHARMS 25MG

A206421 001 Dec 28, 2018 Jul DISC

@ BRECKENRIDGE 25MG

A211031 001 Feb 21, 2019 May DISC

AB BRECKENRIDGE PHARM 25MG

A211031 001 Feb 21, 2019 Feb NEWA

AB MAYNE PHARMA INC 25MG

A208764 001 Aug 08, 2019 Jul NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

>D> @ ACCORD HLTHCARE 10MG

A211550 001 Oct 26, 2018 Nov CMFD

>A> AB 10MG

A211550 001 Oct 26, 2018 Nov CMFD

@ 10MG

A211550 001 Oct 26, 2018 Apr DISC

AB MYLAN 10MG

A201790 001 Apr 26, 2019 Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB GLENMARK PHARMS LTD 10MG; 10MG

A208699 001 Jun 27, 2019 Jun NEWA

AB 10MG; 20MG

A208699 002 Jun 27, 2019 Jun NEWA

AB 10MG; 40MG

A208699 003 Jun 27, 2019 Jun NEWA

AB 10MG; 80MG

A208699 004 Jun 27, 2019 Jun NEWA

FAMOTIDINEFOR SUSPENSION; ORAL
FAMOTIDINE

>D>	AB	LUPIN LTD	40MG/5ML	A090440	001	Jun 29, 2010	Nov CHRS
>A>	AB	!	40MG/5ML	A090440	001	Jun 29, 2010	Nov CHRS
>D>		PEPCID					
>D>	AB	+! SALIX PHARMS	40MG/5ML	N019527	001	Feb 02, 1987	Nov DISC
>A>		+ @	40MG/5ML	N019527	001	Feb 02, 1987	Nov DISC

TABLET; ORAL
FAMOTIDINE

AB		CELLTRION	20MG	A075786	001	Apr 16, 2001	Aug CAHN
AB			40MG	A075786	002	Apr 16, 2001	Aug CAHN
		@ MYLAN	40MG	A075704	002	Apr 16, 2001	Apr DISC

FEBUXOSTATTABLET; ORAL
FEBUXOSTAT

AB		ALEMBIC PHARMS LTD	40MG	A205421	001	Jul 01, 2019	Jun NFTG
AB			80MG	A205421	002	Jul 01, 2019	Jun NFTG
>A>	AB	HIKMA	40MG	A205414	001	Oct 15, 2019	Nov CAHN
>A>	AB		80MG	A205414	002	Oct 15, 2019	Nov CAHN
	AB	MYLAN	40MG	A205385	001	Jul 01, 2019	Jun NFTG
	AB		80MG	A205385	002	Jul 01, 2019	Jun NFTG
	AB	SUN PHARM	40MG	A205467	001	Jul 01, 2019	Jun NFTG
	AB		80MG	A205467	002	Jul 01, 2019	Jun NFTG
>D>	AB	WEST-WARD PHARMS INT	40MG	A205414	001	Oct 15, 2019	Nov CAHN
	AB		40MG	A205414	001	Oct 15, 2019	Sep NEWA
>D>	AB		80MG	A205414	002	Oct 15, 2019	Nov CAHN
	AB		80MG	A205414	002	Oct 15, 2019	Sep NEWA
		ULORIC					
AB	+	TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Jun CFTG
AB	+	!	80MG	N021856	002	Feb 13, 2009	Jun CFTG

FEDRATINIB HYDROCHLORIDECAPSULE; ORAL
INREBIC

+	!	IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019	Aug NEWA
---	---	--------	---------------	---------	-----	--------------	----------

FELBAMATESUSPENSION; ORAL
FELBAMATE

AB		VISTAPHARM	600MG/5ML	A211333	001	May 31, 2019	May NEWA
----	--	------------	-----------	---------	-----	--------------	----------

TABLET; ORAL
FELBAMATE

AB		CADILA	400MG	A208970	001	May 30, 2017	Jul CAHN
AB			600MG	A208970	002	May 30, 2017	Jul CAHN

FELODIPINETABLET, EXTENDED RELEASE; ORAL
FELODIPINE

		@ MYLAN	2.5MG	A078855	001	Apr 17, 2008	Oct DISC
		@	5MG	A078855	002	Apr 17, 2008	Oct DISC
		@	10MG	A078855	003	Apr 17, 2008	Oct DISC
AB	!	TORRENT PHARMS LTD	10MG	A202170	003	Nov 28, 2011	Oct CHRS
AB		YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019	Apr NEWA
AB			5MG	A204800	002	Apr 29, 2019	Apr NEWA
AB			10MG	A204800	003	Apr 29, 2019	Apr NEWA

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB		AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan CAHN
AB			134MG	A207805	002	Nov 16, 2017	Jan CAHN
AB			200MG	A207805	003	Nov 16, 2017	Jan CAHN
AB		INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Apr NEWA
AB			134MG	A207564	002	Apr 19, 2019	Apr NEWA
AB			200MG	A207564	003	Apr 19, 2019	Apr NEWA
		@ NOVAST LABS	67MG	A207564	001	Apr 19, 2019	Oct DISC
AB			67MG	A207564	001	Apr 19, 2019	Sep CAHN
		@	134MG	A207564	002	Apr 19, 2019	Oct DISC
AB			134MG	A207564	002	Apr 19, 2019	Sep CAHN

CAPSULE;ORAL							
FENOFIBRATE (MICRONIZED)							
	@	200MG	A207564	003	Apr 19, 2019	Oct	DISC
AB		200MG	A207564	003	Apr 19, 2019	Sep	CAHN
TABLET;ORAL							
FENOFIBRATE							
AB	ALEMBIC PHARMS LTD	48MG	A210476	001	Aug 09, 2019	Jul	NEWA
AB		145MG	A210476	002	Aug 09, 2019	Jul	NEWA
AB	APPCO PHARMA LLC	54MG	A210670	001	Sep 06, 2019	Aug	NEWA
AB		160MG	A210670	002	Sep 06, 2019	Aug	NEWA
AB	AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan	CAHN
AB		160MG	A207803	002	Dec 19, 2017	Jan	CAHN
	@ GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb	DISC
	@	160MG	A210606	002	Aug 17, 2018	Feb	DISC
AB	NUVO PHARM	54MG	A210670	001	Sep 06, 2019	Sep	CAHN
AB		160MG	A210670	002	Sep 06, 2019	Sep	CAHN
AB	ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan	NEWA
AB		160MG	A209660	002	Feb 11, 2019	Jan	NEWA
FENOGLIDE							
AB	+ SALIX	40MG	N022118	001	Aug 10, 2007	Mar	CAHN
AB	+!	120MG	N022118	002	Aug 10, 2007	Mar	CAHN
TRIGLIDE							
BX	+ SKYEPHARMA AG	160MG	N021350	002	May 07, 2005	Oct	CMFD
	+ @	160MG	N021350	002	May 07, 2005	Sep	DISC
<u>FENOFIBRIC ACID</u>							
TABLET;ORAL							
FIBRICOR							
	+ ATHENA	35MG	N022418	001	Aug 14, 2009	Feb	CAHN
	+!	105MG	N022418	002	Aug 14, 2009	Feb	CAHN
<u>FENOPROFEN CALCIUM</u>							
TABLET;ORAL							
FENOPROFEN CALCIUM							
	@ ANI PHARMS INC	EQ 600MG BASE	A072274	001	May 02, 1988	May	CAHN
<u>FENTANYL</u>							
SPRAY;SUBLINGUAL							
SUBSYS							
	+ BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012	Sep	CAHN
	+	0.2MG	N202788	002	Jan 04, 2012	Sep	CAHN
	+!	0.4MG	N202788	003	Jan 04, 2012	Sep	CAHN
	+	0.6MG	N202788	004	Jan 04, 2012	Sep	CAHN
	+	0.8MG	N202788	005	Jan 04, 2012	Sep	CAHN
	+	1.2MG	N202788	006	Aug 30, 2012	Sep	CAHN
	+	1.6MG	N202788	007	Aug 30, 2012	Sep	CAHN
<u>FENTANYL CITRATE</u>							
INJECTABLE;INJECTION							
FENTANYL CITRATE PRESERVATIVE FREE							
AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr	NEWA
SPRAY, METERED;NASAL							
LAZANDA							
	+ BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	CAHN
	+ @	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep	DISC
	+ @	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep	CAHN
	+!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	CAHN
TABLET;SUBLINGUAL							
ABSTRAL							
	+ @ SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Oct	DISC
	+ @	EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Oct	DISC
	+ @	EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Oct	DISC
	+ @	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Oct	DISC
	+ @	EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Oct	DISC
	+ @	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Oct	DISC
FENTANYL CITRATE							
	@ ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Oct	DISC
	@	EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Oct	DISC
	@	EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Oct	DISC
	@	EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Oct	DISC
	@	EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Oct	DISC
	@	EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Oct	DISC

FERRIC CARBOXYMALTOSEINJECTABLE;INTRAVENOUS
INJECTAFER

+! AM REGENT 750MG IRON/15ML (50MG IRON/ML) N203565 001 Jul 25, 2013 Jun CAHN

FERRIC MALTOLCAPSULE;ORAL
ACCRUFER

+! SHIELD TX 30MG IRON N212320 001 Jul 25, 2019 Jul NEWA

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATEAB DR REDDYS LABS LTD 4MG A204975 001 Aug 13, 2019 Jul NEWA
AB 8MG A204975 002 Aug 13, 2019 Jul NEWAFEXOFENADINE HYDROCHLORIDESUSPENSION;ORAL
FEXOFENADINE HYDROCHLORIDE

@ P AND L 30MG/5ML A201311 001 Jul 25, 2012 Aug CAHN

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE
@ MYLAN 30MG A077081 002 Apr 11, 2008 Jul DISCFINAFLOXACINSUSPENSION/DROPS;OTIC
XTORO

+ @ MERLION PHARMS GMBH 0.3% N206307 001 Dec 17, 2014 Apr DISC

FINASTERIDETABLET;ORAL
FINASTERIDE

@ MYLAN 5MG A077578 001 Dec 18, 2006 Jul DISC

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

>A>	FINGOLIMOD HYDROCHLORIDE						
>A> AB	BIOCON LTD	EQ 0.5MG BASE	A207979	001	Dec 04, 2019	Nov	NFTG
>A> AB	HEC PHARM CO LTD	EQ 0.5MG BASE	A207939	001	Dec 04, 2019	Nov	NFTG
>A> AB	SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Nov	NFTG
	GILENYA						
>D>	+! NOVARTIS	EQ 0.5MG BASE	N022527	001	Sep 21, 2010	Nov	CFTG
>A> AB	+!	EQ 0.5MG BASE	N022527	001	Sep 21, 2010	Nov	CFTG

FLOXURIDINEINJECTABLE;INJECTION
FLOXURIDINE

@ LUITPOLD 500MG/VIAL A203008 001 Nov 22, 2017 Mar DISC

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP WOODWARD 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Oct CAHN
AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Oct CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

@ DR REDDYS 200MG/100ML (2MG/ML) A076653 001 Jul 29, 2004 May CAHN
@ 400MG/200ML (2MG/ML) A076653 002 Jul 29, 2004 May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	May	CAHN
	@	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	May	CAHN
	WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Oct	CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Oct	CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Oct	CAHN

TABLET;ORAL

FLUCONAZOLE

AB	CHARTWELL	50MG	A076665	001	Jul 29, 2004	Jun	CAHN
AB		100MG	A076665	002	Jul 29, 2004	Jun	CAHN
AB		150MG	A076665	003	Jul 29, 2004	Jun	CAHN
AB		200MG	A076665	004	Jul 29, 2004	Jun	CAHN

FLUCYTOSINECAPSULE; ORAL
ANCOBON

AB	+	BAUSCH	250MG	N017001	001		Feb	CAHN
AB	+	!	500MG	N017001	002		Feb	CAHN

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE
@ MYLAN LABS LTD

50MG/2ML (25MG/ML)

A200647 001 Dec 21, 2011 Oct DISC

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP DECATUR 20-300mCi/ML

A204463 001 Oct 21, 2014 Apr CAHN

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

	@	DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	May	CAHN
	@		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	May	CAHN
AP	!	HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A078527	002	Mar 23, 2009	Aug	CHRS
	@	MYLAN LABS LTD	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Aug	DISC

FLUNISOLIDEAEROSOL, METERED; INHALATION
AEROSPAN HFA

+ @ MYLAN SPECIALITY LP 0.078MG/INH

N021247 001 Jan 27, 2006 Jul DISC

SPRAY, METERED; NASAL
FLUNISOLIDE

>D>		APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Nov	DISC
>A>		@	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Nov	DISC
			0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun	CMFD
AB		APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun	CMFD

FLUOCINOLONE ACETONIDEOIL/DROPS; OTIC
FLAC

AT ANDA REPOSITORY 0.01%

A210736 001 Apr 11, 2018 Sep CAHN

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE

	@	ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar	DISC
AT		ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan	NEWA
AT		GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan	CMFD
AT		LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb	CAHN

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

	@	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb	DISC
AB		TELIGENT PHARMA INC	0.1%	A211758	001	Apr 03, 2019	Mar	NEWA

OINTMENT; TOPICAL
FLUOCINONIDE

>A> AB CHEMO RESEARCH SL 0.05% A212976 001 Nov 26, 2019 Nov NEWA

SOLUTION; TOPICAL
FLUOCINONIDE

AT TELIGENT PHARMA INC 0.05% A207554 001 Mar 18, 2019 Mar NEWA

FLUORODOPA F-18SOLUTION; INTRAVENOUS
FLUORODOPA F18

+! FEINSTEIN 0.42-8.33mCi/ML N200655 001 Oct 10, 2019 Oct NEWA

FLUOROMETHOLONESUSPENSION/DROPS; OPHTHALMIC
FML FORTE

	+	ALLERGAN	0.25%	N019216	001	Apr 23, 1986	Jun	CHRS
	+		0.25%	N019216	001	Apr 23, 1986	Jun	CRLD

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
FLAREX

+! EYEVANCE 0.1%

N019079 001 Feb 11, 1986 Feb CAHN

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

@ EYEVANCE 0.1%;0.3%

N050628 001 Jul 21, 1989 May CAHN

FLUOROURACILCREAM;TOPICAL
EFUDEX

AB +! BAUSCH 5%

N016831 003 Aug CAHN

FLUOROPLEX

+! ALMIRALL 1%

N016988 001 Feb CAHN

INJECTABLE;INJECTION
FLUOROURACIL

>A> AP INGENUS PHARMS LLC 500MG/10ML (50MG/ML)

A209271 001 Dec 11, 2019 Nov NEWA

>A> AP 2.5GM/50ML (50MG/ML)

A209271 002 Dec 11, 2019 Nov NEWA

@ MYLAN LABS LTD 500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012 Sep DISC

@ 1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012 Sep DISC

SOLUTION;TOPICAL
EFUDEX

AT +! BAUSCH 2%

N016831 001 Aug CAHN

AT +! 5%

N016831 002 Aug CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB1 APNAR PHARMA LP EQ 10MG BASE

A075049 001 Aug 02, 2001 Jun CAHN

AB1 EQ 20MG BASE

A075049 002 Jan 29, 2002 Jun CAHN

AB EQ 40MG BASE

A075049 003 Jan 29, 2002 Jun CAHN

@ BEXIMCO PHARMS USA EQ 10MG BASE

A075807 001 Jan 29, 2002 Feb CAHN

@ EQ 20MG BASE

A075807 002 Jan 29, 2002 Feb CAHN

AB1 CADILA PHARMS LTD EQ 10MG BASE

A206993 001 May 23, 2019 May NEWA

AB1 EQ 20MG BASE

A206993 002 May 23, 2019 May NEWA

AB EQ 40MG BASE

A206993 003 May 23, 2019 May NEWA

@ CELLTRION EQ 10MG BASE

A078143 001 Jan 16, 2008 Aug CAHN

@ EQ 20MG BASE

A078143 002 Jan 16, 2008 Aug CAHN

@ EQ 40MG BASE

A078143 003 Jan 16, 2008 Aug CAHN

@ MYLAN EQ 10MG BASE

A078045 001 Nov 17, 2008 Oct DISC

@ EQ 20MG BASE

A078045 002 Nov 17, 2008 Oct DISC

@ PAR PHARM EQ 40MG BASE

A076922 003 Dec 16, 2004 Mar DISC

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

@ BARR EQ 90MG BASE

A076237 001 Mar 24, 2010 Apr DISC

! DR REDDYS LABS LTD EQ 90MG BASE

A078572 001 Mar 22, 2010 Apr CTEC

AB ! EQ 90MG BASE

A078572 001 Mar 22, 2010 Apr CHRS

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@ NOSTRUM LABS INC EQ 20MG BASE/5ML

A075292 001 Feb 07, 2002 May CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB APPCO PHARMA LLC EQ 10MG BASE

A211696 001 Jan 30, 2019 Jan NEWA

AB EQ 20MG BASE

A211696 002 Jan 30, 2019 Jan NEWA

AB DR REDDYS LABS LTD EQ 60MG BASE

A211721 001 Jan 25, 2019 Jan NEWA

AB G AND W LABS INC EQ 60MG BASE

A212191 001 Jul 05, 2019 Jun NEWA

AB LUPIN LTD EQ 10MG BASE

A211653 001 Apr 15, 2019 Apr NEWA

AB EQ 20MG BASE

A211653 002 Apr 15, 2019 Apr NEWA

AB EQ 60MG BASE

A211632 001 Feb 08, 2019 Feb NEWA

AB SCIEGEN PHARMS INC EQ 10MG BASE

A210935 001 Mar 20, 2019 Mar NEWA

AB EQ 20MG BASE

A210935 002 Mar 20, 2019 Mar NEWA

AB TARO EQ 60MG BASE

A211477 001 Nov 21, 2018 Sep CAHN

AB UPSHER SMITH LABS EQ 10MG BASE

A211696 001 Jan 30, 2019 May CAHN

AB EQ 20MG BASE

A211696 002 Jan 30, 2019 May CAHN

FLUOXYMESTERONETABLET;ORAL
FLUOXYMESTERONE

! UPSHER SMITH LABS 10MG A088342 001 Oct 21, 1983 Jul CAHN

FLUPHENAZINE HYDROCHLORIDETABLET;ORAL
FLUPHENAZINE HYDROCHLORIDEAB ! LANNETT CO INC 10MG A089743 001 Aug 25, 1988 May CHRS
AB MYLAN 10MG A089804 001 Aug 12, 1988 May CHRSFLURANDRENOLIDECREAM;TOPICAL
CORDRAN SPAT +! ALMIRALL 0.025% N012806 003 Feb CAHN
+! 0.05% N012806 002 Feb CAHNLOTION;TOPICAL
CORDRAN

AT +! ALMIRALL 0.05% N013790 001 Feb CAHN

OINTMENT;TOPICAL
CORDRANAT + @ ALMIRALL 0.025% N012806 004 Feb CAHN
+! 0.05% N012806 001 Feb CAHNTAPE;TOPICAL
CORDRAN

+! ALMIRALL 0.004MG/SQ CM N016455 001 Feb CAHN

FLURBIPROFENTABLET;ORAL
FLURBIPROFENMYLAN 50MG A074358 001 Jun 20, 1994 Oct CTEC
@ SUN PHARM INDS INC 50MG A075058 001 Apr 27, 2001 Oct DISC
@ 100MG A075058 002 Apr 27, 2001 Oct DISCFLUTAMIDECAPSULE;ORAL
FLUTAMIDE

@ ACTAVIS LABS FL INC 125MG A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATECREAM;TOPICAL
FLUTICASONE PROPIONATE

AB ! PERRIGO ISRAEL 0.05% A076793 001 May 14, 2004 May CAHN

POWDER;INHALATION
ARMONAIR RESPICLICK+ @ TEVA PHARM 0.055MG/INH N208798 001 Jan 27, 2017 Sep DISC
+ @ 0.113MG/INH N208798 002 Jan 27, 2017 Jul DISC
+ @ 0.232MG/INH N208798 003 Jan 27, 2017 Sep DISCFLUTICASONE PROPIONATE; SALMETEROL XINAFOATEPOWDER;INHALATION
ADVAIR DISKUS 100/50

AB +! GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH N021077 001 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 250/50

AB +! GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH N021077 002 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 500/50

AB +! GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH N021077 003 Aug 24, 2000 Jan CFTG

AIRDUO DIGIHALER

+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH N208799 004 Jul 12, 2019 Jul NEWA
+ 0.113MG/INH;EQ 0.014MG BASE/INH N208799 005 Jul 12, 2019 Jul NEWA
+ 0.232MG/INH;EQ 0.014MG BASE/INH N208799 006 Jul 12, 2019 Jul NEWA

AIRDUO RESPICLICK

+! TEVA PHARM 0.232MG/INH;EQ 0.014MG BASE/INH N208799 003 Jan 27, 2017 Jul CMS1

WIXELA INHUB

AB MYLAN 0.1MG/INH;EQ 0.05MG BASE/INH A208891 001 Jan 30, 2019 Jan NFTG
AB 0.25MG/INH;EQ 0.05MG BASE/INH A208891 002 Jan 30, 2019 Jan NFTG
AB 0.5MG/INH;EQ 0.05MG BASE/INH A208891 003 Jan 30, 2019 Jan NFTG

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL
FLUVASTATIN SODIUM

@ MYLAN EQ 80MG BASE A202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE

TABLET;ORAL
FLUVOXAMINE MALEATE

@ MYLAN 25MG A075889 001 Nov 29, 2000 May DISC
@ 50MG A075889 002 Nov 29, 2000 May DISC
@ 100MG A075889 003 Nov 29, 2000 May DISC

FOLIC ACID

INJECTABLE;INJECTION
FOLIC ACID

AP EXELA PHARMA SCS LLC 5MG/ML A202522 001 Nov 06, 2019 Oct NEWA
AP ! FRESenius KABI USA 5MG/ML A089202 001 Feb 18, 1986 Oct CTEC
FOLVITE
>D> @ WYETH PHARMS INC 5MG/ML N005897 008 Nov CRLD
>A> + @ 5MG/ML N005897 008 Nov CRLD
TABLET;ORAL
FOLIC ACID
AA QINGDAO BAHEAL PHARM 1MG A091145 001 Jul 12, 2013 May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS
GONAL-F RFF REDI-JECT

>A> +! EMD SERONO 150 IU/0.25ML N021684 004 Nov 25, 2019 Nov NEWA

FOMEPIZOLE

INJECTABLE;INJECTION
ANTIZOL

+ @ PAR PHARM INC 1.5GM/1.5ML (1GM/ML) N020696 001 Dec 04, 1997 Jun DISC
FOMEPIZOLE
AP ! MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML) A078639 001 Mar 03, 2008 Jun CHRS

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION
DULERA

+ MERCK SHARP DOHME 0.005MG/INH;0.05MG/INH N022518 003 Aug 12, 2019 Aug NEWA

FOSAMPRENAVIR CALCIUM

TABLET;ORAL
FOSAMPRENAVIR CALCIUM

>A> AB SUN PHARM EQ 700MG BASE A204024 001 Nov 20, 2019 Nov NEWA

FOSAPREPITANT

POWDER;INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE
TEVA PHARMS USA

150MG/VIAL N210064 001 Sep 05, 2019 Sep NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE

AP APOTEX EQ 150MG BASE/VIAL A205020 001 Sep 05, 2019 Aug NEWA
AP BAXTER HLTHCARE CORP EQ 150MG BASE/VIAL A211860 001 Sep 05, 2019 Aug NEWA
AP BE PHARMS EQ 150MG BASE/VIAL A212309 001 Sep 05, 2019 Aug NEWA
AP LUPIN LTD EQ 150MG BASE/VIAL A210689 001 Sep 05, 2019 Aug NEWA
AP MSN LABS PVT LTD EQ 150MG BASE/VIAL A209965 001 Sep 05, 2019 Aug NEWA
MYLAN LABS LTD EQ 115MG BASE/VIAL A204015 001 Sep 05, 2019 Aug NFTG
AP EQ 150MG BASE/VIAL A204015 002 Sep 05, 2019 Aug NEWA
AP SUNGEN PHARMA EQ 150MG BASE/VIAL A211624 001 Sep 05, 2019 Aug NEWA
TEVA PHARMS USA EQ 150MG BASE/VIAL N210064 001 Sep 05, 2019 Oct CPOT
150MG/VIAL N210064 001 Sep 05, 2019 Oct CAIN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	10MG; 12.5MG	A076608	001	Dec 03, 2004	May CAHN
@	20MG; 12.5MG	A076608	002	Dec 03, 2004	May CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN
@ LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007	Feb DISC
@	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010	Feb DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

AB	AMNEAL PHARMS CO	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	Aug CMFD
	@	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	May DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

AO	+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Apr CMS1
AP	+		50MG/ML	N021344	001	Apr 25, 2002	Feb CFTG

FULVESTRANT

AO	GLENMARK PHARMS INC	50MG/ML	A207754	001	Aug 22, 2019	Aug NEWA
>A> AO	HBT LABS INC	50MG/ML	A209714	001	Nov 21, 2019	Nov NEWA
AO	MYLAN INSTITUTIONAL	50MG/ML	A208811	001	Jul 23, 2019	Jul NEWA
AO	SAGENT PHARMS INC	50MG/ML	A205871	001	Aug 22, 2019	Aug NEWA
AO	SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Apr NEWA

SOLUTION; INTRAMUSCULAR

FULVESTRANT

	FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019	May NEWA
	TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Aug NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	AUROBINDO PHARMA LTD	10MG/ML	A212174	001	May 03, 2019	Apr NEWA
----	----------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

FUROSEMIDE

	@ ANI PHARMS INC	20MG	A071379	001	Jan 02, 1987	Jul CAHN
	@	40MG	A070413	001	Feb 26, 1986	Sep CAHN
AB	AVET	20MG	N018413	001	Nov 30, 1983	Oct CAHN
AB		40MG	N018413	002	Nov 30, 1983	Oct CAHN
AB	HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Feb CAHN
AB		40MG	N018413	002	Nov 30, 1983	Feb CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	GRANULES INDIA LTD	100MG	A075360	001	Apr 06, 2005	Jun CAHN
AB		300MG	A075360	002	Apr 06, 2005	Jun CAHN
AB		400MG	A075360	003	Apr 06, 2005	Jun CAHN

SOLUTION; ORAL

GABAPENTIN

>A> AA	VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Nov NEWA
--------	------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

GABAPENTIN

	@ IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005	Jul DISC
	@	800MG	A076017	005	Apr 29, 2005	Jul DISC
	@ LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar DISC
	@	800MG	A209306	002	Aug 24, 2018	Mar DISC
AB	RUBICON	600MG	A077661	004	Sep 13, 2006	Aug CAHN
AB		800MG	A077661	005	Sep 13, 2006	Aug CAHN

GADOTERATE MEGLUMINESOLUTION; INTRAVENOUS
CLARISCAN

AP	GE HEALTHCARE	7.538GM/20ML (376.9MG/ML)	A210016	003	Nov 01, 2019	Oct	NFTG
AP		3.769GM/10ML (376.9MG/ML)	A210016	001	Nov 01, 2019	Oct	NFTG
AP		5.6535GM/15ML (376.9MG/ML)	A210016	002	Nov 01, 2019	Oct	NFTG
DOTAREM							
AP	+! GUERBET	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Oct	CFTG
AP	+!	5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Oct	CFTG
AP	+!	7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Oct	CFTG

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	@ HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009	May	CAHN
	@	EQ 4MG BASE	A077587	001	Jul 09, 2009	Sep	DISC
AB		EQ 4MG BASE	A077587	001	Jul 09, 2009	May	CAHN
	@	EQ 8MG BASE	A077585	002	Sep 15, 2009	May	CAHN
	@	EQ 8MG BASE	A077587	002	Jul 09, 2009	Sep	DISC
AB		EQ 8MG BASE	A077587	002	Jul 09, 2009	May	CAHN
	@	EQ 12MG BASE	A077585	003	Sep 15, 2009	May	CAHN
	@	EQ 12MG BASE	A077587	003	Jul 09, 2009	Sep	DISC
AB		EQ 12MG BASE	A077587	003	Jul 09, 2009	May	CAHN

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS	CURIUM	2mCi/ML	N018058	001		Jan	CAHN
----	--------	---------	---------	-----	--	-----	------

GALLIUM DOTATOC GA-68

SOLUTION; INTRAVENOUS

GALLIUM DOTATOC GA 68

	+! UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Aug	NEWA
--	---------------------	-------------	---------	-----	--------------	-----	------

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

@ CHEPLAPHARM

25MG/ML

N019961 002 Jan 17, 1991 Aug CAHN

GANCICLOVIR

SOLUTION; INTRAVENOUS

GANZYK-RTU

	+! EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Sep	CTNA
--	-------------------------	----------------------	---------	-----	--------------	-----	------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

AP	+! CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Aug	CAHN
GANCICLOVIR SODIUM							
AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658	001	Jun 21, 2010	Jul	CTNA
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul	CTNA
	@ LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Jul	CTNA
	@	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Feb	DISC
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Jul	CTNA
AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Jul	CTNA

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

AP	+! ORGANON USA INC	250MCG/0.5ML	N021057	001	Jul 29, 1999	Mar	CPOT
AP	SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	Mar	CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	Jan	CAHN
	@ INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Oct	DISC
AP		200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb	NEWA
	@	1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Oct	DISC

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb NEWA
	@	2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Oct DISC
AP		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb NEWA
	@ LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Feb DISC
	@	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Feb DISC
	@ SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Oct DISC
AP		EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Feb NEWA
AP		200MG/5.26ML (38MG/ML)	A210991	001	Oct 04, 2019	Sep NEWA
	@	EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Oct DISC
AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Feb NEWA
AP		1GM/26.3ML (38MG/ML)	A210991	002	Oct 04, 2019	Sep NEWA
AP		2GM/52.6ML (38MG/ML)	A210991	003	Oct 04, 2019	Sep NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

	@ SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Oct DISC
--	----------------------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT	TELIGENT PHARMA INC	EQ 0.1% BASE	A209304	001	Oct 18, 2019	Oct NEWA
	INJECTABLE;INJECTION					
	GENTAMICIN SULFATE					
AP	! FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Jul CHRS
	OINTMENT;OPHTHALMIC					
	GENTAMICIN SULFATE					
AT	FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Sep CAHN

>A> GIVOSIRAN SODIUM

>A> SOLUTION;SUBCUTANEOUS

>A> GIVLAARI

>A>	+! ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194	001	Nov 20, 2019	Nov NEWA
-----	-----------------------	-------------------------------------	---------	-----	--------------	----------

GLASDEGIB MALEATE

TABLET;ORAL

DAURISMO

+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018	Feb CAIN
+	!	EQ 100MG BASE	N210656	002	Nov 21, 2018	Feb CAIN

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

AB	MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
AB		2MG	A091220	002	Jun 29, 2012	Mar CAHN
		3MG	A091220	003	Jun 29, 2012	Mar CAHN
AB		4MG	A091220	004	Jun 29, 2012	Mar CAHN
		6MG	A091220	005	Jun 29, 2012	Mar CAHN
AB		8MG	A091220	006	Jun 29, 2012	Mar CAHN
	@ TEVA	1MG	A076802	001	Oct 06, 2005	Oct DISC
	@	2MG	A076802	002	Oct 06, 2005	Oct DISC
	@	4MG	A076802	003	Oct 06, 2005	Oct DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

	@ BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb CAHN
	@	10MG	A074542	002	Jun 20, 1995	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

	@ MYLAN	2.5MG	A202298	001	May 19, 2015	Feb DISC
	@	5MG	A202298	002	May 19, 2015	Feb DISC
	@	10MG	A202298	003	May 19, 2015	Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

	@ MYLAN	2.5MG;250MG	A078083	001	Apr 12, 2007	Apr	DISC
>D> AB		2.5MG;500MG	A078083	002	Apr 12, 2007	Nov	DISC
>A>	@	2.5MG;500MG	A078083	002	Apr 12, 2007	Nov	DISC
>D> AB		5MG;500MG	A078083	003	Apr 12, 2007	Nov	DISC
>A>	@	5MG;500MG	A078083	003	Apr 12, 2007	Nov	DISC
	@ SUN PHARM INDS INC	2.5MG;250MG	A077620	001	Jan 11, 2008	Oct	DISC
	@	2.5MG;500MG	A077620	002	Jan 11, 2008	Oct	DISC
	@	5MG;500MG	A077620	003	Jan 11, 2008	Oct	DISC

GLUCAGON

POWDER;NASAL

BAQSIMI

+!	ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019	Jul	NEWA
	SOLUTION;SUBCUTANEOUS						
	GVOKE HYPOFEN						
+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019	Sep	NEWA
+!		1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019	Sep	NEWA
	GVOKE PFS						
+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Sep	NEWA
+!		1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019	Sep	NEWA

GLYBURIDE

TABLET;ORAL

GLYBURIDE

	@ ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Jul	DISC
AB1		1.25MG	A206483	001	Feb 22, 2019	Feb	NEWA
	@	2.5MG	A206483	002	Feb 22, 2019	Jul	DISC
AB1		2.5MG	A206483	002	Feb 22, 2019	Feb	NEWA
	@	5MG	A206483	003	Feb 22, 2019	Jul	DISC
AB1		5MG	A206483	003	Feb 22, 2019	Feb	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

	@ HERITAGE PHARMS INC	1.25MG;250MG	A079009	001	Jun 03, 2009	Aug	DISC
	@	2.5MG;500MG	A079009	002	Jun 03, 2009	Aug	DISC
	@	5MG;500MG	A079009	003	Jun 03, 2009	Aug	DISC

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+!	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb	CAHN
----	----------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP	APOTEX	0.2MG/ML	A210246	001	Oct 29, 2019	Oct	NEWA
AP	CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar	NEWA
AP	GLAND PHARMA LTD	0.2MG/ML	A212612	001	Sep 30, 2019	Sep	NEWA
AP	PIRAMAL CRITICAL	0.2MG/ML	A210842	001	Oct 25, 2018	Jun	CAHN
AP	SANDOZ INC	0.2MG/ML	A211334	001	May 14, 2019	Apr	NEWA
	ROBINUL						
+ @	HIKMA	0.2MG/ML	N017558	001		Aug	CAHN

TABLET;ORAL

GLYCOPYRROLATE

AA	AUROLIFE PHARMA LLC	2MG	A202675	002	Oct 30, 2018	May	NEWA
AA	KENTON	1MG	A091182	001	Feb 03, 2014	Mar	CAHN
AA		2MG	A091182	002	Feb 03, 2014	Mar	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Apr	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Apr	CAHN
AP	! DR REDDYS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May	CAHN
AP	!	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May	CAHN

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE					
AP	@ LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010 Feb DISC
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008 Apr CAHN
	@ DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007 May CAHN

TABLET; ORAL

GRANISETRON HYDROCHLORIDE					
	@ TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007 Jan DISC

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

OBREDON					
	+ @ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N205474	001	Nov 14, 2014 Jun DISC

TABLET; ORAL

XTRELUS					
	+ @ ECI PHARMS LLC	400MG; 5MG	N208085	001	Apr 25, 2018 Jun DISC

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE					
AB	EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997 Apr CMFD
AB		EQ 2MG BASE	A074673	002	Feb 28, 1997 Apr CMFD

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE					
	@ MYLAN	EQ 1MG BASE	A202578	001	Jun 02, 2015 May DISC
	@	EQ 2MG BASE	A202578	002	Jun 02, 2015 May DISC
	@	EQ 3MG BASE	A202578	003	Jun 02, 2015 May DISC
	@	EQ 4MG BASE	A202578	004	Jun 02, 2015 May DISC

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE					
AB	MYLAN	0.1%	A211027	001	Aug 12, 2019 Jul NEWA
HALOG					
AB	+! SUN PHARM INDS INC	0.1%	N017556	001	Aug CFTG

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

LEXETTE					
	+! MAYNE PHARMA	0.05%	N210566	001	May 24, 2018 Sep CTNA

CREAM; TOPICAL

ULTRAVATE					
>D>	AB	+ SUN PHARM INDS INC	0.05%	N019967	001 Dec 27, 1990 Nov DISC
>A>		+ @	0.05%	N019967	001 Dec 27, 1990 Nov DISC

LOTION; TOPICAL

BRYHALI					
	+! BAUSCH	0.01%	N209355	001	Nov 06, 2018 Apr CAHN
	+! DOW PHARM	0.01%	N209355	001	Nov 06, 2018 Jan CHRS
	+	0.01%	N209355	001	Nov 06, 2018 Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII					
	+! BAUSCH	0.01%; 0.045%	N209354	001	Apr 25, 2019 Apr NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL					
AB	INNOGENIX	0.5MG	A071173	002	Jan 02, 1987 Oct CMFD
	@	0.5MG	A071173	002	Jan 02, 1987 May CMS1
AB		1MG	A071173	003	Jan 02, 1987 Oct CMFD
	@	1MG	A071173	003	Jan 02, 1987 May CMS1
AB		2MG	A071173	004	Jan 02, 1987 Oct CMFD
	@	2MG	A071173	004	Jan 02, 1987 May CMS1
AB		5MG	A071173	005	Jan 07, 1988 Oct CMFD
	@	5MG	A071173	005	Jan 07, 1988 May CMS1
AB		10MG	A071173	001	Jan 07, 1988 Oct CMFD
	@	10MG	A071173	001	Jan 07, 1988 Mar CAHN
AB		20MG	A071173	006	Jan 07, 1988 Oct CMFD
	@	20MG	A071173	006	Jan 07, 1988 May CMS1

TABLET;ORAL
HALOPERIDOL

	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Jan CTEC
AB	!		2MG	A070278	001	Jun 10, 1986	Jan CHRS
	@	SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan DISC

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

AO		ZYDUS PHARMS	EQ 50MG BASE/ML	A211180	001	Oct 22, 2019	Oct NEWA
AO			EQ 100MG BASE/ML	A211180	002	Oct 22, 2019	Oct NEWA

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL

AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CHRS
	@	TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988	May DISC
		HALOPERIDOL INTENSOL					
	@	HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	Sep CAHN
		INJECTABLE;INJECTION					
		HALOPERIDOL					
AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Jun NEWA

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Aug CAHN
AP	+	!	HIKMA	1,000 UNITS/ML	N017037	001	Feb CAHN
AP	+		5,000 UNITS/ML	N017037	002		Feb CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb CAHN
AP	+		10,000 UNITS/ML	N017037	003		Feb CAHN
AP		NANJING KING-FRIEND	1,000 UNITS/ML	A211007	001	May 28, 2019	May NEWA
AP			5,000 UNITS/ML	A211007	002	May 28, 2019	May NEWA
AP			10,000 UNITS/ML	A211007	003	May 28, 2019	May NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL
HYCODAN

AA	+	GENUS	1.5MG/5ML;5MG/5ML	N005213	002	Jul 26, 1988	Jun CMFD
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
	@	BRECKENRIDGE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
AA		BRECKENRIDGE PHARM	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	May NEWA
>D> AA		TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Nov DISC
>A>	@		1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Nov DISC
AA			1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	May CMFD
	@		1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jan CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

	@	LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb DISC
		TABLET;ORAL					
		HYDRALAZINE HYDROCHLORIDE					
AA		STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Oct NEWA
AA		UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Jun CAHN
AA			25MG	A209251	002	Jul 09, 2018	Jun CAHN
AA			50MG	A209251	003	Jul 09, 2018	Jun CAHN
AA			100MG	A209251	004	Jul 09, 2018	Jun CAHN

HYDROCHLOROTHIAZIDE

TABLET;ORAL
HYDROCHLOROTHIAZIDE

>D> AB		ACCORD HLTHCARE	12.5MG	A202556	001	Sep 24, 2012	Nov CHRS
>A> AB	!		12.5MG	A202556	001	Sep 24, 2012	Nov CHRS
	@	SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008	Oct DISC
	@		25MG	A040810	001	Mar 27, 2007	Oct DISC
	@		50MG	A040810	002	Mar 27, 2007	Oct DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

@ APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
@	12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

@ HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Aug DISC
AB	12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN
@	12.5MG;20MG	A075776	002	Jul 01, 2002	Aug DISC
AB	12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN
@	25MG;20MG	A075776	003	Jul 01, 2002	Aug DISC
AB	25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

@ ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019	Aug DISC
AB	12.5MG;20MG	A209281	001	Feb 07, 2019	Jan NEWA
@	12.5MG;40MG	A209281	002	Feb 07, 2019	Aug DISC
AB	12.5MG;40MG	A209281	002	Feb 07, 2019	Jan NEWA
@	25MG;40MG	A209281	003	Feb 07, 2019	Aug DISC
AB	25MG;40MG	A209281	003	Feb 07, 2019	Jan NEWA
>D> AB MYLAN	12.5MG;20MG	A078827	001	Oct 26, 2016	Nov DISC
>A> @	12.5MG;20MG	A078827	001	Oct 26, 2016	Nov DISC
>D> AB	12.5MG;40MG	A078827	002	Oct 26, 2016	Nov DISC
>A> @	12.5MG;40MG	A078827	002	Oct 26, 2016	Nov DISC
>D> AB	25MG;40MG	A078827	003	Oct 26, 2016	Nov DISC
>A> @	25MG;40MG	A078827	003	Oct 26, 2016	Nov DISC
@ TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
@	25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC
AB UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	Sep NEWA
AB	12.5MG;40MG	A208847	003	Sep 17, 2019	Sep NEWA
AB	25MG;40MG	A208847	002	Sep 17, 2019	Sep NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005	May DISC
@	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005	May DISC
@	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005	May DISC
QUINARETIC					
AB LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
AB	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
AB	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
AB	12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
AB	25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30, 1995	Jun DISC
@ CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Jun DISC
AB ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

@ ZYDUS PHARMS	12.5MG;80MG	A203000	001	Mar 15, 2019	Aug DISC
AB	12.5MG;80MG	A203000	001	Mar 15, 2019	Mar NEWA
@	12.5MG;160MG	A203000	002	Mar 15, 2019	Aug DISC
AB	12.5MG;160MG	A203000	002	Mar 15, 2019	Mar NEWA
@	12.5MG;320MG	A203000	003	Mar 15, 2019	Aug DISC
AB	12.5MG;320MG	A203000	003	Mar 15, 2019	Mar NEWA
@	25MG;160MG	A203000	004	Mar 15, 2019	Aug DISC

TABLET;ORAL						
VALSARTAN AND HYDROCHLOROTHIAZIDE						
AB		25MG;160MG	A203000	004	Mar 15, 2019	Mar NEWA
	@	25MG;320MG	A203000	005	Mar 15, 2019	Aug DISC
AB		25MG;320MG	A203000	005	Mar 15, 2019	Mar NEWA
<u>HYDROCODONE BITARTRATE</u>						
CAPSULE, EXTENDED RELEASE;ORAL						
ZOHYDRO ER						
+!	PERSION	10MG	N202880	001	Oct 25, 2013	Apr CAHN
+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
+		50MG	N202880	006	Oct 25, 2013	Apr CAHN
TABLET, EXTENDED RELEASE;ORAL						
HYSINGLA ER						
+!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
+		30MG	N206627	002	Nov 20, 2014	Jul CMS1
+		40MG	N206627	003	Nov 20, 2014	Jul CMS1
+		60MG	N206627	004	Nov 20, 2014	Jul CMS1
+		80MG	N206627	005	Nov 20, 2014	Jul CMS1
+		100MG	N206627	006	Nov 20, 2014	Jul CMS1
+		120MG	N206627	007	Nov 20, 2014	Jul CMS1
<u>HYDROCODONE BITARTRATE; IBUPROFEN</u>						
TABLET;ORAL						
HYDROCODONE BITARTRATE AND IBUPROFEN						
	@ ANI PHARMS INC	5MG;200MG	A077454	001	Jun 23, 2010	May CAHN
	@ SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013	Oct DISC
	@	5MG;200MG	A091633	002	May 28, 2013	Oct DISC
	@	7.5MG;200MG	A091633	003	May 28, 2013	Oct DISC
	@	10MG;200MG	A091633	004	May 28, 2013	Oct DISC
REPREXAIN						
	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007	Oct CTEC
<u>HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
SOLUTION;ORAL						
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
	@ MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015	Jun DISC
	@ PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014	Jun DISC
	@ TORRENT	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Feb DISC
AA		5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Jan NEWA
REZIRA						
+	@ PERSION	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Jun DISC
AA	+!	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN
<u>HYDROCORTISONE</u>						
CREAM;TOPICAL						
NUTRACORT						
	@ BAUSCH	0.5%	A080442	002		Feb CAHN
	@	1%	A080442	003		Feb CAHN
LOTION;TOPICAL						
CETACORT						
	@ BAUSCH	0.5%	A080426	002		Feb CAHN
	@	1%	A080426	001		Feb CAHN
TABLET;ORAL						
HYDROCORTISONE						
AB	BRECKENRIDGE	5MG	A207029	001	Apr 27, 2017	Aug CAHN
AB		10MG	A207029	002	Apr 27, 2017	Aug CAHN
AB		20MG	A207029	003	Apr 27, 2017	Aug CAHN
<u>HYDROCORTISONE BUTYRATE</u>						
CREAM;TOPICAL						
LOCOID						
AB1	+! BAUSCH	0.1%	N018514	001	Mar 31, 1982	May CAHN
LOTION;TOPICAL						
LOCOID						
AB	+! BAUSCH	0.1%	N022076	001	May 18, 2007	May CAHN

SOLUTION;TOPICAL							
LOCOID							
AT	+	BAUSCH	0.1%	N019116	001	Feb 25, 1987	May CAHN
<u>HYDROCORTISONE VALERATE</u>							
CREAM;TOPICAL							
HYDROCORTISONE VALERATE							
AB		LUPIN LTD	0.2%	A210307	001	Aug 15, 2019	Aug NEWA
AB		PERRIGO ISRAEL	0.2%	A075666	001	May 24, 2000	May CAHN
<u>HYDROGEN PEROXIDE</u>							
SOLUTION;TOPICAL							
ESKATA							
	+	@ ACLARIS	40%	N209305	001	Dec 14, 2017	Aug DISC
<u>HYDROMORPHONE HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
EXALGO							
	+	@ SPECGX LLC	8MG	N021217	001	Mar 01, 2010	Mar DISC
	+	@	12MG	N021217	002	Mar 01, 2010	Mar DISC
	+	@	16MG	N021217	003	Mar 01, 2010	Mar DISC
	+	@	32MG	N021217	004	Aug 24, 2012	Mar DISC
HYDROMORPHONE HYDROCHLORIDE							
AB	!	OSMOTICA	32MG	A205629	004	Jul 07, 2016	Mar CHRS
<u>HYDROXYCHLOROQUINE SULFATE</u>							
TABLET;ORAL							
HYDROXYCHLOROQUINE SULFATE							
	@	LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Sep DISC
AB			200MG	A210959	001	Jan 15, 2019	Jan CAHN
	@	LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Feb DISC
<u>HYDROXYPROGESTERONE CAPROATE</u>							
SOLUTION;INTRAMUSCULAR							
HYDROXYPROGESTERON CAPROATE							
AP1		AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jul NEWA
HYDROXYPROGESTERONE CAPROATE							
AP		ASPEN	250MG/ML (250MG/ML)	A211777	001	Aug 08, 2019	Jul NEWA
AP2	!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Nov CTEC
	!		1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Nov CTEC
AP2	!		1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr CPOT
AP2	!		250MG/ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr CTEC
AP		EUGIA PHARMA	250MG/ML (250MG/ML)	A211071	001	Apr 16, 2019	Apr NEWA
AP1			1250MG/5ML (250MG/ML)	A211070	001	Apr 16, 2019	Apr NEWA
AP2			1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019	Nov DISC
	@		1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019	Nov DISC
AP2			1250MG/5ML (250MG/ML)	A211142	001	May 09, 2019	Apr NEWA
AP		SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877	001	Mar 22, 2019	Mar NEWA
AP1			1250MG/5ML (250MG/ML)	A210618	001	Dec 28, 2018	Apr CTEC
AP1		SUN PHARM	1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Apr CTEC
AP			1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Mar NEWA
MAKENA							
AP1	+	AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Apr CTEC
<u>HYDROXYPROPYL CELLULOSE</u>							
INSERT;OPHTHALMIC							
LACRISERT							
	+	VALEANT PHARMS INTL	5MG	N018771	001		Jan CAHN
<u>HYDROXYZINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
HYDROXYZINE HYDROCHLORIDE							
	!	LUITPOLD	50MG/ML	A087408	002		Mar CMFD
	@		50MG/ML	A087408	002		Feb DISC
SYRUP;ORAL							
HYDROXYZINE HYDROCHLORIDE							
	@	ANIMA	10MG/5ML	A086880	001		Sep CAHN
AA		TORRENT	10MG/5ML	A210634	001	Feb 26, 2019	Nov DISC
	@		10MG/5ML	A210634	001	Feb 26, 2019	Nov DISC
AA			10MG/5ML	A210634	001	Feb 26, 2019	Feb NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	10MG	A040604	002	Dec 28, 2004	Jan CAHN
AB		25MG	A040604	003	Dec 28, 2004	Jan CAHN
AB		50MG	A040604	001	Dec 28, 2004	Jan CAHN
AB	KVK TECH	25MG	A040786	002	Mar 20, 2007	Feb CMS1
AB		50MG	A040786	003	Mar 20, 2007	Feb CMS1
	@ MYLAN	10MG	A091176	001	Jun 07, 2010	Aug DISC
	@	25MG	A091176	002	Jun 07, 2010	Aug DISC
	@	50MG	A091176	003	Jun 07, 2010	Aug DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

>D> AB	@ BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991	Feb CAHN
>A> AB	SANDOZ	EQ 50MG HYDROCHLORIDE	A086183	001		Nov CHRS
>D>	!	EQ 50MG HYDROCHLORIDE	A086183	001		Nov CHRS
>D>	VISTARIL					
>D> AB	+ PFIZER	EQ 25MG HYDROCHLORIDE	N011459	002		Nov DISC
>A>	+ @	EQ 25MG HYDROCHLORIDE	N011459	002		Nov DISC
>D> AB	+!	EQ 50MG HYDROCHLORIDE	N011459	004		Nov DISC
>A>	+ @	EQ 50MG HYDROCHLORIDE	N011459	004		Nov DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

>D> AP	EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014	Nov DISC
>A>	@	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014	Nov DISC

TABLET;ORAL

IBANDRONATE SODIUM

@ SUN PHARM INDUSTRIES EQ 150MG BASE

A078996 001 Aug 15, 2012 Oct DISC

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

+! CUMBERLAND PHARMS 800MG/200ML (4MG/ML) N022348 003 Jan 25, 2019 Jan NEWA

SUSPENSION;ORAL

CHILDREN'S ADVIL

>A>	@ GLAXOSMITHKLINE	100MG/5ML	N019833	002	Sep 19, 1989	Nov CAHN
>D>	@ WYETH CONS	100MG/5ML	N019833	002	Sep 19, 1989	Nov CAHN

IBUPROFEN

AB	L PERRIGO CO	100MG/5ML	A076925	001	Sep 23, 2004	May CAHN
----	--------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

	@ HEC PHARM	400MG	A204062	001	Sep 10, 2018	Mar DISC
	@	600MG	A204062	002	Sep 10, 2018	Mar DISC
	@	800MG	A204062	003	Sep 10, 2018	Mar DISC
AB	PERRIGO PHARMS CO	400MG	A077114	001	Jul 18, 2005	May CAHN
AB		600MG	A077114	002	Jul 18, 2005	May CAHN
AB		800MG	A077114	003	Jul 18, 2005	May CAHN

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

@ LUITPOLD 0.1MG/ML

A090240 001 Jan 11, 2010 Feb DISC

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	+! SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CFTG
AP	TEVA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A210118	001	Jul 15, 2019	Jul NFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDARUBICIN HYDROCHLORIDE

@ MYLAN LABS LTD 1MG/ML

A200144 001 Oct 11, 2012 Oct DISC

IFOSFAMIDEINJECTABLE; INJECTION
IFOSFAMIDE

@ MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012	Sep DISC
@	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012	Sep DISC

ILOPERIDONETABLET; ORAL
FANAPT

+! VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Aug CTEC
+	2MG	N022192	002	May 06, 2009	Aug CTEC
+	4MG	N022192	003	May 06, 2009	Aug CTEC
+	6MG	N022192	004	May 06, 2009	Aug CTEC
+	8MG	N022192	005	May 06, 2009	Aug CTEC
+	10MG	N022192	006	May 06, 2009	Aug CTEC
+	12MG	N022192	007	May 06, 2009	Aug CTEC

ILOPERIDONE

@ INVENTIA	1MG	A207231	001	Nov 28, 2016	Aug CAHN
@	2MG	A207231	002	Nov 28, 2016	Aug CAHN
@	4MG	A207231	003	Nov 28, 2016	Aug CAHN
@	6MG	A207231	004	Nov 28, 2016	Aug CAHN
@	8MG	A207231	005	Nov 28, 2016	Aug CAHN
@	10MG	A207231	006	Nov 28, 2016	Aug CAHN
@	12MG	A207231	007	Nov 28, 2016	Aug CAHN
@ INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Jul DISC
@	2MG	A207231	002	Nov 28, 2016	Jul DISC
@	4MG	A207231	003	Nov 28, 2016	Jul DISC
@	6MG	A207231	004	Nov 28, 2016	Jul DISC
@	8MG	A207231	005	Nov 28, 2016	Jul DISC
@	10MG	A207231	006	Nov 28, 2016	Jul DISC
@	12MG	A207231	007	Nov 28, 2016	Jul DISC
@ TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019	Aug DISC
AB	1MG	A207098	001	Jul 22, 2019	Jul NEWA
@	2MG	A207098	002	Jul 22, 2019	Aug DISC
AB	2MG	A207098	002	Jul 22, 2019	Jul NEWA
@	4MG	A207098	003	Jul 22, 2019	Aug DISC
AB	4MG	A207098	003	Jul 22, 2019	Jul NEWA
@	6MG	A207098	004	Jul 22, 2019	Aug DISC
AB	6MG	A207098	004	Jul 22, 2019	Jul NEWA
@	8MG	A207098	005	Jul 22, 2019	Aug DISC
AB	8MG	A207098	005	Jul 22, 2019	Jul NEWA
@	10MG	A207098	006	Jul 22, 2019	Aug DISC
AB	10MG	A207098	006	Jul 22, 2019	Jul NEWA
@	12MG	A207098	007	Jul 22, 2019	Aug DISC
AB	12MG	A207098	007	Jul 22, 2019	Jul NEWA

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

@ AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Aug DISC
AB	EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb NEWA
@	EQ 400MG BASE	A207495	002	Feb 08, 2019	Aug DISC
AB	EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb NEWA
AB	BRECKENRIDGE	A205990	001	Feb 08, 2019	Feb NEWA
AB	EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
AB	NATCO PHARMA LTD	A207818	001	Mar 01, 2019	Feb NEWA
AB	EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
AB	SHILPA MEDICARE LTD	A208302	001	Jan 17, 2019	Jan NEWA
AB	EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
AB	WOCKHARDT BIO AG	A208429	001	Jan 17, 2019	Jan NEWA
AB	EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
@	25MG	A040751	002	Feb 28, 2008	Mar DISC

IMIQUIMODCREAM; TOPICAL
ALDARA

AB	+	BAUSCH	5%	N020723	001	Feb 27, 1997	Aug CAHN
		ZYCLARA					
	+	BAUSCH	2.5%	N022483	002	Jul 15, 2011	Aug CAHN
	+		3.75%	N022483	001	Mar 25, 2010	Aug CAHN

INDIUM IN-111 CHLORIDEINJECTABLE; INJECTION
INDICLOR

	+	@ GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun DISC
		INDIUM IN 111 CHLORIDE					
	+	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE; INJECTION
OCTREOSCAN

	+	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
--	---	--------	---------	---------	-----	--------------	----------

INDOMETHACINCAPSULE; ORAL
INDOCIN

	+	@ EGALET	25MG	N016059	001		Feb CAHN
	+	@	50MG	N016059	002		Feb CAHN
		INDOMETHACIN					
		@ ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May CAHN
		@	50MG	A071149	001	Mar 18, 1987	May CAHN
AB		CADILA	25MG	A090403	001	Nov 15, 2010	May CAHN
AB			50MG	A090403	002	Nov 15, 2010	May CAHN
AB	!	GLENMARK GENERICS	50MG	A091276	002	Dec 22, 2010	Aug CHRS
AB		HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb CAHN
AB			50MG	A070756	001	Feb 12, 1986	Feb CAHN
		@ MYLAN	25MG	N018858	001	Apr 20, 1984	Aug DISC
		@	50MG	A070624	001	Sep 04, 1985	Aug DISC
		@ SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Oct DISC
		@	50MG	A091401	002	Mar 28, 2013	Oct DISC
		TIVORBEX					
>D>	+	EGALET	20MG	N204768	001	Feb 24, 2014	Nov CAHN
	+		20MG	N204768	001	Feb 24, 2014	Feb CAHN
>D>	+		40MG	N204768	002	Feb 24, 2014	Nov CAHN
	+		40MG	N204768	002	Feb 24, 2014	Feb CAHN
>A>	+	GENUS	20MG	N204768	001	Feb 24, 2014	Nov CAHN
>A>	+		40MG	N204768	002	Feb 24, 2014	Nov CAHN

CAPSULE, EXTENDED RELEASE; ORAL
INDOCIN SR

	+	@ EGALET	75MG	N018185	001	Feb 23, 1982	Feb CAHN
--	---	----------	------	---------	-----	--------------	----------

SUPPOSITORY; RECTAL
INDOCIN

	+	@ EGALET	50MG	N017814	001	Aug 13, 1984	Feb CAHN
--	---	----------	------	---------	-----	--------------	----------

SUSPENSION; ORAL
INDOCIN

	+	EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb CAHN
		INDOMETHACIN					
		@ HIKMA	25MG/5ML	A071412	001	Mar 18, 1987	Sep CAHN

INSULIN ASPARTSOLUTION; SUBCUTANEOUS
FIASP PENFILL

	+	NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018	Jun NEWA
--	---	------	------------------------------	---------	-----	--------------	----------

INSULIN ASPART; INSULIN DEGLUDECSOLUTION; SUBCUTANEOUS
RYZODEG 70/30

	+	@ NOVO	90 UNITS/3ML; 210 UNITS/3ML (30 UNITS/ML; 70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun DISC
--	---	--------	--	---------	-----	--------------	----------

INSULIN DEGLUDECSOLUTION; SUBCUTANEOUS
TRESIBA

NOVO

1000 UNITS/10ML (100 UNITS/ML)

N203314 003 Nov 21, 2018 Jun NEWA

INSULIN HUMANSOLUTION; INTRAVENOUS
MYXREDLIN

+! BAXTER HLTHCARE CORP 100 UNITS/100ML (1 UNIT/ML)

N208157 001 Jun 20, 2019 Jul CAHN

+! CELERITY PHARMS 100 UNITS/100ML (1 UNIT/ML)

N208157 001 Jun 20, 2019 Jun NEWA

IOPROMIDEINJECTABLE; INJECTION
ULTRAVIST (PHARMACY BULK)

+ @ BAYER HLTHCARE 49.9%

N021425 003 Mar 12, 2004 Aug DISC

+! 49.9%

N021425 003 Mar 12, 2004 Apr CMFD

+ @ 49.9%

N021425 003 Mar 12, 2004 Feb DISC

ULTRAVIST 240

+ @ BAYER HLTHCARE 49.9%

N020220 003 May 10, 1995 Aug DISC

+! 49.9%

N020220 003 May 10, 1995 Apr CMFD

+ @ 49.9%

N020220 003 May 10, 1995 Feb DISC

IOTHALAMATE MEGLUMINEINJECTABLE; INJECTION
CONRAY 43

+ @ LIEBEL-FLARSHEIM 43%

N013295 002 Jun DISC

IPRATROPIUM BROMIDESPRAY, METERED; NASAL
IPRATROPIUM BROMIDE

@ MYLAN SPECIALITY LP 0.021MG/SPRAY

A075552 001 Mar 31, 2003 Mar DISC

@ 0.042MG/SPRAY

A075553 001 Mar 31, 2003 Mar DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

@ FRESENIUS KABI USA 40MG/2ML (20MG/ML)

A078188 001 Feb 27, 2008 Oct DISC

AP 40MG/2ML (20MG/ML)

A078188 001 Feb 27, 2008 Jan CAHN

@ 100MG/5ML (20MG/ML)

A078188 002 Feb 27, 2008 Oct DISC

AP 100MG/5ML (20MG/ML)

A078188 002 Feb 27, 2008 Jan CAHN

>A> AP GLAND PHARMA LTD 40MG/2ML (20MG/ML)

A212993 001 Nov 18, 2019 Nov NEWA

>A> AP 100MG/5ML (20MG/ML)

A212993 002 Nov 18, 2019 Nov NEWA

AP ZENNOVA 40MG/2ML (20MG/ML)

A090393 002 May 13, 2011 Sep CAHN

AP 100MG/5ML (20MG/ML)

A090393 003 May 13, 2011 Sep CAHN

IRON DEXTRANINJECTABLE; INJECTION
DEXFERRUM

@ LUITPOLD EQ 50MG IRON/ML

N040024 001 Feb 23, 1996 Mar DISC

PROFERDEX

@ NEW RIVER EQ 50MG IRON/ML

N017807 001 Mar DISC

IRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER+ AM REGENT EQ 50MG BASE/2.5ML (EQ 20MG
BASE/ML)

N021135 002 Mar 20, 2005 Apr CAHN

@ EQ 65MG BASE/3.25ML (EQ 20MG
BASE/ML)

N021135 005 Mar 29, 2013 Apr CAHN

@ EQ 75MG BASE/3.75ML (EQ 20MG
BASE/ML)

N021135 003 Mar 29, 2005 Apr CAHN

+! EQ 100MG BASE/5ML (EQ 20MG
BASE/ML)

N021135 001 Nov 06, 2000 Apr CAHN

+ EQ 200MG BASE/10ML (EQ 20MG
BASE/ML)

N021135 004 Feb 09, 2007 Apr CAHN

ISONIAZIDTABLET; ORAL
ISONIAZID

AA ! BARR 100MG

A080936 001 Aug CHRS

AA ! 300MG

A080937 002 Aug CHRS

+ @ SANDOZ 100MG

N008678 002 Aug DISC

TABLET;ORAL									
ISONIAZID									
	+	@	300MG		N008678	003		Aug	DISC
LANIAZID									
	@	LANNETT	300MG		A089776	001	Jun 13, 1988	Oct	DISC
<u>ISOPROPYL ALCOHOL</u>									
SOLUTION;TOPICAL									
ZURAGARD									
	+	!	ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Apr	NEWA
<u>ISOPROTERENOL HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
ISOPROTERENOL HYDROCHLORIDE									
AP			CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Jun	NEWA
ISUPREL									
AP	+	!	BAUSCH	0.2MG/ML	N010515	001		Mar	CAHN
<u>ISOSORBIDE DINITRATE</u>									
TABLET;ORAL									
ISORDIL									
AB	+		BAUSCH	5MG	N012093	007	Jul 29, 1988	Mar	CAHN
	+	@		10MG	N012093	002	Jul 29, 1988	Mar	CAHN
	+	@		20MG	N012093	006	Jul 29, 1988	Mar	CAHN
	+	@		30MG	N012093	005	Jul 29, 1988	Mar	CAHN
>D>	+	!		40MG	N012093	001	Jul 29, 1988	Nov	CTEC
>A>	AB	+	!	40MG	N012093	001	Jul 29, 1988	Nov	CTEC
		+	!	40MG	N012093	001	Jul 29, 1988	Mar	CAHN
ISOSORBIDE DINITRATE									
>A>	AB		ZYDUS	5MG	A213057	001	Nov 20, 2019	Nov	NEWA
>A>	AB			10MG	A213057	002	Nov 20, 2019	Nov	NEWA
>A>	AB			20MG	A213057	003	Nov 20, 2019	Nov	NEWA
>A>	AB			30MG	A213057	004	Nov 20, 2019	Nov	NEWA
>A>	AB			40MG	A213057	005	Nov 20, 2019	Nov	NEWA
<u>ISOSORBIDE MONONITRATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
ISOSORBIDE MONONITRATE									
AB			HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar	CAHN
AB				60MG	A076813	001	Jan 07, 2005	Mar	CAHN
<u>ISOSULFAN BLUE</u>									
INJECTABLE;INJECTION									
ISOSULFAN BLUE									
AP			ANDA REPOSITORY	1%	A210558	001	Jul 12, 2019	Sep	CAHN
	@		BELOTECA INC	1%	A210714	001	Jan 16, 2019	Jul	DISC
AP			SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	Oct	CAHN
AP				1%	A210558	001	Jul 12, 2019	Jul	NEWA
<u>ISOTRETINOIN</u>									
CAPSULE;ORAL									
ABSORICA LD									
>A>	+		SUN PHARM	8MG	N211913	001	Nov 05, 2019	Nov	NEWA
>A>	+			16MG	N211913	002	Nov 05, 2019	Nov	NEWA
>A>	+			20MG	N211913	003	Nov 05, 2019	Nov	NEWA
>A>	+			24MG	N211913	004	Nov 05, 2019	Nov	NEWA
>A>	+			28MG	N211913	005	Nov 05, 2019	Nov	NEWA
>A>	+	!		32MG	N211913	006	Nov 05, 2019	Nov	NEWA
<u>ISTRADEFYLLINE</u>									
TABLET;ORAL									
NOURIANZ									
	+		KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019	Aug	NEWA
	+	!		40MG	N022075	002	Aug 27, 2019	Aug	NEWA
<u>ITRACONAZOLE</u>									
CAPSULE;ORAL									
ITRACONAZOLE									
AB			ANDA REPOSITORY	100MG	A206410	001	Jul 02, 2019	Aug	CAHN
AB			PII	100MG	A206410	001	Jul 02, 2019	Jun	NEWA

SOLUTION;ORAL							
ITRACONAZOLE							
AA	APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Jul	NEWA
<u>IVABRADINE</u>							
SOLUTION;ORAL							
CORLANOR							
	+! AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Apr	NEWA
<u>IVACAFTOR</u>							
GRANULE;ORAL							
KALYDECO							
+	VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019	May	NEWA
TABLET;ORAL							
KALYDECO							
+	VERTEX PHARMS	75MG	N203188	002	May 20, 2019	May	NEWA
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR</u>							
TABLET, TABLET;ORAL							
SYMDEKO (COPACKAGED)							
>D>	+! VERTEX PHARMS INC	75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Nov	CHRS
>A>	+	75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Nov	CHRS
	+!	75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Jul	NEWA
<u>IVERMECTIN</u>							
CREAM;TOPICAL							
IVERMECTIN							
AB	TEVA PHARMS USA	1%	A210019	001	Sep 13, 2019	Sep	NFTG
SOOLANTRA							
AB	+! GALDERMA LABS LP	1%	N206255	001	Dec 19, 2014	Sep	CFTG
<u>KETOCONAZOLE</u>							
GEL;TOPICAL							
XOLEGEL							
	+! ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb	CAHN
SHAMPOO;TOPICAL							
KETOCONAZOLE							
AB	PERRIGO ISRAEL	2%	A076419	001	Jan 07, 2004	May	CAHN
TABLET;ORAL							
KETOCONAZOLE							
	@ HERITAGE PHARMA	200MG	A074971	001	Jun 15, 1999	May	CAHN
	@	200MG	A075362	001	Jun 15, 1999	May	CAHN
AB	! TARO	200MG	A075319	001	Jun 15, 1999	Apr	CHRS
	@ TEVA	200MG	A075273	001	Jun 15, 1999	Apr	DISC
<u>KETOROLAC TROMETHAMINE</u>							
INJECTABLE;INJECTION							
KETOROLAC TROMETHAMINE							
AP	WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb	CMFD
AP		30MG/ML	A075772	002	Jul 21, 2004	Feb	CMFD
SOLUTION/DROPS;OPHTHALMIC							
KETOROLAC TROMETHAMINE							
	@ AUROBINDO PHARMA LTD	0.4%	A205191	001	Nov 15, 2018	May	DISC
AT	MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar	NEWA
	@ SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	May	DISC
SPRAY, METERED;NASAL							
SPRIX							
	+! ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010	Jul	CAHN
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE</u>							
SOLUTION;IRRIGATION							
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE							
AT	LUPIN LTD	EQ 0.3% BASE;EQ 1% BASE	A210183	001	Jul 01, 2019	Jun	NFTG
OMIDRIA							
AT	+! OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Jun	CFTG

L-GLUTAMINEFOR SOLUTION;ORAL
NUTRESTORE

+ @ EMMAUS MEDCL 5GM/PACKET N021667 001 Jun 10, 2004 Jun DISC

LABETALOL HYDROCHLORIDEINJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

@ MYLAN ASI 5MG/ML A079134 001 Feb 03, 2010 Sep DISC

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr	NEWA
AB		200MG	A211325	002	May 13, 2019	Apr	NEWA
AB		300MG	A211325	003	May 13, 2019	Apr	NEWA
	@ HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Oct	DISC
AB		100MG	A074787	001	Aug 03, 1998	Feb	CAHN
	@	200MG	A074787	002	Aug 03, 1998	Oct	DISC
AB		200MG	A074787	002	Aug 03, 1998	Feb	CAHN
	@	300MG	A074787	003	Aug 03, 1998	Oct	DISC
AB		300MG	A074787	003	Aug 03, 1998	Feb	CAHN
	TRANDATE						
AB	+ CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan	CRLD
AB	+	200MG	N018716	002	Aug 01, 1984	Jan	CRLD
AB	+	300MG	N018716	003	Aug 01, 1984	Jan	CRLD

LACTULOSE

SOLUTION;ORAL

LACTULOSE

	@ BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan	CAHN
>D> AA	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Nov	DISC
>A>	@	10GM/15ML	A207786	001	Jun 11, 2018	Nov	DISC
AA		10GM/15ML	A207786	001	Jun 11, 2018	Jan	CAHN
AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Aug	CMFD
	@	10GM/15ML	A075911	001	Feb 21, 2002	Mar	CAHN

SOLUTION;ORAL, RECTAL

LACTULOSE

	@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan	CAHN
>D> AA	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Nov	DISC
>A>	@	10GM/15ML	A203762	001	Mar 27, 2015	Nov	DISC
AA		10GM/15ML	A203762	001	Mar 27, 2015	Jan	CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar	NEWA
AB	MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr	NEWA
AB		300MG	A090198	002	May 01, 2019	Apr	NEWA
	@ MYLAN	100MG	A204002	001	Dec 31, 2014	Oct	DISC
	@	150MG	A204528	001	Mar 04, 2016	Apr	DISC
	@	300MG	A204528	002	Mar 04, 2016	Apr	DISC
AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb	NEWA
AB		300MG	A078545	002	Mar 05, 2019	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	ANDA REPOSITORY	150MG;300MG	A206375	001	Apr 10, 2018	Sep	CAHN
	@ MYLAN	150MG;300MG	A079079	001	Aug 12, 2019	Aug	DISC
AB		150MG;300MG	A079079	001	Aug 12, 2019	Jul	NEWA
	@	150MG;300MG	A204005	001	Aug 28, 2014	Jan	DISC

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

	@ CELLTRION	25MG	A078982	001	Jan 27, 2009	Aug	CAHN
	@	100MG	A078982	002	Jan 27, 2009	Aug	CAHN
	@	150MG	A078982	003	Jan 27, 2009	Aug	CAHN
	@	200MG	A078982	004	Jan 27, 2009	Aug	CAHN
AB	RUBICON	25MG	A078625	001	Jan 27, 2009	Jul	CAHN
AB		100MG	A078625	002	Jan 27, 2009	Jul	CAHN
AB		150MG	A078625	003	Jan 27, 2009	Jul	CAHN

TABLET;ORAL
LAMOTRIGINE

AB		200MG	A078625	004	Jan 27, 2009	Jul CAHN	
>D>	AB	TEVA	25MG	A076388	001	Aug 30, 2006	Nov DISC
>A>	@	25MG	A076388	001	Aug 30, 2006	Nov DISC	
>D>	AB	100MG	A076388	002	Aug 30, 2006	Nov DISC	
>A>	@	100MG	A076388	002	Aug 30, 2006	Nov DISC	
>D>	AB	150MG	A076388	003	Aug 30, 2006	Nov DISC	
>A>	@	150MG	A076388	003	Aug 30, 2006	Nov DISC	
>D>	AB	200MG	A076388	004	Aug 30, 2006	Nov DISC	
>A>	@	200MG	A076388	004	Aug 30, 2006	Nov DISC	

TABLET, CHEWABLE;ORAL
LAMOTRIGINE

@	TEVA	5MG	A076420	001	Jun 21, 2006	Jul DISC
@		25MG	A076420	002	Jun 21, 2006	Jul DISC

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

@	RUBICON	25MG	A202887	001	Jun 17, 2013	Mar CAHN
@		50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB		100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB		200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

@	AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016	Sep DISC
@		30MG	A203957	002	Oct 14, 2016	Sep DISC
AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
@	BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018	May DISC
@		30MG	A203964	002	Oct 17, 2018	May DISC
AB	INVENTIA	15MG	A205868	001	Aug 30, 2017	Aug CAHN
AB		30MG	A205868	002	Aug 30, 2017	Aug CAHN
@	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC
@		30MG	A091212	002	Sep 16, 2013	Feb DISC
AB	XIROMED	15MG	A203203	001	Jul 25, 2016	Aug CAHN
AB		30MG	A203203	002	Jul 25, 2016	Aug CAHN

LAROTRECTINIB

CAPSULE;ORAL
VITRAKVI

+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+	!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION;ORAL
VITRAKVI

+	!	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
---	---	------------------	---------	---------	-----	--------------	----------

LAROTRECTINIB SULFATE

CAPSULE;ORAL
VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CAIN
+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CPOT
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CAIN
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CPOT

SOLUTION;ORAL
VITRAKVI

+	!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CAIN
+	!		EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CPOT

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

AT	AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Aug NEWA
AT	SOMERSET	0.005%	A201786	001	Mar 22, 2011	Oct CAHN

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN

+	!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
---	---	------------------	----------------------	---------	-----	--------------	----------

LEDIPASVIR; SOFOSBUVIR

PELLETS; ORAL
HARVONI

+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019	Aug NEWA
+	!	45MG;200MG/PACKET	N212477	002	Aug 28, 2019	Aug NEWA

TABLET; ORAL
HARVONI

+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019	Aug NEWA
---	---------------------	------------	---------	-----	--------------	----------

LEFAMULIN ACETATE

SOLUTION; INTRAVENOUS
XENLETA

+	!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Aug NEWA
---	---	---------	--------------------------------------	---------	-----	--------------	----------

TABLET; ORAL
XENLETA

+	!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019	Aug NEWA
---	---	---------	---------------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET; ORAL
LEFLUNOMIDE

AB	ABHAI LLC	10MG	A212453	001	Jun 03, 2019	May NEWA
AB		20MG	A212453	002	Jun 03, 2019	May NEWA
AB	ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr NEWA
AB		20MG	A212308	002	Apr 24, 2019	Apr NEWA

LESINURAD

TABLET; ORAL
ZURAMPIC

+	@	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr DISC
---	---	---------------------	-------	---------	-----	--------------	----------

LETROZOLE

TABLET; ORAL
LETROZOLE

AB	EUGIA PHARMA	2.5MG	A211717	001	Jan 11, 2019	Sep CMFD
	@	2.5MG	A211717	001	Jan 11, 2019	Jul DISC
	@	FRESENIUS KABI USA	A090491	001	Jun 03, 2011	Oct DISC
AB		2.5MG	A090491	001	Jun 03, 2011	Feb CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

	@	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Oct DISC
AP			EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT

LEUPROLIDE ACETATE

FOR SUSPENSION; INTRAMUSCULAR
LUTRATE DEPOT KIT

+	@	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun DISC
---	---	-------------	-------------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

@	MYLAN SPECIALITY LP	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Oct DISC
@		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Oct DISC
@		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Oct DISC

LEVETIRACETAM

INJECTABLE; INTRAVENOUS
KEPPRA

AP	+	!	UCB INC	500MG/5ML (100MG/ML)	N021872	001	Jul 31, 2006	Jun CDFR
			LEVETIRACETAM					
			@	AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018
AP					500MG/5ML (100MG/ML)	A209934	001	May 04, 2018
AP				AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016
AP				FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010
AP					500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015
AP				HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018
AP				HIKMA FARMACEUTICA	500MG/5ML (100MG/ML)	A090981	001	Oct 13, 2011
AP				HOSPIRA INC	500MG/5ML (100MG/ML)	A202869	001	Apr 06, 2012
AP				JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016

INJECTABLE; INTRAVENOUS							
LEVETIRACETAM							
AP	MICRO LABS	500MG/5ML (100MG/ML)	A211954	001	Aug 09, 2019	Jul	NEWA
AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Jun	CDFR
AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun	CDFR
AP	SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	Jun	CDFR
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jun	CDFR
LEVETIRACETAM IN SODIUM CHLORIDE							
AP	AUROBINDO PHARMA LTD	500MG/100ML (5MG/ML)	A207160	001	Jan 04, 2017	Jun	CDFR
AP		1000MG/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Jun	CDFR
AP		1500MG/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Jun	CDFR
AP	GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Jun	CDFR
AP		1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Jun	CDFR
AP		1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Jun	CDFR
AP	! HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011	Jun	CDFR
AP	!	1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Jun	CDFR
AP	!	1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Jun	CDFR
SOLUTION; ORAL							
LEVETIRACETAM							
AA	ANDA REPOSITORY	100MG/ML	A079107	001	Jan 15, 2009	Aug	CAHN
TABLET; ORAL							
LEVETIRACETAM							
AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Oct	CTNA
AB		500MG	A090906	001	Nov 05, 2010	Oct	CTNA
AB		750MG	A090906	003	Oct 31, 2016	Oct	CTNA
AB		1GM	A090906	004	Oct 31, 2016	Oct	CTNA
TABLET, EXTENDED RELEASE; ORAL							
LEVETIRACETAM							
AB	ANDA REPOSITORY	500MG	A204511	001	Feb 23, 2016	Sep	CAHN
AB		750MG	A204511	002	Feb 23, 2016	Sep	CAHN
AB	HISUN PHARM HANGZHOU	500MG	A207175	001	Sep 28, 2017	Sep	CAHN
AB		750MG	A207175	002	Sep 28, 2017	Sep	CAHN
	@ SUN PHARM INDUSTRIES	500MG	A091285	001	Sep 12, 2011	Oct	DISC
	@	750MG	A091285	002	Sep 12, 2011	Oct	DISC
<u>LEVOBUNOLOL HYDROCHLORIDE</u>							
SOLUTION/DROPS; OPHTHALMIC							
LEVOBUNOLOL HYDROCHLORIDE							
	@ SANDOZ INC	0.5%	A074850	001	Oct 28, 1996	May	DISC
<u>LEVOCARNITINE</u>							
SOLUTION; ORAL							
LEVOCARNITINE							
AA	NOVITIUM PHARMA	1GM/10ML	A211676	001	Aug 14, 2019	Jul	NEWA
LEVOCARNITINE SF							
AA	NOVITIUM PHARMA	1GM/10ML	A211676	002	Aug 14, 2019	Jul	NEWA
<u>LEVOCETIRIZINE DIHYDROCHLORIDE</u>							
SOLUTION; ORAL							
LEVOCETIRIZINE HYDROCHLORIDE							
AA	HETERO LABS LTD III	2.5MG/5ML	A210914	001	Apr 01, 2019	Mar	NEWA
<u>LEVOFLOXACIN</u>							
INJECTABLE; INJECTION							
LEVOFLOXACIN							
AP	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011	Oct	CMFD
AP		EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011	Oct	CMFD
SOLUTION/DROPS; OPHTHALMIC							
LEVOFLOXACIN							
	MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019	Feb	NEWA
TABLET; ORAL							
LEVOFLOXACIN							
AB	CELLTRION	250MG	A090367	001	Jun 20, 2011	Aug	CAHN
AB		500MG	A090367	002	Jun 20, 2011	Aug	CAHN
AB		750MG	A090367	003	Jun 20, 2011	Aug	CAHN
AB	HEC PHARM	250MG	A204968	001	Feb 05, 2019	Jan	NEWA
AB		500MG	A204968	002	Feb 05, 2019	Jan	NEWA
AB		750MG	A204968	003	Feb 05, 2019	Jan	NEWA

LEVOLEUCOVORINPOWDER; INTRAVENOUS
KHAPZORY

+	!	ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018	Mar CAHN
+	!		300MG/VIAL	N211226	002	Oct 19, 2018	Mar CAHN

LEVOLEUCOVORIN CALCIUMPOWDER; INTRAVENOUS
FUSILEV

AP	+	!	ACROTECH	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar CAHN
			LEVOLEUCOVORIN CALCIUM					
	+	@	ACTAVIS LLC	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016	Jun DISC
>A>	AP		MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Nov CAHN
>D>	AP		NANJING KING-FRIEND	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Nov CAHN
	AP			EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Aug NEWA
			SOLUTION; INTRAVENOUS					
			FUSILEV					
	+	@	ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 29, 2011	Mar CAHN
	+	@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 29, 2011	Mar CAHN
			LEVOLEUCOVORIN CALCIUM					
>A>	AP		MEITHEAL	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Nov CAHN
>A>	AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Nov CAHN
		@	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Aug DISC
		@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Aug DISC
>D>	AP		NANJING KING-FRIEND	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Nov CAHN
	AP			EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A211002	001	Aug 16, 2019	Aug NEWA
>D>	AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Nov CAHN
	AP			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002	002	Aug 16, 2019	Aug NEWA

LEVOMILNACIPRAN HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
FETZIMA

+		ALLERGAN	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jun CTEC
+			EQ 40MG BASE	N204168	002	Jul 25, 2013	Jun CTEC
+			EQ 80MG BASE	N204168	003	Jul 25, 2013	Jun CTEC
+	!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jun CTEC
AB	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CFTG
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CFTG
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CFTG
AB	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CFTG

LEVOMILNACIPRAN HYDROCHLORIDE

	@	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun DISC
AB			EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan NFTG
	@		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun DISC
AB			EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan NFTG
	@		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun DISC
AB			EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan NFTG
	@		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun DISC
AB			EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan NFTG

LEVONORGESTRELTABLET; ORAL
LEVONORGESTREL

AB	!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May CAHN
----	---	--------------	--------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

	@	SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb DISC
!			3MG	A074278	003	Jun 18, 2018	May CMFD
	@		3MG	A074278	003	Jun 18, 2018	Feb DISC

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

@ PAR STERILE PRODUCTS 200MCG/VIAL

A205366 001 Dec 07, 2015 Apr DISC

SOLUTION; INTRAVENOUS

LEVOTHYROXINE SODIUM

+! FRESENIUS KABI USA 100MCG/5ML (20MCG/ML)

N210632 001 Apr 11, 2019 Apr NEWA

+! 200MCG/5ML (40MCG/ML)

N210632 002 Apr 11, 2019 Apr NEWA

+! 500MCG/5ML (100MCG/ML)

N210632 003 Apr 11, 2019 Apr NEWA

SOLUTION; ORAL

TIROSINT-SOL

+ INSTITUT BIOCHIMIQUE 13MCG/ML

N206977 001 Dec 15, 2016 Jan CMFD

+ 25MCG/ML

N206977 002 Dec 15, 2016 Jan CMFD

+ 50MCG/ML

N206977 003 Dec 15, 2016 Jan CMFD

+ 75MCG/ML

N206977 004 Dec 15, 2016 Jan CMFD

+ 88MCG/ML

N206977 005 Dec 15, 2016 Jan CMFD

+ 100MCG/ML

N206977 006 Dec 15, 2016 Jan CMFD

+ 112MCG/ML

N206977 007 Dec 15, 2016 Jan CMFD

+ 125MCG/ML

N206977 008 Dec 15, 2016 Jan CMFD

+ 137MCG/ML

N206977 009 Dec 15, 2016 Jan CMFD

+ 150MCG/ML

N206977 010 Dec 15, 2016 Jan CMFD

+ 175MCG/ML

N206977 011 Dec 15, 2016 Jan CMFD

+! 200MCG/ML

N206977 012 Dec 15, 2016 Jan CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

	@ AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Jun DISC
AB2		0.025MG	A210831	001	Feb 19, 2019	May CTEC
AB1, AB2		0.025MG	A210831	001	Feb 19, 2019	Feb NEWA
	@	0.05MG	A210831	002	Feb 19, 2019	Jun DISC
AB2		0.05MG	A210831	002	Feb 19, 2019	May CTEC
AB1, AB2		0.05MG	A210831	002	Feb 19, 2019	Feb NEWA
	@	0.075MG	A210831	003	Feb 19, 2019	Jun DISC
AB2		0.075MG	A210831	003	Feb 19, 2019	May CTEC
AB1, AB2		0.075MG	A210831	003	Feb 19, 2019	Feb NEWA
	@	0.088MG	A210831	004	Feb 19, 2019	Jun DISC
AB2		0.088MG	A210831	004	Feb 19, 2019	May CTEC
AB1, AB2		0.088MG	A210831	004	Feb 19, 2019	Feb NEWA
	@	0.1MG	A210831	005	Feb 19, 2019	Jun DISC
AB2		0.1MG	A210831	005	Feb 19, 2019	May CTEC
AB1, AB2		0.1MG	A210831	005	Feb 19, 2019	Feb NEWA
	@	0.112MG	A210831	006	Feb 19, 2019	Jun DISC
AB2		0.112MG	A210831	006	Feb 19, 2019	May CTEC
AB1, AB2		0.112MG	A210831	006	Feb 19, 2019	Feb NEWA
	@	0.125MG	A210831	007	Feb 19, 2019	Jun DISC
AB2		0.125MG	A210831	007	Feb 19, 2019	May CTEC
AB1, AB2		0.125MG	A210831	007	Feb 19, 2019	Feb NEWA
	@	0.137MG	A210831	008	Feb 19, 2019	Jun DISC
AB2		0.137MG	A210831	008	Feb 19, 2019	May CTEC
AB1, AB2		0.137MG	A210831	008	Feb 19, 2019	Feb NEWA
	@	0.15MG	A210831	009	Feb 19, 2019	Jun DISC
AB2		0.15MG	A210831	009	Feb 19, 2019	May CTEC
AB1, AB2		0.15MG	A210831	009	Feb 19, 2019	Feb NEWA
	@	0.175MG	A210831	010	Feb 19, 2019	Jun DISC
AB2		0.175MG	A210831	010	Feb 19, 2019	May CTEC
AB1, AB2		0.175MG	A210831	010	Feb 19, 2019	Feb NEWA
	@	0.2MG	A210831	011	Feb 19, 2019	Jun DISC
AB2		0.2MG	A210831	011	Feb 19, 2019	May CTEC
AB1, AB2		0.2MG	A210831	011	Feb 19, 2019	Feb NEWA
	@	0.3MG	A210831	012	Feb 19, 2019	Jun DISC
AB2		0.3MG	A210831	012	Feb 19, 2019	May CTEC

TABLET;ORAL							
LEVOTHYROXINE SODIUM							
AB1,		0.3MG	A210831	012	Feb 19, 2019	Feb	NEWA
AB2							
AB1,	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.025MG	A209713	001	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.025MG	A209713	001	Jan 18, 2019	Jan	NEWA
AB1,		0.05MG	A209713	002	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.05MG	A209713	002	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan	NEWA
AB1,		0.075MG	A209713	003	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.075MG	A209713	003	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan	NEWA
AB1,		0.088MG	A209713	004	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.088MG	A209713	004	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan	NEWA
AB1,		0.1MG	A209713	005	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.1MG	A209713	005	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan	NEWA
AB1,		0.112MG	A209713	006	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.112MG	A209713	006	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.112MG	A209713	006	Jan 18, 2019	Jan	NEWA
AB1,		0.125MG	A209713	007	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.125MG	A209713	007	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.125MG	A209713	007	Jan 18, 2019	Jan	NEWA
AB1,		0.137MG	A209713	008	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.137MG	A209713	008	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.137MG	A209713	008	Jan 18, 2019	Jan	NEWA
AB1,		0.15MG	A209713	009	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.15MG	A209713	009	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.15MG	A209713	009	Jan 18, 2019	Jan	NEWA
AB1,		0.175MG	A209713	010	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.175MG	A209713	010	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.175MG	A209713	010	Jan 18, 2019	Jan	NEWA
AB1,		0.2MG	A209713	011	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.2MG	A209713	011	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.2MG	A209713	011	Jan 18, 2019	Jan	NEWA
AB1,		0.3MG	A209713	012	Jan 18, 2019	Oct	CTEC
AB2,							
AB3							
AB1,		0.3MG	A209713	012	Jan 18, 2019	Sep	CTEC
AB2							
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan	NEWA
THYRO-TABS							
AB2,	+ ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar	CAHN
AB4							
AB2,	+	0.05MG	N021116	002	Oct 24, 2002	Mar	CAHN

TABLET;ORAL
THYRO-TABS

AB4									
AB2, +		0.075MG		N021116	003	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.088MG		N021116	010	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.1MG		N021116	004	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.112MG		N021116	011	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.125MG		N021116	005	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.137MG		N021116	012	Dec 07, 2004	Mar	CAHN	
AB4									
AB2, +		0.15MG		N021116	006	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.175MG		N021116	007	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +		0.2MG		N021116	008	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +!		0.3MG		N021116	009	Oct 24, 2002	Mar	CAHN	
AB4									
AB2, +	LLOYD	0.025MG		N021116	001	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.05MG		N021116	002	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.075MG		N021116	003	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.088MG		N021116	010	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.1MG		N021116	004	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.112MG		N021116	011	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.125MG		N021116	005	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.137MG		N021116	012	Dec 07, 2004	Feb	CMFD	
AB4									
AB2, +		0.15MG		N021116	006	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.175MG		N021116	007	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.2MG		N021116	008	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +!		0.3MG		N021116	009	Oct 24, 2002	Feb	CMFD	
AB4									

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

AT	NOVAST LABS	5%		A208604	001	Sep 20, 2017	Sep	CAHN	
AT	SUNGEN PHARMA	5.0%		A212486	001	Oct 17, 2019	Oct	NEWA	

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%		A080404	002		Jun	CTNA	
AP		2%		A080404	003		Jun	CTNA	
AP	! HOSPIRA	1%		A083158	001		Sep	CHRS	
AP	!	2%		A083158	002		Sep	CHRS	
	@	20%		A083158	003		Sep	DISC	
	@ LUITPOLD	1%		A080850	001		Mar	DISC	
	@	1%		A091564	001	Aug 14, 2015	Feb	DISC	
	XYLOCAINE PRESERVATIVE FREE								
+ @	FRESENIUS KABI USA	1%		N016801	005	Jan 19, 1988	Sep	DISC	
+ @		2%		N016801	001		Sep	DISC	
+ @		4%		N016801	002		Sep	DISC	
+ @		20%		N016801	004		Sep	DISC	

JELLY;TOPICAL

ANESTACON

@ BIONPHARMA INC 2%

A080429 001 Apr CAHN

SOLUTION;ORAL

XYLOCAINE VISCOUS

+ @ FRESENIUS KABI USA 2%

N009470 001 Aug CRLD

SOLUTION;TOPICAL							
LIDOCAINE HYDROCHLORIDE							
AT	LANNETT CO INC	4%	A040710	001	Feb 27, 2007	Sep	CMFD
<u>LIDOCAINE; PRILOCAINE</u>							
CREAM;TOPICAL							
EMLA							
AB	+! TEVA BRANDED PHARM	2.5%;2.5%	N019941	001	Dec 30, 1992	Apr	CAHN
<u>LIFITEGRAST</u>							
SOLUTION/DROPS;OPHTHALMIC							
XIIDRA							
	+! NOVARTIS	5%	N208073	001	Jul 11, 2016	Sep	CAHN
<u>LINEZOLID</u>							
TABLET;ORAL							
LINEZOLID							
AB	CELLTRION	600MG	A210702	001	Apr 25, 2019	Apr	NEWA
	@ MYLAN	600MG	A078845	001	Dec 21, 2015	Jun	DISC
<u>LIOTHYRONINE SODIUM</u>							
TABLET;ORAL							
CYTOMEL							
AB	+ KING PHARMS	EQ 0.05MG BASE	N010379	003		Jun	CHRS
	LIOTHYRONINE SODIUM						
	@ MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar	DISC
	@	EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar	DISC
	@	EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar	DISC
AB	! SIGMAPHARM LABS LLC	EQ 0.05MG BASE	A200295	003	Nov 29, 2012	Jun	CHRS
	@ SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jun	DISC
	@	EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jun	DISC
	@	EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jun	DISC
	@ TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Apr	DISC
	@	EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Apr	DISC
	@	EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Apr	DISC
<u>LISINOPRIL</u>							
TABLET;ORAL							
LISINOPRIL							
	@ HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug	DISC
AB		2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN
	@	5MG	A075752	002	Jul 01, 2002	Aug	DISC
AB		5MG	A075752	002	Jul 01, 2002	Feb	CAHN
	@	10MG	A075752	003	Jul 01, 2002	Aug	DISC
AB		10MG	A075752	003	Jul 01, 2002	Feb	CAHN
	@	20MG	A075752	004	Jul 01, 2002	Aug	DISC
AB		20MG	A075752	004	Jul 01, 2002	Feb	CAHN
	@	30MG	A075752	005	Jul 01, 2002	Aug	DISC
AB		30MG	A075752	005	Jul 01, 2002	Feb	CAHN
	@	40MG	A075752	006	Jul 01, 2002	Aug	DISC
AB		40MG	A075752	006	Jul 01, 2002	Feb	CAHN
	@ MYLAN	2.5MG	A076071	001	Jul 01, 2002	Aug	DISC
	@	5MG	A076071	002	Jul 01, 2002	Aug	DISC
	@	10MG	A076071	003	Jul 01, 2002	Aug	DISC
	@	20MG	A076071	004	Jul 01, 2002	Aug	DISC
	@	30MG	A076071	005	Jul 01, 2002	Aug	DISC
	@	40MG	A076071	006	Jul 01, 2002	Aug	DISC
PRINIVIL							
	@ MERCK	10MG	N019558	002	Dec 29, 1987	Oct	DISC
	@	20MG	N019558	003	Dec 29, 1987	Oct	DISC
<u>LITHIUM CARBONATE</u>							
CAPSULE;ORAL							
LITHIUM CARBONATE							
	@ MYLAN	600MG	A078763	001	Apr 15, 2008	Jun	DISC
TABLET, EXTENDED RELEASE;ORAL							
LITHIUM CARBONATE							
	@ HERITAGE PHARMA	300MG	A076170	001	Jun 10, 2002	May	CAHN
	@	450MG	A076366	001	Aug 21, 2003	May	CAHN

LORAZEPAMCONCENTRATE; ORAL
LORAZEPAM

AA	LANNETT CO INC	2MG/ML	A 079244	001	Apr 28, 2009	Jul	CAHN
AA	SAPTALIS PHARMS	2MG/ML	A 079244	001	Apr 28, 2009	Feb	CAHN
INJECTABLE; INJECTION							
ATIVAN							
AP	+! HIKMA	2MG/ML	N 018140	001		Mar	CAHN
AP	+!	4MG/ML	N 018140	002		Mar	CAHN
TABLET; ORAL							
ATIVAN							
AB	+ BAUSCH	0.5MG	N 017794	001		Feb	CAHN
AB	+	1MG	N 017794	002		Feb	CAHN
AB	+!	2MG	N 017794	003		Feb	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

	@ HISUN PHARM HANGZHOU	25MG	A 204795	001	Apr 04, 2019	Oct	DISC
AB		25MG	A 204795	001	Apr 04, 2019	Mar	NEWA
	@	50MG	A 204795	002	Apr 04, 2019	Oct	DISC
AB		50MG	A 204795	002	Apr 04, 2019	Mar	NEWA
	@	100MG	A 204795	003	Apr 04, 2019	Oct	DISC
AB		100MG	A 204795	003	Apr 04, 2019	Mar	NEWA
AB	MICRO LABS	25MG	A 091541	001	Sep 24, 2012	Mar	CAHN
AB		50MG	A 091541	002	Sep 24, 2012	Mar	CAHN
AB		100MG	A 091541	003	Sep 24, 2012	Mar	CAHN
AB	STRIDES PHARMA	25MG	A 090382	001	Oct 06, 2010	Apr	CAHN
AB		50MG	A 090382	002	Oct 06, 2010	Apr	CAHN
AB		100MG	A 090382	003	Oct 06, 2010	Apr	CAHN
	@ TEVA	25MG	A 076958	001	Apr 06, 2010	Jul	DISC
	@	50MG	A 076958	002	Apr 06, 2010	Jul	DISC
	@	100MG	A 076958	003	Apr 06, 2010	Jul	DISC

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX SM

	+! BAUSCH AND LOMB INC	0.38%	N 208219	001	Feb 22, 2019	Feb	NEWA
SUSPENSION/DROPS; OPHTHALMIC							
LOTEMAX							
AB	+! BAUSCH AND LOMB	0.5%	N 020583	001	Mar 09, 1998	Apr	CFTG
LOTEPREDNOL ETABONATE							
AB	HI TECH	0.5%	A 207609	001	Apr 17, 2019	Apr	NFTG

LOVASTATIN

TABLET; ORAL

LOVASTATIN

AB	BEXIMCO PHARMS USA	10MG	A 075300	001	Dec 17, 2001	Feb	CAHN
AB		20MG	A 075300	002	Dec 17, 2001	Feb	CAHN
AB		40MG	A 075300	003	Dec 17, 2001	Feb	CAHN
	@ MYLAN	10MG	A 075451	001	Dec 17, 2001	Feb	DISC
	@	20MG	A 075451	002	Dec 17, 2001	Feb	DISC
	@	40MG	A 075451	003	Dec 17, 2001	Feb	DISC
	@ SUN PHARM INDUSTRIES	10MG	A 077520	001	Apr 14, 2006	Oct	DISC
	@	20MG	A 077520	002	Apr 14, 2006	Oct	DISC
	@	40MG	A 077520	003	Apr 14, 2006	Oct	DISC

LOXAPINE

POWDER; INHALATION

ADASUVE

	+! ALEXZA PHARMS	10MG	N 022549	001	Dec 21, 2012	Aug	CAHN
--	------------------	------	----------	-----	--------------	-----	------

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

	@ TEVA BRANDED PHARM	EQ 25MG BASE/ML	N 017658	001		Feb	CAHN
--	----------------------	-----------------	----------	-----	--	-----	------

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXITANE

+ @ TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb CAHN
+ @	EQ 10MG BASE	N017525	002		Feb CAHN
+ @	EQ 25MG BASE	N017525	003		Feb CAHN
+ @	EQ 50MG BASE	N017525	004		Feb CAHN

TABLET;ORAL

LOXITANE

+ @ TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb CAHN
+ @	EQ 25MG BASE	N017525	007		Feb CAHN
+ @	EQ 50MG BASE	N017525	008		Feb CAHN
+ @	EQ 50MG BASE	N017525	008		Feb CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

	@ AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Jun DISC
	@	40MG	A208002	002	Jan 03, 2019	Jun DISC
	@	60MG	A208002	003	Jan 03, 2019	Jun DISC
	@	80MG	A208002	004	Jan 03, 2019	Jun DISC
	@	120MG	A208002	005	Jan 03, 2019	Jun DISC
	@ EMCURE PHARMS LTD	20MG	A208058	001	Sep 04, 2019	Sep DISC
AB		20MG	A208058	001	Sep 04, 2019	Aug NEWA
	@	40MG	A208058	002	Sep 04, 2019	Sep DISC
AB		40MG	A208058	002	Sep 04, 2019	Aug NEWA
	@	60MG	A208058	003	Sep 04, 2019	Sep DISC
AB		60MG	A208058	003	Sep 04, 2019	Aug NEWA
	@	80MG	A208058	004	Sep 04, 2019	Sep DISC
AB		80MG	A208058	004	Sep 04, 2019	Aug NEWA
	@ INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Jul DISC
	@	40MG	A208028	002	Jan 03, 2019	Jul DISC
	@	60MG	A208028	003	Jan 03, 2019	Jul DISC
	@	80MG	A208028	004	Jan 03, 2019	Jul DISC
	@	120MG	A208028	005	Jan 03, 2019	Jul DISC
	@ LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Jul DISC
	@	40MG	A208031	002	Jan 03, 2019	Jul DISC
	@	60MG	A208031	003	Jan 03, 2019	Jul DISC
	@	80MG	A208031	004	Jan 03, 2019	Jul DISC
	@	120MG	A208031	005	Jan 03, 2019	Jul DISC
>D> AB	TEVA PHARMS USA	20MG	A208060	001	May 17, 2019	Nov DISC
>A>	@	20MG	A208060	001	May 17, 2019	Nov DISC
AB		20MG	A208060	001	May 17, 2019	May NEWA
>D> AB		40MG	A208060	002	May 17, 2019	Nov DISC
>A>	@	40MG	A208060	002	May 17, 2019	Nov DISC
AB		40MG	A208060	002	May 17, 2019	May NEWA
>D> AB		60MG	A208060	003	May 17, 2019	Nov DISC
>A>	@	60MG	A208060	003	May 17, 2019	Nov DISC
AB		60MG	A208060	003	May 17, 2019	May NEWA
>D> AB		80MG	A208060	004	May 17, 2019	Nov DISC
>A>	@	80MG	A208060	004	May 17, 2019	Nov DISC
AB		80MG	A208060	004	May 17, 2019	May NEWA
>D> AB		120MG	A208060	005	May 17, 2019	Nov DISC
>A>	@	120MG	A208060	005	May 17, 2019	Nov DISC
AB		120MG	A208060	005	May 17, 2019	May NEWA
	@ TORRENT	20MG	A208055	001	Jan 03, 2019	Feb DISC
	@	40MG	A208055	002	Jan 03, 2019	Feb DISC
	@	80MG	A208055	003	Jan 03, 2019	Feb DISC
	@	120MG	A208055	004	Jan 03, 2019	Feb DISC
	@ ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Aug DISC
AB		20MG	A208052	001	Mar 19, 2019	Mar NEWA
	@	40MG	A208052	002	Mar 19, 2019	Aug DISC
AB		40MG	A208052	002	Mar 19, 2019	Mar NEWA
	@	60MG	A208052	003	Mar 19, 2019	Aug DISC
AB		60MG	A208052	003	Mar 19, 2019	Mar NEWA
	@	80MG	A208052	004	Mar 19, 2019	Aug DISC
AB		80MG	A208052	004	Mar 19, 2019	Mar NEWA
	@	120MG	A208052	005	Mar 19, 2019	Aug DISC
AB		120MG	A208052	005	Mar 19, 2019	Mar NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP	+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan CTEC

MALATHION

LOTION;TOPICAL
MALATHION

!	SUVEN LIFE	0.5%	A091559	001	May 23, 2012	Aug CHRS
		0.5%	A091559	001	May 23, 2012	Aug CTEC
	OVIDE					
+	@ TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	Aug DISC

MANNITOL

INJECTABLE;INJECTION
MANNITOL 25%

@	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar DISC
---	----------	-------------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET;ORAL
ANTIVERT

AA	+	CASPER PHARMA LLC	12.5MG	N010721	006		Feb CMFD
	+	@	12.5MG	N010721	006		Jan CRLD
AA	+		25MG	N010721	004		Feb CMFD
	+	@	25MG	N010721	004		Jan CRLD
AA	+		50MG	N010721	001	Jan 20, 1982	Feb CMFD
	+	@	50MG	N010721	001	Jan 20, 1982	Jan CRLD
		MECLIZINE HYDROCHLORIDE					
AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan CHRS
AA	!		25MG	A201451	002	Feb 23, 2011	Jan CHRS
	@	ANI PHARMS INC	12.5MG	A084657	002		Sep CMS1
	@		12.5MG	A088732	001	Dec 11, 1985	May CAHN
AA		AUREX	12.5MG	A087127	001		Oct CAHN
AA			25MG	A087128	001		Oct CAHN
AA		INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Feb NEWA
AA			25MG	A205136	002	Feb 22, 2019	Feb NEWA
			50MG	A205136	003	Feb 22, 2019	Feb NEWA

TABLET, CHEWABLE;ORAL
ANTIVERT

AA	+	CASPER PHARMA LLC	25MG	N010721	005		Feb CMFD
	+	@	25MG	N010721	005		Jan CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION
MEDROXYPROGESTERONE ACETATE

	@	CIPLA	150MG/ML	A210335	001	Jan 25, 2019	Jul DISC
AB			150MG/ML	A210335	001	Jan 25, 2019	Jan NEWA
AB		SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Apr NEWA
AB			150MG/ML	A210761	001	Apr 24, 2019	Apr NEWA

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE
@ UPSHER SMITH LABS 10MG

A088484	001	Jul 26, 1984	Jul CAHN
---------	-----	--------------	----------

MEFENAMIC ACID

CAPSULE;ORAL
MEFENAMIC ACID
@ BRECKENRIDGE 250MG

A090359	001	Feb 05, 2013	Feb DISC
---------	-----	--------------	----------

MELOXICAM

CAPSULE;ORAL
VIVLODEX

+	EGALET	5MG	N207233	001	Oct 22, 2015	Feb CAHN
+	!	10MG	N207233	002	Oct 22, 2015	Feb CAHN
+	ZYLA	5MG	N207233	001	Oct 22, 2015	Jul CAHN
+	!	10MG	N207233	002	Oct 22, 2015	Jul CAHN

SUSPENSION;ORAL
MOBIC

+	@	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	Jun CAHN
---	---	-----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

MELOXICAM

	@ HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006	Sep DISC
AB		7.5MG	A077936	001	Jul 19, 2006	Feb CAHN
	@	15MG	A077936	002	Jul 19, 2006	Sep DISC
AB		15MG	A077936	002	Jul 19, 2006	Feb CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

AP	+ APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Feb CMFD
	MELPHALAN HYDROCHLORIDE					
AP	ALVOGEN INC	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	May NEWA
AP	GLAND PHARMA LTD	EQ 50MG BASE/VIAL	A209826	001	May 28, 2019	May NEWA
AP	NORATECH	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep NEWA
	@ US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Oct DISC
AP		EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Apr NEWA

POWDER;INTRAVENOUS

EVOMELA

	+! ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar CAHN
--	-------------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

>D> AA	LANNETT CO INC	2MG/ML	A204033	001	Oct 13, 2015	Nov CHRS
>A> AA	!	2MG/ML	A204033	001	Oct 13, 2015	Nov CHRS
>D> AA	! TORRENT	2MG/ML	A205446	001	Dec 07, 2015	Nov DISC
>A>	@	2MG/ML	A205446	001	Dec 07, 2015	Nov DISC
AA	!	2MG/ML	A205446	001	Dec 07, 2015	Jan CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

	@ APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jan DISC
	@	10MG	A090244	002	Jul 11, 2018	Jan DISC
AB	CADILA	5MG	A090961	001	Jul 10, 2017	Feb CAHN
AB		10MG	A090961	002	Jul 10, 2017	Feb CAHN
AB	CELLTRION	5MG	A090073	001	Sep 04, 2015	Aug CAHN
AB		10MG	A090073	002	Sep 04, 2015	Aug CAHN
	@ MYLAN	5MG	A079225	001	Jan 30, 2015	Oct DISC
	@	10MG	A079225	002	Jan 30, 2015	Oct DISC

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

DEMEROL

	+ @ US PHARM HOLDINGS	50MG	N005010	001		Aug DISC
	+ @	100MG	N005010	004		Aug DISC

MEPERIDINE HYDROCHLORIDE

	@ SPECGX LLC	50MG	A040352	001	Jun 13, 2000	Aug DISC
	@	100MG	A040352	002	Jun 13, 2000	Aug DISC
	@ SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002	Oct DISC
	@	100MG	A040446	002	Aug 08, 2002	Oct DISC

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

	@ HIKMA	25MG/ML;25MG/ML	N011730	001		Jun CAHN
--	---------	-----------------	---------	-----	--	----------

MEQUINOL; TRETINOIN

SOLUTION;TOPICAL

SOLAGE

	@ ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999	Feb CAHN
--	------------	----------	---------	-----	--------------	----------

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

	@ HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010	Sep DISC
	@	1GM/VIAL	A090940	002	Jun 22, 2010	Sep DISC
AP	HQ SPCLT PHARMA	500MG/VIAL	A210773	001	Aug 16, 2019	Aug NEWA
AP		1GM/VIAL	A210773	002	Aug 16, 2019	Aug NEWA

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL

AB +! APIL 400MG N204412 001 Feb 01, 2013 Apr CFTG

AB TEVA PHARMS USA 400MG A207873 001 May 09, 2019 Apr NFTG
CAPSULE, EXTENDED RELEASE;ORAL

APRISO

>D> +! VALEANT PHARMS INTL 375MG N022301 001 Oct 31, 2008 Nov CFTG

>A> AB +! 375MG N022301 001 Oct 31, 2008 Nov CFTG

>A> MESALAMINE

>A> AB MYLAN 375MG A207271 001 Nov 20, 2019 Nov NFTG

SUPPOSITORY;RECTAL
MESALAMINE

AB AMRING PHARMS 1GM A208362 001 Jun 21, 2019 Jun NEWA

AB PHARM SOURCING 1GM A207448 001 Apr 19, 2019 Apr NEWA

AB SANDOZ INC 1GM A202065 001 Jun 12, 2019 May NEWA

TABLET, DELAYED RELEASE;ORAL
MESALAMINE

AB @ SUN PHARM 1.2GM A211858 001 Jan 25, 2019 Aug DISC

AB 1.2GM A211858 001 Jan 25, 2019 Jan NEWA

MESTRANOL; NORETHINDRONE

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+ @ ACTAVIS LABS UT INC 0.05MG;1MG N016659 001 Jul DISC

METAPROTERENOL SULFATE

TABLET;ORAL

METAPROTERENOL SULFATE

@ HERITAGE PHARMA 10MG A072519 001 Mar 30, 1990 May CAHN

@ 20MG A072520 001 Mar 30, 1990 May CAHN

@ PAR PHARM 10MG A072024 001 Jun 28, 1988 Jul DISC

@ 20MG A072025 001 Jun 28, 1988 Jul DISC

METAXALONE

TABLET;ORAL

METAXALONE

AB APPCO 800MG A208774 001 Sep 24, 2018 Feb CAHN

METFORMIN HYDROCHLORIDEFOR SUSPENSION, EXTENDED RELEASE;ORAL
RIOMET ER

+! SUN PHARM 500MG/5ML N212595 001 Aug 29, 2019 Aug NEWA

TABLET;ORAL

GLUCOPHAGE

+ @ BRISTOL MYERS SQUIBB 500MG N020357 001 Mar 03, 1995 Jun DISC

+ @ 850MG N020357 002 Mar 03, 1995 Jun DISC

+ @ 1GM N020357 005 Nov 05, 1998 Jun DISC

+ @ EMD SERONO INC 500MG N020357 001 Mar 03, 1995 Jul CAHN

+ @ 625MG N020357 003 Nov 05, 1998 Jul CAHN

+ @ 750MG N020357 004 Nov 05, 1998 Jul CAHN

+ @ 850MG N020357 002 Mar 03, 1995 Jul CAHN

+ @ 1GM N020357 005 Nov 05, 1998 Jul CAHN

METFORMIN HYDROCHLORIDE

AB ! GRANULES INDIA 1GM A090564 003 Apr 22, 2010 Jun CHRS

AB HERITAGE PHARMA 500MG A075978 001 Jan 25, 2002 Feb CAHN

AB 850MG A075978 002 Jan 25, 2002 Feb CAHN

AB 1GM A075978 003 Nov 05, 2002 Feb CAHN

@ SUN PHARM INDUSTRIES 500MG A076038 001 Feb 21, 2002 Oct DISC

@ 850MG A076038 002 Feb 21, 2002 Oct DISC

@ 1GM A076038 003 Feb 21, 2002 Oct DISC

@ SUNSHINE LAKE 500MG A208999 001 Oct 12, 2018 Apr DISC

@ 850MG A208999 002 Oct 12, 2018 Apr DISC

@ 1GM A208999 003 Oct 12, 2018 Apr DISC

TABLET, EXTENDED RELEASE;ORAL
GLUCOPHAGE XR

+ @ BRISTOL MYERS SQUIBB 500MG N021202 001 Oct 13, 2000 Jun DISC

+ @ 750MG N021202 004 Apr 11, 2003 Jun DISC

+ @ EMD SERONO INC 500MG N021202 001 Oct 13, 2000 Jul CAHN

+ @ 750MG N021202 004 Apr 11, 2003 Jul CAHN

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

AB	!	AMNEAL PHARMS NY	750MG	A078596	002	Jan 03, 2008	Jun CHRS
AB1		CADILA	500MG	A077060	001	Apr 20, 2005	Feb CAHN
AB			750MG	A077078	001	Apr 21, 2005	Feb CAHN
>A>	AB3	GLENMARK PHARMS LTD	500MG	A212969	001	Nov 25, 2019	Nov NEWA
>A>	AB3		1GM	A212969	002	Nov 25, 2019	Nov NEWA
	AB1	INVENTIA	500MG	A201991	001	Jan 18, 2012	Aug CAHN
	AB2	!	LUPIN LTD	A090692	002	Jun 29, 2011	Apr CHRS
	AB1	SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Sep CHRS
	AB1	!		A077336	001	Feb 09, 2006	Jun CHRS
		@ YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Mar DISC
		@	750MG	A211052	002	Sep 24, 2018	Mar DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN 500MG; EQ 15MG BASE

A090406 001 Feb 25, 2011 Jul DISC

@ 850MG; EQ 15MG BASE

A090406 002 Feb 25, 2011 Jul DISC

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

+ @ TAKEDA PHARMS USA 1GM; EQ 15MG BASE

N022024 001 May 12, 2009 Mar DISC

+ @ 1GM; EQ 30MG BASE

N022024 002 May 12, 2009 Mar DISC

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

AA PHARM ASSOC 10MG/ML

A207368 001 Aug 22, 2019 Aug NEWA

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

AA PHARM ASSOC 5MG/5ML

A207537 001 Oct 02, 2019 Sep NEWA

AA 10MG/5ML

A207537 002 Oct 01, 2019 Sep NEWA

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

@ MICRO LABS 25MG

A207438 001 Oct 05, 2018 Mar DISC

@ 50MG

A207438 002 Oct 05, 2018 Mar DISC

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB MICRO LABS 1GM

A212172 001 Aug 01, 2019 Jul NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

@ SUN PHARM INDS INC 5MG

A040870 001 Sep 25, 2007 Oct DISC

@ 10MG

A040870 002 Sep 25, 2007 Oct DISC

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP SLATE 1GM/10ML (100MG/ML)

A208116 001 Jan 19, 2017 Feb CAHN

ROBAXIN

AP +! HIKMA 1GM/10ML (100MG/ML)

N011790 001 Feb CAHN

TABLET; ORAL

METHOCARBAMOL

AA ANI PHARMS INC 500MG

A084277 001 Sep CAHN

AA ! GRANULES INDIA LTD 500MG

A209312 001 May 07, 2018 Jul CHRS

ROBAXIN

+ @ AUXILIUM PHARMS LLC 500MG

N011011 004 Jul DISC

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+! MEDEXUS 7.5MG/0.15ML (7.5MG/0.15ML)

N205776 001 Jul 10, 2014 Apr CAHN

+! 10MG/0.20ML (10MG/0.20ML)

N205776 002 Jul 10, 2014 Apr CAHN

+! 12.5MG/0.25ML (12.5MG/0.25ML)

N205776 003 Jul 10, 2014 Apr CAHN

+! 15MG/0.30ML (15MG/0.30ML)

N205776 004 Jul 10, 2014 Apr CAHN

+! 17.5MG/0.35ML (17.5MG/0.35ML)

N205776 005 Jul 10, 2014 Apr CAHN

+! 20MG/0.4ML (20MG/0.4ML)

N205776 006 Jul 10, 2014 Apr CAHN

SOLUTION;SUBCUTANEOUS
RASUVO

	+	22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr CAHN	
	+	25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr CAHN	
	+ @	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr CAHN	
	+	30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CAHN	
>A>	REDITREX						
>A>	CUMBERLAND PHARMS		7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Nov NEWA
>A>			10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Nov NEWA
>A>			12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Nov NEWA
>A>			15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019	Nov NEWA
>A>			17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Nov NEWA
>A>			20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019	Nov NEWA
>A>			22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Nov NEWA
>A>			25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019	Nov NEWA

METHOXSALENCAPSULE;ORAL
OXSORALEN-ULTRA

AB	+	BAUSCH	10MG	N019600	001	Oct 30, 1986	Aug CAHN
----	---	--------	------	---------	-----	--------------	----------

METHSCOPOLAMINE BROMIDETABLET;ORAL
METHSCOPOLAMINE BROMIDE

		BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Oct CTEC
	!		5MG	A200602	002	Sep 24, 2012	Oct CHRS
			5MG	A200602	002	Sep 24, 2012	Oct CTEC
	@	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Jun DISC
	@		5MG	A040642	002	Dec 06, 2011	Jun DISC
	@	VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Oct DISC
	@		5MG	A040624	002	Dec 28, 2006	Oct DISC

METHYLDOPATABLET;ORAL
METHYLDOPA

AB		HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb CAHN
AB			500MG	A070343	001	Feb 20, 1986	Feb CAHN

METHYLDOPATE HYDROCHLORIDEINJECTABLE;INJECTION
METHYLDOPATE HYDROCHLORIDE

	@	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Mar DISC
--	---	----------	---------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATETABLET;ORAL
METHYLERGONOVINE MALEATE

AB		TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019	Mar NEWA
----	--	-----------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR

	+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar CRLD
			25MG	N212038	001	Feb 27, 2019	Feb NEWA
	+		35MG	N212038	002	Feb 27, 2019	Feb NEWA
	+		45MG	N212038	003	Feb 27, 2019	Feb NEWA
	+		55MG	N212038	004	Feb 27, 2019	Feb NEWA
	+		70MG	N212038	005	Feb 27, 2019	Feb NEWA
	+		85MG	N212038	006	Feb 27, 2019	Feb NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB1		GRANULES PHARMS	10MG	A211796	001	May 23, 2019	May NEWA
AB1			20MG	A211796	002	May 23, 2019	May NEWA
AB1			30MG	A211796	003	May 23, 2019	May NEWA
AB1			40MG	A211796	004	May 23, 2019	May NEWA
AB1			60MG	A211796	005	May 23, 2019	May NEWA
AB1	!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	May CTEC

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Jan DISC
--	---	---------------------	--------	---------	-----	--------------	----------

QUILLIVANT XR

	+	NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012	Feb CAHN
	+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Jan CTEC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOVELGENIX THERAPS	5MG/5ML	A210139	001	Oct 03, 2018	Sep CAHN
AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ALKEM LABS LTD	5MG	A211779	001	Oct 04, 2019	Sep NEWA
AB		10MG	A211779	002	Oct 04, 2019	Sep NEWA
AB		20MG	A211779	003	Oct 04, 2019	Sep NEWA
	@ AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018	Apr DISC
	@	10MG	A209276	002	Oct 25, 2018	Apr DISC
	@	20MG	A209276	003	Oct 25, 2018	Apr DISC
	@ CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Aug DISC
AB		5MG	A208737	001	Feb 01, 2019	Jan NEWA
	@	10MG	A208737	002	Feb 01, 2019	Aug DISC
AB		10MG	A208737	002	Feb 01, 2019	Jan NEWA
	@	20MG	A208737	003	Feb 01, 2019	Aug DISC
AB		20MG	A208737	003	Feb 01, 2019	Jan NEWA
	@ LANNETT CO INC	5MG	A086429	001		Jan DISC
	@	10MG	A085799	001		Jan DISC
	@	20MG	A086428	001		Jan DISC

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

	@ LANNETT CO INC	20MG	A089601	001	Jun 01, 1988	Jan DISC
--	------------------	------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

AB	! ABHAI LLC	20MG	A207488	002	Jun 09, 2015	Jan NEWA
AB	ANDOR PHARMS	18MG	A211918	001	Apr 24, 2019	Apr NEWA
AB		27MG	A211918	002	Apr 24, 2019	Apr NEWA
AB		36MG	A211918	003	Apr 24, 2019	Apr NEWA
AB		54MG	A211918	004	Apr 24, 2019	Apr NEWA
AB	ASCENT PHARMS INC	18MG	A211009	001	Sep 03, 2019	Aug NEWA
AB		27MG	A211009	002	Sep 03, 2019	Aug NEWA
AB		36MG	A211009	003	Sep 03, 2019	Aug NEWA
AB		54MG	A211009	004	Sep 03, 2019	Aug NEWA
>D> AB	@ HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001	May CAHN
>A>	PAR PHARM	36MG	A204659	001	Jul 15, 2019	Nov DISC
	@	36MG	A204659	001	Jul 15, 2019	Nov DISC
AB		36MG	A204659	001	Jul 15, 2019	Jul NEWA
>D> AB		54MG	A204659	002	Jul 15, 2019	Nov DISC
>A>	@	54MG	A204659	002	Jul 15, 2019	Nov DISC
AB		54MG	A204659	002	Jul 15, 2019	Jul NEWA

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	+ PHARMACIA AND UPJOHN	2MG	N011153	002		Mar CFTG
	METHYLPREDNISOLONE					
	@ LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Sep DISC
AB		2MG	A209097	001	Feb 22, 2019	Mar NFTG
AB		2MG	A209097	001	Feb 22, 2019	Feb NEWA
	@	4MG	A209097	002	Feb 22, 2019	Sep DISC
AB		4MG	A209097	002	Feb 22, 2019	Feb NEWA
	@	8MG	A209097	003	Feb 22, 2019	Sep DISC
AB		8MG	A209097	003	Feb 22, 2019	Feb NEWA
	@	16MG	A209097	004	Feb 22, 2019	Sep DISC
AB		16MG	A209097	004	Feb 22, 2019	Feb NEWA
	@	32MG	A209097	005	Feb 22, 2019	Sep DISC
AB		32MG	A209097	005	Feb 22, 2019	Feb NEWA
	@ NOVAST LABS	4MG	A210985	001	Jan 09, 2019	Oct DISC
AB		4MG	A210985	001	Jan 09, 2019	Sep CAHN
AB	SUNGEN PHARMA	4MG	A212262	001	Jun 27, 2019	Jun NEWA
AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

VIRILON

	@ CHARTWELL	10MG	A087750	001	Nov 24, 1982	Jun CAHN
--	-------------	------	---------	-----	--------------	----------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

METIPRANOLOL

@ SANDOZ INC 0.3%

A075720 001 Aug 06, 2001 May DISC

OPTIPRANOLOL

+ @ BAUSCH AND LOMB 0.3%

N019907 001 Dec 29, 1989 Aug DISC

+! 0.3%

N019907 001 Dec 29, 1989 May CTEC

METOLAZONE

TABLET;ORAL

METOLAZONE

@ ANI PHARMS INC 5MG

A076833 001 Mar 01, 2004 Sep CAHN

@ 10MG

A075543 003 Dec 24, 2003 Sep CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

TOPROL-XL

AB + TOPROL EQ 25MG TARTRATE

N019962 004 Feb 05, 2001 Mar CAHN

AB +! EQ 50MG TARTRATE

N019962 001 Jan 10, 1992 Mar CAHN

AB + EQ 100MG TARTRATE

N019962 002 Jan 10, 1992 Mar CAHN

AB +! EQ 200MG TARTRATE

N019962 003 Jan 10, 1992 Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

LOPRESSOR

+ @ NOVARTIS 1MG/ML

N018704 001 Mar 30, 1984 Jun DISC

METOPROLOL TARTRATE

AP ! HOSPIRA 1MG/ML

A078085 001 Apr 29, 2008 Jun CHRS

@ LUITPOLD 1MG/ML

A090386 001 Sep 30, 2009 Mar DISC

@ 1MG/ML

A091307 001 Dec 29, 2010 Feb DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB HERITAGE PHARMA 50MG

A074141 001 Jan 31, 1995 Apr CAHN

AB 100MG

A074141 002 Jan 31, 1995 Apr CAHN

AB MYLAN 37.5MG

A076704 004 Mar 18, 2015 Oct CTEC

AB 75MG

A076704 005 Mar 18, 2015 Oct CTEC

AB RUBICON 37.5MG

A200981 004 Aug 21, 2019 Oct NEWA

AB 75MG

A200981 005 Aug 21, 2019 Oct NEWA

@ SUN PHARM INDUSTRIES 25MG

A073654 002 Jul 15, 2009 Oct DISC

@ 50MG

A073654 003 Dec 21, 1993 Oct DISC

@ 100MG

A073654 001 Dec 21, 1993 Oct DISC

@ WATSON LABS 50MG

A074217 001 May 27, 1994 Oct DISC

@ 100MG

A074217 002 May 27, 1994 Oct DISC

METRONIDAZOLE

GEL;VAGINAL

METROGEL-VAGINAL

AB +! BAUSCH 0.75%

N020208 001 Aug 17, 1992 Mar CAHN

METRONIDAZOLE

AB GAGE DEVELOPMENT 0.75%

A211786 001 Jul 02, 2019 Jun NEWA

AB PERRIGO UK FINCO 0.75%

A211786 001 Jul 02, 2019 Jul CAHN

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP INFORLIFE 500MG/100ML

A206191 001 Feb 25, 2019 Feb NEWA

TABLET;ORAL

METRONIDAZOLE

AB CADILA 250MG

A206560 001 Nov 16, 2016 Mar CAHN

AB 500MG

A206560 002 Nov 16, 2016 Mar CAHN

AB STRIDES PHARMA 250MG

A070040 001 Jan 29, 1985 Apr CAHN

AB 500MG

A070039 001 Jan 29, 1985 Apr CAHN

METYROSINE

CAPSULE;ORAL

DEMSEER

+! BAUSCH 250MG

N017871 001 Mar CAHN

MICAFUNGIN SODIUMINJECTABLE; INTRAVENOUS
MICAFUNGIN SODIUM

AP	FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	May NFTG
AP		EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	May NFTG
	MYCAMINE					
AP	+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May CFTG
AP	+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May CDFR

MICONAZOLETABLET; BUCCAL
ORAVIG

+!	FORTOVIA	50MG	N022404	001	Apr 16, 2010	Oct CAHN
----	----------	------	---------	-----	--------------	----------

MIDAZOLAMSPRAY; NASAL
NAYZILAM

+!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019	May NEWA
----	---------	-----------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDEINJECTABLE; INJECTION
MIDOZALAM HYDROCHLORIDE

	@ MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Sep DISC
AP		EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr CAHN
	@	EQ 5MG BASE/ML	A090316	002	May 04, 2011	Sep DISC
AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr CAHN

MIDODRINE HYDROCHLORIDETABLET; ORAL
MIDODRINE HYDROCHLORIDE

	@ CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	May DISC
	@	5MG	A076514	002	Sep 11, 2003	May DISC
	@	10MG	A076514	003	Jul 02, 2004	May DISC
AB	MYLAN PHARMS INC	5MG	A076577	002	Sep 10, 2003	May CHRS
AB	RUBICON	2.5MG	A212543	001	Aug 19, 2019	Aug NEWA
AB		5MG	A212543	002	Aug 19, 2019	Aug NEWA
AB		10MG	A212543	003	Aug 19, 2019	Aug NEWA
	ORVATEN					
AB	! UPSHER SMITH LABS	5MG	A076725	002	Nov 03, 2004	May CHRS

MIFEPRISTONETABLET; ORAL
MIFEPREX

AB	+! DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar CFTG
	MIFEPRISTONE					
AB	GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar NFTG

MILRINONE LACTATEINJECTABLE; INJECTION
MILRINONE LACTATE IN DEXTROSE 5%

AP	WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Oct CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	@ WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Oct CAHN

MINOCYCLINE HYDROCHLORIDEAEROSOL, FOAM; TOPICAL
AMZEEQ

+!	FOAMIX	EQ 4% BASE	N212379	001	Oct 18, 2019	Oct NEWA
----	--------	------------	---------	-----	--------------	----------

CAPSULE; ORAL
MINOCIN

AB	+ BAUSCH	EQ 50MG BASE	N050649	001	May 31, 1990	May CAHN
	+ @	EQ 75MG BASE	N050649	003	Feb 12, 2001	May CAHN
AB	+ @	EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN

CAPSULE, EXTENDED RELEASE; ORAL
XIMINO

	SUN PHARM INDS INC	EQ 45MG BASE	N201922	001	Jul 11, 2012	Aug CAHN
	@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Aug CAHN
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Aug CAHN
	@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Aug CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XIMINO

EQ 135MG BASE N201922 005 Jul 11, 2012 Aug CAHN

SUSPENSION;ORAL
MINOCIN

@ BAUSCH EQ 50MG BASE/5ML N050445 001 May CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

@ SUN PHARM INDUSTRIES EQ 50MG BASE A090217 001 Jan 29, 2016 Oct DISC

@ EQ 75MG BASE A090217 002 Jan 29, 2016 Oct DISC

@ EQ 100MG BASE A090217 003 Jan 29, 2016 Oct DISC

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD EQ 55MG BASE A202261 008 Aug 21, 2019 Aug NEWA

AB BARR LABS INC EQ 80MG BASE A065485 007 Apr 26, 2017 Jan CMFD

AB EQ 105MG BASE A065485 008 Apr 26, 2017 Jan CMFD

@ MYLAN EQ 55MG BASE A203443 001 Aug 21, 2019 Aug NEWA

@ MYLAN LABS LTD EQ 65MG BASE A201467 001 Jul 30, 2019 Aug DISC

AB EQ 65MG BASE A201467 001 Jul 30, 2019 Jul NEWA

@ EQ 115MG BASE A201467 002 Jul 30, 2019 Aug DISC

AB EQ 115MG BASE A201467 002 Jul 30, 2019 Jul NEWA

>A> AB SUN PHARM INDS LTD EQ 65MG BASE A091118 003 Dec 03, 2019 Nov NEWA

>A> AB EQ 115MG BASE A091118 007 Dec 03, 2019 Nov NEWA

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

@ WATSON LABS 15MG A076312 001 Jun 19, 2003 May DISC

@ 30MG A076312 002 Jun 19, 2003 May DISC

@ 45MG A076312 003 Jun 19, 2003 May DISC

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP WEST-WARD PHARMS INT 20MG/VIAL A064117 002 Apr 19, 1995 Jan CMFD

AP 40MG/VIAL A064117 003 Jun 02, 1999 Jan CMFD

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

@ MYLAN INSTITUTIONAL EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A078980 001 Apr 13, 2009 Mar DISC

@ EQ 30MG BASE/15ML (EQ 2MG BASE/ML) A078980 002 Apr 13, 2009 Mar DISC

@ MYLAN LABS LTD EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A201014 001 Dec 11, 2012 Sep DISC

NOVANTRONE

+ @ EMD SERONO EQ 20MG BASE/10ML (EQ 2MG BASE/ML) N019297 001 Dec 23, 1987 Sep CRLD

MODAFINIL

TABLET;ORAL

MODAFINIL

>A> AB APPCO 100MG A207196 001 Aug 16, 2017 Nov CAHN

>A> AB 200MG A207196 002 Aug 16, 2017 Nov CAHN

AB CADILA 100MG A209966 001 Sep 14, 2017 Aug CMFD

@ 100MG A209966 001 Sep 14, 2017 May CAHN

AB 200MG A209966 002 Sep 14, 2017 Aug CMFD

@ 200MG A209966 002 Sep 14, 2017 May CAHN

>D> AB HERITAGE PHARMS INC 100MG A207196 001 Aug 16, 2017 Nov CAHN

>D> AB 200MG A207196 002 Aug 16, 2017 Nov CAHN

@ HIKMA PHARMS 100MG A090543 001 Sep 26, 2012 Aug DISC

@ 200MG A090543 002 Sep 26, 2012 Aug DISC

@ ZYDUS PHARMS 100MG A209966 001 Sep 14, 2017 Apr DISC

@ 200MG A209966 002 Sep 14, 2017 Apr DISC

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

+ MERCK SHARP DOHME 0.05MG/INH N205641 003 Aug 12, 2019 Aug NEWA

CREAM;TOPICAL

ELOCON

+ @ MERCK SHARP DOHME 0.1% N019625 002 Apr 19, 2013 Aug DISC

MOMETASONE FUROATE

AB ! GLENMARK GENERICS 0.1% A078541 001 May 28, 2008 Aug CHRS

OINTMENT;TOPICAL
ELOCON

	+ @ MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	Jul DISC
	MOMETASONE FUROATE					
AB	! GLENMARK GENERICS	0.1%	A078571	001	May 28, 2008	Jul CHRS

MONTELUKAST SODIUM

GRANULE;ORAL

	MONTELUKAST SODIUM					
	@ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb DISC
AB	TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar CAHN

TABLET;ORAL

	MONTELUKAST SODIUM					
AB	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	May CAHN
	@ MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012	Jul DISC
	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb DISC

TABLET, CHEWABLE;ORAL

	MONTELUKAST SODIUM					
	@ MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr DISC
	@	EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr DISC
	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb DISC
	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb DISC

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>A>	AB	IMPAX LABS INC	40MG	A200411	007	Jul 25, 2018	Nov NEWA
-----	----	----------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

	ASTRAMORPH PF					
	@ FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986	Mar DISC
	MITIGO					
AP	PIRAMAL CRITICAL	10MG/ML	A204393	001	Jul 16, 2018	Aug CAHN
AP		25MG/ML	A204393	002	Jul 16, 2018	Aug CAHN

MORPHINE SULFATE

	+ @ ICU MEDICAL INC	5MG/ML	N019916	002	Oct 27, 2006	Sep DISC
	SOLUTION;ORAL					
	MORPHINE SULFATE					
	@ LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb DISC
	@	20MG/5ML	A202310	001	Oct 30, 2015	Jan DISC
	@	100MG/5ML	N201517	001	Jun 23, 2011	Jan DISC

TABLET;ORAL

	MORPHINE SULFATE					
AB	UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	Jul NFTG
AB		30MG	A210610	002	Jul 22, 2019	Jul NFTG

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

	+ @ EGALET	15MG	N208603	001	Jan 09, 2017	Mar CAHN
	+ @	30MG	N208603	002	Jan 09, 2017	Mar CAHN
	+ @	60MG	N208603	003	Jan 09, 2017	Mar CAHN
	+ @ ZYLA	15MG	N208603	001	Jan 09, 2017	Jul CAHN
	+ @	30MG	N208603	002	Jan 09, 2017	Jul CAHN
	+ @	60MG	N208603	003	Jan 09, 2017	Jul CAHN

MORPHINE SULFATE

	@ MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Aug DISC
	@	30MG	A200824	002	Oct 18, 2011	Aug DISC
	@	60MG	A200824	003	Oct 18, 2011	Aug DISC
	@	100MG	A200824	004	Oct 18, 2011	Aug DISC
	@	200MG	A200824	005	Oct 18, 2011	Feb DISC
	@ SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016	Oct DISC
	@	30MG	A205634	002	Aug 25, 2016	Oct DISC
	@	60MG	A205634	003	Aug 25, 2016	Oct DISC
	@	100MG	A205634	004	Aug 25, 2016	Oct DISC
	@	200MG	A205634	005	Aug 25, 2016	Oct DISC

>D> MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

>D>	+ ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009	Nov DISC
>A>	+ @	20MG;0.8MG	N022321	001	Aug 13, 2009	Nov DISC
>D>	+ @	30MG;1.2MG	N022321	002	Aug 13, 2009	Nov DISC
>A>	+ @	30MG;1.2MG	N022321	002	Aug 13, 2009	Nov DISC
>D>	+ @	50MG;2MG	N022321	003	Aug 13, 2009	Nov DISC

CAPSULE, EXTENDED RELEASE;ORAL
EMBEDA

>A>	+	@	50MG;2MG	N022321	003	Aug 13, 2009	Nov	DISC
>D>	+	!	60MG;2.4MG	N022321	004	Aug 13, 2009	Nov	DISC
>A>	+	@	60MG;2.4MG	N022321	004	Aug 13, 2009	Nov	DISC
>D>	+		80MG;3.2MG	N022321	005	Aug 13, 2009	Nov	DISC
>A>	+	@	80MG;3.2MG	N022321	005	Aug 13, 2009	Nov	DISC
>D>	+		100MG;4MG	N022321	006	Aug 13, 2009	Nov	DISC
>A>	+	@	100MG;4MG	N022321	006	Aug 13, 2009	Nov	DISC

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1		ALEMBIC PHARMS LTD	EQ 0.5% BASE	A209469	001	Feb 13, 2019	Jan	NEWA
		TABLET;ORAL						
		MOXIFLOXACIN HYDROCHLORIDE						
		@ MYLAN	EQ 400MG BASE	A204635	001	Aug 31, 2015	Oct	DISC
		@ SUNSHINE LAKE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Mar	DISC

MUPIROCINOINTMENT;TOPICAL
MUPIROCIN

AB	!	PERRIGO ISRAEL	2%	A065123	001	Nov 07, 2003	May	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETILSUSPENSION;ORAL
MYCOPHENOLATE MOFETIL

AB		VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan	NEWA
		TABLET;ORAL						
		MYCOPHENOLATE MOFETIL						
		@ OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010	Aug	DISC
		@ TEVA PHARMS	500MG	A065457	001	May 04, 2009	Sep	DISC

NABUMETONETABLET;ORAL
NABUMETONE

AB		NEXGEN PHARMA INC	500MG	A203166	001	Aug 30, 2019	Aug	NEWA
AB			750MG	A203166	002	Aug 30, 2019	Aug	NEWA
			1GM	A203166	003	Aug 30, 2019	Aug	NEWA
AB		NOSTRUM LABS INC	500MG	A090427	001	Dec 30, 2011	Oct	CAHN
AB			750MG	A090427	002	Dec 30, 2011	Oct	CAHN
AB		SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008	Sep	CMFD
AB			750MG	A078420	002	Sep 24, 2008	Sep	CMFD

NADOLOLTABLET;ORAL
NADOLOL

AB		HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr	CAHN
AB			40MG	A074229	002	Aug 30, 1996	Apr	CAHN
AB			80MG	A074255	001	Jan 24, 1996	Apr	CAHN
		@	120MG	A074255	002	Jan 24, 1996	Apr	CAHN
		@	160MG	A074255	003	Jan 24, 1996	Apr	CAHN
AB		VGYAAN	20MG	A212856	001	Sep 13, 2019	Sep	NEWA
AB			40MG	A212856	002	Sep 13, 2019	Sep	NEWA
AB			80MG	A212856	003	Sep 13, 2019	Sep	NEWA

NAFCILLIN SODIUMINJECTABLE;INJECTION
NAFCILLIN SODIUM

>A>	AP	FRESENIUS	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019	Nov	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019	Nov	NEWA
		@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Sep	DISC
		@	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Sep	DISC

NAFTIFINE HYDROCHLORIDEGEL;TOPICAL
NAFTIFINE HYDROCHLORIDE

		@ TARO	2%	A208201	001	Apr 10, 2019	May	DISC
AB			2%	A208201	001	Apr 10, 2019	Mar	NFTG
AB		TOLMAR	1%	A206165	001	Mar 20, 2019	Mar	NFTG
		NAFTIN						
AB	+	SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar	CFTG

GEL; TOPICAL								
NAFTIN								
AB	+	!	2%	N204286	001	Jun 27, 2013	Mar CFTG	
<u>NALBUPHINE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
NALBUPHINE HYDROCHLORIDE								
	@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May CAHN	
	@		20MG/ML	A074471	002	Mar 19, 1998	May CAHN	
AP		MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan NEWA	
AP			20MG/ML	A206506	002	Feb 06, 2019	Jan NEWA	
<u>NALDEMEDINE TOSYLATE</u>								
TABLET; ORAL								
SYMPROIC								
	+	!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Apr CAHN
<u>NALOXONE HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
NALOXONE HYDROCHLORIDE								
AP		AUROBINDO PHARMA LTD	0.4MG/ML	A212455	001	Oct 15, 2019	Sep NEWA	
AP			0.4MG/ML	A212456	001	Nov 04, 2019	Oct NEWA	
	@	VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018	Oct DISC	
AP			0.4MG/ML	A207846	001	Dec 17, 2018	Jul CAHN	
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS								
EVZIO (AUTOINJECTOR)								
	+	!	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb CTNA
SPRAY, METERED; NASAL								
NALOXONE HYDROCHLORIDE								
	@	TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	May DISC	
AB			4MG/SPRAY	A209522	001	Apr 19, 2019	Apr NFTG	
NARCAN								
	+	!	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	May CTEC
AB			4MG/SPRAY	N208411	001	Nov 18, 2015	Apr CFTG	
<u>NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE</u>								
TABLET; ORAL								
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE								
AB		LUPIN	EQ 0.5MG BASE; EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb CAHN	
<u>NANDROLONE DECANOATE</u>								
INJECTABLE; INJECTION								
NANDROLONE DECANOATE								
	@	LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010	Feb DISC	
<u>NAPROXEN</u>								
SUSPENSION; ORAL								
NAPROSYN								
AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CHRS	
TABLET; ORAL								
NAPROXEN								
AB		PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr CAHN	
AB			375MG	A077339	002	Apr 27, 2005	Apr CAHN	
AB			500MG	A077339	003	Apr 27, 2005	Apr CAHN	
<u>NAPROXEN SODIUM</u>								
TABLET; ORAL								
NAPROXEN SODIUM								
AB		SCIEGEN PHARMS INC	EQ 250MG BASE	A212199	001	Oct 30, 2019	Oct NEWA	
AB			EQ 500MG BASE	A212199	002	Oct 30, 2019	Oct NEWA	
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE</u>								
TABLET; ORAL								
TREXIMET								
	+	@	CURRAX	60MG; EQ 10MG BASE	N021926	002	May 14, 2015	Apr CAHN
AB			500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr CAHN	

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	ANI PHARMS INC	EQ 1MG BASE	A078751	001	Jul 07, 2010	Sep CAHN
AB		EQ 2.5MG BASE	A078751	002	Jul 07, 2010	Sep CAHN
	@ CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun DISC
	@	EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun DISC
	@ MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012	Oct DISC
	@	EQ 2.5MG BASE	A202431	002	May 31, 2012	Oct DISC

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr NEWA
AB		120MG	A206432	002	Apr 19, 2019	Apr NEWA
AB	! ZYDUS PHARMS	120MG	A205248	002	Jul 06, 2016	Jul CHRS
	STARLIX					
	+ @ NOVARTIS	60MG	N021204	001	Dec 22, 2000	Jul DISC
	+ @	120MG	N021204	002	Dec 22, 2000	Jul DISC

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

	+ @ ALLERGAN	EQ 5MG BASE; 80MG	N206302	001	Jun 03, 2016	Sep DISC
--	--------------	-------------------	---------	-----	--------------	----------

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

	@ LANNETT CO INC	500MG	A204435	001	Jun 10, 2016	Jun DISC
--	------------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

	@ WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jul DISC
--	---------------	-----------------------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan CAHN
AP		10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan CAHN
AP	BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019	Apr NEWA
AP		10MG/10ML (1MG/ML)	A212512	002	May 13, 2019	Apr NEWA
AP	GLAND PHARMA LTD	5MG/10ML (0.5MG/ML)	A212968	001	Oct 16, 2019	Sep NEWA
AP		10MG/10ML (1MG/ML)	A212968	002	Oct 16, 2019	Sep NEWA

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

	+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Aug DISC
--	---------------	------------	---------	-----	--------------	----------

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

	@ MYLAN	100MG	A206271	001	Nov 09, 2015	Oct DISC
--	---------	-------	---------	-----	--------------	----------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Sep CMFD
	@	500MG	A209156	001	May 14, 2018	Apr DISC
AB		750MG	A209156	002	May 14, 2018	Sep CMFD
	@	750MG	A209156	002	May 14, 2018	Apr DISC
AB		1GM	A209156	003	May 14, 2018	Sep CMFD
	@	1GM	A209156	003	May 14, 2018	Apr DISC
AB	MYLAN	500MG	A203742	001	Feb 22, 2019	Feb NEWA
AB		750MG	A203742	002	Feb 22, 2019	Feb NEWA
AB		1GM	A203742	003	Feb 22, 2019	Feb NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

@ ANI PHARMS INC

20MG

A074670 001 Oct 28, 1996 Sep CAHN

@

30MG

A074670 002 Oct 28, 1996 Sep CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>D> AB2 MYLAN 30MG

A090649 001 Jun 21, 2010 Nov DISC

>A> @ 30MG

A090649 001 Jun 21, 2010 Nov DISC

>D> AB2 60MG

A090649 002 Jun 21, 2010 Nov DISC

>A> @ 60MG

A090649 002 Jun 21, 2010 Nov DISC

>D> AB2 90MG

A090649 003 Jun 21, 2010 Nov DISC

>A> @ 90MG

A090649 003 Jun 21, 2010 Nov DISC

AB2 NOVAST LABS 30MG

A210614 001 Mar 12, 2019 Feb NEWA

AB2 60MG

A210614 002 Mar 12, 2019 Feb NEWA

AB2 90MG

A210614 003 Mar 12, 2019 Feb NEWA

AB2 OSMOTICA PHARM US 90MG

A077127 003 Oct 03, 2007 Apr CMS1

AB2 SPIL 30MG

A210838 001 Apr 16, 2019 Apr NEWA

AB2 60MG

A210838 002 Apr 16, 2019 Apr NEWA

AB2 90MG

A210838 003 Apr 16, 2019 Apr NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

@ SUN PHARM INDS INC

30MG

A077067 001 Apr 17, 2007 Oct DISC

NITISINONE

CAPSULE;ORAL

NITISINONE

AB NOVITIUM PHARMA 2MG

A211041 001 Aug 26, 2019 Aug NFTG

AB 5MG

A211041 002 Aug 26, 2019 Aug NFTG

AB 10MG

A211041 003 Aug 26, 2019 Aug NFTG

ORFADIN

AB + SWEDISH ORPHAN 2MG

N021232 001 Jan 18, 2002 Aug CFTG

AB + 5MG

N021232 002 Jan 18, 2002 Aug CFTG

AB + 10MG

N021232 003 Jan 18, 2002 Aug CFTG

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

@ MYLAN

50MG

A074967 001 Jul 09, 1997 Jul DISC

@

100MG

A077025 001 Aug 18, 2004 Jul DISC

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

NITROMIST

+! EVUS 0.4MG/SPRAY

N021780 001 Nov 02, 2006 May CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

@ MEDICIS

0.4MG/HR

A089773 001 Aug 30, 1996 May DISC

@ VALEANT PHARMS

0.1MG/HR

A089771 001 Aug 30, 1996 May DISC

@

0.6MG/HR

A089774 001 Aug 30, 1996 Jun DISC

@ VALEANT PHARMS NORTH 0.2MG/HR

A089772 001 Aug 30, 1996 May DISC

NITRO-DUR

+! USPHARMA 0.1MG/HR

N020145 001 Apr 04, 1995 May CTEC

+! 0.2MG/HR

N020145 002 Apr 04, 1995 May CTEC

+! 0.4MG/HR

N020145 004 Apr 04, 1995 May CTEC

+! 0.6MG/HR

N020145 005 Apr 04, 1995 Jun CTEC

NITROGLYCERIN

AB2 HERCON PHARM 0.1MG/HR

A089885 002 Oct 30, 2017 Feb NEWA

AB2 ! MYLAN TECHNOLOGIES 0.1MG/HR

A074559 004 Feb 06, 1998 Feb CTEC

TABLET;SUBLINGUAL

NITROGLYCERIN

AB ALVOGEN 0.3MG

A211604 001 Apr 30, 2019 Apr NEWA

AB 0.4MG

A211604 002 Apr 30, 2019 Apr NEWA

AB 0.6MG

A211604 003 Apr 30, 2019 Apr NEWA

NORETHINDRONE

	TABLET; ORAL-28						
	MICRONOR						
	+ @ JANSSEN PHARMS	0.35MG	N016954	001			Mar DISC
	NORETHINDRONE						
AB2	! MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013		Mar CHRS

NYSTATIN

	CREAM; TOPICAL						
	NYSTATIN						
AT	TORRENT	100,000 UNITS/GM	A212557	001	Jul 24, 2019		Jul NEWA
	OINTMENT; TOPICAL						
	NYSTATIN						
AT	CADILA	100,000 UNITS/GM	A207767	001	May 25, 2018		Oct CAHN
AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019		Jan NEWA
	POWDER; TOPICAL						
	NYSTATIN						
AT	LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004		Feb CAHN
	TABLET; ORAL						
	NYSTATIN						
	@ UPSHER SMITH LABS	500,000 UNITS	A062524	001	Nov 26, 1985		Jul CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

	OINTMENT; TOPICAL						
	NYSTATIN AND TRIAMCINOLONE ACETONIDE						
	@ CROWN LABS INC	100,000 UNITS/GM; 0.1%	A207731	001	Dec 26, 2017		Sep DISC
>A> AT	VITRUVIAS THERAP	100000 UNITS/GM; 0.1%	A207316	001	Nov 18, 2019		Nov NEWA
	@ ZYDUS PHARMS	100,000 UNITS/GM; 0.1%	A207764	001	Nov 08, 2018		Mar DISC

OCTREOTIDE ACETATE

	INJECTABLE; INJECTION						
	OCTREOTIDE ACETATE						
AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018		Apr CAHN
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018		Apr CAHN
	@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018		Mar DISC
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018		Jan CAHN
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018		Apr CAHN
	@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018		Mar DISC
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018		Jan CAHN
	@ SUN PHARM INDS	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007		Jul DISC
	@	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007		Jul DISC
	@	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007		Jul DISC
	@	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007		Jul DISC
	@	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007		Jul DISC

OFLOXACIN

	SOLUTION/DROPS; OPHTHALMIC						
	OFLOXACIN						
AT	APOTEX INC	0.3%	A076513	001	May 14, 2004		Feb CMFD
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004		Mar DISC
	SOLUTION/DROPS; OTIC						
	OFLOXACIN						
	@ ALVOGEN	0.3%	A090395	001	Aug 11, 2009		Oct DISC
	@ SANDOZ INC	0.3%	A078222	001	Mar 17, 2008		Mar DISC
	TABLET; ORAL						
	OFLOXACIN						
	@ LARKEN LABS	400MG	A076093	003	Sep 02, 2003		Sep DISC

OLANZAPINE

	TABLET; ORAL						
	OLANZAPINE						
	@ SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018		Apr DISC
	@	5MG	A206238	002	Nov 19, 2018		Apr DISC
	@	7.5MG	A206238	003	Nov 19, 2018		Apr DISC
	@	10MG	A206238	004	Nov 19, 2018		Apr DISC
	@	15MG	A206238	005	Nov 19, 2018		Apr DISC
	@	20MG	A206238	006	Nov 19, 2018		Apr DISC
	TABLET, ORALLY DISINTEGRATING; ORAL						
	OLANZAPINE						
	@ HEC PHARM	5MG	A208146	001	Jul 02, 2018		Feb DISC
	@	10MG	A208146	002	Jul 02, 2018		Feb DISC

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

@	15MG	A208146	003	Jul 02, 2018	Feb DISC
@	20MG	A208146	004	Jul 02, 2018	Feb DISC

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS
CLINOLIPID 20%

+!	BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Aug CMFD
+	@	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CDFR

OLMESARTAN MEDOXOMIL

TABLET; ORAL
OLMESARTAN MEDOXOMIL

AB	MICRO LABS	5MG	A206372	001	Sep 17, 2019	Sep NEWA
AB		20MG	A206372	002	Sep 17, 2019	Sep NEWA
AB		40MG	A206372	003	Sep 17, 2019	Sep NEWA
AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA
>D> AB	TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017	Nov DISC
>A>	@	5MG	A091079	001	Apr 24, 2017	Nov DISC
>D> AB		20MG	A091079	002	Apr 24, 2017	Nov DISC
>A>	@	20MG	A091079	002	Apr 24, 2017	Nov DISC
>D> AB		40MG	A091079	003	Apr 24, 2017	Nov DISC
>A>	@	40MG	A091079	003	Apr 24, 2017	Nov DISC
AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019	Jul NEWA
AB		20MG	A207135	002	Jul 18, 2019	Jul NEWA
AB		40MG	A207135	003	Jul 18, 2019	Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar NEWA
AT	FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019	Sep NEWA
AT	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul NEWA
AT	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL
TECHNIVIE

+	@ ABBVIE INC	12.5MG; 75MG; 50MG	N207931	001	Jul 24, 2015	Apr DISC
---	--------------	--------------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb NEWA
AB	BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Jul NEWA
	@ PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun DISC

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	HETERO LABS LTD III	10MG	A204012	001	Sep 26, 2019	Sep NEWA
AB		20MG	A204012	002	Sep 26, 2019	Sep NEWA
	@ MYLAN	10MG	A075876	001	May 29, 2003	Jun DISC
	@	40MG	A075876	003	Jan 21, 2009	Sep DISC

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

>D> AB	PAR PHARM	20MG; 1.1GM	A078966	001	May 25, 2010	Nov DISC
>A>	@	20MG; 1.1GM	A078966	001	May 25, 2010	Nov DISC
>D> AB		40MG; 1.1GM	A078966	002	May 25, 2010	Nov DISC
>A>	@	40MG; 1.1GM	A078966	002	May 25, 2010	Nov DISC

CAPSULE;ORAL							
ZEGERID							
AB	+ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Sep	CAHN
AB	+!	40MG;1.1GM	N021849	002	Feb 27, 2006	Sep	CAHN
FOR SUSPENSION;ORAL							
ZEGERID							
AB	+ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr	CAHN
AB	+!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr	CAHN
<u>ONDANSETRON HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
ONDANSETRON HYDROCHLORIDE							
	@ LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb	DISC
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
	@ HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006	Feb	DISC
	@ LUITPOLD	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008	Feb	DISC
	@ TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006	Aug	DISC
TABLET;ORAL							
ONDANSETRON HYDROCHLORIDE							
	@ MYLAN	EQ 24MG BASE	A076930	004	Jun 25, 2007	Feb	DISC
<u>ORPHENADRINE CITRATE</u>							
INJECTABLE;INJECTION							
NORFLEX							
	+ @ TELIGENT	30MG/ML	N013055	001		Jan	CRLD
TABLET, EXTENDED RELEASE;ORAL							
ORPHENADRINE CITRATE							
AB	LUPIN	100MG	A040284	001	Jun 19, 1998	Feb	CAHN
<u>OSELTAMIVIR PHOSPHATE</u>							
CAPSULE;ORAL							
OSELTAMIVIR PHOSPHATE							
AB	ALEMBIC PHARMS LTD	EQ 30MG BASE	A211823	001	Jun 24, 2019	Jun	NEWA
AB		EQ 45MG BASE	A211823	002	Jun 24, 2019	Jun	NEWA
AB		EQ 75MG BASE	A211823	003	Jun 24, 2019	Jun	NEWA
FOR SUSPENSION;ORAL							
OSELTAMIVIR PHOSPHATE							
AB	TEVA PHARMS USA	EQ 6MG BASE/ML	A211125	001	Feb 27, 2019	Feb	NEWA
<u>OXACILLIN SODIUM</u>							
INJECTABLE;INJECTION							
OXACILLIN SODIUM							
	@ HOSPIRA INC	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015	Oct	DISC
	@	EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015	Oct	DISC
AP	PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Jul	CAHN
AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Jul	CAHN
AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Jul	CAHN
<u>OXALIPLATIN</u>							
INJECTABLE;INTRAVENOUS							
ELOXATIN							
	+ @ SANOFI AVENTIS US	50MG/VIAL	N021492	001	Aug 09, 2002	Feb	CDFR
AP	+!	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Feb	CDFR
	+ @	100MG/VIAL	N021492	002	Aug 09, 2002	Feb	CDFR
AP	+!	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Feb	CDFR
	+ @	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Feb	CDFR
OXALIPLATIN							
AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Feb	CDFR
AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Feb	CDFR
AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	CDFR
AP	! ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul	CHRS
AP		50MG/VIAL	A078803	001	Aug 08, 2012	Feb	CDFR
AP	!	100MG/VIAL	A078803	002	Aug 08, 2012	Jul	CHRS
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Feb	CDFR
AP	CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Feb	CDFR
AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Feb	CDFR
AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A078811	001	Jun 10, 2010	Feb	CDFR
AP		100MG/20ML (5MG/ML)	A078811	002	Jun 10, 2010	Feb	CDFR

INJECTABLE; INTRAVENOUS
OXALIPLATIN

AP		50MG/VIAL	A078819	001	Jun 02, 2010	Feb CDFR
AP		50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Feb CDFR
AP		100MG/VIAL	A078819	002	Jun 02, 2010	Feb CDFR
AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Feb CDFR
AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Feb CDFR
AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Feb CDFR
AP		50MG/VIAL	A207385	001	May 23, 2017	Feb CDFR
AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Feb CDFR
AP		100MG/VIAL	A207385	002	May 23, 2017	Feb CDFR
AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb CDFR
AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb CDFR
AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb CDFR
AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb CDFR
AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb CDFR
AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb CDFR
AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Feb CDFR
	@	50MG/VIAL	A200979	001	Aug 08, 2012	Oct DISC
AP		50MG/VIAL	A200979	001	Aug 08, 2012	Feb CDFR
AP		100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Feb CDFR
	@	100MG/VIAL	A200979	002	Aug 08, 2012	Oct DISC
AP		100MG/VIAL	A200979	002	Aug 08, 2012	Feb CDFR
	@	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Sep DISC
AP		200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Feb CDFR
AP	QILU	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb CDFR
AP		50MG/VIAL	A204616	001	May 11, 2016	Feb CDFR
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP		100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
	@	50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
	@	100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
	@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
	@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
	@ SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009	Jul DISC
	@	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul DISC
	@	100MG/VIAL	A078818	002	Aug 07, 2009	Jul DISC
	@	100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul DISC
	@	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul DISC
AP		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR
AP	! SUN PHARMA GLOBAL	50MG/VIAL	A078818	001	Aug 07, 2009	Feb CDFR
AP		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Feb CDFR
AP	!	100MG/VIAL	A078818	002	Aug 07, 2009	Feb CDFR
AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Feb CDFR
AP	+! TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
AP	+!	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR

INJECTABLE; IV (INFUSION)
OXALIPLATIN

AP	SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb NEWA
----	-------------------	---------------------	---------	-----	--------------	----------

OXAPROZIN

TABLET; ORAL
OXAPROZIN

	@ BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001	Mar CAHN
	@ SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002	Oct DISC

OXCARBAZEPINE

TABLET; ORAL
OXCARBAZEPINE

>D>	AB	APOTEX INC	150MG	A077747	001	Apr 09, 2008	Nov CAHN
>D>	AB		300MG	A077747	002	Apr 09, 2008	Nov CAHN
>D>	AB		600MG	A077747	003	Apr 09, 2008	Nov CAHN
>A>	AB	RUBICON	150MG	A077747	001	Apr 09, 2008	Nov CAHN
>A>	AB		300MG	A077747	002	Apr 09, 2008	Nov CAHN
>A>	AB		600MG	A077747	003	Apr 09, 2008	Nov CAHN

OXYBUTYNIN CHLORIDEGEL;TRANSDERMAL
GELNIQUE

>D>	AB	+!	ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Nov CTEC
>A>		+!		10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Nov CTEC

OXYBUTYNIN CHLORIDE

>D>	AB		PAR PHARM INC	10% (100MG/PACKET)	A207329	001	May 31, 2018	Nov DISC
>A>		@		10% (100MG/PACKET)	A207329	001	May 31, 2018	Nov DISC

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	Sep DISC
---	----------------	---------	---------	-----	--------------	----------

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	ARISE	5MG	A209025	001	Dec 21, 2017	Sep CAHN
AB	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019	Apr NEWA
AB	NOVAST LABS	5MG	A210611	001	Oct 30, 2019	Oct NEWA

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB	!	ACCORD HLTHCARE	15MG	A207138	003	Feb 29, 2016	Aug CHRS
AB		AJANTA PHARMA LTD	5MG	A211655	001	Feb 28, 2019	Feb NEWA
AB			10MG	A211655	002	Feb 28, 2019	Feb NEWA
AB			15MG	A211655	003	Feb 28, 2019	Feb NEWA
AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Aug CHRS

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ALKEM LABS LTD	5MG/5ML	A211748	001	Feb 07, 2019	Feb NEWA
AA			100MG/5ML	A211749	001	Feb 04, 2019	Jan NEWA
AA		EYWA	5MG/5ML	A207511	001	Nov 23, 2016	Sep CAHN
AA			100MG/5ML	A209897	001	Sep 06, 2017	Sep CAHN
	@	LANNETT CO INC	100MG/5ML	A204085	001	Sep 09, 2014	Jan DISC
AA		PHARM ASSOC	5MG/5ML	A206914	001	Feb 01, 2019	May CPOT
AA			5MG/ML	A206914	001	Feb 01, 2019	Jan NEWA

TABLET;ORAL

OXAYDO

ZYLA

5MG
7.5MG

N202080	001	Jun 17, 2011	Jul CAHN
N202080	002	Jun 17, 2011	Jul CAHN

OXYCODONE HYDROCHLORIDE

>D>	AB		AVANTHI INC	10MG	A091393	002	Aug 31, 2009	Nov CHRS
>A>	AB	!		10MG	A091393	002	Aug 31, 2009	Nov CHRS
		@	VINTAGE PHARMS	5MG	A077712	003	Mar 02, 2009	Apr DISC
		@		10MG	A077712	004	Apr 13, 2015	Apr DISC
		@		15MG	A077712	001	Jan 31, 2007	Apr DISC
		@		20MG	A077712	005	Apr 13, 2015	Apr DISC
		@		30MG	A077712	002	Jan 31, 2007	Apr DISC

ROXYBOND

@ INSPIRION DELIVERY

@

@

5MG
15MG
30MG

N209777	001	Apr 20, 2017	Sep CAHN
N209777	002	Apr 20, 2017	Sep CAHN
N209777	003	Apr 20, 2017	Sep CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFAD

+!	EPI HLTH	1%	N208552	001	Jan 18, 2017	Oct CAHN
----	----------	----	---------	-----	--------------	----------

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

@ DR REDDYS

@

10USP UNITS/ML (10USP UNITS/ML)
100USP UNITS/10ML (10USP UNITS/ML)

A077453	001	Jan 24, 2008	May CAHN
A077453	002	Jan 24, 2008	May CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

@ ACCORD HLTHCARE

6MG/ML

A205720	001	Aug 17, 2018	Mar DISC
---------	-----	--------------	----------

PALBOCICLIB

>A>	TABLET;ORAL							
>A>	IBRANCE							
>A>	+ PFIZER INC	75MG	N212436	001	Nov 01, 2019	Nov	NEWA	
>A>	+	100MG	N212436	002	Nov 01, 2019	Nov	NEWA	
>A>	+	125MG	N212436	003	Nov 01, 2019	Nov	NEWA	

PALIPERIDONE

	TABLET, EXTENDED RELEASE;ORAL							
	PALIPERIDONE							
AB	AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep	NEWA	
AB		3MG	A204707	002	Sep 23, 2019	Sep	NEWA	
AB		6MG	A204707	003	Sep 23, 2019	Sep	NEWA	
AB		9MG	A204707	004	Sep 23, 2019	Sep	NEWA	
AB	INVENTIA	1.5MG	A204452	001	Jun 12, 2019	Aug	CAHN	
AB		3MG	A204452	002	Jun 12, 2019	Aug	CAHN	
AB		6MG	A204452	003	Jun 12, 2019	Aug	CAHN	
AB		9MG	A204452	004	Jun 12, 2019	Aug	CAHN	
AB	INVENTIA HLTHCARE	1.5MG	A204452	001	Jun 12, 2019	May	NEWA	
AB		3MG	A204452	002	Jun 12, 2019	May	NEWA	
AB		6MG	A204452	003	Jun 12, 2019	May	NEWA	
AB		9MG	A204452	004	Jun 12, 2019	May	NEWA	

PALONOSETRON HYDROCHLORIDE

	INJECTABLE;INTRAVENOUS							
	PALONOSETRON HYDROCHLORIDE							
	@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Mar	DISC	
	SOLUTION;INTRAVENOUS							
	PALONOSETRON HYDROCHLORIDE							
	HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016	Jul	CAHN	

PAMIDRONATE DISODIUM

	INJECTABLE;INJECTION							
	PAMIDRONATE DISODIUM							
AP	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May	CAHN	
AP		60MG/10ML (6MG/ML)	A078156	002	Aug 19, 2008	May	CAHN	
AP		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May	CAHN	
	@ LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar	DISC	
	@	90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar	DISC	

PANCURONIUM BROMIDE

	INJECTABLE;INJECTION							
	PANCURONIUM BROMIDE							
AP	! DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CAHN	
	!	2MG/ML	A072760	001	Jul 31, 1990	May	CAHN	

PANOBINOSTAT LACTATE

	CAPSULE;ORAL							
	FARYDAK							
	+ SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015	Jun	CAHN	
	+	EQ 15MG BASE	N205353	002	Feb 23, 2015	Jun	CAHN	
	+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Jun	CAHN	

PANTOPRAZOLE SODIUM

	INJECTABLE;IV (INFUSION)							
	PANTOPRAZOLE SODIUM							
	@ MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Oct	DISC	
AP	SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Aug	NEWA	
	POWDER;IV (INFUSION)							
	PANTOPRAZOLE SODIUM							
	+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Sep	CRLD	
	!	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Sep	CHRS	
		EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CAHN	
	TABLET, DELAYED RELEASE;ORAL							
	PANTOPRAZOLE SODIUM							
AB	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Feb	NEWA	
AB	L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	May	CAHN	
AB	RUBICON	EQ 20MG BASE	A090807	001	May 02, 2012	Aug	CAHN	
AB		EQ 40MG BASE	A090807	002	May 02, 2012	Aug	CAHN	

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

@ SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Oct DISC
@	EQ 20MG BASE	A078194	002	Jun 29, 2007	Oct DISC
@	EQ 30MG BASE	A078194	003	Jun 29, 2007	Oct DISC
@	EQ 40MG BASE	A078194	004	Jun 29, 2007	Oct DISC

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ @ LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990	Oct DISC
-------------------------	--------------	---------	-----	--------------	----------

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

AB	@ VALEANT PHARMS INTL	125MG	N019853	002	Jan CAHN
	+!	250MG	N019853	001	Apr CFTG
	+!	250MG	N019853	001	Jan CAHN

PENICILLAMINE

AB	AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Apr NFTG
AB	WATSON LABS INC	250MG	A210976	001	Jun 24, 2019	Jun NEWA

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

AN	+! FRESenius KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr CFTG
	PENTAMIDINE ISETHIONATE					
AN	SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr NFTG

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

AP	ATHENEX	50MG/ML	A206677	001	Nov 27, 2017	Sep CAHN
----	---------	---------	---------	-----	--------------	----------

PENTOSTATIN

INJECTABLE; INJECTION

PENTOSTATIN

@ MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Mar DISC
-----------------------	-----------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

@ ANI PHARMS INC	400MG	A074878	001	Jul 09, 1997	May CAHN
@	400MG	A075107	001	Sep 04, 1998	Sep CAHN
@ MYLAN	400MG	A074425	001	Jul 08, 1997	Jun DISC

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

AB	ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019	Mar NEWA
AB	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	May CAHN

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL

TURALIO

+! DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019	Aug NEWA
-----------------------	---------------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

@ UPSHER SMITH LABS	35MG	A084399	001		Jul CAHN
---------------------	------	---------	-----	--	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

@ LANNETT CO INC	30MG	A091359	001	Jul 16, 2010	Oct DISC
------------------	------	---------	-----	--------------	----------

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012	Oct DISC
---------------	--------	---------	-----	--------------	----------

TABLET;ORAL				
PHENTERMINE HYDROCHLORIDE				
@ SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007 Oct DISC
<u>PHENYLEPHRINE HYDROCHLORIDE</u>				
SOLUTION;INTRAVENOUS				
BIORPHEN				
+! ETON PHARMS	0.1MG/ML (0.1MG/ML)	N212909	001	Oct 21, 2019 Oct NEWA
PHENYLEPHRINE HYDROCHLORIDE				
AP2 FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019 Oct CTEC
AP	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019 Jan NEWA
AP1	50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019 Aug CTEC
AP	50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019 Jan NEWA
AP1	100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019 Aug CTEC
AP	100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019 Jan NEWA
AP2 MEITHEAL	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018 Aug CTEC
AP	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018 Jun CAHN
AP1	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018 Aug CTEC
AP	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018 Jun CAHN
AP1	100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018 Aug CTEC
AP	100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018 Jun CAHN
AP1 PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018 Aug CTEC
AP1	50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018 Aug CTEC
AP1	100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018 Aug CTEC
AP1 SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019 Aug CTEC
AP	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019 Jan NEWA
AP1	50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019 Aug CTEC
AP	50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019 Jan NEWA
AP1	100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019 Aug CTEC
AP	100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019 Jan NEWA
AP2 +! WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012 Aug CTEC
AP2 +!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019 Aug NEWA
AP2 +!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019 Aug NEWA
VAZCULEP				
AP1 +! AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014 Oct CTEC
AP +!	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014 Aug CHRS
AP1 +!	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014 Oct CTEC
AP +!	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014 Aug CHRS
AP1 +!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014 Aug CTEC
SOLUTION/DROPS;OPHTHALMIC				
PHENYLEPHRINE HYDROCHLORIDE				
AT +! AKORN INC	2.5%	N207926	001	Jan 15, 2015 Jan CTEC
AT +!	10%	N207926	002	Jan 15, 2015 Jan CTEC
AT +! PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013 Jan CTEC
AT +!	10%	N203510	002	Mar 21, 2013 Jan CTEC
<u>PHENYTOIN SODIUM</u>				
CAPSULE;ORAL				
EXTENDED PHENYTOIN SODIUM				
AB LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019 Sep NEWA
@ SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006 Jul DISC
INJECTABLE;INJECTION				
PHENYTOIN SODIUM				
@ LUITPOLD	50MG/ML	A040781	001	Dec 04, 2007 Feb DISC
<u>PHYTONADIONE</u>				
INJECTABLE;INJECTION				
PHYTONADIONE				
AB DR REDDYS LABS LTD	10MG/ML	A207719	001	May 22, 2019 May NEWA
VITAMIN K1				
AB ! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983 May CTEC
TABLET;ORAL				
MEPHYTON				
AB +! BAUSCH	5MG	N010104	003	Feb CAHN
AB +! VALEANT PHARMS INTL	5MG	N010104	003	Jan CAHN
PHYTONADIONE				
AB ZYDUS	5MG	A210189	001	Feb 20, 2019 Feb NEWA

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

>A>	AT	SOMERSET THERAPS LLC	1%	A210384	001	Nov 25, 2019	Nov NEWA
>A>	AT		2%	A210384	002	Nov 25, 2019	Nov NEWA
>A>	AT		4%	A210384	003	Nov 25, 2019	Nov NEWA

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019	Jul NEWA
AB			7.5MG	A212377	002	Aug 13, 2019	Jul NEWA
		SALAGEN					
AB	+	CONCORDIA	5MG	N020237	001	Mar 22, 1994	Jul CAHN
AB	+	!	7.5MG	N020237	002	Apr 18, 2003	Jul CAHN

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

	+	@ ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Jan DISC
--	---	---------------------	--------------	---------	-----	--------------	----------

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

AB	+	!	BAUSCH	1%	N021302	001	Dec 13, 2001	Aug CAHN
			PIMECROLIMUS					
AB			GLENMARK PHARMS LTD	1%	A211769	001	Aug 29, 2019	Aug NEWA

PIMOZIDE

TABLET;ORAL

ORAP

	+	@	TEVA	1MG	N017473	003	Aug 27, 1997	Sep DISC
	+	@		2MG	N017473	001	Jul 31, 1984	Sep DISC

PIMOZIDE

			PAR PHARM	1MG	A204521	001	Sep 28, 2015	Sep CTEC
	!			2MG	A204521	002	Sep 28, 2015	Sep CHRS
				2MG	A204521	002	Sep 28, 2015	Sep CTEC

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		BAYSHORE PHARMS LLC	5MG	A211712	001	Aug 01, 2019	Jul NEWA
AB			10MG	A211712	002	Aug 01, 2019	Jul NEWA
		@ ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017	Jun DISC
		@	10MG	A209866	002	Aug 18, 2017	Jun DISC

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Jul NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Jul NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Jul NEWA
		@ HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Oct DISC
		@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Oct DISC
		@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Oct DISC
		@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Oct DISC
>A>	AP	QILU	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Nov CAHN
>A>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Nov CAHN
>A>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Nov CAHN
>D>	AP	QILU TIANHE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A204959	001	Aug 10, 2018	Nov CAHN
>D>	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A204959	002	Aug 10, 2018	Nov CAHN
>D>	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A204959	003	Aug 10, 2018	Nov CAHN

PIROXICAMCAPSULE;ORAL
PIROXICAM

AB	BRECKENRIDGE	10MG	A206136	001	Jun 20, 2017	Aug CAHN
AB		20MG	A206136	002	Jun 20, 2017	Aug CAHN
AB	CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
AB		20MG	A205585	002	Jul 17, 2018	Feb CAHN
	@ SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct DISC
	@	20MG	A073536	001	Mar 12, 1993	Oct DISC

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

	@ MYLAN	EQ 1MG BASE	A206070	001	Apr 04, 2019	Apr DISC
	@	EQ 2MG BASE	A206070	002	Apr 04, 2019	Apr DISC
	@	EQ 4MG BASE	A206070	003	Apr 04, 2019	Apr DISC
AB	MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
AB		EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
AB		EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	@ MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017	Sep DISC
+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Oct CAHN
+	!	EQ 4MG BASE	N208379	003	Jul 14, 2017	Oct CAHN

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

WAKIX

+	BIOPROJET PHARMA	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Aug NEWA
+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Aug NEWA
+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Sep CAHN
+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Sep CAHN

PLAZOMICIN SULFATESOLUTION;INTRAVENOUS
ZEMDRI

+	!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN
---	---	-----------	--------------------------------------	---------	-----	--------------	----------

PLECANATIDE

TABLET;ORAL

TRULANCE

+	!	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar CAHN
+	!	SALIX	3MG	N208745	001	Jan 19, 2017	Apr CAHN

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAX

@ LANNETT CO INC 17GM/SCOOPFUL

A076652 001 Jul 02, 2004 May DISC

POLYETHYLENE GLYCOL 3350

@ NEXGEN PHARMA INC 17GM/SCOOPFUL

A077706 001 Sep 27, 2006 May DISC

@ PADDOCK LLC 17GM/SCOOPFUL

A077893 001 May 26, 2006 May DISC

POLYMYXIN B SULFATEINJECTABLE;INJECTION
POLYMYXIN B SULFATE

AP	!	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Oct CHRS
		@ WEST-WARD PHARMS INT	EQ 500,000 UNITS BASE/VIAL	A060716	001		Oct DISC

PORFIMER SODIUMINJECTABLE;INJECTION
PHOTOFRIN

PINNACLE BIOLGS 75MG/VIAL

N020451 001 Dec 27, 1995 Oct CAHN

POSACONAZOLETABLET, DELAYED RELEASE;ORAL
NOXAFIL

AB	+	!	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Aug CFTG
AB			POSACONAZOLE					
AB			SINOTHERAPEUTICS INC	100MG	A212411	001	Aug 21, 2019	Aug NFTG

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB			ANDA REPOSITORY	8MEQ	A205549	001	Dec 08, 2015	Aug CAHN
AB				10MEQ	A205549	002	Dec 08, 2015	Aug CAHN
AB			PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May NEWA
AB				10MEQ	A209026	002	Jun 11, 2019	May NEWA
AB			ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
AB				10MEQ	A208445	002	Mar 11, 2019	Feb NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

AA			AMNEAL PHARMS LLC	20MEQ	A210902	001	May 23, 2019	May NEWA
AA			BELCHER PHARMS LLC	20MEQ	A212183	001	May 06, 2019	Apr NEWA

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA			PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
AA				40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

K-TAB

AB3	+	!	ABBVIE	20MEQ	N018279	003	Nov 25, 2013	Sep CTEC
			KLOR-CON M15					
AB1			UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar CTEC
			POTASSIUM CHLORIDE					
AB1			ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun NEWA
		@	ANDA REPOSITORY	8MEQ	A206881	001	Jan 22, 2019	Aug CAHN
		@		10MEQ	A206881	002	Jan 22, 2019	Aug CAHN
>D>	AB1		BRECKENRIDGE	10MEQ	A206630	001	Mar 29, 2019	Nov DISC
>A>		@		10MEQ	A206630	001	Mar 29, 2019	Nov DISC
	AB1			10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
>D>	AB1			15MEQ	A206630	002	Mar 29, 2019	Nov DISC
>A>		@		15MEQ	A206630	002	Mar 29, 2019	Nov DISC
	AB1			15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
>D>	AB1			20MEQ	A206630	003	Mar 29, 2019	Nov DISC
>A>		@		20MEQ	A206630	003	Mar 29, 2019	Nov DISC
	AB1			20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
		@	PII	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
AB2				8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
AB1				10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
		@		10MEQ	A206881	002	Jan 22, 2019	Jul DISC
AB2				10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
AB1				15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
AB1				20MEQ	A206630	003	Mar 29, 2019	Mar NEWA
AB1			PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr NEWA
AB1				15MEQ	A209922	002	Apr 30, 2019	Apr NEWA
AB1				20MEQ	A209922	003	Apr 30, 2019	Apr NEWA
AB3			VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Sep CTEC
AB3			YICHANG HUMANWELL	10MEQ	A212561	001	Sep 30, 2019	Sep NEWA
AB3				20MEQ	A212561	002	Sep 30, 2019	Sep NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASICSOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES

>A>	+	!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Nov CPOT
>D>	+	!		4500MG/15ML (300MG/ML);2650MG/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Nov CPOT
	+	!		4500MG/15ML (300MG/ML);2650MG/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Sep NEWA
>A>	+	!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019	Nov NEWA
>A>	+	!		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019	Nov NEWA
>A>	+	!		11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)	N212832	003	Nov 26, 2019	Nov NEWA

PRALATREXATESOLUTION; INTRAVENOUS
FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
+	!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	May CAHN
	@	0.125MG	A091254	001	Nov 30, 2010	May CAHN
AB		0.25MG	A077724	002	Feb 19, 2008	May CAHN
	@	0.25MG	A091254	002	Nov 30, 2010	May CAHN
AB		0.5MG	A077724	003	Feb 19, 2008	May CAHN
	@	0.5MG	A091254	003	Nov 30, 2010	May CAHN
	@	0.75MG	A091254	004	Nov 30, 2010	May CAHN
AB		1MG	A077724	004	Feb 19, 2008	May CAHN
	@	1MG	A091254	005	Nov 30, 2010	May CAHN
AB		1.5MG	A077724	005	Feb 19, 2008	May CAHN
	@	1.5MG	A091254	006	Nov 30, 2010	May CAHN
	@ SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Oct DISC
	@	0.25MG	A091683	002	Mar 27, 2013	Oct DISC
	@	0.5MG	A091683	003	Mar 27, 2013	Oct DISC
	@	0.75MG	A091683	004	Mar 27, 2013	Oct DISC
	@	1MG	A091683	005	Mar 27, 2013	Oct DISC
	@	1.5MG	A091683	006	Mar 27, 2013	Oct DISC

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB	APNAR PHARMA LP	10MG	A076397	003	Oct 23, 2006	Jun CAHN
AB		20MG	A076397	002	Oct 23, 2006	Jun CAHN
AB		40MG	A076397	001	Oct 23, 2006	Jun CAHN
AB		80MG	A077491	001	Feb 11, 2008	Jun CAHN

PREDNISOLONE ACETATESUSPENSION/DROPS; OPHTHALMIC
ECONOPRED

@	EYEVANCE	0.125%	N017468	001		May CAHN
---	----------	--------	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	May CTEC
@	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	May DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Jul CMFD
	@	1MG	A211496	001	Dec 28, 2018	May DISC
AB		2.5MG	A211495	001	Dec 07, 2018	Jul CMFD
	@	2.5MG	A211495	001	Dec 07, 2018	May DISC
AB		5MG	A211495	002	Dec 07, 2018	Jul CMFD
	@	5MG	A211495	002	Dec 07, 2018	May DISC
AB		10MG	A210525	001	Dec 04, 2018	Jul CMFD
	@	10MG	A210525	001	Dec 04, 2018	May DISC
AB		20MG	A210525	002	Dec 04, 2018	Jul CMFD
	@	20MG	A210525	002	Dec 04, 2018	May DISC
AB		50MG	A210525	003	Dec 04, 2018	Jul CMFD
	@	50MG	A210525	003	Dec 04, 2018	May DISC
>A> AB	NOVITIUM PHARMA	2.5MG	A211575	001	Nov 15, 2019	Nov NEWA
>A> AB		5MG	A211575	002	Nov 15, 2019	Nov NEWA
>A> AB		10MG	A211575	003	Nov 15, 2019	Nov NEWA
>A> AB		20MG	A211575	004	Nov 15, 2019	Nov NEWA
>A> AB		50MG	A211575	005	Nov 15, 2019	Nov NEWA
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jul CFTG
AB	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
AB	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
AB	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
AB	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
AB	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
AB	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
AB	+		300MG	N021446	008	Dec 30, 2004	Jul CFTG

PREGABALIN

AB		ALEMBIC PHARMS LTD	25MG	A203459	001	Jul 19, 2019	Jul NFTG
AB			50MG	A203459	002	Jul 19, 2019	Jul NFTG
AB			75MG	A203459	003	Jul 19, 2019	Jul NFTG
AB			100MG	A203459	004	Jul 19, 2019	Jul NFTG
AB			150MG	A203459	005	Jul 19, 2019	Jul NFTG
AB			200MG	A203459	006	Jul 19, 2019	Jul NFTG
AB			225MG	A203459	007	Jul 19, 2019	Jul NFTG
AB			300MG	A203459	008	Jul 19, 2019	Jul NFTG
AB		ALKEM LABS LTD	25MG	A211177	001	Sep 30, 2019	Sep NEWA
AB			50MG	A211177	002	Sep 30, 2019	Sep NEWA
AB			75MG	A207799	001	Jul 19, 2019	Jul NFTG
AB			100MG	A207799	002	Jul 19, 2019	Jul NFTG
AB			150MG	A207799	003	Jul 19, 2019	Jul NFTG
AB			200MG	A207799	004	Jul 19, 2019	Jul NFTG
AB			225MG	A207799	005	Jul 19, 2019	Jul NFTG
AB			300MG	A207799	006	Jul 19, 2019	Jul NFTG
AB		AMNEAL PHARMS CO	25MG	A209743	001	Jul 19, 2019	Jul NFTG
AB			50MG	A209743	002	Jul 19, 2019	Jul NFTG
AB			75MG	A209743	003	Jul 19, 2019	Jul NFTG
AB			100MG	A209743	004	Jul 19, 2019	Jul NFTG
AB			150MG	A209743	005	Jul 19, 2019	Jul NFTG
AB			200MG	A209743	006	Jul 19, 2019	Jul NFTG
AB			225MG	A209743	007	Jul 19, 2019	Jul NFTG
AB			300MG	A209743	008	Jul 19, 2019	Jul NFTG
AB		DR REDDYS	25MG	A209664	001	Jul 19, 2019	Jul NFTG
AB			50MG	A209664	002	Jul 19, 2019	Jul NFTG
AB			75MG	A209664	003	Jul 19, 2019	Jul NFTG
AB			100MG	A209664	004	Jul 19, 2019	Jul NFTG
AB			150MG	A209664	005	Jul 19, 2019	Jul NFTG
AB			200MG	A209664	006	Jul 19, 2019	Jul NFTG
AB			225MG	A209664	007	Jul 19, 2019	Jul NFTG
AB			300MG	A209664	008	Jul 19, 2019	Jul NFTG
AB		HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019	Sep NEWA
AB			50MG	A206912	002	Oct 08, 2019	Sep NEWA
AB			75MG	A206912	003	Oct 08, 2019	Sep NEWA
AB			100MG	A206912	004	Oct 08, 2019	Sep NEWA
AB			150MG	A206912	005	Oct 08, 2019	Sep NEWA
AB			200MG	A206912	006	Oct 08, 2019	Sep NEWA
AB			225MG	A206912	007	Oct 08, 2019	Sep NEWA
AB			300MG	A206912	008	Oct 08, 2019	Sep NEWA
AB		INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019	Jul NFTG
AB			50MG	A211384	002	Jul 19, 2019	Jul NFTG
AB			75MG	A211384	003	Jul 19, 2019	Jul NFTG
AB			100MG	A211384	004	Jul 19, 2019	Jul NFTG
AB			150MG	A211384	005	Jul 19, 2019	Jul NFTG
AB			200MG	A211384	006	Jul 19, 2019	Jul NFTG
AB			225MG	A211384	007	Jul 19, 2019	Jul NFTG
AB			300MG	A211384	008	Jul 19, 2019	Jul NFTG
AB		MSN LABS PVT LTD	25MG	A209357	001	Jul 19, 2019	Jul NFTG
AB			50MG	A209357	002	Jul 19, 2019	Jul NFTG
AB			75MG	A209357	003	Jul 19, 2019	Jul NFTG
AB			100MG	A209357	004	Jul 19, 2019	Jul NFTG
AB			150MG	A209357	005	Jul 19, 2019	Jul NFTG
AB			200MG	A209357	006	Jul 19, 2019	Jul NFTG
AB			225MG	A209357	007	Jul 19, 2019	Jul NFTG
AB			300MG	A209357	008	Jul 19, 2019	Jul NFTG
AB		MYLAN	25MG	A091228	001	Sep 20, 2019	Sep NEWA
AB			50MG	A091228	002	Sep 20, 2019	Sep NEWA
AB			75MG	A091228	003	Sep 20, 2019	Sep NEWA
AB			100MG	A091228	004	Sep 20, 2019	Sep NEWA
AB			150MG	A091228	005	Sep 20, 2019	Sep NEWA

CAPSULE; ORAL
PREGABALIN

AB		200MG	A091228	006	Sep 20, 2019	Sep NEWA
AB		225MG	A091228	007	Sep 20, 2019	Sep NEWA
AB		300MG	A091228	008	Sep 20, 2019	Sep NEWA
AB	RISING	25MG	A210432	001	Jul 19, 2019	Jul NFTG
AB		50MG	A210432	002	Jul 19, 2019	Jul NFTG
AB		75MG	A210432	003	Jul 19, 2019	Jul NFTG
AB		100MG	A210432	004	Jul 19, 2019	Jul NFTG
AB		150MG	A210432	005	Jul 19, 2019	Jul NFTG
AB		200MG	A210432	006	Jul 19, 2019	Jul NFTG
AB		225MG	A210432	007	Jul 19, 2019	Jul NFTG
AB		300MG	A210432	008	Jul 19, 2019	Jul NFTG
AB	SCIEGEN PHARMS INC	25MG	A208677	001	Jul 19, 2019	Jul NFTG
AB		50MG	A208677	002	Jul 19, 2019	Jul NFTG
AB		75MG	A208677	003	Jul 19, 2019	Jul NFTG
AB		100MG	A208677	004	Jul 19, 2019	Jul NFTG
AB		150MG	A208677	005	Jul 19, 2019	Jul NFTG
AB		200MG	A208677	006	Jul 19, 2019	Jul NFTG
AB		225MG	A208677	007	Jul 19, 2019	Jul NFTG
AB		300MG	A208677	008	Jul 19, 2019	Jul NFTG
AB	SHUANGCHENG	75MG	A210891	001	Sep 30, 2019	Sep NEWA
AB		300MG	A210891	002	Sep 30, 2019	Sep NEWA
>A> AB	SUN PHARM	25MG	A091157	001	Nov 29, 2019	Nov NEWA
>A> AB		50MG	A091157	002	Nov 29, 2019	Nov NEWA
>A> AB		75MG	A091157	003	Nov 29, 2019	Nov NEWA
>A> AB		100MG	A091157	004	Nov 29, 2019	Nov NEWA
>A> AB		150MG	A091157	005	Nov 29, 2019	Nov NEWA
>A> AB		200MG	A091157	006	Nov 29, 2019	Nov NEWA
>A> AB		225MG	A091157	007	Nov 29, 2019	Nov NEWA
>A> AB		300MG	A091157	008	Nov 29, 2019	Nov NEWA
AB	TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Jul NFTG
AB		50MG	A091219	002	Jul 19, 2019	Jul NFTG
AB		75MG	A091224	001	Jul 19, 2019	Jul NFTG
AB		100MG	A091224	002	Jul 19, 2019	Jul NFTG
AB		150MG	A091224	003	Jul 19, 2019	Jul NFTG
AB		200MG	A091224	004	Jul 19, 2019	Jul NFTG
AB		225MG	A091224	005	Jul 19, 2019	Jul NFTG
AB		300MG	A091224	006	Jul 19, 2019	Jul NFTG

SOLUTION; ORAL
LYRICA

AA	+! PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG
AA	PREGABALIN					
AA	ALKEM LABS LTD	20MG/ML	A207623	001	Jul 19, 2019	Jul NFTG

PRETOMANIDTABLET; ORAL
PRETOMANID

+!	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019	Oct CAHN
+!	TB ALLIANCE	200MG	N212862	001	Aug 14, 2019	Aug NEWA

PROBENECIDTABLET; ORAL
PROBENECID

AB	MYLAN	500MG	A084211	002		Sep CHRS
!	WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Sep CHRS

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP	NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb NEWA
----	--------------	----------------	---------	-----	--------------	----------

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

@	TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996	Jul DISC
@		EQ 10MG BASE	A040120	002	Jul 11, 1996	Jul DISC

PROGESTERONECAPSULE; ORAL
PROGESTERONE

>D>	AB	SANDOZ INC	100MG	A205229	001	Oct 20, 2017	Nov CAHN
>D>	AB		200MG	A205229	002	Oct 20, 2017	Nov CAHN
>A>	AB	XIROMED	100MG	A205229	001	Oct 20, 2017	Nov CAHN
>A>	AB		200MG	A205229	002	Oct 20, 2017	Nov CAHN

INJECTABLE; INJECTION
PROGESTERONE

@	LUITPOLD	50MG/ML	A090845	001	Jun 22, 2009	Mar DISC
---	----------	---------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDESUPPOSITORY; RECTAL
PROMETHAZINE HYDROCHLORIDE

AB		PERRIGO ISRAEL	12.5MG	A040500	001	Jun 30, 2003	May CAHN
AB			25MG	A040500	002	Jun 30, 2003	May CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

@	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Mar DISC
@		25MG	A040791	003	Feb 12, 2008	Mar DISC

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
INNOPRAN XL

BX	+	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Jul CRLD
BX	+	!	120MG	N021438	002	Mar 12, 2003	Jul CHRS
BX	+		120MG	N021438	002	Mar 12, 2003	Jul CRLD

PROPRANOLOL HYDROCHLORIDE

AB		ADARE PHARMS INC	60MG	A078703	001	Jul 15, 2011	Sep CAHN
AB			80MG	A078703	002	Jul 15, 2011	Sep CAHN
AB			120MG	A078703	003	Jul 15, 2011	Sep CAHN
AB			160MG	A078703	004	Jul 15, 2011	Sep CAHN

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@	ANI PHARMS INC	60MG	A071791	001	Jul 15, 1987	Sep CAHN	
AB		INNOGENIX	10MG	A070322	002	Oct 22, 1985	Oct CMFD
	@		10MG	A070322	002	Oct 22, 1985	May CMS1
AB			20MG	A070322	003	Oct 22, 1985	Oct CMFD
	@		20MG	A070322	003	Oct 22, 1985	May CMS1
AB			40MG	A070322	004	Oct 22, 1985	Oct CMFD
	@		40MG	A070322	004	Oct 22, 1985	May CMS1
AB			60MG	A070322	005	Sep 24, 1986	Oct CMFD
	@		60MG	A070322	005	Sep 24, 1986	May CMS1
AB			80MG	A070322	001	Aug 04, 1986	Oct CMFD
	@		80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROPYLTHIOURACILTABLET; ORAL
PROPYLTHIOURACIL

>D>		@	HIKMA INTL PHARMS	50MG	A080154	001	Nov CAHN
>A>		@	QUAGEN	50MG	A080154	001	Nov CAHN

PROTRIPTYLINE HYDROCHLORIDETABLET; ORAL
VIVACTIL

AB		HERITAGE PHARMA	5MG	A073644	001	Aug 24, 1995	May CAHN
AB	!		10MG	A073645	001	Aug 24, 1995	May CAHN

PYRIDOSTIGMINE BROMIDEINJECTABLE; INJECTION
MESTINON

AP	+	!	BAUSCH	5MG/ML	N009830	001	Feb CAHN
----	---	---	--------	--------	---------	-----	----------

SYRUP; ORAL
MESTINON

AA	+	!	BAUSCH	60MG/5ML	N015193	001	Feb CFTG
	+	!		60MG/5ML	N015193	001	Feb CAHN

PYRIDOSTIGMINE BROMIDE

AA			NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019	Feb NFTG
----	--	--	-----------------	----------	---------	-----	--------------	----------

TABLET;ORAL									
MESTINON									
AB	+	BAUSCH	60MG	N009829	002			Feb	CAHN
PYRIDOSTIGMINE BROMIDE									
		APNAR PHARMA LP	30MG	A211181	002	May 14, 2019		May	NEWA
		ELYSIUM	30MG	A211181	002	May 14, 2019		Sep	CAHN
AB			60MG	A211181	001	Jul 20, 2018		Sep	CAHN
TABLET, EXTENDED RELEASE;ORAL									
MESTINON									
AB	+	BAUSCH	180MG	N011665	001			Feb	CAHN
<u>PYRIDOXINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
PYRIDOXINE HYDROCHLORIDE									
	@	DR REDDYS	100MG/ML	A080572	001			May	CAHN
<u>QUETIAPINE FUMARATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
QUETIAPINE FUMARATE									
	@	AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018		Apr	DISC
<u>QUINIDINE GLUCONATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
QUINAGLUTE									
+	@	BAYER HLTHCARE	324MG	N016647	001			Sep	CRLD
QUINIDINE GLUCONATE									
!		SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987		Sep	CTEC
<u>QUINIDINE SULFATE</u>									
TABLET;ORAL									
QUINIDINE SULFATE									
	@	SUN PHARM INDUSTRIES	200MG	A081030	001	Apr 14, 1989		Oct	DISC
	@		300MG	A081031	001	Apr 14, 1989		Oct	DISC
<u>QUININE SULFATE</u>									
CAPSULE;ORAL									
QUININE SULFATE									
	@	MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012		Mar	DISC
<u>RABEPRAZOLE SODIUM</u>									
CAPSULE, DELAYED RELEASE;ORAL									
ACIPHEX SPRINKLE									
>A>	+	AYTU	5MG	N204736	001	Mar 26, 2013		Nov	CAHN
>A>	+	!	10MG	N204736	002	Mar 26, 2013		Nov	CAHN
>D>	+	CERECOR INC	5MG	N204736	001	Mar 26, 2013		Nov	CAHN
>D>	+	!	10MG	N204736	002	Mar 26, 2013		Nov	CAHN
TABLET, DELAYED RELEASE;ORAL									
RABEPRAZOLE SODIUM									
	@	MYLAN	20MG	A076885	001	Nov 08, 2013		Jul	DISC
AB		RUBICON	20MG	A204237	001	Nov 18, 2015		Feb	CAHN
<u>RAMELTEON</u>									
TABLET;ORAL									
RAMELTEON									
AB		ZYDUS PHARMS	8MG	A211567	001	Jul 22, 2019		Jul	NEWA
<u>RANITIDINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
RANITIDINE HYDROCHLORIDE									
AB		APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019		Mar	NEWA
AB			EQ 300MG BASE	A211893	002	Apr 05, 2019		Mar	NEWA
SYRUP;ORAL									
RANITIDINE HYDROCHLORIDE									
>D> AA		ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007		Nov	DISC
>A>		@	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007		Nov	DISC
		@ TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009		Jul	DISC
AA			EQ 15MG BASE/ML	A090102	001	May 26, 2009		Jan	CAHN
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
	@	ANI PHARMS INC	EQ 150MG BASE	A074488	001	Jul 31, 1997		Oct	DISC
	@		EQ 300MG BASE	A074488	002	Jul 31, 1997		Oct	DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Feb CAHN
AB		EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb CAHN
AB	STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Apr CAHN
AB		EQ 300MG BASE	A210010	002	Aug 01, 2018	Apr CAHN
AB	VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019	Jan NEWA
AB		EQ 300MG BASE	A211289	002	Jan 31, 2019	Jan NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
AB	+!	1GM	N021526	001	Feb 12, 2007	Feb CTEC

RANOLAZINE

AB	ACTAVIS ELIZABETH	500MG	A208862	001	May 28, 2019	May NEWA
AB		1GM	A208862	002	May 28, 2019	May NEWA
AB	AJANTA PHARMA LTD	500MG	A210054	001	May 28, 2019	May NEWA
AB		1GM	A210054	002	May 28, 2019	May NEWA
AB	AMERIGEN PHARMS LTD	500MG	A210482	001	Oct 29, 2019	Oct NEWA
AB		1GM	A210482	002	Oct 29, 2019	Oct NEWA
AB	CADILA	500MG	A210188	001	Aug 19, 2019	Aug NEWA
AB		1GM	A210188	002	Aug 19, 2019	Aug NEWA
AB	CIPLA	500MG	A211291	001	May 28, 2019	May NEWA
AB		1GM	A211291	002	May 28, 2019	May NEWA
AB	GLENMARK PHARMS LTD	500MG	A211082	001	Jul 05, 2019	Jun NEWA
AB		1GM	A211082	002	Jul 05, 2019	Jun NEWA
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb CMFD
AB		1GM	A201046	002	Jul 29, 2013	Feb CMFD
AB	SCIEGEN PHARMS INC	500MG	A211829	001	Jun 04, 2019	May NEWA
AB		1GM	A211829	002	Jun 04, 2019	May NEWA
AB	SUN PHARM	500MG	A211707	001	May 28, 2019	May NEWA
AB		1GM	A211707	002	May 28, 2019	May NEWA

RASAGILINE

TABLET;ORAL

RASAGILINE

AB	INDOCO REMEDIES	EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Sep NEWA
AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Sep NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

	+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
	+ @	1MG	N020741	002	Dec 22, 1997	Mar DISC
	+ @	2MG	N020741	003	Dec 22, 1997	Mar DISC

REPAGLINIDE

AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb DISC
	@	1MG	A090252	002	Jan 22, 2014	Jul DISC
	@	2MG	A090252	003	Jan 22, 2014	Jul DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

	+! ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
--	-------------	----	---------	-----	--------------	----------

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

	@ CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun DISC
--	-------------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

REBETOL

	+ @ SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun DISC
--	--------------	---------	---------	-----	--------------	----------

TABLET;ORAL

RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
AB		400MG	A202546	002	Aug 12, 2014	Feb CAHN
AB		500MG	A202546	003	Aug 12, 2014	Feb CAHN
AB		600MG	A202546	004	Aug 12, 2014	Feb CAHN
	@ HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	Oct DISC
AB		200MG	A077053	001	Dec 05, 2005	May CAHN

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE;ORAL

AEMCOLO

+	COSMO TECHNOLOGIES	EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct CPOT
+		194MG	N210910	001	Nov 16, 2018	Oct CAIN

>A> RILUZOLE

>A> FILM;ORAL

>A> EXSERVAN

>A>	+	AQUESTIVE THERAP	50MG	N212640	001	Nov 22, 2019	Nov NEWA
-----	---	------------------	------	---------	-----	--------------	----------

TABLET;ORAL

RILUZOLE

	@	DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
>A> AB		STANDARD CHEM PHARM	50MG	A206045	001	Dec 09, 2019	Nov NEWA

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@	HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May CAHN
---	-----------------	-------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

@	EYEVANCE	1%	N020474	001	Dec 30, 1994	May CAHN
---	----------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

	@	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Aug DISC
AB			35MG	A207516	001	Feb 15, 2019	Feb NEWA
	@	MYLAN	5MG	A200477	001	Nov 30, 2015	May DISC
	@		30MG	A200477	002	Nov 30, 2015	May DISC
	@		35MG	A200477	003	Nov 30, 2015	May DISC
	@		75MG	A200477	004	Jun 10, 2014	May DISC
	@		150MG	A200477	005	Jun 10, 2014	May DISC
AB		ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr NEWA
AB			35MG	A205280	002	May 13, 2019	Apr NEWA

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

AB		SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun NEWA
	@	ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA		PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Oct CAHN
	@	TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Oct DISC
AA			1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN

TABLET;ORAL

RISPERIDONE

AB		CELLTRION	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
AB			0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
AB			1MG	A078871	003	Oct 09, 2008	Aug CAHN
AB			2MG	A078871	004	Oct 09, 2008	Aug CAHN
AB			3MG	A078871	005	Oct 09, 2008	Aug CAHN
AB			4MG	A078871	006	Oct 09, 2008	Aug CAHN
	@	HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008	Aug DISC
AB			0.25MG	A076228	001	Jun 30, 2008	May CAHN
AB			0.25MG	A077769	001	Oct 16, 2008	May CAHN
	@		0.5MG	A076228	002	Jun 30, 2008	Aug DISC
AB			0.5MG	A076228	002	Jun 30, 2008	May CAHN
AB			0.5MG	A077769	002	Oct 16, 2008	May CAHN
	@		1MG	A076228	003	Jun 30, 2008	Aug DISC

TABLET;ORAL
RISPERIDONE

AB		1MG	A076228	003	Jun 30, 2008	May CAHN
AB		1MG	A077769	003	Oct 16, 2008	May CAHN
	@	2MG	A076228	004	Jun 30, 2008	Aug DISC
AB		2MG	A076228	004	Jun 30, 2008	May CAHN
AB		2MG	A077769	004	Oct 16, 2008	May CAHN
	@	3MG	A076228	005	Jun 30, 2008	Aug DISC
AB		3MG	A076228	005	Jun 30, 2008	May CAHN
AB		3MG	A077769	005	Oct 16, 2008	May CAHN
	@	4MG	A076228	006	Jun 30, 2008	Aug DISC
AB		4MG	A076228	006	Jun 30, 2008	May CAHN
AB		4MG	A077769	006	Oct 16, 2008	May CAHN
AB	RISING	0.25MG	A078269	001	Oct 08, 2008	Sep CAHN
AB		0.5MG	A078269	002	Oct 08, 2008	Sep CAHN
AB		1MG	A078269	003	Oct 08, 2008	Sep CAHN
AB		2MG	A078269	004	Oct 08, 2008	Sep CAHN
AB		3MG	A078269	005	Oct 08, 2008	Sep CAHN
AB		4MG	A078269	006	Oct 08, 2008	Sep CAHN
	@ SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Oct DISC
	@	0.5MG	A078036	002	Mar 10, 2014	Oct DISC
	@	1MG	A078036	003	Mar 10, 2014	Oct DISC
	@	2MG	A078036	004	Mar 10, 2014	Oct DISC
	@	3MG	A078036	005	Mar 10, 2014	Oct DISC
	@	4MG	A078036	006	Mar 10, 2014	Oct DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	May CAHN
AB		1MG	A076908	002	Mar 12, 2012	May CAHN
AB		2MG	A076908	003	Mar 12, 2012	May CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

>A>	AB	BRECKENRIDGE	4.6MG/24HR	A209063	001	Nov 26, 2019	Nov NEWA
>A>	AB		9.5MG/24HR	A209063	002	Nov 26, 2019	Nov NEWA
>A>	AB		13.3MG/24HR	A209063	003	Nov 26, 2019	Nov NEWA
	AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
	AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
	AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
EXELON

+	@	NOVARTIS	EQ 1.5MG BASE	N020823	003	Apr 21, 2000	Aug DISC
+	@		EQ 3MG BASE	N020823	004	Apr 21, 2000	Aug DISC
+	@		EQ 4.5MG BASE	N020823	005	Apr 21, 2000	Aug DISC
+	@		EQ 6MG BASE	N020823	006	Apr 21, 2000	Aug DISC

RIVASTIGMINE TARTRATE

AB	!	DR REDDYS LABS INC	EQ 1.5MG BASE	A077130	001	Oct 31, 2007	Aug CHRS
AB	!		EQ 6MG BASE	A077130	004	Oct 31, 2007	Aug CHRS

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	CAMARGO PHARM	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Jul NEWA
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Jul NEWA
AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Aug CAHN
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Aug CAHN

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN
AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jul CAHN
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jul CAHN
AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jul CAHN
AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jul CAHN
AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jul CAHN
AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jul CAHN
AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jul CAHN
AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar CAHN
AB	MLV	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Sep CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Sep CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Sep CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Sep CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Sep CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Sep CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

>D>	AB	+	GLAXOSMITHKLINE LLC	EQ 4MG BASE	N022008	003	Jun 13, 2008	Nov DISC
>A>		+	@	EQ 4MG BASE	N022008	003	Jun 13, 2008	Nov DISC

ROPINIROLE HYDROCHLORIDE

AB	CELLTRION	EQ 2MG BASE	A091395	001	Aug 27, 2012	Aug CAHN
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Aug CAHN
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Aug CAHN
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Aug CAHN
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Aug CAHN

ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE

@	ANI PHARMS INC	EQ 2MG BASE	A076747	001	Jan 25, 2013	Sep CAHN
@		EQ 4MG BASE	A076747	002	Jan 25, 2013	Sep CAHN
@		EQ 8MG BASE	A076747	003	Jan 25, 2013	Sep CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

	@	AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr DISC
	@		10MG	A208850	002	Oct 16, 2018	Apr DISC
	@		20MG	A208850	003	Oct 16, 2018	Apr DISC
	@		40MG	A208850	004	Oct 16, 2018	Apr DISC
	@	MYLAN	5MG	A079161	001	Jul 19, 2016	Jul DISC
	@		10MG	A079161	002	Jul 19, 2016	Jul DISC
	@		20MG	A079161	003	Jul 19, 2016	Jul DISC
	@		40MG	A079161	004	Jul 19, 2016	Jul DISC
>D>	AB	SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24, 2019	Nov DISC
>A>	@		5MG	A206381	001	Apr 24, 2019	Nov DISC
	AB		5MG	A206381	001	Apr 24, 2019	Apr NEWA
>D>	AB		10MG	A206381	002	Apr 24, 2019	Nov DISC
>A>	@		10MG	A206381	002	Apr 24, 2019	Nov DISC
	AB		10MG	A206381	002	Apr 24, 2019	Apr NEWA
>D>	AB		20MG	A206381	003	Apr 24, 2019	Nov DISC
>A>	@		20MG	A206381	003	Apr 24, 2019	Nov DISC
	AB		20MG	A206381	003	Apr 24, 2019	Apr NEWA
>D>	AB		40MG	A206381	004	Apr 24, 2019	Nov DISC
>A>	@		40MG	A206381	004	Apr 24, 2019	Nov DISC
	AB		40MG	A206381	004	Apr 24, 2019	Apr NEWA
	AB	SHANDONG	5MG	A207375	001	May 07, 2019	Apr NEWA
	AB		10MG	A207375	002	May 07, 2019	Apr NEWA
	AB		20MG	A207375	003	May 07, 2019	Apr NEWA
	AB		40MG	A207375	004	May 07, 2019	Apr NEWA
	@	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul DISC
	@		10MG	A079166	002	Jul 19, 2016	Jul DISC
	@		20MG	A079166	003	Jul 19, 2016	Jul DISC

TABLET;ORAL									
ROSUVASTATIN CALCIUM									
	@	40MG	A079166	004	Jul 19, 2016	Jul	DISC		
	@ UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Oct	DISC		
AB		5MG	A207626	001	Apr 09, 2019	Mar	NEWA		
	@	10MG	A207626	002	Apr 09, 2019	Oct	DISC		
AB		10MG	A207626	002	Apr 09, 2019	Mar	NEWA		
	@	20MG	A207626	003	Apr 09, 2019	Oct	DISC		
AB		20MG	A207626	003	Apr 09, 2019	Mar	NEWA		
	@	40MG	A207626	004	Apr 09, 2019	Oct	DISC		
AB		40MG	A207626	004	Apr 09, 2019	Mar	NEWA		
AB	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Oct	NEWA		
AB		10MG	A212059	002	Nov 04, 2019	Oct	NEWA		
AB		20MG	A212059	003	Nov 04, 2019	Oct	NEWA		
AB		40MG	A212059	004	Nov 04, 2019	Oct	NEWA		
	@ ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Aug	DISC		
AB		5MG	A206513	001	Mar 01, 2019	Feb	NEWA		
	@	10MG	A206513	002	Mar 01, 2019	Aug	DISC		
AB		10MG	A206513	002	Mar 01, 2019	Feb	NEWA		
	@	20MG	A206513	003	Mar 01, 2019	Aug	DISC		
AB		20MG	A206513	003	Mar 01, 2019	Feb	NEWA		
	@	40MG	A206513	004	Mar 01, 2019	Aug	DISC		
AB		40MG	A206513	004	Mar 01, 2019	Feb	NEWA		
<u>RUFINAMIDE</u>									
SUSPENSION;ORAL									
BANZEL									
AB	+! EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr	CFTG		
RUFINAMIDE									
AB	BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr	NFTG		
AB	HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr	NFTG		
TABLET;ORAL									
RUFINAMIDE									
	@ MYLAN	200MG	A205095	001	May 16, 2016	Feb	DISC		
	@	400MG	A205095	002	May 16, 2016	Feb	DISC		
<u>SAPROPTERIN DIHYDROCHLORIDE</u>									
POWDER;ORAL									
KUVAN									
AB	+! BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Aug	CFTG		
	+	500MG/PACKET	N205065	002	Oct 27, 2015	Sep	CTEC		
AB	+	500MG/PACKET	N205065	002	Oct 27, 2015	Aug	CFTG		
SAPROPTERIN DIHYDROCHLORIDE									
AB	PAR PHARM INC	100MG/PACKET	A207207	001	Aug 20, 2019	Aug	NFTG		
	@	500MG/PACKET	A210027	001	Aug 20, 2019	Sep	DISC		
AB		500MG/PACKET	A210027	001	Aug 20, 2019	Aug	NFTG		
TABLET;ORAL									
KUVAN									
	+! BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May	CTEC		
AB	+!	100MG	N022181	001	Dec 13, 2007	Apr	CFTG		
SAPROPTERIN DIHYDROCHLORIDE									
	@ PAR PHARM INC	100MG	A207200	001	May 10, 2019	May	DISC		
AB		100MG	A207200	001	May 10, 2019	Apr	NFTG		
<u>SCOPOLAMINE</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
SCOPOLAMINE									
AB	MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun	NEWA		
<u>SELEGILINE HYDROCHLORIDE</u>									
TABLET;ORAL									
SELEGILINE HYDROCHLORIDE									
AB	BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun	CAHN		
AB	KENTON	5MG	A074912	001	Apr 30, 1998	Mar	CAHN		
	@ MYLAN	5MG	A074866	001	Nov 26, 1997	Aug	DISC		
TABLET, ORALLY DISINTEGRATING;ORAL									
ZELAPAR									
	+! BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar	CAHN		

SELENIOS ACIDSOLUTION;INTRAVENOUS
SELENIOS ACID

+!	AM REAGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr NEWA
----	------------	--	---------	-----	--------------	----------

SELINEXORTABLET;ORAL
XPOVIO

+!	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Jul NEWA
----	--------------------	------	---------	-----	--------------	----------

SEMAGLUTIDETABLET;ORAL
RYBELSUS

+	NOVO	3MG	N213051	001	Sep 20, 2019	Sep NEWA
+		7MG	N213051	002	Sep 20, 2019	Sep NEWA
+		14MG	N213051	003	Sep 20, 2019	Sep NEWA

SERTACONAZOLE NITRATECREAM;TOPICAL
ERTACZO

+!	BAUSCH	2%	N021385	001	Dec 10, 2003	Jun CAHN
----	--------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDETABLET;ORAL
SERTRALINE HYDROCHLORIDE

	@ CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun DISC
AB		EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
	@	EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun DISC
AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
	@	EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun DISC
AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN
	@ HERITAGE PHARMA	EQ 25MG BASE	A076465	001	Aug 11, 2006	Oct DISC
AB		EQ 25MG BASE	A076465	001	Aug 11, 2006	May CAHN
	@	EQ 25MG BASE	A077299	001	Feb 06, 2007	May CAHN
	@	EQ 25MG BASE	A077345	001	Feb 06, 2007	May CAHN
	@	EQ 50MG BASE	A076465	002	Aug 11, 2006	Oct DISC
AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	May CAHN
	@	EQ 50MG BASE	A077299	002	Feb 06, 2007	May CAHN
	@	EQ 50MG BASE	A077345	002	Feb 06, 2007	May CAHN
	@	EQ 100MG BASE	A076465	003	Aug 11, 2006	Oct DISC
AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	May CAHN
	@	EQ 100MG BASE	A077299	003	Feb 06, 2007	May CAHN
	@	EQ 100MG BASE	A077345	003	Feb 06, 2007	May CAHN
	@ MYLAN PHARMS INC	EQ 25MG BASE	A078626	001	Jan 31, 2008	May DISC
	@	EQ 50MG BASE	A078626	002	Jan 31, 2008	May DISC

SEVELAMER HYDROCHLORIDETABLET;ORAL
RENAGEL

AB	+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+		800MG	N021179	002	Jul 12, 2000	Feb CFTG
		SEVELAMER HYDROCHLORIDE					
AB		GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB			800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATEFOR SUSPENSION;ORAL
REVATIO

AB	+	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	May CFTG
		SILDENAFIL CITRATE					
>A>	AB	AJANTA PHARMA LTD	EQ 10MG BASE/ML	A212883	001	Nov 27, 2019	Nov NEWA
>A>	AB	ALKEM LABS LTD	EQ 10MG BASE/ML	A212440	001	Nov 27, 2019	Nov NEWA
>A>	AB	AMNEAL PHARMS	EQ 10MG BASE/ML	A211092	001	Nov 27, 2019	Nov NEWA
	AB	NOVITIUM PHARMA	EQ 10MG BASE/ML	A212260	001	May 31, 2019	May NFTG
		TABLET;ORAL					
		SILDENAFIL CITRATE					
AB		LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
AB			EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
AB			EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
AB		MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA

TABLET;ORAL
SILDENAFIL CITRATE

AB		EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
AB		EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SILODOSIN

CAPSULE;ORAL
SILODOSIN

>A>	AB	ALEMBIC PHARMS LTD	4MG	A211731	001	Nov 22, 2019	Nov NEWA
>A>	AB		8MG	A211731	002	Nov 22, 2019	Nov NEWA

SIMVASTATIN

TABLET;ORAL
SIMVASTATIN

AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar CAHN
AB		10MG	A090383	002	Sep 16, 2011	Mar CAHN
AB		20MG	A090383	003	Sep 16, 2011	Mar CAHN
AB		40MG	A090383	004	Sep 16, 2011	Mar CAHN
AB		80MG	A090383	005	Sep 16, 2011	Mar CAHN

SIPONIMOD

TABLET;ORAL
MAYZENT

+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar NEWA
+	!	2MG	N209884	002	Mar 26, 2019	Mar NEWA

SIPONIMOD FUMARIC ACID

TABLET;ORAL
MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CAIN
+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CAIN

SIROLIMUS

SOLUTION;ORAL
RAPAMUNE

AA	+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan CFTG
AA		SIROLIMUS					
AA		AMNEAL PHARMS LLC	1MG/ML	A211212	001	Oct 18, 2019	Oct NEWA
AA		APOTEX	1MG/ML	A211406	001	Oct 22, 2019	Oct NEWA
AA		NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan NFTG

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

AP		EXELA PHARMA SCS LLC	0.5MEQ/ML	A211091	001	Jun 20, 2019	Oct CTEC
			0.5MEQ/ML	A211091	001	Jun 20, 2019	Jun NEWA
AP			0.9MEQ/ML	A211091	002	Jun 20, 2019	Jun NEWA
AP			1MEQ/ML	A211091	003	Jun 20, 2019	Jun NEWA
AP		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Oct CMFD

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Sep CAHN
	+	@ LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Aug DISC
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
AP		FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb NEWA

SODIUM CHROMATE CR-51

INJECTABLE;INJECTION
SODIUM CHROMATE CR 51
@ CURIUM

100uCi/ML	N016708	001		Jan CAHN
-----------	---------	-----	--	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP		DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr CAHN
----	--	---------	--------------	---------	-----	--------------	----------

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

@ CURIUM	0.8-100mCi	N016515	002		Jan CAHN
+ @	0.8-100mCi	N016517	001		Jan CAHN
@	15-100uCi	N016517	002		Jan CAHN

SOLUTION;ORAL

SODIUM IODIDE I 131

+ @ CURIUM	3.5-150mCi/VIAL	N016515	001		Jan CAHN
------------	-----------------	---------	-----	--	----------

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

>A>	AP	CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Nov NEWA
	AP	DR REDDYS LABS LTD	25MG/ML	A210114	001	Apr 10, 2019	Mar NEWA
	AP	SAGENT PHARMS INC	25MG/ML	A207426	001	Dec 08, 2016	Sep CAHN
		@ SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018	Jul DISC
		@ VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018	Oct DISC
	AP		25MG/ML	A209834	001	Jun 26, 2018	Jul CAHN
		SOLUTION;INTRAVENOUS					
		NIPRIDE RTU IN SODIUM CHLORIDE 0.9%					
		+ @ EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Jul DISC

SODIUM PHENYLEBUTYRATE

POWDER;ORAL

BUPHENYL

AB	+!	HORIZON THERAP	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Feb CAHN
----	----	----------------	-----------------	---------	-----	--------------	----------

TABLET;ORAL

BUPHENYL

AB	+!	HORIZON THERAP	500MG	N020572	001	May 13, 1996	Feb CAHN
----	----	----------------	-------	---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		NOVELGENIX THERAPS	454GM/BOT	A206815	001	Feb 18, 2016	Sep CAHN
----	--	--------------------	-----------	---------	-----	--------------	----------

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

>A>							
>A>	AP	CUSTOPHARM INC	60MG/2ML (30MG/ML)	A209937	001	Dec 09, 2019	Nov NEWA
		SOTRADECOL					
>D>	!	MYLAN INSTITUTIONAL	60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004	Nov CTEC
>A>	AP	!	60MG/2ML (30MG/ML)	A040541	002	Nov 12, 2004	Nov CTEC

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

		+ GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019	Aug NEWA
		+!	200MG/PACKET	N212480	002	Aug 28, 2019	Aug NEWA

TABLET;ORAL

SOVALDI

		+ GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019	Aug NEWA
--	--	-----------------------	-------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB		AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	May NEWA
AB			10MG	A205483	002	May 20, 2019	May NEWA
AB		ALEMBIC PHARMS LTD	5MG	A205575	001	May 20, 2019	May NEWA
AB			10MG	A205575	002	May 20, 2019	May NEWA
AB		ALKEM LABS LTD	5MG	A210224	001	May 20, 2019	May NEWA
AB			10MG	A210224	002	May 20, 2019	May NEWA
AB		AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	May NEWA
AB			10MG	A209719	002	May 20, 2019	May NEWA
AB		BRECKENRIDGE	5MG	A209818	001	May 20, 2019	May NEWA
AB			10MG	A209818	002	May 20, 2019	May NEWA
AB		CELLTRION	5MG	A210582	001	May 20, 2019	May NEWA
AB			10MG	A210582	002	May 20, 2019	May NEWA
AB		CIPLA	5MG	A209839	001	May 20, 2019	May NEWA
AB			10MG	A209839	002	May 20, 2019	May NEWA
>A>	AB	CSPC OUYI	5MG	A211423	001	Dec 11, 2019	Nov NEWA

TABLET;ORAL

SOLIFENACIN SUCCINATE

>A>	AB		10MG	A211423	002	Dec 11, 2019	Nov	NEWA
	AB	GLENMARK PHARMS INC	5MG	A209239	001	May 20, 2019	May	NEWA
	AB		10MG	A209239	002	May 20, 2019	May	NEWA
	AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019	May	NEWA
	AB		10MG	A210281	002	May 20, 2019	May	NEWA
	AB	MSN LABS PVT LTD	5MG	A210688	001	May 20, 2019	May	NEWA
	AB		10MG	A210688	002	May 20, 2019	May	NEWA
	AB	QILU	5MG	A209333	001	May 20, 2019	May	NEWA
	AB		10MG	A209333	002	May 20, 2019	May	NEWA
	AB	SCIEGEN PHARMS INC	5MG	A211657	001	May 20, 2019	May	NEWA
	AB		10MG	A211657	002	May 20, 2019	May	NEWA
	AB	STRIDES PHARMA	5MG	A212214	001	Sep 26, 2019	Sep	NEWA
	AB		10MG	A212214	002	Sep 26, 2019	Sep	NEWA
	AB	UNICHEM LABS LTD	5MG	A211701	001	Aug 27, 2019	Aug	NEWA
	AB		10MG	A211701	002	Aug 27, 2019	Aug	NEWA
	AB	WATSON LABS INC	5MG	A202551	001	May 20, 2019	May	NEWA
	AB		10MG	A202551	002	May 20, 2019	May	NEWA

SOLRIAMFETOL

TABLET;ORAL

SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019	Jun	NEWA
+		150MG	N211230	002	Jun 17, 2019	Jun	NEWA

SOMATROPIN

INJECTABLE;INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995	Aug	CAIN
	+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Aug	CAIN
		GENOTROPIN PRESERVATIVE FREE						
	+	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998	Aug	CAIN
	+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Aug	CAIN
	+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Aug	CAIN
	+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Aug	CAIN
	+		1MG/VIAL	N020280	008	Jan 27, 1998	Aug	CAIN
	+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Aug	CAIN
	+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Aug	CAIN
	+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Aug	CAIN
	+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Aug	CAIN
	+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Aug	CAIN
	+	!	2MG/VIAL	N020280	013	Jan 27, 1998	Aug	CAIN
		NORDITROPIN						
	@	NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000	Aug	CAIN
	@		10MG/1.5ML	N021148	002	Jun 20, 2000	Aug	CAIN
	@		15MG/1.5ML	N021148	003	Jun 20, 2000	Aug	CAIN
		NORDITROPIN FLEXPOR						
BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Aug	CAIN
BX			10MG/1.5ML	N021148	009	Mar 01, 2010	Aug	CAIN
			15MG/1.5ML	N021148	010	Mar 01, 2010	Aug	CAIN
			30MG/3ML	N021148	011	Jan 23, 2015	Aug	CAIN
		NORDITROPIN NORDIFLEX						
	@	NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004	Aug	CAIN
	@		10MG/1.5ML	N021148	005	Oct 01, 2004	Aug	CAIN
	@		15MG/1.5ML	N021148	006	Oct 01, 2004	Aug	CAIN
	@		30MG/3ML	N021148	007	Mar 10, 2009	Aug	CAIN
		NUTROPIN						
	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Aug	CAIN
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Aug	CAIN
		NUTROPIN AQ						
	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Aug	CAIN
		NUTROPIN AQ NUSPIN						
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Aug	CAIN
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Aug	CAIN
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Aug	CAIN
		NUTROPIN AQ PEN						
	+	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Aug	CAIN
	+	@	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Aug	CAIN
		OMNITROPE						
BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006	Aug	CAIN
BX			5MG/1.5ML	N021426	003	Jan 16, 2008	Aug	CAIN
BX			5.8MG/VIAL	N021426	001	May 30, 2006	Aug	CAIN

INJECTABLE; INJECTION							
OMNITROPE							
BX		10MG/1.5ML	N021426	004	Aug 25, 2008	Aug CAIN	
SAIZEN							
	@ EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007	Aug CAIN	
BX	+	5MG/VIAL	N019764	002	Oct 08, 1996	Aug CAIN	
	@	6MG/VIAL	N019764	001	Oct 08, 1996	Aug CAIN	
	+!	8.8MG/VIAL	N019764	003	Aug 29, 2000	Aug CAIN	
SEROSTIM							
	EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Aug CAIN	
BX		5MG/VIAL	N020604	002	Aug 23, 1996	Aug CAIN	
BX		6MG/VIAL	N020604	001	Aug 23, 1996	Aug CAIN	
	@	8.8MG/VIAL	N020604	004	Sep 06, 2001	Aug CAIN	
INJECTABLE; SUBCUTANEOUS							
SEROSTIM LQ							
	@ EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005	Aug CAIN	
<u>SOTALOL HYDROCHLORIDE</u>							
TABLET; ORAL							
BETAPACE							
AB	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CTEC
AB	+		120MG	N019865	005	Apr 20, 1994	May CTEC
AB	+		160MG	N019865	002	Oct 30, 1992	May CTEC
AB	+		240MG	N019865	003	Oct 30, 1992	May CTEC
BETAPACE AF							
AB	+	COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000	May CTEC
AB	+		120MG	N021151	002	Feb 22, 2000	May CTEC
AB	+		160MG	N021151	003	Feb 22, 2000	May CTEC
SORINE							
AB		UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	May CTEC
AB			120MG	A075500	004	Apr 27, 2001	May CTEC
AB			160MG	A075500	002	Apr 27, 2001	May CTEC
AB			240MG	A075500	003	Apr 27, 2001	May CTEC
SOTALOL HYDROCHLORIDE							
AB		APOTEX	80MG	A076140	001	Sep 26, 2002	May CTEC
AB			80MG	A076214	001	Aug 27, 2003	May CTEC
AB			120MG	A076140	002	Sep 26, 2002	May CTEC
AB			120MG	A076214	002	Aug 27, 2003	May CTEC
AB			160MG	A076140	003	Sep 26, 2002	May CTEC
AB			160MG	A076214	003	Aug 27, 2003	May CTEC
AB			240MG	A076140	004	Sep 26, 2002	May CTEC
AB		BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	May CTEC
AB			80MG	A207429	001	Nov 02, 2018	May CTEC
AB			120MG	A207428	002	Oct 21, 2016	May CTEC
AB			120MG	A207429	002	Nov 02, 2018	May CTEC
AB			160MG	A207428	003	Oct 21, 2016	May CTEC
AB			160MG	A207429	003	Nov 02, 2018	May CTEC
AB		EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May CTEC
AB			120MG	A077070	002	Nov 04, 2005	May CTEC
AB			160MG	A077070	003	Nov 04, 2005	May CTEC
AB		MYLAN	80MG	A077616	001	Feb 07, 2007	May CTEC
AB			120MG	A077616	002	Feb 07, 2007	May CTEC
AB			160MG	A077616	003	Feb 07, 2007	May CTEC
AB		OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May CTEC
AB			120MG	A075563	002	Nov 07, 2003	May CTEC
AB			160MG	A075563	003	Nov 07, 2003	May CTEC
AB			240MG	A075563	004	Nov 07, 2003	May CTEC
AB		TEVA	80MG	A075429	001	May 01, 2000	May CTEC
AB			120MG	A075429	002	May 01, 2000	May CTEC
AB			160MG	A075429	003	May 01, 2000	May CTEC
AB			240MG	A075429	004	May 01, 2000	May CTEC
<u>SPIRONOLACTONE</u>							
TABLET; ORAL							
SPIRONOLACTONE							
	@ ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun DISC	
	@	50MG	A040353	001	Jul 29, 1999	Jun DISC	
	@	100MG	A040353	002	Jul 29, 1999	Jun DISC	
	@ CASI PHARMS INC	25MG	A086809	001		Jun DISC	

STAVUDINECAPSULE;ORAL
STAVUDINE

>D>	AB	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008	Nov	DISC
>A>	@		15MG	A078957	001	Dec 29, 2008	Nov	DISC
>D>	AB		20MG	A078957	002	Dec 29, 2008	Nov	DISC
>A>	@		20MG	A078957	002	Dec 29, 2008	Nov	DISC
>D>	AB		30MG	A078957	003	Dec 29, 2008	Nov	DISC
>A>	@		30MG	A078957	003	Dec 29, 2008	Nov	DISC
>D>	AB		40MG	A078957	004	Dec 29, 2008	Nov	DISC
>A>	@		40MG	A078957	004	Dec 29, 2008	Nov	DISC
	@	MYLAN	15MG	A079069	001	Dec 29, 2008	Oct	DISC
	@		20MG	A079069	002	Dec 29, 2008	Oct	DISC
	@		30MG	A079069	003	Dec 29, 2008	Oct	DISC
	@		40MG	A079069	004	Dec 29, 2008	Oct	DISC
		FOR SOLUTION;ORAL						
		ZERIT						
	+	@ BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996	Mar	DISC

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

>A>	+	@ HOSPIRA	100% (1ML)	N018801	001	Oct 27, 1982	Nov	DISC	
>A>	AP	+	100% (1ML)	N018801	001	Oct 27, 1982	Nov	CPOT	
>A>	AP	+	100% (10ML)	N018801	002	Oct 27, 1982	Nov	NEWA	
>A>		+	100% (20ML)	N018801	003	Oct 27, 1982	Nov	NEWA	
>A>		+	100% (50ML)	N018801	004	Oct 27, 1982	Nov	NEWA	
>A>		+	100% (100ML)	N018801	005	Oct 27, 1982	Nov	NEWA	
>A>		MEDEFIL INC	100% (1ML)	A211188	001	Dec 02, 2019	Nov	NEWA	
>A>		!	100% (2.5ML)	A211188	002	Dec 02, 2019	Nov	NEWA	
>A>		!	100% (3ML)	A211188	003	Dec 02, 2019	Nov	NEWA	
>A>		!	100% (5ML)	A211188	004	Dec 02, 2019	Nov	NEWA	
>A>	AP		100% (10ML)	A211188	005	Dec 02, 2019	Nov	NEWA	
>D>	AP	WEST-WARD PHARMS INT	100%	A206369	001	Sep 02, 2015	Nov	CPOT	
>A>	AP		100% (10ML)	A206369	001	Sep 02, 2015	Nov	CPOT	
>A>		@	100% (20ML)	A206369	002	Sep 02, 2015	Nov	DISC	
>A>			100% (20ML)	A206369	002	Sep 02, 2015	Nov	NEWA	
		STERILE WATER FOR INJECTION IN PLASTIC CONTAINER							
>D>	AP	+	HOSPIRA	100%	N018801	001	Oct 27, 1982	Nov	CPOT

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER

AT	+	BAXTER HLTHCARE	100%	N017428	001		Oct	CRLD
----	---	-----------------	------	---------	-----	--	-----	------

STRONTIUM CHLORIDE SR-89INJECTABLE;INJECTION
METASTRON

AP	+	! Q BIOMED	1mCi/ML	N020134	001	Jun 18, 1993	Jan	CAHN
		STRONTIUM CHLORIDE SR-89						
AP		Q BIOMED	1mCi/ML	A075941	001	Jan 06, 2003	Oct	CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

AP		AMRING PHARMS	20MG/ML	A210231	001	Jun 04, 2018	Jan	CAHN
>A>	AP	BRECKENRIDGE	20MG/ML	A212638	001	Oct 09, 2019	Nov	CAHN
AP		DR REDDYS	20MG/ML	A210698	001	Aug 02, 2019	Jul	NEWA
>D>	AP	GPP	20MG/ML	A212638	001	Oct 09, 2019	Nov	CAHN
AP			20MG/ML	A212638	001	Oct 09, 2019	Sep	NEWA

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

>D>	+	ALLERGAN	1GM/10ML	N019183	001	Dec 16, 1993	Nov	CFTG
>A>	AB	+	1GM/10ML	N019183	001	Dec 16, 1993	Nov	CFTG
>A>		SUCRALFATE						
>A>	AB	AMNEAL PHARMS LLC	1GM/10ML	A209356	001	Dec 02, 2019	Nov	NFTG

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	ANDA REPOSITORY	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Sep CAHN
AP	! MYLAN LABS LTD	80MG/ML;16MG/ML	A206607	001	Aug 30, 2017	Aug CHRS
AP	SOMERSET	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Oct CAHN
AP	SOMERSET THERAPS LLC	80MG/ML;16MG/ML	A212231	001	Jun 26, 2019	Jun NEWA
	@ TEVA PHARMS USA	80MG/ML;16MG/ML	A073303	001	Oct 31, 1991	Aug DISC

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	ANI PHARMS INC	200MG/5ML;40MG/5ML	A077612	001	Nov 13, 2006	Oct CMFD
----	----------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

>D>						
>D>	AB	HERITAGE PHARMA	800MG;160MG	A070037	001	Jun 02, 1987
>A>		@	800MG;160MG	A070037	001	Jun 02, 1987
	AB		800MG;160MG	A070037	001	Jun 02, 1987
>D>						
>D>	AB	HERITAGE PHARMA	400MG;80MG	A070030	001	Jun 02, 1987
>A>		@	400MG;80MG	A070030	001	Jun 02, 1987
	AB		400MG;80MG	A070030	001	Jun 02, 1987

SUMATRIPTAN

SPRAY; NASAL

TOSYMRA

+	!	DR REDDYS LABS LTD	10MG/SPRAY	N210884	001	Jan 25, 2019	Jan NEWA
+	!	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019	Sep CAHN
+	!		10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

	@	MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Sep DISC
	@	PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr DISC
	@	ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr CAHN

POWDER; NASAL

ONZETRA XSAIL

+	!	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep CDJR
+	!	CURRAX	EQ 11MG BASE	N206099	001	Jan 27, 2016	Sep CAHN

SOLUTION; SUBCUTANEOUS

ZEMBRACE SYMTOUCH

+		UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul CAHN
---	--	-------------------	---------------------------------------	---------	-----	--------------	----------

TACROLIMUS

OINTMENT; TOPICAL

TACROLIMUS

AB		ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan NEWA
AB			0.1%	A211688	002	Jan 31, 2019	Jan NEWA

TADALAFIL

TABLET; ORAL

ALYQ

AB2		TEVA PHARMS USA	20MG	A209942	001	Feb 05, 2019	Jan NEWA
		TADALAFIL					
AB		ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar NEWA
AB			5MG	A209167	002	Mar 26, 2019	Mar NEWA
AB1			20MG	A209167	004	Mar 26, 2019	Mar NEWA
AB		AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar NEWA
AB			5MG	A209654	002	Mar 26, 2019	Mar NEWA
AB			10MG	A209654	003	Mar 26, 2019	Mar NEWA
AB1			20MG	A209654	004	Mar 26, 2019	Mar NEWA
AB2			20MG	A210392	001	Feb 05, 2019	Jan NEWA
AB		ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar NEWA
AB			5MG	A204809	002	Mar 26, 2019	Mar NEWA
AB			10MG	A204809	003	Mar 26, 2019	Mar NEWA
AB1			20MG	A204809	004	Mar 26, 2019	Mar NEWA
AB		AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar NEWA
AB			5MG	A209744	002	Mar 26, 2019	Mar NEWA
AB			10MG	A209744	003	Mar 26, 2019	Mar NEWA

TABLET;ORAL							
TADALAFIL							
AB1		20MG	A209744	004	Mar 26, 2019	Mar	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan	NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209539	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210069	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210145	001	Feb 05, 2019	Jan	NEWA
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209908	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209908	003	Mar 26, 2019	Mar	NEWA
AB2		20MG	A209907	001	Feb 05, 2019	Jan	NEWA
AB1		20MG	A209908	004	Mar 26, 2019	Mar	NEWA
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210567	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210567	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210567	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A210572	001	Feb 05, 2019	Jan	NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Sep	NEWA
AB		5MG	A207244	002	Oct 07, 2019	Sep	NEWA
AB		10MG	A207244	003	Oct 07, 2019	Sep	NEWA
AB1		20MG	A207244	004	Oct 07, 2019	Sep	NEWA
AB2		20MG	A207290	001	Oct 16, 2019	Sep	NEWA
AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr	NEWA
AB		5MG	A206957	001	Apr 29, 2019	Apr	NEWA
AB		10MG	A206956	002	Apr 29, 2019	Apr	NEWA
AB1		20MG	A206956	003	Apr 29, 2019	Apr	NEWA
AB	QILU	2.5MG	A210420	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A210420	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A210420	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A210420	004	Mar 26, 2019	Mar	NEWA
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar	NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar	NEWA
AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar	NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar	NEWA
	@ WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Sep	DISC
AB		2.5MG	A205885	001	Mar 29, 2019	Mar	NEWA
	@	5MG	A205885	002	Mar 29, 2019	Sep	DISC
AB		5MG	A205885	002	Mar 29, 2019	Mar	NEWA
	@	10MG	A205885	003	Mar 29, 2019	Sep	DISC
AB		10MG	A205885	003	Mar 29, 2019	Mar	NEWA
	@	20MG	A205885	004	Mar 29, 2019	Sep	DISC
AB1		20MG	A205885	004	Mar 29, 2019	Mar	NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar	NEWA

TAFAMIDISCAPSULE;ORAL
VYNDAMAX

+! FOLDRX PHARMS 61MG N212161 001 May 03, 2019 May NEWA

TAFAMIDIS MEGGLUMINECAPSULE;ORAL
VYNDAQEL

+! FOLDRX PHARMS 20MG N211996 001 May 03, 2019 May NEWA

TAFLUPROSTSOLUTION/DROPS;OPHTHALMIC
TAFLUPROST

AT MICRO LABS 0.0015% A209051 001 Aug 19, 2019 Aug NFTG

AT ZIOPTAN
+! OAK PHARMS INC 0.0015% N202514 001 Feb 10, 2012 Aug CFTGTAMOXIFEN CITRATESOLUTION;ORAL
SOLTAMOX

FORTOVIA EQ 20MG BASE/10ML N021807 001 Oct 29, 2005 Aug CAHN

TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

AB ANBISON LAB 0.4MG A211885 001 Oct 17, 2019 Oct NEWA

>D> AB MYLAN 0.4MG A090408 001 Apr 27, 2010 Nov DISC

>A> @ 0.4MG A090408 001 Apr 27, 2010 Nov DISC

TAZAROTENECREAM;TOPICAL
TAZAROTENE

@ FOUGERA PHARMS INC 0.1% A211175 001 Jan 28, 2019 Aug DISC

AB 0.1% A211175 001 Jan 28, 2019 May CPOT

AB 1% A211175 001 Jan 28, 2019 Jan NEWA

TECHNETIUM TC-99M DISOFENIN KITINJECTABLE;INJECTION
HEPATOLITE

@ PHARMALUCENCE N/A N018467 001 Mar 16, 1982 Aug DISC

TECHNETIUM TC-99M MERTIATIDE KITINJECTABLE;INJECTION
TECHNESCAN MAG3

AP +! CURIUM N/A N019882 001 Jun 15, 1990 Jul CFTG

+! N/A N019882 001 Jun 15, 1990 Jan CAHN

TECHNETIUM TC99M MERTIATIDE KIT
AP PHARMALUCENCE N/A A208994 001 Jul 12, 2019 Jul NFTGTECHNETIUM TC-99M OXIDRONATE KITINJECTABLE;INJECTION
TECHNESCAN

+! CURIUM N/A N018321 001 Jan CAHN

TECHNETIUM TC-99M PENTETATE KITINJECTABLE;INJECTION
DRAXIMAGE DTPA

+! JUBILANT DRAXIMAGE N/A N018511 001 Dec 29, 1989 Sep CTNA

TECHNETIUM TC-99M PYROPHOSPHATE KITINJECTABLE;INJECTION
TECHNESCAN PYP KIT

AP CURIUM N/A N017538 001 Jan CAHN

TECHNETIUM TC-99M RED BLOOD CELL KITINJECTABLE;INJECTION
ULTRATAG

+! CURIUM N/A N019981 001 Jun 10, 1991 Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS
ULTRA-TECHNEKOW FM

+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan CAHN
@		0.25-3 CI/GENERATOR	N017243	002		Jan CAHN

SOLUTION; INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

+	@ GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Feb DISC
---	-----------------	----------------------	---------	-----	--------------	----------

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM

+	@ ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002	Aug CAHN
+	!	EQ 6MG BASE	N021200	002	Jul 24, 2002	Sep CMFD
+	@	EQ 6MG BASE	N021200	002	Jul 24, 2002	Aug CAHN
+	@ US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jul CRLD
+	@	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jul CRLD

TELMISARTAN

TABLET; ORAL
TELMISARTAN

	@ CIPLA	20MG	A078710	001	Jan 08, 2014	Jun DISC
AB		20MG	A078710	001	Jan 08, 2014	Feb CAHN
	@	40MG	A078710	002	Jan 08, 2014	Feb CAHN
	@	80MG	A078710	003	Jan 08, 2014	Feb CAHN
	@ HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Aug DISC
AB		20MG	A207843	001	Feb 19, 2019	Feb NEWA
	@	40MG	A207843	002	Feb 19, 2019	Aug DISC
AB		40MG	A207843	002	Feb 19, 2019	Feb NEWA
	@	80MG	A207843	003	Feb 19, 2019	Aug DISC
AB		80MG	A207843	003	Feb 19, 2019	Feb NEWA
AB	INVENTIA	20MG	A205150	001	Oct 30, 2015	Aug CAHN
AB		40MG	A205150	002	Oct 30, 2015	Aug CAHN
AB		80MG	A205150	003	Oct 30, 2015	Aug CAHN
	@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar DISC
	@	40MG	A207016	002	Oct 03, 2017	Mar DISC
	@	80MG	A207016	003	Oct 03, 2017	Mar DISC
	@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb DISC

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

@	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan DISC
@		20MG	A204159	002	Jul 05, 2018	Jan DISC
@		100MG	A204159	003	Jul 05, 2018	Jan DISC
@		140MG	A204159	004	Jul 05, 2018	Jan DISC
@		180MG	A204159	005	Jul 05, 2018	Jan DISC
@		250MG	A204159	006	Jul 05, 2018	Jan DISC
@	LANNETT CO INC	5MG	A203898	001	Feb 10, 2016	Oct DISC
@		20MG	A203898	002	Feb 10, 2016	Oct DISC
@		100MG	A203898	003	Feb 10, 2016	Oct DISC
@		140MG	A203898	004	Feb 10, 2016	Oct DISC
@		180MG	A203898	005	Feb 10, 2016	Oct DISC
@		250MG	A203898	006	Feb 10, 2016	Oct DISC

TEMSIROLIMUS

SOLUTION; INTRAVENOUS
TEMSIROLIMUS

AP	GLAND PHARMA LTD	25MG/ML (25MG/ML)	A207383	001	Aug 16, 2019	Aug NEWA
----	------------------	-------------------	---------	-----	--------------	----------

TENAPANOR HYDROCHLORIDE

TABLET; ORAL
IBSRELA

+	!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Sep NEWA
---	---	-------------	--------------	---------	-----	--------------	----------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL
TENOFOVIR DISOPROXIL FUMARATE

>D>	@	APOTEX	300MG	A206481	001	Jul 26, 2018	Nov CAHN
	@		300MG	A206481	001	Jul 26, 2018	Jan DISC
>A>	@	CHARTWELL	300MG	A206481	001	Jul 26, 2018	Nov CAHN

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun CAHN
AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun CAHN
	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar CAHN
AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun CAHN
AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun CAHN
AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun CAHN
AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

>D>	@ APOTEX	EQ 250MG BASE	A078199	001	Jul 02, 2007	Nov CAHN
>A>	@ CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007	Nov CAHN
AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May CAHN

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

	@ DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May CAHN
--	-------------	--------	---------	-----	--------------	----------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

BX	+! FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May CAHN
	SUPPOSITORY; VAGINAL					
	TERCONAZOLE					
AB	! PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May CAHN

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AB	ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr NEWA
AB		14MG	A209572	002	Apr 19, 2019	Apr NEWA
	@ AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb DISC
	@	14MG	A209613	002	Sep 28, 2018	Feb DISC
	@ APOTEX	7MG	A209601	001	Nov 02, 2018	Jan DISC
	@	14MG	A209601	002	Nov 02, 2018	Jan DISC
	@ AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb DISC
	@	14MG	A209638	002	Oct 26, 2018	Feb DISC
	@ MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Oct DISC
AB		7MG	A209623	001	Apr 24, 2019	Apr NEWA
	@	14MG	A209623	002	Apr 24, 2019	Oct DISC
AB		14MG	A209623	002	Apr 24, 2019	Apr NEWA
	@ TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar DISC
	@	14MG	A209700	002	Sep 04, 2018	Mar DISC
	@ WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb DISC
	@	14MG	A209549	002	Jul 27, 2018	Feb DISC
	@ ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May DISC
	@	14MG	A209668	002	Nov 30, 2018	May DISC

TERIPARATIDE RECOMBINANT HUMAN

SOLUTION; SUBCUTANEOUS

BONSITY

>A>	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Nov CAHN
>D>	PFENEX INC	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Nov CAHN
		0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Oct NEWA

TESTOSTERONE

GEL;TRANSDERMAL					
TESTOSTERONE					
@ PAR PHARM		25MG/2.5GM PACKET	A076744	001	May 23, 2007 Mar DISC
GEL, METERED;TRANSDERMAL					
TESTOSTERONE					
AB	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019 Mar NEWA
AB	AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019 Mar NEWA
AB	DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019 Mar NEWA
AB	LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019 Mar NEWA
AB	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019 Sep NEWA
TABLET, EXTENDED RELEASE;BUCCAL					
STRIANT					
+ @ AUXILIUM PHARMS LLC		30MG	N021543	001	Jun 19, 2003 Jul DISC

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION					
TESTOSTERONE CYPIONATE					
@ MYLAN INSTITUTIONAL		200MG/ML	A040652	001	Dec 11, 2006 Mar DISC
AO	WILSHIRE PHARMS INC	200MG/ML	A206368	001	Apr 24, 2019 Apr NEWA

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL					
JATENZO					
+ CLARUS		158MG	N206089	001	Mar 27, 2019 Mar NEWA
+		198MG	N206089	002	Mar 27, 2019 Mar NEWA
+!		237MG	N206089	003	Mar 27, 2019 Mar NEWA

TETRABENAZINE

TABLET;ORAL					
TETRABENAZINE					
AB	MYLAN	12.5MG	A207682	001	Jan 31, 2017 Jul CAHN
AB		25MG	A207682	002	Jan 31, 2017 Jul CAHN

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC					
TETRACAINE HYDROCHLORIDE					
BAUSCH		0.5%	N210821	001	Mar 12, 2019 Apr CAHN
VALEANT PHARMS		0.5%	N210821	001	Mar 12, 2019 Mar NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL					
ACHROMYCIN V					
AB	+ AVET	250MG	N050278	003	Oct CAHN
AB	+!	500MG	N050278	001	Oct CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION					
THALLOUS CHLORIDE TL 201					
AP	+! CURIUM	1mCi/ML	N018150	001	Jan CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL					
THEOPHYLLINE					
AB	! HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990 Feb CAHN
AB	!	200MG	A089808	001	Apr 30, 1990 Feb CAHN
AB		300MG	A089763	001	Apr 30, 1990 Feb CAHN
	@	450MG	A081236	001	Nov 09, 1992 Feb CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL					
THIORIDAZINE HYDROCHLORIDE					
MYLAN		10MG	A088004	002	Mar 15, 1983 Oct CTEC
		25MG	A088004	003	Mar 15, 1983 Oct CTEC
		50MG	A088004	004	Mar 15, 1983 Oct CTEC
!		100MG	A088004	001	Nov 18, 1983 Oct CTEC
@ SUN PHARM INDUSTRIES		10MG	A089953	004	Aug 01, 1986 Oct DISC
@		25MG	A089953	003	Aug 01, 1986 Oct DISC
@		50MG	A089953	002	Aug 01, 1986 Oct DISC
@		100MG	A089953	001	Oct 07, 1988 Oct DISC

THIOTHIXENECAPSULE;ORAL
THIOTHIXENE

AB	MYLAN	1MG	A071093	002	Jun 23, 1987	Mar CTEC
AB		2MG	A071093	003	Jun 23, 1987	Mar CTEC
AB		5MG	A071093	004	Jun 23, 1987	Jul CHRS
AB	!	5MG	A071093	004	Jun 23, 1987	Mar CTEC
AB		10MG	A071093	001	Jun 23, 1987	Mar CTEC
AB	NOVITIUM PHARMA	1MG	A211642	001	Apr 05, 2019	Mar NEWA
AB		2MG	A211642	002	Apr 05, 2019	Mar NEWA
AB	!	5MG	A211642	003	Apr 05, 2019	Jul CHRS
AB		5MG	A211642	003	Apr 05, 2019	Mar NEWA
AB		10MG	A211642	004	Apr 05, 2019	Mar NEWA

THIOTHIXENE HYDROCHLORIDECONCENTRATE;ORAL
THIOTHIXENE HYDROCHLORIDE INTENSOL
@ HIKMA EQ 5MG BASE/ML

A073494 001 Jun 30, 1992 Sep CAHN

TICAGRELORTABLET;ORAL
BRILINTA

	+ ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jun CTEC
	TICAGRELOR					
	@ AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jun DISC
AB		90MG	A208531	001	Jan 23, 2019	Jan NEWA
AB	HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan NEWA
	@ WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb DISC
	@	90MG	A208390	002	Sep 04, 2018	Feb DISC

TICLOPIDINE HYDROCHLORIDETABLET;ORAL
TICLOPIDINE HYDROCHLORIDE
@ SUN PHARM INDS INC 250MG

A075526 001 Sep 26, 2002 Oct DISC

TIGECYCLINEPOWDER;INTRAVENOUS
TIGECYCLINE

AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Jul CMFD
	@	50MG/VIAL	N211158	001	Aug 02, 2018	Feb DISC
AP	AUROBINDO PHARMA LTD	50MG/VIAL	A206335	001	Jun 11, 2019	May NEWA
AP	XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019	Oct NEWA

TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT	+ VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan CAHN
AT1	+ TIMOPTIC IN OCUDOSE	EQ 0.5% BASE	N018086	002		Jan CAHN
	+! VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan CAHN
	+! EQ 0.5% BASE		N019463	002	Nov 05, 1986	Jan CAHN
	TIMOPTIC IN OCUDOSE					
	TABLET;ORAL					
	BLOCADREN					
	+ @ MERCK	5MG	N018017	001		Apr CRLD
	+ @	10MG	N018017	002		Apr CRLD
	+ @	20MG	N018017	004		Apr CRLD
	TIMOLOL MALEATE					
	@ ANI PHARMS INC	5MG	A072917	001	Jul 31, 1991	Sep CAHN
	@	10MG	A072918	001	Jul 31, 1991	Sep CAHN
	@	20MG	A072919	001	Jul 31, 1991	Sep CAHN
AB	ELYSIUM	5MG	A207556	001	May 02, 2019	Sep CAHN
AB		10MG	A207556	002	May 02, 2019	Sep CAHN
AB		20MG	A207556	003	May 02, 2019	Sep CAHN
AB	INVATECH PHARMA	5MG	A207556	001	May 02, 2019	Apr NEWA
AB		10MG	A207556	002	May 02, 2019	Apr NEWA
AB		20MG	A207556	003	May 02, 2019	Apr NEWA
AB	MYLAN	5MG	A072668	002	Jun 08, 1990	Apr CTEC
AB		10MG	A072668	003	Jun 08, 1990	Apr CTEC
AB	!	20MG	A072668	001	Jun 08, 1990	Apr CTEC

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL
THIOLA EC

+	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Jun NEWA
+	!	300MG	N211843	002	Jun 28, 2019	Jun NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar NEWA
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar NEWA
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar NEWA
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar NEWA
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar NEWA
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar NEWA
AB	NOVAST LABS	EQ 2MG BASE	A210267	001	Mar 12, 2019	Sep CAHN
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Sep CAHN
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Sep CAHN
AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb NEWA
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb NEWA
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan NEWA
	@ ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002	May CAHN
AB		EQ 2MG BASE	A076284	001	Jul 03, 2002	Sep CAHN
	@	EQ 2MG BASE	A076371	001	Apr 09, 2003	May CAHN
	@	EQ 4MG BASE	A076283	002	Jul 12, 2002	May CAHN
AB		EQ 4MG BASE	A076284	002	Jul 03, 2002	Sep CAHN
	@	EQ 4MG BASE	A076371	002	Apr 09, 2003	May CAHN
	@ PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar DISC
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar DISC

TOBRAMYCIN

SOLUTION;INHALATION
BETHKIS

	+	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Jul CTEC
AN	+	!	300MG/4ML	N201820	001	Oct 12, 2012	Jun CFTG

TOBRAMYCIN

AN	DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar CMFD
	@	300MG/5ML	A207080	001	Jul 09, 2018	Jan DISC
	@ TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
AN		300MG/4ML	A210915	001	Jun 26, 2019	Jun NFTG

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr NEWA
----	--------------------	------	---------	-----	--------------	----------

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	May CHRS
---	-------------	-------------	---------	-----	--------------	----------

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	COSETTE	100MG	N018894	001	Nov 02, 1984	Jun CAHN
@		250MG	N018894	002	Nov 02, 1984	Jun CAHN
@		500MG	N018894	003	Nov 02, 1984	Jun CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar CAHN
	@		200MG	N020697	002	Jan 29, 1998	Mar CAHN

TOLCAPONE

AB	KINEDEXE UK	100MG	A210095	001	Aug 01, 2019	Jul NEWA
AB	MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep CAHN
AB	NOVAST LABS	100MG	A208937	001	Aug 07, 2018	Sep CAHN

TOLMETIN SODIUM

CAPSULE;ORAL

TOLECTIN DS

>D>	@ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001		Nov	CRLD
>A>	+ @	EQ 400MG BASE	N018084	001		Nov	CRLD

TOLMETIN SODIUM

@ ANI PHARMS INC

@

EQ 400MG BASE

EQ 400MG BASE

A073308	001	Jan 24, 1992	May	CAHN
A073519	001	May 29, 1992	Sep	CAHN

TABLET;ORAL

TOLECTIN

>D>	@ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001		Nov	CRLD
>A>	+ @	EQ 200MG BASE	N017628	001		Nov	CRLD

TOLECTIN 600

>D>	@ ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989	Nov	CRLD
>A>	+ @	EQ 600MG BASE	N017628	002	Mar 08, 1989	Nov	CRLD

TOLMETIN SODIUM

@ ANI PHARMS INC

EQ 600MG BASE

A073527	001	Jun 30, 1992	May	CAHN
---------	-----	--------------	-----	------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB	INVENTIA HLTHCARE	2MG	A204562	001	Aug 19, 2019	Aug	NEWA
AB		4MG	A204562	002	Aug 19, 2019	Aug	NEWA

TOLVAPTAN

TABLET;ORAL

JYNARQUE

+!	OTSUKA PHARM CO LTD	45MG
+		90MG

N204441	003	Apr 23, 2018	Jun	CHRS
N204441	005	Apr 23, 2018	Jun	CHRS

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QUDEXY XR

BC	+ UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb	CTEC
BC	+	50MG	N205122	002	Mar 11, 2014	Feb	CTEC
BC	+	100MG	N205122	003	Mar 11, 2014	Feb	CTEC
BC	+!	200MG	N205122	005	Mar 11, 2014	Feb	CTEC

TROKENDI XR

BC	+! SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Apr	CTEC
----	--------------------	-------	---------	-----	--------------	-----	------

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

>D>	AP	@ FRESSENIUS KABI USA	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010	Oct	CAHN
		HONG KONG	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Nov	CAHN
>A>	AP	MEITHEAL	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Nov	CAHN
		@ MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Oct	DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB	RUBICON	50MG	A208708	001	Jun 28, 2019	Jun	NEWA	
AB		100MG	A208708	002	Jun 28, 2019	Jun	NEWA	
>D>	AB	SPECGX LLC	50MG	A075983	001	Jun 25, 2002	Nov	DISC
>A>	@	50MG	A075983	001	Jun 25, 2002	Nov	DISC	
	@ SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002	Oct	DISC	
AB	UNICHEM LABS LTD	50MG	A211825	001	Aug 09, 2019	Jul	NEWA	

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB1	PAR PHARM INC	100MG	A078783	001	Nov 13, 2009	Nov	DISC
>A>	@	100MG	A078783	001	Nov 13, 2009	Nov	DISC	
>D>	AB1		200MG	A078783	002	Nov 13, 2009	Nov	DISC
>A>	@	200MG	A078783	002	Nov 13, 2009	Nov	DISC	
>D>	AB1		300MG	A078783	003	Sep 20, 2011	Nov	DISC
>A>	@	300MG	A078783	003	Sep 20, 2011	Nov	DISC	

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
TARKA

+ @ ABBVIE	1MG;240MG	N020591	003	Oct 22, 1996	Aug DISC
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE					
GLENMARK GENERICS	1MG;240MG	A079135	004	Aug 30, 2010	Aug CTEC

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

AP	APOLLO PHARMS INC	100MG/ML	A212676	001	Jul 17, 2019	Jul NEWA
AP	CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jul NEWA
+	EXELA PHARMA SCS LLC	10MG/ML	N212020	001	Apr 15, 2019	Apr NEWA
AP	MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Mar CAHN
SOLUTION;INTRAVENOUS						
TRANEXAMIC ACID						
+	EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019	May CPOT

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	PAR STERILE PRODUCTS	1MG/ML	A209382	001	Sep 24, 2019	Sep NEWA
AP		2.5MG/ML	A209382	002	Sep 24, 2019	Sep NEWA
AP		5MG/ML	A209382	003	Sep 24, 2019	Sep NEWA
AP		10MG/ML	A209382	004	Sep 24, 2019	Sep NEWA
AP	TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Sep NEWA
AP		2.5MG/ML	A206648	002	Sep 26, 2019	Sep NEWA
AP		5MG/ML	A206648	003	Sep 26, 2019	Sep NEWA
AP		10MG/ML	A206648	004	Sep 26, 2019	Sep NEWA

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL
ORENITRAM

+	UNITED THERAP	EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb CHRS
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb CHRS

TRETINOIN

CREAM;TOPICAL
TRETINOIN

AB1	TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan NEWA
AB		0.1%	A211645	001	Jan 22, 2019	Jan NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	MLV	0.025%	A040671	001	Jun 09, 2006	Sep CAHN
AT		0.1%	A040671	002	Jun 09, 2006	Sep CAHN
AT	SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	May CAHN
AT		0.1%	A040671	002	Jun 09, 2006	May CAHN
AT	STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan NEWA
AT		0.1%	A210346	002	Feb 11, 2019	Jan NEWA
AT		0.5%	A210346	003	Feb 11, 2019	Jan NEWA

INJECTABLE;INJECTION
KENALOG-80

+	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019	Apr NEWA
TRIAMCINOLONE ACETONIDE						
AB	TEVA PHARMS USA	40MG/ML	A209852	001	Oct 05, 2018	Jul CMFD
@		40MG/ML	A209852	001	Oct 05, 2018	Mar DISC

LOTION;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	ALLIED	0.1%	A040672	002	Dec 13, 2006	Sep CAHN
AT	SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	May CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

>A>	AT	ENCUBE	0.05%	A212384	001	Nov 29, 2019	Nov NEWA
		TRIAMCINOLONE ACETONIDE	IN ABSORBASE				
>D>	!	CMP PHARMA INC	0.05%	A089595	001	Mar 23, 1995	Nov CTEC
>A>	AT	!	0.05%	A089595	001	Mar 23, 1995	Nov CTEC

TRIAMTERENE

CAPSULE;ORAL						
DYRENIUM						
AB	+	CONCORDIA	50MG	N013174	001	Aug CFTG
AB	+	!	100MG	N013174	002	Aug CFTG
TRIAMTERENE						
AB		AGNITIO	50MG	A211581	001	Aug 19, 2019 Aug NFTG
AB			100MG	A211581	002	Aug 19, 2019 Aug NFTG

TRICLABENDAZOLE

TABLET;ORAL						
EGATEN						
+	!	NOVARTIS	250MG	N208711	001	Feb 13, 2019 Feb NEWA

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL						
CLOVIQUE						
>A>						
>A>	AB	KADMON PHARMS LLC	250MG	A209731	001	Oct 21, 2019 Nov CTNA
		SYPRINE				
	AB	+	!	BAUSCH	250MG	N019194 001 Nov 08, 1985 Sep CAHN
		TRIENTINE HYDROCHLORIDE				
	AB	AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019 Feb NEWA
	AB	DR REDDYS LABS LTD	250MG	A211076	001	Jul 03, 2019 Jun NEWA
	AB	KADMON PHARMS LLC	250MG	A209415	001	Sep 16, 2019 Sep NEWA
>D>	AB		250MG	A209731	001	Oct 21, 2019 Nov CTNA
	AB		250MG	A209731	001	Oct 21, 2019 Oct NEWA
	AB	MSN LABS PVT LTD	250MG	A211134	001	May 22, 2019 May NEWA
	AB	PAR PHARM INC	250MG	A210096	001	Sep 25, 2019 Sep NEWA
	AB	ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019 Apr NEWA

TRIFAROTENE

CREAM;TOPICAL						
AKLIEF						
+	!	GALDERMA R AND D	0.005%	N211527	001	Oct 04, 2019 Oct NEWA

TRIMETHADIONE

TABLET;ORAL						
TRIDIONE						
+	@	ABBVIE	150MG	N005856	009	Jul DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL						
TRIMETHOBENZAMIDE HYDROCHLORIDE						
AB		LUPIN	300MG	A076546	001	Aug 20, 2003 Feb CAHN
INJECTABLE;INJECTION						
TIGAN						
+	!	PAR STERILE PRODUCTS	100MG/ML	N017530	001	May CTEC

TRIMIPRAMINE MALEATE

CAPSULE;ORAL						
SURMONTIL						
+	@	ODYSSEY PHARMS	EQ 25MG BASE	N016792	001	Jul DISC
+	@		EQ 50MG BASE	N016792	002	Jul DISC
+	@		EQ 100MG BASE	N016792	003	Sep 15, 1982 Jul DISC
TRIMIPRAMINE MALEATE						
AB	!	CROSSMEDIKA SA	EQ 50MG BASE	A208127	002	Apr 15, 2016 Jul CHRS

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL						
RINVOQ						
>D>	+	!	ABBVIE INC	EQ 15MG BASE	N211675	001 Aug 16, 2019 Nov CPOT
>A>	+	!		15MG	N211675	001 Aug 16, 2019 Nov CPOT
	+	!		EQ 15MG BASE	N211675	001 Aug 16, 2019 Aug NEWA

URSODIOL

CAPSULE;ORAL						
URSODIOL						
AB		AMNEAL PHARMS CO	300MG	A211301	001	Oct 16, 2018 Jun CMFD
	@		300MG	A211301	001	Oct 16, 2018 Apr DISC
AB		EYWA PHARMA	300MG	A212452	001	Oct 30, 2019 Oct NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

@ WATSON LABS INC EQ 500MG BASE
@ EQ 1GM BASE

A090370 001 Mar 16, 2011 Apr DISC
A090370 002 Mar 16, 2011 Apr DISC

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

+ @ ABBVIE EQ 100MG BASE/ML
VALPROATE SODIUM

N020593 001 Dec 30, 1996 Apr DISC

AP ! HIKMA FARMACEUTICA EQ 100MG BASE/ML

A078523 001 Feb 17, 2010 Apr CHRS

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

+ @ ABBVIE 250MG
VALPROIC ACID

N018081 001 Oct DISC

AB ! BIONPHARMA INC 250MG

A073484 001 Jun 29, 1993 Oct CHRS

AB NOVELGENIX THERAPS 250MG

A207611 001 Aug 05, 2019 Jul NEWA

@ UPSHER SMITH LABS 250MG

A070631 001 Jun 11, 1987 Jul CAHN

SYRUP; ORAL

DEPAKENE

+ @ ABBVIE 250MG/5ML
VALPROIC ACID

N018082 001 Aug DISC

@ APOTEX 250MG/5ML

A077105 001 Jul 29, 2005 Oct CAHN

@ PD PARTNERS 250MG/5ML

A077105 001 Jul 29, 2005 May CAHN

AA ! PHARM ASSOC 250MG/5ML

A075379 001 Dec 15, 2000 Aug CHRS

VALRUBICIN

SOLUTION; INTRAVESICAL

VALRUBICIN

AO CUSTOPHARM INC 40MG/ML

A206430 001 Apr 19, 2019 Apr NFTG

VALSTAR PRESERVATIVE FREE

AO +! ENDO PHARM 40MG/ML

N020892 001 Sep 25, 1998 Apr CFTG

VALSARTAN

TABLET; ORAL

VALSARTAN

AB ALKEM LABS LTD 40MG

A205536 001 Mar 12, 2019 Feb NEWA

AB 80MG

A205536 002 Mar 12, 2019 Feb NEWA

AB 160MG

A205536 003 Mar 12, 2019 Feb NEWA

AB 320MG

A205536 004 Mar 12, 2019 Feb NEWA

>D> AB TORRENT 40MG

A202728 001 Jan 05, 2015 Nov DISC

>A> @ 40MG

A202728 001 Jan 05, 2015 Nov DISC

>D> AB 80MG

A202728 002 Jan 05, 2015 Nov DISC

>A> @ 80MG

A202728 002 Jan 05, 2015 Nov DISC

>D> AB 160MG

A202728 003 Jan 05, 2015 Nov DISC

>A> @ 160MG

A202728 003 Jan 05, 2015 Nov DISC

>D> AB 320MG

A202728 004 Jan 05, 2015 Nov DISC

>A> @ 320MG

A202728 004 Jan 05, 2015 Nov DISC

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

AB ORIENT PHARMA CO LTD EQ 125MG BASE

A210729 001 Apr 29, 2019 Apr NEWA

AB EQ 250MG BASE

A210729 002 Apr 29, 2019 Apr NEWA

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983 Jul CMFD

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>D> AP EMCURE PHARMS LTD EQ 500MG BASE/VIAL

A202275 001 Oct 31, 2013 Nov DISC

>A> @ EQ 500MG BASE/VIAL

A202275 001 Oct 31, 2013 Nov DISC

>D> AP EQ 1GM BASE/VIAL

A202275 002 Oct 31, 2013 Nov DISC

>A> @ EQ 1GM BASE/VIAL

A202275 002 Oct 31, 2013 Nov DISC

>D> AP EQ 10GM BASE/VIAL

A202464 001 Oct 09, 2013 Nov DISC

>A> @ EQ 10GM BASE/VIAL

A202464 001 Oct 09, 2013 Nov DISC

>D> AP EQ 5GM BASE/VIAL

A202274 001 Oct 31, 2013 Nov DISC

>A> @ EQ 5GM BASE/VIAL

A202274 001 Oct 31, 2013 Nov DISC

SOLUTION; INTRAVENOUS
VANCOMYCIN HYDROCHLORIDE

+	!	XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb NEWA
+	!		EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb NEWA
+	!		EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb NEWA
+	!		EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb NEWA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

		VARDENAFIL HYDROCHLORIDE					
		@ AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018	Apr DISC
		@	10MG	A210738	002	Oct 31, 2018	Apr DISC
		@	20MG	A210738	003	Oct 31, 2018	Apr DISC
AB		MACLEODS PHARMS LTD	2.5MG	A204632	001	Oct 22, 2019	Oct NEWA
AB			5MG	A204632	002	Oct 22, 2019	Oct NEWA
AB			10MG	A204632	003	Oct 22, 2019	Oct NEWA
AB			20MG	A204632	004	Oct 22, 2019	Oct NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS
VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar CDFR
+	!		200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar CDFR

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP		HIKMA	10MG/VIAL	A203725	001	Jul 30, 2019	Jul NEWA
AP			20MG/VIAL	A203725	002	Jul 30, 2019	Jul NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB		ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019	Jun NEWA
AB			EQ 75MG BASE	A212277	002	Jul 08, 2019	Jun NEWA
AB			EQ 150MG BASE	A212277	003	Jul 08, 2019	Jun NEWA

TABLET; ORAL

		VENLAFAXINE HYDROCHLORIDE					
		@ PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Oct DISC
		@	EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Oct DISC
		@	EQ 50MG BASE	A090027	003	Aug 04, 2010	Oct DISC
		@	EQ 75MG BASE	A090027	004	Aug 04, 2010	Oct DISC
		@	EQ 100MG BASE	A090027	005	Aug 04, 2010	Oct DISC

TABLET, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

AB		CADILA PHARMS LTD	EQ 75MG BASE	A211323	001	Aug 29, 2019	Aug NEWA
AB			EQ 150MG BASE	A211323	002	Aug 29, 2019	Aug NEWA
AB			EQ 225MG BASE	A211323	003	Aug 29, 2019	Aug NEWA
AB		DEXCEL PHARMA	EQ 150MG BASE	A209193	001	Oct 31, 2019	Oct NEWA
AB			EQ 225MG BASE	A209193	002	Oct 31, 2019	Oct NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERAPAMIL HYDROCHLORIDE

>D>	AB	MYLAN	100MG	A078306	001	Aug 09, 2007	Nov DISC
>A>		@	100MG	A078306	001	Aug 09, 2007	Nov DISC
>D>	AB		200MG	A078306	002	Aug 09, 2007	Nov DISC
>A>		@	200MG	A078306	002	Aug 09, 2007	Nov DISC
		@	300MG	A078306	003	Aug 09, 2007	May DISC

VERELAN PM

>D>	AB	+ RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Nov CTEC
>A>		+	100MG	N020943	001	Nov 25, 1998	Nov CTEC
>D>	AB	+	200MG	N020943	002	Nov 25, 1998	Nov CTEC
>A>		+	200MG	N020943	002	Nov 25, 1998	Nov CTEC
		+	300MG	N020943	003	Nov 25, 1998	May CTEC

SOLUTION; INTRAVENOUS
VERAPAMIL HYDROCHLORIDE

AP		ANDA REPOSITORY	5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Sep CAHN
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Sep CAHN
AP		SOMERSET	5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Oct CAHN
AP			10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Oct CAHN

		TABLET;ORAL							
		CALAN							
		+ @ GD SEARLE LLC	80MG	N018817	001	Sep 10, 1984	May	DISC	
>D>	AB	+	120MG	N018817	002	Sep 10, 1984	Nov	DISC	
>A>		+ @	120MG	N018817	002	Sep 10, 1984	Nov	DISC	
	AB	+	120MG	N018817	002	Sep 10, 1984	May	CHRS	
		VERAPAMIL HYDROCHLORIDE							
	AB	!	HERITAGE PHARMS INC 120MG	A071881	001	Apr 05, 1988	May	CHRS	
		<u>VIGABATRIN</u>							
		FOR SOLUTION;ORAL							
		VIGABATRIN							
>A>	AA	INVAGEN PHARMS	500MG/PACKET	A211592	001	Dec 03, 2019	Nov	NEWA	
		VIGADRONE							
	AA	AUCTA	500MG/PACKET	A210196	001	Jun 21, 2018	Jun	CAHN	
	AA	SHANGHAI	500MG/PACKET	A210196	001	Jun 21, 2018	Mar	CAHN	
		<u>VILAZODONE HYDROCHLORIDE</u>							
		TABLET;ORAL							
		VIIBRYD							
	AB	+	ALLERGAN 10MG	N022567	001	Jan 21, 2011	Sep	CFTG	
	AB	+	20MG	N022567	002	Jan 21, 2011	Sep	CFTG	
	AB	+	40MG	N022567	003	Jan 21, 2011	Sep	CFTG	
		VILAZODONE HYDROCHLORIDE							
	AB	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	Sep	NFTG	
	AB		20MG	A208212	002	Sep 30, 2019	Sep	NFTG	
	AB		40MG	A208212	003	Sep 30, 2019	Sep	NFTG	
		<u>VINCRIStINE SULFATE</u>							
		INJECTABLE;INJECTION							
		VINCRIStINE SULFATE PFS							
		!	HOSPIRA 1MG/ML	A071484	001	Apr 19, 1988	Oct	CTEC	
		@	TEVA PHARMS USA 1MG/ML	A075493	001	Sep 01, 1999	Oct	DISC	
		INJECTABLE, LIPOSOMAL;INTRAVENOUS							
		MARQIBO KIT							
		+	ACROTECH 5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Mar	CAHN	
		<u>VINORELBINE TARTRATE</u>							
		INJECTABLE;INJECTION							
		NAVELBINE							
		+	@ PIERRE FABRE EQ 10MG BASE/ML	N020388	001	Dec 23, 1994	Jun	DISC	
		VINORELBINE TARTRATE							
	AP	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	Jul	NEWA	
		@ NOVAST LABS	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	Oct	DISC	
	AP		EQ 10MG BASE/ML	A208997	001	Aug 05, 2019	Sep	CAHN	
		<u>VORAPAXAR SULFATE</u>							
		TABLET;ORAL							
		ZONTIVITY							
		+	TOPROL EQ 2.08MG BASE	N204886	001	May 08, 2014	May	CAHN	
		<u>VORICONAZOLE</u>							
		INJECTABLE;INTRAVENOUS							
		VFEND							
	AP	+	PF PRISM CV 200MG/VIAL	N021267	001	May 24, 2002	May	CDFR	
		VORICONAZOLE							
	AP	ALVOGEN	200MG/VIAL	A206398	001	Mar 23, 2016	Sep	CAHN	
	AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	May	CDFR	
	AP	HAINAN POLY PHARM	200MG/VIAL	A211661	001	Nov 30, 2018	May	CDFR	
	AP	SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May	CDFR	
	AP	ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	May	CDFR	
		POWDER;INTRAVENOUS							
		VORICONAZOLE							
	AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	May	CDFR	
		POWDER;IV (INFUSION)							
		VORICONAZOLE							
	AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb	CTEC	
		TABLET;ORAL							
		VORICONAZOLE							
	AB	APPCO	50MG	A206762	001	May 24, 2016	Feb	CAHN	
	AB		200MG	A206762	002	May 24, 2016	Feb	CAHN	

TABLET;ORAL									
VORICONAZOLE									
AB	CADILA	50MG	A206747	001	May 24, 2016	Apr	CAHN		
AB		200MG	A206747	002	May 24, 2016	Apr	CAHN		
>D>	AB	TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Nov	DISC	
>A>	@	50MG	A091658	001	Apr 06, 2012	Nov	DISC		
>D>	AB	200MG	A091658	002	Apr 06, 2012	Nov	DISC		
>A>	@	200MG	A091658	002	Apr 06, 2012	Nov	DISC		
>A> VOXELOTOR									
>A> TABLET;ORAL									
>A> OXBRYTA									
>A>	+!	GLOBAL BLOOD THERAPS	500MG	N213137	001	Nov 25, 2019	Nov	NEWA	
<u>WARFARIN SODIUM</u>									
TABLET;ORAL									
JANTOVEN									
AB	UPSHER SMITH LABS	1MG	A040416	001	Oct 02, 2003	Jul	CAHN		
AB		2MG	A040416	002	Oct 02, 2003	Jul	CAHN		
AB		2.5MG	A040416	003	Oct 02, 2003	Jul	CAHN		
AB		3MG	A040416	004	Oct 02, 2003	Jul	CAHN		
AB		4MG	A040416	005	Oct 02, 2003	Jul	CAHN		
AB		5MG	A040416	006	Oct 02, 2003	Jul	CAHN		
AB		6MG	A040416	007	Oct 02, 2003	Jul	CAHN		
AB		7.5MG	A040416	008	Oct 02, 2003	Jul	CAHN		
AB		10MG	A040416	009	Oct 02, 2003	Jul	CAHN		
<u>XENON XE-133</u>									
GAS; INHALATION									
XENON XE 133									
	CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982	May	CAHN		
		20mCi/VIAL	N018327	002	Mar 09, 1982	May	CAHN		
>A> <u>ZANUBRUTINIB</u>									
>A> CAPSULE;ORAL									
>A> BRUKINSA									
>A>	+!	BEIGENE	80MG	N213217	001	Nov 14, 2019	Nov	NEWA	
<u>ZIDOVUDINE</u>									
INJECTABLE;INJECTION									
ZIDOVUDINE									
	@	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	DISC	
<u>ZILEUTON</u>									
TABLET, EXTENDED RELEASE;ORAL									
ZILEUTON									
AB	LUPIN LTD	600MG	A211972	001	Nov 05, 2019	Oct	NEWA		
<u>ZINC SULFATE</u>									
SOLUTION;INTRAVENOUS									
ZINC SULFATE									
+!	AM	REAGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Oct	CMS1	
+!			EQ 25MG BASE/5ML (EQ 5 BASE/ML)	N209377	002	Jul 18, 2019	Jul	NEWA	
+!			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Jul	NEWA	
<u>ZIPRASIDONE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
ZIPRASIDONE HYDROCHLORIDE									
	@	CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun	DISC	
AB			EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb	CAHN	
	@		EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun	DISC	
AB			EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb	CAHN	
	@		EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun	DISC	
AB			EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb	CAHN	
	@		EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun	DISC	
AB			EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb	CAHN	

ZOLEDRONIC ACIDINJECTABLE; INTRAVENOUS
RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CDFR
		ZOLEDRONIC					
AP		GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar CDFR
		ZOLEDRONIC ACID					
AP		ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar CDFR
	@	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Jul DISC
AP			EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar CDFR
AP		AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar CDFR
AP		AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar CDFR
AP		APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar CDFR
AP		AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar CDFR
AP			EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar CDFR
AP		BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar CDFR
AP		BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar CDFR
AP			EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar CDFR
AP			EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar CDFR
AP		CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar CDFR
AP		DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	May CDFR
	@		EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Oct DISC
AP			EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar CDFR
AP			EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar CDFR
AP		EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar CDFR
AP			EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar CDFR
AP		FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar CDFR
AP		GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar CDFR
AP			EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar CDFR
AP			EQ 5MG BASE/100ML	A209578	001	Aug 08, 2019	Jul NEWA
AP		HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar CDFR
AP		HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar CDFR
AP			EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar CDFR
AP		INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar CDFR
AP			EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar CDFR
AP		MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar CDFR
AP			EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar CDFR
AP			EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar CDFR
AP		SAGENT PHARMS INC	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar CDFR
	@	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Oct DISC
AP			EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr NEWA
	@	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar CDFR
	@		EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar CDFR
AP		USV	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun CAHN
AP		USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CDFR
		ZOMETA					
	+	@ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar CDFR
AP	+		EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar CDFR
AP	+		EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar CDFR

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

AP		DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar CDFR
		SOLUTION; INTRAVENOUS					
		ZOLEDRONIC ACID					
		HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar CDFR

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

	@	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Oct DISC
	@		5MG	A203772	002	Sep 30, 2015	Oct DISC
AB		ORCHID HLTHCARE	2.5MG	A203726	001	Oct 21, 2019	Oct NEWA
AB			5MG	A203726	002	Oct 21, 2019	Oct NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

	@	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct DISC
	@		5MG	A204336	002	Oct 22, 2015	Oct DISC
AB		MYLAN	2.5MG	A202855	001	Sep 20, 2019	Sep NEWA
AB			5MG	A202855	002	Sep 20, 2019	Sep NEWA

ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL
ZOLPIMIST

+! AYTU 5MG/SPRAY

N022196 001 Dec 19, 2008 Feb CAHN

TABLET; ORAL

ZOLPIDEM TARTRATE

>D>	AB	MYLAN	5MG	A076578	001	Apr 23, 2007	Nov DISC
>A>		@	5MG	A076578	001	Apr 23, 2007	Nov DISC
>D>	AB		10MG	A076578	002	Apr 23, 2007	Nov DISC
>A>		@	10MG	A076578	002	Apr 23, 2007	Nov DISC
		@ STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr CAHN
		@	10MG	A076062	002	Apr 23, 2007	Apr CAHN
		@ SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Oct DISC
		@	10MG	A077359	002	Apr 23, 2007	Oct DISC

TABLET; SUBLINGUAL

ZOLPIDEM TARTRATE

AB ! NOVEL LABS INC 3.5MG

A204299 002 Jun 03, 2015 Mar CHRS

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB		BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr CAHN
AB			50MG	A077813	002	Aug 16, 2006	Apr CAHN
AB			100MG	A077813	003	Aug 16, 2006	Apr CAHN
AB		CELLTRION	25MG	A077636	003	Jul 27, 2006	Aug CAHN
AB			50MG	A077636	002	Jul 27, 2006	Aug CAHN
AB			100MG	A077636	001	Dec 22, 2005	Aug CAHN
>D>	AB	MYLAN	25MG	A077637	001	Dec 22, 2005	Nov DISC
>A>		@	25MG	A077637	001	Dec 22, 2005	Nov DISC
>D>	AB		50MG	A077637	002	Dec 22, 2005	Nov DISC
>A>		@	50MG	A077637	002	Dec 22, 2005	Nov DISC
>D>	AB		100MG	A077637	003	Dec 22, 2005	Nov DISC
>A>		@	100MG	A077637	003	Dec 22, 2005	Nov DISC

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb CAHN
@	650MG	N018060	002		Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019	Apr NEWA
HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Sep CMFD
@	650MG	A207035	001	May 31, 2018	Mar DISC

ADAPALENE

GEL;TOPICAL

ADAPALENE

GLENMARK GENERICS	0.1%	A091314	002	Jul 09, 2019	Jul NEWA
-------------------	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

QUAGEN	5MG/5ML	A212266	001	May 16, 2019	May NEWA
--------	---------	---------	-----	--------------	----------

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ATHEM	5MG/5ML	A091327	001	Oct 17, 2011	Sep CAHN
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb NEWA
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Nov DISC
@	5MG/5ML	A090474	002	Mar 30, 2009	Nov DISC
	5MG/5ML	A090474	002	Mar 30, 2009	Jan CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ATHEM	5MG/5ML	A091327	002	Oct 17, 2011	Sep CAHN
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Nov DISC
@	5MG/5ML	A090474	001	Mar 30, 2009	Nov DISC
	5MG/5ML	A090474	001	Mar 30, 2009	Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007	May CAHN
@	10MG	A078615	004	Dec 28, 2007	May CAHN
@ SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007	Oct DISC
@	10MG	A077499	002	Dec 27, 2007	Oct DISC
CETIRIZINE HYDROCHLORIDE HIVES					
@ SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007	Oct DISC
@	10MG	A077499	004	Dec 27, 2007	Oct DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	May DISC
-------------------	-----------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

CHLORHEXIDINE GLUCONATE

BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr CTNA
	0.75%	N020111	001	Sep 11, 1997	Jan CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan CHRS
---------------	------	---------	-----	--------------	----------

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

! P AND L	1%	A074165	001	Jul 16, 1993	Aug CAHN
-----------	----	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A210676 001 Feb 14, 2019 Jan NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

@ ACTAVIS ELIZABETH 25MG;220MG

A207597 001 Jan 25, 2019 Jul DISC

25MG;220MG

A207597 001 Jan 25, 2019 Jan NEWA

APOTEX 25MG;220MG

A211830 001 Aug 22, 2019 Aug NEWA

@ P AND L 25MG;220MG

A207597 001 Jan 25, 2019 Aug CAHN

PERRIGO R AND D 25MG;220MG

A208499 001 May 10, 2019 Apr NEWA

DOCOSANOL

CREAM; TOPICAL

DOCOSANOL

P AND L 10%

A208754 001 Nov 19, 2018 Aug CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE

A209716 001 Jun 05, 2019 May NEWA

MYLAN EQ 20MG BASE

A212376 001 Oct 16, 2019 Sep NEWA

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS ELIZABETH EQ 20MG BASE

A209202 001 Mar 05, 2019 Apr DISC

EQ 20MG BASE

A209202 001 Mar 05, 2019 Feb NEWA

@ P AND L EQ 20MG BASE

A209202 001 Mar 05, 2019 Aug CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

P AND L 10MG

A075512 001 Jul 26, 2001 Aug CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P AND L 30MG/5ML

A203330 001 Nov 18, 2014 Aug CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

! P AND L 30MG/5ML

A203330 002 Nov 18, 2014 Aug CAHN

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ MYLAN 30MG

A077081 004 Jul 21, 2011 Jul DISC

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ MYLAN 30MG

A077081 005 Jul 21, 2011 Jul DISC

FEXOFENADINE HYDROCHLORIDE ALLERGY

GRANULES INDIA LTD 60MG

A211075 001 Oct 18, 2019 Oct NEWA

180MG

A211075 002 Oct 18, 2019 Oct NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

HI TECH 0.05MG/SPRAY

A208024 001 Apr 17, 2019 Apr NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

AUROBINDO PHARMA LTD 600MG

A210453 001 Oct 21, 2019 Oct NEWA

1.2GM

A210453 002 Oct 21, 2019 Oct NEWA

@ OHM LABS INC 600MG

A209254 001 Jul 16, 2018 Mar DISC

@ 1.2GM

A209254 002 Jul 16, 2018 Mar DISC

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

@ MOBERG PHARMA NORTH 100MG/5ML

N021604 001 Jan 07, 2004 Sep DISC

IBUPROFEN

@ GUARDIAN DRUG 100MG/5ML

A210149 001 Aug 17, 2018 Feb DISC

P AND L 100MG/5ML

A074916 001 Apr 30, 1999 Aug CAHN

TABLET;ORAL

IBUPROFEN

!	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005	Jun CHRS
	IBUPROHM					
@	OHM LABS	200MG	A071214	001	Dec 01, 1986	Oct DISC
	MOTRIN IB					
+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	May CHRS

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+	@ ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Sep DISC
+	!	70% (10.5ML)	N210872	001	Apr 26, 2019	May CMS2

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL A-D

+	!	KRAMER	1%	N020310	001	Oct 10, 1997	Jan CAHN
---	---	--------	----	---------	-----	--------------	----------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Oct CMFD
	ZADITOR					
!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>D>		PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019	Nov DISC
>A>		@	5MG	A211983	001	Mar 28, 2019	Nov DISC
			5MG	A211983	001	Mar 28, 2019	Jul CMS1
			5MG	A211983	001	Mar 26, 2019	Mar NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D>		ACCORD HLTHCARE	1.5MG	A207660	001	May 02, 2019	Nov DISC
>A>		@	1.5MG	A207660	001	May 02, 2019	Nov DISC
			1.5MG	A207660	001	May 02, 2019	Apr NEWA
		ALVOGEN	1.5MG	A202246	001	Jun 05, 2015	Jul CAHN
	@	APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan DISC
	@	FDN CONSUMER	1.5MG	A200670	001	Jul 12, 2012	Jun DISC
!		L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May CAHN
		NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015	Sep CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

@	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	Mar DISC
---	----------------	------	---------	-----	--------------	----------

TABLET;ORAL

LORATADINE

	GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019	Mar CAHN
	NEWGEN PHARMS LLC	10MG	A207569	001	Mar 12, 2019	Feb NEWA

TABLET, CHEWABLE;ORAL

LORATADINE

	PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019	May NEWA
	SUN PHARM	5MG	A210088	001	Apr 16, 2018	Mar CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

@	HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004	May CAHN
	P AND L	10MG;240MG	A075706	001	Feb 21, 2003	Aug CAHN

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 7

	P AND L	2%	A074164	001	Mar 29, 1996	Aug CAHN
--	---------	----	---------	-----	--------------	----------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK

P AND L	2%,200MG	A074926	001	Apr 16, 1999	Aug CAHN
---------	----------	---------	-----	--------------	----------

SUPPOSITORY;VAGINAL
MICONAZOLE NITRATE

P AND L	100MG	A073507	001	Nov 19, 1993	Aug CAHN
---------	-------	---------	-----	--------------	----------

MINOXIDILAEROSOL, FOAM;TOPICAL
MINOXIDIL (FOR MEN)

P AND L	5%	A208092	001	Feb 17, 2017	Aug CAHN
---------	----	---------	-----	--------------	----------

MINOXIDIL (FOR WOMEN)

P AND L	5%	A208092	002	Jul 27, 2017	Aug CAHN
TARO	5%	A209074	002	Apr 22, 2019	Apr NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

P AND L	2%	A074588	001	Apr 05, 1996	Aug CAHN
---------	----	---------	-----	--------------	----------

MINOXIDIL EXTRA STRENGTH (FOR MEN)

P AND L	5%	A075518	001	Nov 17, 2000	Aug CAHN
---------	----	---------	-----	--------------	----------

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

>D>	@ CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019	Nov CMFD
>A>		EQ 200MG BASE	A202807	001	Jan 04, 2019	Nov CMFD
	@	EQ 200MG BASE	A202807	001	Jan 04, 2019	Jul DISC

TABLET;ORAL

ALEVE

+!	BAYER	220MG	N020204	002	Jan 11, 1994	Sep CPOT
----	-------	-------	---------	-----	--------------	----------

NAPROXEN SODIUM

	AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008	Sep CPOT
	AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016	Sep CPOT
	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997	Sep CPOT
@		220MG	A074789	001	Feb 27, 1997	Sep CPOT
	DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998	Sep CPOT
	GRANULES INDIA	220MG	A091353	001	Sep 20, 2011	Sep CPOT
	LNK INTL INC	220MG	A204872	001	Jan 23, 2017	Sep CPOT
	MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011	Sep CPOT
	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018	Sep CPOT
	PERRIGO	220MG	A074661	001	Jan 13, 1997	Sep CPOT
@	PLD ACQUISITIONS LLC	220MG	A074646	001	Jan 13, 1997	Sep CPOT
	SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011	Sep CPOT
	YICHANG HUMANWELL	EQ 200MG BASE	A212033	001	Aug 30, 2019	Aug NEWA
		220MG	A212033	001	Aug 30, 2019	Sep CPOT

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+!	BAYER	EQ 200MG BASE;120MG	N021076	001	Nov 29, 1999	Mar CPOT
+!		220MG;120MG	N021076	001	Nov 29, 1999	Sep CPOT

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006	Sep CPOT
	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004	Sep CPOT

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999	Aug CAHN
	EQ 2MG BASE	A076569	001	Jul 29, 2004	Aug CAHN
	EQ 2MG BASE	A078699	001	Dec 29, 2008	Aug CAHN
	EQ 2MG BASE	A079044	001	Jul 08, 2009	Aug CAHN
	EQ 2MG BASE	A079216	001	Jul 08, 2009	Aug CAHN
	EQ 2MG BASE	A204794	001	May 10, 2016	Aug CAHN
	EQ 4MG BASE	A074707	001	Mar 19, 1999	Aug CAHN
	EQ 4MG BASE	A076568	002	Jul 29, 2004	Aug CAHN
	EQ 4MG BASE	A078697	001	Dec 29, 2008	Aug CAHN
	EQ 4MG BASE	A079038	001	Jul 08, 2009	Aug CAHN
	EQ 4MG BASE	A079219	001	Jul 08, 2009	Aug CAHN
	EQ 4MG BASE	A204833	001	Feb 26, 2016	Aug CAHN

TROPHE/LOZENGE;ORAL
NICOTINE POLACRILEX

	P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019	Oct NEWA
>D>	@	EQ 2MG BASE	A209206	001	Jun 26, 2018	Nov CMFD
>A>		EQ 2MG BASE	A209206	001	Jun 26, 2018	Nov CMFD
	@	EQ 2MG BASE	A209206	001	Jun 26, 2018	Aug CAHN
>D>	@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Nov CMFD
>A>		EQ 2MG BASE	A209519	001	Jul 02, 2018	Nov CMFD
	@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Aug CAHN
		EQ 2MG BASE	A209520	001	Oct 31, 2019	Oct NEWA
		EQ 2MG BASE	A210711	001	Oct 31, 2019	Oct NEWA
		EQ 2MG BASE	A210712	001	Sep 06, 2019	Aug NEWA
		EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul CAHN
		EQ 4MG BASE	A208875	002	Oct 31, 2019	Oct NEWA
>D>	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Nov CMFD
>A>		EQ 4MG BASE	A209206	002	Jun 26, 2018	Nov CMFD
	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Aug CAHN
>D>	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Nov CMFD
>A>		EQ 4MG BASE	A209519	002	Jul 02, 2018	Nov CMFD
	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Aug CAHN
		EQ 4MG BASE	A209520	002	Oct 31, 2019	Oct NEWA
		EQ 4MG BASE	A210711	002	Oct 31, 2019	Oct NEWA
		EQ 4MG BASE	A210712	002	Sep 06, 2019	Aug NEWA
		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul CAHN
	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb NEWA
		EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb NEWA
	TEVA PHARMS USA INC	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul NEWA
		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul NEWA
	@ WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb DISC
	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb DISC
	@ WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb DISC
	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb DISC

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

@ APOTEX	20MG	A210070	001	Feb 11, 2019	Aug DISC
APOTEX INC	20MG	A210070	001	Feb 11, 2019	Apr CTEC

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAX

@ LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jun DISC
@	17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jun DISC
POLYETHYLENE GLYCOL 3350					
NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ ANI PHARMS INC	EQ 75MG BASE	A075296	001	Jan 14, 2000	Oct DISC
@ MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Oct DISC
STRIDES PHARMA	EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr CAHN
	EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr CAHN
UNIQUE PHARM LABS	EQ 75MG BASE	A210250	001	Aug 30, 2019	Aug NEWA
	EQ 150MG BASE	A210228	001	Aug 30, 2019	Aug NEWA

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+ @ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar DISC
-----------------------	------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2019

NO NOVEMBER 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327 001					PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579	Y		
	8822438	Aug 24, 2027	U-1580	Y		
	8822438	Aug 24, 2027	U-2235	Y		
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		>A> I-817	Nov 21, 2022
	10272083	Jan 21, 2035	U-2519			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767 001	8741959	Apr 19, 2030	DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10034867	Jul 07, 2020	DP U-2513			
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	7078412	Jul 07, 2020	DS DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10034867	Jul 07, 2020	DP U-2513		NC	Mar 29, 2022
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	7078412	Jul 07, 2020	DS DP U-2513			
	7750023	Jul 07, 2020	DP U-2513			
	8051851	Apr 22, 2027	DP			
	8129405	Jul 07, 2020	DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACYCLOVIR - AVACLYR</u>						
N 202408 001					ODE-235	Mar 29, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797 001	>A> 10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
	>A> 8334265	Mar 11, 2029	U-2638		>A> ODE-270	Oct 08, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					ODE-230	Jan 12, 2025
<u>AIR POLYMER-TYPE A - EXEM FOAM KIT</u>						
N 212279 001					>A> NCE	Nov 07, 2024
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10124131	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALPELISIB - PIQRAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321 001					ODE-244	May 06, 2026
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214 GAIN	Sep 28, 2025 Sep 28, 2030
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212492 001					>A> CGT	May 30, 2020
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780 001					CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-804			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMOXICILIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	>A> 10238606	Feb 12, 2034	DP			
	>A> 9050263	Feb 12, 2034	DP U-2660			
	>A> 9498445	Feb 12, 2034	DP U-2660			
	>A> 9603806	Feb 12, 2034	DP U-2660			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		I-808	Sep 17, 2022
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	>A> 10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	>A> 10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	>A> 6962940	Mar 19, 2023	U-1504			
	>A> 6962940	Mar 19, 2023	U-2656			
	>A> 6962940	Mar 19, 2023	U-2657			
	>A> 6962940	Mar 19, 2023	U-2658			
	>A> 7659302	Mar 19, 2023	U-1505			
	>A> 7659302	Mar 19, 2023	U-1595			
	>A> 7659302	Mar 19, 2023	U-2657			
	>A> 7659302	Mar 19, 2023	U-2658			
	>A> 8455536	Mar 19, 2023	U-1505			
	>A> 8455536	Mar 19, 2023	U-1595			
	>A> 8455536	Mar 19, 2023	U-2657			
	>A> 8455536	Mar 19, 2023	U-2658			
	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
	>A> 9018243	Mar 19, 2023	U-2656			
	>A> 9018243	Mar 19, 2023	U-2657			
	>A> 9018243	Mar 19, 2023	U-2658			
	>A> 9724330	Mar 19, 2023	U-1561			
	>A> 9724330	Mar 19, 2023	U-1595			
	>A> 9724330	Mar 19, 2023	U-2656			
	>A> 9724330	Mar 19, 2023	U-2657			
	>A> 9724330	Mar 19, 2023	U-2658			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	>A> 10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	>A> 10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	>A> 6962940	Mar 19, 2023	U-1504			
	>A> 6962940	Mar 19, 2023	U-2656			
	>A> 6962940	Mar 19, 2023	U-2657			
	>A> 6962940	Mar 19, 2023	U-2658			
	>A> 7659302	Mar 19, 2023	U-1505			
	>A> 7659302	Mar 19, 2023	U-1595			
	>A> 7659302	Mar 19, 2023	U-2657			
	>A> 7659302	Mar 19, 2023	U-2658			
	>A> 8455536	Mar 19, 2023	U-1505			
	>A> 8455536	Mar 19, 2023	U-1595			
	>A> 8455536	Mar 19, 2023	U-2657			
	>A> 8455536	Mar 19, 2023	U-2658			
	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
	>A> 9018243	Mar 19, 2023	U-2656			
	>A> 9018243	Mar 19, 2023	U-2657			
	>A> 9018243	Mar 19, 2023	U-2658			
	>A> 9724330	Mar 19, 2023	U-1561			
	>A> 9724330	Mar 19, 2023	U-1595			
	>A> 9724330	Mar 19, 2023	U-2656			
	>A> 9724330	Mar 19, 2023	U-2657			
	>A> 9724330	Mar 19, 2023	U-2658			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	>A> 10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	>A> 10092541	May 29, 2034	U-2659		ODE-248	Jul 19, 2026
	>A> 6962940	Mar 19, 2023	U-1504			
	>A> 6962940	Mar 19, 2023	U-2656			
	>A> 6962940	Mar 19, 2023	U-2657			
	>A> 6962940	Mar 19, 2023	U-2658			
	>A> 7659302	Mar 19, 2023	U-1505			
	>A> 7659302	Mar 19, 2023	U-1595			
	>A> 7659302	Mar 19, 2023	U-2657			
	>A> 7659302	Mar 19, 2023	U-2658			
	>A> 8455536	Mar 19, 2023	U-1505			
	>A> 8455536	Mar 19, 2023	U-1595			
	>A> 8455536	Mar 19, 2023	U-2657			
	>A> 8455536	Mar 19, 2023	U-2658			
	>A> 9018243	Mar 19, 2023	U-1505			
	>A> 9018243	Mar 19, 2023	U-1595			
	>A> 9018243	Mar 19, 2023	U-2656			
	>A> 9018243	Mar 19, 2023	U-2657			
	>A> 9018243	Mar 19, 2023	U-2658			
	>A> 9724330	Mar 19, 2023	U-1561			
	>A> 9724330	Mar 19, 2023	U-1595			
	>A> 9724330	Mar 19, 2023	U-2656			
	>A> 9724330	Mar 19, 2023	U-2657			
	>A> 9724330	Mar 19, 2023	U-2658			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	May 12, 2029	DP			
	8114021	Jun 21, 2030	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
	9687474	Jul 25, 2033	DP			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	8338429	Jun 30, 2023	U-2577		I-802	Jun 26, 2022
	8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
	8765764	Jan 15, 2023	U-2578			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-2508			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-2509			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	10322085	Oct 24, 2023	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9387249	Jul 01, 2031	U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9387249	Jul 01, 2031	U-3			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10392406	Apr 27, 2036	DS		I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10392406	Apr 27, 2036	DS		I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					NPP ODE-251	Aug 09, 2022 Aug 09, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-1761		NPP	Jul 25, 2022
	6753013	Jan 27, 2020	DP U-193		PED	Jan 25, 2023
	6753013	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-88			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10130640	Jun 10, 2031	DP		NPP	Jul 30, 2022
	10130640*PED	Dec 10, 2031			PED	Jan 30, 2023
	6753013	Jan 27, 2020	DP U-1761			
	6753013	Jan 27, 2020	DP U-2627			
	9119781	Jun 10, 2031	DP U-1761			
	9119781	Jun 10, 2031	DP U-2627			
	9119781*PED	Dec 10, 2031				
>A>	9566286	Jun 10, 2031	DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10385067	Jun 19, 2035	U-257		NPP	Jun 18, 2022
					ODE-256	Jun 18, 2026
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	>A> 8263580	May 07, 2028	DP U-1280			
	>A> 8263580	May 07, 2028	DP U-2662			
	>A> 8629128	May 26, 2026	DP U-1280			
	>A> 8629128	May 26, 2026	DP U-1767			
	>A> 8629128	May 26, 2026	DP U-2662			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-2441		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-2441		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10195159	May 07, 2022	DS			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001					CGT	Dec 29, 2019
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CEFIDEROCOL SULFATE TOSYLATE - FETROJA</u>						
N 209445 001	>A> 10004750	Sep 03, 2035	DS DP		>A> NCE	Nov 14, 2024
	>A> 9238657	Nov 19, 2031	DS DP U-282		>A> GAIN	Nov 14, 2029
	>A> 9949982	Sep 03, 2035	DP			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565			
	10028963	Sep 07, 2032	U-2566			
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP			
	7964592	Jan 13, 2027	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - OUZYTIR</u>						
N 211415 001	8263581	Feb 28, 2030	U-2635		NP	Oct 04, 2022
	8314083	Feb 28, 2030	U-2634			
	8513259	Feb 11, 2030	U-2636			
	9119771	Feb 11, 2030	U-2635			
	9180090	Feb 11, 2030	U-2635			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001	8969412	Sep 05, 2026	DP U-2609			
	9504666	Dec 11, 2033	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253 001					>A> CGT	May 25, 2020
<u>CHLORZOXAZONE - CHLORZOXAZONE</u>						
A 212253 002					>A> CGT	May 25, 2020
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>CLOZAPINE - VERSACLOZ</u>						
N 203479 001	>A> 8057811	May 01, 2028	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001					NPP ODE-260	Aug 22, 2022 Aug 22, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	10420760	Feb 07, 2037	U-2478			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOOPA</u>						
N 209936 001	10383876	Mar 29, 2032	DS DP			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP U-1319			
	9585868	Oct 31, 2031	U-1319			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001 >A>	10441630	Aug 23, 2033	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10328037	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10328037	Aug 16, 2036	U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001 >A>	10478453	Jan 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					M-246	Oct 06, 2022
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					M-246	Oct 06, 2022
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8007826	May 26, 2027	U-1030	Y		
	8354437	Dec 22, 2026	U-1030	Y		
	8440703	Apr 08, 2025	U-1030	Y		
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 001					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 002					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 003					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 004					NPP	May 16, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	005				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	006				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	007				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	008				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	009				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	010				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	011				NPP	May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	001	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	002	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	003	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-493		I-804	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6414126	Oct 04, 2020	DS DP U-493		NS	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPSONE - ACZONE</u>						
N 207154 001					NPP	Sep 10, 2022
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667 001					CGT	Jan 12, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			
	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
<u>DARUNAVIR - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 001					PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 002					PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560 003					PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-239 M-241	Dec 12, 2021 Jul 24, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910 001					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910 002					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910 003					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003					M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328 8703156	Jun 28, 2021 Oct 29, 2029	U-735 DP U-735			
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					ODE-252	Jun 07, 2026
<u>DELAFLUXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001					>A> I-815	Oct 24, 2022
<u>DELAFLUXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001					>A> I-815	Oct 24, 2022
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	10307459	May 07, 2023	DP			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	10307459	May 07, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
	8563027	Feb 12, 2030	U-2487		NP	Nov 30, 2021
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001					>A> ODE-271	Oct 03, 2026
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129 001					PC	Nov 30, 2019
<u>DIGOXIN - DIGOXIN</u>						
A 213000 001					CGT	Apr 01, 2020
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	>A> 10080733	Sep 20, 2033	DS DP U-1384			
	>A> 8669281	Sep 20, 2033	DS DP			
	>A> 9090558	Sep 20, 2033	U-1384			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	10426780	Jan 24, 2031	DS DP U-257			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394			
	8486975	Oct 07, 2031	DS DP U-2630			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394			
	8486975	Oct 07, 2031	DS DP U-2630			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		I-806	Sep 19, 2022
	8486975	Oct 07, 2031	DS DP U-2629			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					>A> NCE	May 05, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-243	Aug 09, 2022
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
	>A> 10081621	Mar 25, 2031	DP U-2652		NCE	Oct 21, 2024
	>A> 10239867	Apr 09, 2027	DS DP U-2653			
	>A> 7495103	May 20, 2027	DS DP			
	>A> 7645789	May 01, 2027	DS DP			
	>A> 7776905	Jun 03, 2027	DS DP			
	>A> 8324242	Aug 05, 2027	U-2645			
	>A> 8354427	Jul 06, 2026	U-2646			
	>A> 8410274	Dec 28, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	>A> 8415387	Nov 12, 2027	U-2645			
	>A> 8598181	May 01, 2027	U-2645			
	>A> 8623905	May 01, 2027	DS DP			
	>A> 8629162	Jun 24, 2025	U-2648			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 9012496	Jul 15, 2033	U-2649			
	>A> 9670163	Dec 28, 2026	DP U-2650			
	>A> 9931334	Dec 28, 2026	DP U-2650			
	>A> 9974781	Apr 09, 2027	DP U-2645			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	>A> 6642245	Nov 04, 2020	U-1663		I-812	Oct 03, 2022
	>A> 6642245*PED	May 04, 2021				
	>A> 7803788	Feb 02, 2022	U-1663			
	>A> 8754065	Aug 15, 2032	DS DP U-1259			
	>A> 8754065	Aug 15, 2032	DS DP U-1663			
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 9296769	Aug 15, 2032	DS DP U-1259			
	>A> 9296769	Aug 15, 2032	DS DP U-1663			
	>A> 9296769	Aug 15, 2032	DS DP U-257			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10294215	Jan 07, 2033	DP U-2087			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800 003 >A>	10166344	Jan 21, 2025	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 020800 004 >A>	10166344	Jan 21, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 001					>A> CGT	May 09, 2020
<u>ERYTHROMYCIN ETHYLSUCCINATE - ERYTHROMYCIN ETHYLSUCCINATE</u>						
A 211991 002					>A> CGT	May 09, 2020
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031	U-2502		NCE*	Mar 05, 2024
	9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
>A>	10471072	Jun 18, 2033	U-2316			
>A>	10471072	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
>A>	10471072	Jun 18, 2033	U-2316			
>A>	10471072	Jun 18, 2033	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6414126	Oct 04, 2020	U-2588			
	6515117	Oct 04, 2020	U-2588			
	>A> 6872700	Jan 14, 2020	U-2589			
	>A> 6872700	Jan 14, 2020	U-2590			
	>A> 6872700	Jan 14, 2020	U-2591			
	6936590	Oct 04, 2020	U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2589			
	>A> 7456254	Jun 30, 2025	DP U-2590			
	>A> 7456254	Jun 30, 2025	DP U-2592			
	>A> 7612176	Apr 13, 2025	DP U-2589			
	>A> 7612176	Apr 13, 2025	DP U-2590			
	>A> 7612176	Apr 13, 2025	DP U-2592			
	>A> 8329648	Aug 18, 2026	U-2588			
	>A> 8329648	Aug 18, 2026	U-2589			
	>A> 8329648	Aug 18, 2026	U-2590			
	>A> 8329648	Aug 18, 2026	U-2593			
	>A> 8329648	Aug 18, 2026	U-2594			
	>A> 8329648	Aug 18, 2026	U-2595			
	>A> 8329648	Aug 18, 2026	U-2596			
	8361972	Mar 21, 2028	U-2588			
	>A> 8431685	Apr 13, 2025	DP U-2589			
	>A> 8431685	Apr 13, 2025	DP U-2590			
	>A> 8431685	Apr 13, 2025	DP U-2597			
	>A> 8431685	Apr 13, 2025	DP U-2598			
	>A> 8461105	Apr 13, 2025	DP U-2589			
	>A> 8461105	Apr 13, 2025	DP U-2590			
	>A> 8461105	Apr 13, 2025	DP U-2597			
	>A> 8461105	Apr 13, 2025	DP U-2598			
	8501698	Jun 20, 2027	U-2588			
	>A> 8895033	Oct 04, 2030	DP U-2589			
	>A> 8895033	Oct 04, 2030	DP U-2590			
	>A> 8895033	Oct 04, 2030	DP U-2597			
	>A> 8895033	Oct 04, 2030	DP U-2600			
	>A> 8895033	Oct 04, 2030	DP U-2601			
	>A> 8895033	Oct 04, 2030	DP U-2602			
	>A> 8906851	Aug 18, 2026	U-2589			
	>A> 8906851	Aug 18, 2026	U-2590			
	>A> 8906851	Aug 18, 2026	U-2593			
	>A> 8906851	Aug 18, 2026	U-2597			
	9198925	Oct 04, 2020	U-2588			
	>A> 9238076	Apr 15, 2024	DP U-2589			
	>A> 9238076	Apr 15, 2024	DP U-2590			
	>A> 9238076	Apr 15, 2024	DP U-2597			
	>A> 9238076	Apr 15, 2024	DP U-2599			
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092	Aug 18, 2026	U-2597			
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 001					PC	Dec 28, 2019
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 002					PC	Dec 28, 2019
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	10391094	May 29, 2032	DP U-2607		NCE	Aug 16, 2024
	7528143	Dec 16, 2026	DS		ODE-259	Aug 16, 2026
	7825246	Dec 16, 2026	DS			
	8138199	Jun 30, 2028	U-2607			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP U-1432			
	7754702	Feb 15, 2028	DP U-2555			
	7754702	Feb 15, 2028	DP U-2556			
	7754702	Feb 15, 2028	DP U-2557			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549		I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP U-1577			
<u>FERRIC MALTOSE - ACCRUFER</u>						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002 >A>	8933097	Aug 02, 2030	DP			
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	9187405	Jun 25, 2027	U-2613			
	9187405*PED	Dec 25, 2027				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FLUORODOPA F-18 - FLUORODOPA F18</u>						
N 200655 001					NCE W	Oct 10, 2024 Oct 10, 2024
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-2546			
	8703806	May 28, 2030	U-2546			
	8808713	May 28, 2030	DP U-2546			
	8815258	Mar 17, 2031	U-2546			
	9415009	May 28, 2030	U-2546			
	9463161	May 28, 2030	DP U-2546			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-801	Jul 12, 2022
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001					NCE W	Aug 21, 2024 Aug 21, 2024
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001					>A> NCE	Nov 20, 2024
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	10414748	Apr 13, 2036	DS DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	10414748	Apr 13, 2036	DS DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-2532		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2141		ODE-232	Apr 30, 2026
	10039754	Jun 10, 2030	U-2532		ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532			
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-2532			
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10213487	Feb 16, 2036	DP U-2604		NP	Jul 24, 2022
	6938798	Jan 03, 2022	DP			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002					NP	Sep 10, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	003				NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097	004				NP	Sep 10, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284	001	10183002	Sep 22, 2030	U-1816		
		10183003	Sep 22, 2030	U-1816		
		10183004	Sep 22, 2030	U-1816		
		10183005	Sep 22, 2030	U-1816		
		10183006	Sep 22, 2030	U-1816		
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437	001	10376661	Sep 14, 2035	DP		
<u>GRANISETRON - SUSTOL</u>						
N 022445	001	10357570	Sep 28, 2024	U-2253		
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355	001	>A> 10478502	Nov 02, 2031	DP	U-2625	
		6517847	Aug 03, 2020	DP		
		8809307	Nov 02, 2031	DP		
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354	001	10251895	Jun 06, 2036	DP		NP Apr 25, 2022
		10426787	Jun 06, 2036		U-2625	
	>A>	10478502	Nov 02, 2031	DP	U-2625	
		6517847	Aug 03, 2020	DP		
		8809307	Nov 02, 2031	DP		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001	10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003	10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004	10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006	10322120	Jul 25, 2033	DP		
		10456393	Jul 25, 2033		U-1810	
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	001	10369109	Jun 16, 2023	DP		
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627	002	10369109	Jun 16, 2023	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	10369109	Jun 16, 2023	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004 >A>	10471075	May 02, 2036	U-2236			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
	>A> 10463668	Oct 24, 2034	U-2654			
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
<u>INSULIN ASPART - FIASP</u>						
N 208751 001					M-247	Oct 21, 2022
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 003	10376652	Jan 20, 2026	DP			
	7615532	Jun 28, 2029	DS DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP		M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Nov 11, 2030	DP			
	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	>A> 10456360	Oct 15, 2036	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 001	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 002	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 003	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 004	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 005	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 006	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 006	>A> 9700535	Aug 04, 2035	DP			
	>A> 9750711	May 29, 2035	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
<u>ITRACONAZOLE - TOLSURA</u>						
N 208901 001	>A> 10463740	Jun 21, 2033	DP U-2453			
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7867996	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVACAFTOR - KALYDECO</u>						
N 203188 002					NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027		U-2246		
	8598181	May 01, 2027		U-2246		
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025		U-2247		
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033		U-2248		
	9670163	Dec 28, 2026	DP	U-2246		
	9931334	Dec 28, 2026	DP	U-2275		
	9931334	Dec 28, 2026	DP	U-2575		
	9974781	Apr 09, 2027	DP	U-2318		
	9974781	Apr 09, 2027	DP	U-2574		
<u>IVERMECTIN - IVERMECTIN</u>						
A 210019 001					>A> PC	Apr 11, 2020
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10449184	Mar 13, 2035	DP		>A> I-816	May 02, 2022
	9474779	Aug 19, 2033	DS DP	U-2350	ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP	U-2533		
	9474779	Aug 19, 2033	DS DP	U-2534		
	9850277	Jan 18, 2033	DS DP	U-2350		
	9850277	Jan 18, 2033	DS DP	U-2533		
	9850277	Jan 18, 2033	DS DP	U-2534		
	9968595	Mar 13, 2035	DP	U-2351		
	9968595	Mar 13, 2035	DP	U-2533		
	9968595	Mar 13, 2035	DP	U-2534		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	7442830	Nov 20, 2029	DS DP	U-2434		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	7442830	Nov 20, 2029	DS DP	U-2434		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	7442830	Nov 20, 2029	DS DP	U-2434		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035		U-2470		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035		U-2470		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028	U-2400			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP	U-1524	NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP	U-1524	NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP	U-1524		
	9096569	Jul 11, 2026	DS DP	U-1524		
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP	U-1524		
	9993470	Mar 14, 2034	DS DP	U-1524		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		ODE-136	Apr 07, 2024
	10039779	Jan 30, 2034	DS DP U-2370		PED	Oct 07, 2024
	10039779*PED	Jul 30, 2034				
>A>	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470			
	10039779*PED	Jul 30, 2034				
>A>	10456414	Sep 14, 2032	DP			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001 >A>	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002 >A>	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
	9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVOCARNITINE - LEVOCARNITINE</u>						
A 211676 001					CGT	Apr 13, 2020
<u>LEVOCARNITINE - LEVOCARNITINE SF</u>						
A 211676 002					CGT	Apr 13, 2020
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					>A> M-249	Oct 07, 2022
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					>A> M-249	Oct 07, 2022
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					>A> M-249	Oct 07, 2022
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					>A> M-249	Oct 07, 2022
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001 >A>	10350180	Jan 14, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10201663	Mar 10, 2034	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
	>A> 10463676	Aug 31, 2031	U-2661			
<u>LORLATINIB - LOREBENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633			
<u>LORLATINIB - LOREBENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8779187	Jan 23, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595 001	9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
>A>	10463624	Dec 16, 2019	DP			
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP	U-2357		
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104*PED	Jul 08, 2021				
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104*PED	Jul 08, 2021				
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
	>A> 10495650	Aug 12, 2036	U-1643			
	>A> 10500216	Mar 05, 2033	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
	>A> 10471053	May 30, 2038	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	>A> 10086080	Oct 01, 2030	U-2647			
	>A> 10137200	Oct 01, 2030	U-2647			
	>A> 10213512	Oct 01, 2030	DP U-2647			
	>A> 10265404	Oct 01, 2030	DP			
	>A> 10398641	Sep 08, 2037	U-2647			
	>A> 8865139	Oct 01, 2030	DP U-2647			
	>A> 8945516	Oct 01, 2030	DP			
	>A> 8992896	Oct 01, 2030	DP U-2647			
	>A> 9675700	Oct 01, 2030	DP U-2647			
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	>A> 10232152	Nov 24, 2034	DP U-2272			
	>A> 10406332	Mar 13, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 001					PC	Oct 01, 2019
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 002					PC	Oct 01, 2019
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	10154990	Dec 20, 2025	U-2620		I-805 ODE-261	Sep 06, 2022 Sep 06, 2026
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10154990	Dec 20, 2025	U-2620		I-805 ODE-261	Sep 06, 2022 Sep 06, 2026
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	>A> 8071579	Aug 12, 2027	U-2655		I-813	Oct 23, 2022
	>A> 8143241	Aug 12, 2027	U-2655		I-814	Oct 23, 2022
	>A> 8859562	Aug 04, 2031	U-2655			
<u>NITISINONE - NITYR</u>						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	DP U-1942			
	10266822	Dec 05, 2025	DP U-1943			
	10266822	Dec 05, 2025	DP U-1944			
	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			
	10436802	Sep 11, 2035	U-2093			
	10436802	Sep 11, 2035	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPENIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
	10449173	Nov 06, 2029	DP U-2637			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	9060976	Aug 06, 2022	DP	Y		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		ODE-52	Sep 06, 2020
	7758891*PED	Aug 21, 2026			PED	Mar 06, 2021
	7820788	Oct 27, 2024	DP U-1092			
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7820788*PED	Apr 27, 2025				
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	7923536*PED	Jun 09, 2024				
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8138229*PED	Jun 09, 2024				
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	8314156*PED	Jun 09, 2024				
	8853260	Oct 10, 2020	DP U-1092			
	8853260	Oct 10, 2020	DP U-1290			
	8853260	Oct 10, 2020	DP U-1434			
	8853260*PED	Apr 10, 2021				
	9101543	Feb 21, 2026	U-1434			
	9101543*PED	Aug 21, 2026				
	9393318	Mar 04, 2032	U-1290			
	9393318*PED	Sep 04, 2032				
	9511046	Jan 12, 2034	U-1434			
	9511046*PED	Jul 12, 2034				
	9597409	Mar 04, 2032	U-1290			
	9597409*PED	Sep 04, 2032				
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	>A> 6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	>A> 7456168	Jan 16, 2023	U-2515			
	>A> RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	>A> 6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	>A> 7456168	Jan 16, 2023	U-2515			
	>A> RE47739	Jan 16, 2023	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	>A> 6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	>A> 7456168	Jan 16, 2023	U-2515			
	>A> RE47739	Jan 16, 2023	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 001					>A> ODE-268	Jun 29, 2025
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 002					>A> ODE-268	Jun 29, 2025
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 003					>A> ODE-268	Jun 29, 2025
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004	7473761	Dec 14, 2026	DS DP		>A> ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005	7473761	Dec 14, 2026	DS DP		>A> ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001					CGT	Dec 22, 2019
<u>PERAMIVIR - RAPIVAR</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
	7893075	Oct 13, 2028	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	10028944	Jan 15, 2024	U-1974			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002					NCE	Apr 29, 2021
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10028944	Jan 15, 2024	U-1974			
	10449185	Aug 27, 2038	DP			
	9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001 >A>	8383150	Sep 22, 2026	DP U-2361			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS U-998		NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022	U-1101		ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026	U-1101			
	8486947	Sep 26, 2029	U-1101			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022	U-1101		ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026	U-1101			
	8486947	Sep 26, 2029	U-1101			
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 23, 2022
					PED	Nov 23, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP PED	May 23, 2022 Nov 23, 2022
<u>PRETOMANID - PRETOMANID</u>						
N 212862 001					NCE ODE-253 GAIN	Aug 14, 2024 Aug 14, 2026 Aug 14, 2029
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301	Feb 02, 2027	DP			
	RE47351	Jun 22, 2019	DS DP U-869			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10343995	Mar 10, 2025	U-2440			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Oct 02, 2029	U-1481			
	10335397	Oct 02, 2029	U-2579			
	10456384	Feb 26, 2029	U-2643			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10456384	Feb 26, 2029	U-2644			
<u>RISPERIDONE - PERSEERIS KIT</u>						
N 210655 001	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
<u>RISPERIDONE - PERSEERIS KIT</u>						
N 210655 002	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7592339	Dec 11, 2020	U-1167		I-810	Oct 11, 2022
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
	7592339	Dec 11, 2020	U-2142			
	7592339	Dec 11, 2020	U-2640			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002					I-810	Oct 11, 2022
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003					I-810	Oct 11, 2022
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					I-810	Oct 11, 2022
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 001	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 002	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 003	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 004	10413543	Feb 12, 2036	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10350174	Dec 22, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10350174	Dec 22, 2030	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10278974	Feb 10, 2031	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	U-2583			
<u>SELENIUS ACID - SELENIUS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Sep 15, 2032	DS DP		NCE	Jul 03, 2024
	9079865	Jul 26, 2032	U-2584		ODE-257	Jul 03, 2026
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 212260 001					CGT	Nov 27, 2019
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001	10300041	Apr 26, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002	10300041	Apr 26, 2027	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	10434059	Nov 18, 2022	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-244	Aug 12, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS	U-2312		
	10335432	Feb 10, 2032		U-2312		
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10300087	Oct 14, 2035	DS	U-2312		
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		NPP	Apr 07, 2020
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP		>A> NPP	Nov 13, 2022
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	10398859	Dec 19, 2027	DP			
	>A> 10478574	Nov 04, 2033	U-2404			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					>A> ODE-269	May 24, 2025
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					>A> ODE-269	May 24, 2025
<u>TADALAFIL - CIALIS</u>						
N 021368 003	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035	U-2582			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10376487	Jul 27, 2035	U-2615			
	>A> 10449176	Jan 25, 2033	U-2149			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001					NCE	Jul 07, 2019
					PED	Jan 07, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP			
	>A> 10442829	Feb 03, 2030	DS			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP			
	>A> 10442829	Feb 03, 2030	DS			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	8541448	Dec 30, 2029	DS DP		NCE	Sep 12, 2024
	8969377	Dec 30, 2029	DS DP			
	9006281	May 02, 2030	U-2626			
	9408840	Dec 30, 2029	U-2626			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 004					CGT	Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TIOPRONIN - THIOLA</u>						
N 019569 001					ODE-267	Jun 28, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
	10457666	Jun 17, 2034	DS DP		ODE-229	Feb 22, 2026
	RE46284	Dec 16, 2026	U-1751			
	RE46284	Dec 16, 2026	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
	10457666	Jun 17, 2034	DS DP		ODE-229	Feb 22, 2026
	RE46284	Dec 16, 2026	U-1751			
	RE46284	Dec 16, 2026	U-2503			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	10207066	Nov 04, 2030	DP U-909			
	8664187	Jun 20, 2025	U-909			
	8869794	Sep 12, 2028	DP U-909			
	9421166	Dec 19, 2022	DP U-909			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	10363224	Mar 19, 2033	U-766			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004					PC	Sep 21, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRIAMCINOLONE ACETONIDE - TRIAMCINOLONE ACETONIDE</u>						
A 212384 001					>A> CGT	May 30, 2020
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Oct 01, 2026	DS DP		NCE	Oct 04, 2024
	8227507	Dec 21, 2025	U-818			
	8470871	Dec 21, 2025	U-2639			
	9084778	May 30, 2033	DP U-134			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681	Apr 13, 2030	U-2510			
	9844510	Dec 08, 2028	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	8962629	Jan 15, 2031	DS U-2616		NCE	Aug 16, 2024
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001 >A>	10493028	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002 >A>	10493028	Mar 13, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266 002					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630 001					NPP	Jan 29, 2022
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001					>A> NCE	Nov 25, 2024
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 9447106	Apr 22, 2034	DS DP U-2145		>A> NCE	Nov 14, 2024

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm